2016N277425_03 CONFIDENTIA L
The GlaxoSmithKline group of companies 201749
1TITLE PA GE
Division: Worldwide Development
Information Type: Protocol Amendment
Title: A 24 -week treatment, multi -center, randomized, double- blind, 
double -dummy , parallel group study  to compare 
Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in 
subje cts with chronic obstructive pulmonary  disease (COPD)
Compound Number: [COMPANY_004]2592356
Development Phase: IV
Effective Date: 18-APR -2017
Protocol Amendment Number:  03
Author (s):  
 
 
Copy right 2017 the GlaxoSmithKline group of companies.  All r ights reserved.  
Unauthorised cop ying or use of this information is prohibited 2018N377698_00
[COMPANY_003]
2016N277425_03 CONFIDENTIA L
The GlaxoSmithKline group of companies 201749
2Revision Chronology
GlaxoSmith Kline
Document NumberDate Version
2016N277425_00 2016 -SEP-13 Original
2016N277425_01 2017 -FEB-07 Amendment No. 1
This protocol amendment was cr eated to make the following changes:
Regulatory  Agency  Identify ing Number(s):  A t ypographical error in the EudraCT no. 
corrected. IND no. added
Section 4.1and Section 4.4: Typographical errors and inconsistencies corrected
Inconsistencies between Section 4.4 , Section [IP_ADDRESS] and Section 7.1revised
Section 7.1 Time and Events table:
Un-intentional deletion of the (“x”) were added to confirm that concomitant medications 
should be reviewed at every  clinic visit was corrected.
Increased the visit window 
Typographical error and inconsistencies corrected as described in Appendix 9, Section 
12.9.
Section 7.2.2 Critical procedures performed at Screening (Visit 1): To clarify  that height 
and weight are collected at V1 “Height and weight” added
Section 7.3.2 Spi[INVESTIGATOR_105222]:“At Screening, before the morning dose of usual COPD 
medication(s)” added.
Section 7.3.7 :  Physical activity  monitor (study  subset)
Inconsistency  between Section 1, Section 4.[ADDRESS_864779] y with Health Canada guidelines.  They
require pharmaceutical manufacturers to expeditiously  report domestic cases of unusual 
failure in efficacy  (UFIE) for new drugs to the Marketed Health Products Dire ctorate 
(MHPD) within [ADDRESS_864780] notification.
Changes were made to Section 7.4.1 and Appendix 4 .
2016N277425_03 2017-APR -18 Amendment No. 3
This protocol amendment was created to make the following changes:
Clarifications concerning study  design, stratification ,permitted and prohibited COPD 
medications, s toppi[INVESTIGATOR_3418] ,visit windows, chest x -rays performed in the context of 
the protocol and site professional expertise
Rate of COPD exacerbations from tertiary  endpoints to exploratory endpoints
Addition of an inclusi on criterion specific to Fr ance
Integration of Canadian Amendment 2
Correction of t ypographical errors and inconsistencies 2018N377698_00
 2018N377698_00
[COMPANY_003]
[COMPANY_003]
2016N277425_03 CONFIDENTIA L
201749
4MEDICA L MONITOR/SPONSOR INFOR MATION PA GE
Medical Monitor/SAE Contact [CONTACT_7171]: 
Role Name [CONTACT_387071] -hours 
Phone/Cell/
Pager 
NumberFax 
NumberSite Address
Primary 
Medical 
Monitor Cell: Cell: Fax: GlaxoSmithKline
Stockley Park 
West, [ADDRESS_864781], 
Heathrow, 
Uxbridge, 
Middlesex, UB11 
1BT, United 
Kingdom
Secondary 
Medical 
MonitorMD
Telphone:Cell:  Fax:  GlaxoSmithKline
Stockley Park 
West, [ADDRESS_864782]  
inform ation Telephone: Cell: GlaxoSmithKline
RTP, [ADDRESS_864783], 
Research 
Triangle Park, NC 
[ZIP_CODE] , United 
States
Sponsor Legal Registered Address: 
GlaxoSmithKline Research & Development Limited
[ADDRESS_864784]
Middlesex, TW8 9GS
[LOCATION_006]
In some countries, the clinical trial sponsor may  be the local GlaxoSmithKline Affiliate 
Company  (or designee). If applicable, the details of the alternative Sponsor and contact 
[CONTACT_131980].   
Regulatory  Agency  Identify ing Number(s):  IND no. [ADDRESS_864785] to ensure that site 
staff receives the appropriate information throughout the study . 
Investigator Name:
[CONTACT_132026]:
Investigator Phone Number:
Investigator Signature [CONTACT_1782] 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
6TABLE OF CONTENTS
PAGE
1.PROTOCOL SYNOPSIS FO R STUDY 201749 ...................................................... 10
2.INTRODUCTION .................................................................................................... 16
2.1. Study Rationale .......................................................................................... 16
2.2. Brief Background ........................................................................................ 16
3.OBJECTIVE(S) AND END POINT(S) ...................................................................... 17
4.STUDY DESIGN .................................................................................................... 19
4.1. Overall Design ............................................................................................ 19
4.2. Treatment Arms and Duration ..................................................................... 21
4.3. Type and Number of Subjects ..................................................................... 22
4.4. Design Justification ..................................................................................... 22
4.5. Dose Justification ........................................................................................ 22
4.6. Benefit: Risk Assessment ........................................................................... 22
4.6.1. Risk Assessment ......................................................................... 23
4.6.2. Benefit Assessment ..................................................................... 26
4.6.3. Overa ll Benefit: Risk Conclusion .................................................. [ADDRESS_864786] AWAL CRITERIA ............. 26
5.1. Inclusion Criteria ......................................................................................... 26
5.2. Exclusion Criteria ........................................................................................ 28
5.3. Randomization Criteria ............................................................................... 31
5.4. Screening/Baseline/Run -in Failures ............................................................ 32
5.5. Withdrawal/Stoppi[INVESTIGATOR_2121] ....................................................................... 32
5.5.1. Withdrawal from the Study ........................................................... 32
5.5.2. Reason for Study W ithdrawal ....................................................... 33
5.5.3. Liver Chemistry Stoppi[INVESTIGATOR_2121] ................................................ 34
[IP_ADDRESS]. Study Treatment Restart or Rechallenge .................... [ADDRESS_864787] and Other Study Treatment .................................... 35
6.2. Medical Devices .......................................................................................... 37
6.3. Treatment Assignment ................................................................................ 38
6.4. Planned Dose Adjustments ......................................................................... 38
6.5. Blinding ....................................................................................................... 39
6.6. Packaging and Labeling .............................................................................. 39
6.7. Preparation/Handling/Storage/Accountability .............................................. 39
6.7.1. Study Treatment Return ............................................................... 40
6.8. Compliance with Study Treatment Administration ....................................... 40
6.9. Treatment of Study Treatment Overdose .................................................... 41
6.10. Treatment after the End of the Study .......................................................... 41
6.11. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_014] .................................... 41
6.11.1. Permitted Medi cations and Non- Drug Therapi[INVESTIGATOR_014] .......................... 42
6.11.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014] ......................... 43 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
77.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 43
7.1. Time and Events Table ............................................................................... 44
7.2. Screening and Critical Baseline Assessments ............................................ 47
7.2.1. Pre-screening Visit ....................................................................... 47
7.2.2. Critical procedures performed at Screening (Visit 1) .................... 47
[IP_ADDRESS]. Albuterol/Salbutamol Reversibility Assessment .......... [ADDRESS_864788] treatment Visit 
(Baseline V2) ............................................................................... 48
7.3. Efficacy Assessments ................................................................................. 49
7.3.1. HRQoL assessments: Completion of PRO questionnaires 
in the Electronic Diary .................................................................. 49
[IP_ADDRESS]. Self Administered Computerised Baseline 
Dyspnea Index/Transitional Dyspnea Index 
(SAC BDI/TDI) ............................................................ 49
[IP_ADDRESS]. SGRQ -C..................................................................... 50
[IP_ADDRESS]. COPD Assessment Test (CAT) .................................. 50
[IP_ADDRESS]. EXACT and the Evaluating Respi[INVESTIGATOR_633333] -COPD (E -RS: COPD) .............................. 51
[IP_ADDRESS]. Subject Global Rating of COPD Severity and 
Global Rating of Change in COPD ............................. 51
7.3.2. Spi[INVESTIGATOR_038] ................................................................................... 51
7.3.3. Inspi[INVESTIGATOR_14008] (IC) ............................................................... 52
7.3.4. COPD Exacerbation .................................................................... 53
7.3.5. Clinically important deterioration (CID) ......................................... 53
7.3.6. Rescue albuterol/salbutamol use ................................................. 54
7.3.7. Physical activity monitor (study subset) ....................................... 54
7.4. Safety ......................................................................................................... 54
7.4.1. Adverse Events (AE) and Serious Adverse Events (SAEs) .......... 54
[IP_ADDRESS]. Time period and Frequency for collecting AE 
and SAE information ................................................... 55
[IP_ADDRESS]. Method of Detecting AEs and SAEs ........................... 55
[IP_ADDRESS]. Follow -up of AEs and SAEs ........................................ 55
[IP_ADDRESS]. Pneumonia Events ..................................................... 56
[IP_ADDRESS]. Cardiovascular and Death Events .............................. 56
[IP_ADDRESS]. Disease -Related Events and/or Disease-
Related Outcomes Not Qualifying as SAEs ................ 56
[IP_ADDRESS]. Regulatory Reporting Requirements for SAEs ............ 56
[IP_ADDRESS]. Additional Adverse Event (AE) Reporting 
Requiremen ts for Canadian investigators ................... 57
7.4.2. Pregnancy ................................................................................... 57
7.4.3. Medical Device Incidents (Including Malfunctions) ....................... 57
7.4.4. Electrocardiogram (ECG) ............................................................. 57
7.5. Genetics ..................................................................................................... 58
8.DATA MANAGEMENT ........................................................................................... 58
9.STATISTICAL CONSIDER ATIONS AND DATA ANALYSES ................................ .58
9.1. Hypotheses ................................................................................................ .58
9.2. Sample Size Considerations ....................................................................... 59
9.2.1. Sample Size Sensitivity ................................................................ 59
9.2.2. Sample Size Re- estimation or Adjustment ................................... 60
9.3. Data Analysis Considerations ..................................................................... 60 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
89.3.1. Analysis Populations .................................................................... 60
9.3.2. Interim Analysis ........................................................................... 60
9.4. Key Elements of Analysis Plan ................................................................... 60
9.4.1. Primary Analyses ......................................................................... 61
9.4.2. Other Analyses ............................................................................ 62
10. STUDY GOVERNANCE CON SIDERATIONS ........................................................ 62
10.1. Posting of Information on Publicly Available Clinical Trial Registers ............ 62
10.2. Regulatory and Ethical Con siderations, Including the Informed 
Consent Process ........................................................................................ 62
10.3. Quality Control (Study Monitoring) .............................................................. 63
10.4. Quality Assurance ....................................................................................... 64
10.5. Study and Site Closure ............................................................................... 64
10.6. Records Retention ...................................................................................... 64
10.7. Provision of Study Results to Investigators, Posting of Information 
on Publically Available Clinical Trials Registers and Publication ................. 65
11.REFERENCES ....................................................................................................... 66
12.APPENDICES ........................................................................................................ 69
12.1. Appendix 1: Abbreviations and Trademarks ................................................ 69
12.2. Appendix 2: Liver Safety Required Actions and Follow up 
Assessments .............................................................................................. 71
12.3. Appendix 3: Genetic Research ................................................................... 73
12.4. Appendix 4: Definition of and Procedures for Recording, Evaluating, 
Follow -Up and Reporting of Adverse Events ............................................... 76
12.4.1. Definiti on of Adverse Events ........................................................ 76
12.4.2. Definition of Serious Adverse Events ........................................... 77
12.4.3. Definition of Cardiovascular Events ............................................. 79
12.4.4. Recording of AEs and SAEs ........................................................ 79
12.4.5. Evaluating AEs and SAEs ............................................................ 80
12.4.6. Reporting of SAEs to [COMPANY_004] ........................................................... 81
12.5. Appendix 5: COPD Exacerbation Identification, Categorization and 
Treatment Guidelines .................................................................................. 83
12.5.1. Guidelines for Identifying COPD Exacerbations ........................... 83
12.5.2. COPD Exacerbation Severity ....................................................... 84
12.5.3. Treatment of COPD Exacerbations .............................................. 84
12.5.4. Guidelines for Treatment with Corticosteroids .............................. 84
12.5.5. Guidelines for Treatment with Antibiotics ..................................... 85
12.5.6. Onset and Resolution of COPD Exacerbations ............................ 85
12.5.7. Guideline for assessing multiple mild exacerbations .................... 85
12.5.8. Guideline for assessing exacerbations that increase in 
severity ........................................................................................ 85
12.6. Appendix 6: Definition of and Procedures for Documenting Medic al 
Device Incidents ......................................................................................... 86
12.6.1. Definitions of a Medical Device Incident ....................................... 86
12.6.2. Documenting Medical Device Incidents ....................................... 87
12.7. Appendix 7: Modified List of Highly E ffective Methods for Avoiding 
Pregnancy in FRP and Collection of Pregnancy Information ....................... [ADDRESS_864789] of Highly Effective Methods for Avoiding 
Pregnancy in Females of Reproductive Potential (FRP) .............. 88
12.7.2. Collection of Pregnancy Information ............................................ 88 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
912.8. Appendix 8: Country Specific Requirements ............................................... 90
12.9. Appendix 9: Protocol changes .................................................................... 91
12.9.1. Protocol Amendment 1 ................................................................ 91
12.9.2. Country -specific Protocol Amendment 2 for Canada .................... 97
12.9.3. Protocol Amendment 3 ................................................................ 99 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
101. PROTOCOL SYNOPSIS FOR STUDY 201749
Rationale
The primary  purpose of this study  is to demonstrate improvements in lung function in 
subjects treated with Umeclidinium/Vilanterol (UMEC/VI ) compared with Umeclidinium 
(UMEC) for [ADDRESS_864790] of
UMEC/VI , UMEC, and salmeterol with respect to health- related quality  of life (HRQoL), 
measured through patient reported outcomes (PROs) questionnaires, and lung function .  
Additional assessments to further evaluate other measures of chronic obs tructive 
pulmonary  disease (COPD) efficacy  and sy mptoms control will be performed.
Objective(s)/Endpoint(s)
Objectives Endpoints
Primary
To compare the effect of UMEC/VI  
(62.5/25 mcg once dail y) with UMEC 
(62.5 mcg once daily ) on lung functionChange fro m baseline in trough Forced 
Expi[INVESTIGATOR_645914] 
(FEV 1) at week 24 
Secondary
To compare UMEC/VI (62.5/25 mcg 
once dail y), UMEC (62.5 mcg once 
daily ) with salmeterol (50 mcg twice 
daily ) on patient reported outcomes 
(PROs) Change from baselin e in self 
administered computerised (SAC) 
transient dy spnea index (TDI) 
Percentage of TDI responders 
according to SAC TDI score.  A 
responder is def ined as a ≥1 unit 
improvement in SAC TDI score 
Assessment of respi[INVESTIGATOR_645915] 24 weeks using 
Evaluating Respi[INVESTIGATOR_244774] -
COPD (E- RS) and its subscales 
(breathlessness, cough and sputum and 
chest sy mptoms) 
Percentage of E -RS responders
according to E -RS score (defined as 
reduction in E -RS score of  2 or 3.35 
units) from baseline
Change from baseline in St George’s 
Respi[INVESTIGATOR_21606] (SGRQ -C)
Percentage of responders according to 
SGRQ -C total score (defined as a 4 
point or great er reduction from  2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
11Objectives Endpoints
baseline) 
Change from baseline in COPD 
assessment test ( CAT)
Percentage of responders according to 
CAT (defined as a 2 unit improvement 
in score from baseline)
Other
To compare UMEC/VI (62.5/25 mcg 
once dail y), UMEC (62.5 mcg once 
daily) with salmeterol (50 mcg twice 
daily ) on other COPD efficacy  measures Time to first mild, moderate or severe 
exacerbation
Time to moderate or severe 
exacerbation
Time to severe exacerbations
Time to clinically  important 
deterioration (CID) composite endpoint 
Time to clinically  important 
deterioration composite endpoint 
excluding FEV 1
Rescue albuterol/salbutamol use, 
(percentage of rescue- free day s and 
mean number of Inhalations/day ) 
captured b y the electronic diary 
(eDiary ) over 24 weeks
Inspi[INVESTIGATOR_13521] y capacit y (IC)
Full Vital capacity  (FVC) 
Change from baseline in trough FEV 1
Change from baseline in global 
impression of disease severity   2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
12Objectives Endpoints
Safety
To evaluate safet y and tolerability of 
UMEC/VI  (62.5/25 mcg once dail y), 
UMEC (62.5 mcg once daily ) and 
salmeterol 50 mcg twice daily )Incidence of adverse events
Exploratory
To explore the effect of UMEC/VI  
(62.5/25 mcg once dail y), UMEC 
(62.5 mcg once daily ) with salmeterol 
(50mcg twice dail y) on rate of COPD 
exacerbationRate of mild, moderate or severe
exacerbations
Rate of moderate or severe 
exacerbation
To compare albuterol/salbutamol use 
captured in the eDiary  with the 
electronic metered dose inhaler (eMDI) 
device Rescue albuterol/salbutamol use, 
(percentage of rescue- free day s and 
mean number of Inhalations/day ) 
captured b y the eMDI device over 24 
weeks as data allow
To explore the effect of UMEC/VI  
(62.5/25 mcg once dail y), UMEC (62.5 
mcg once dail y) with salmeterol (50 
mcg twice dail y) on ph ysical activityChange from baseline in phy sical 
activi ty 
To investigate the CID composite 
endpoint ability  to predict short term 
outcomes To compare ph ysical activity  levels, 
ER-S, rescue medication use, 
exacerbations and mortality  in subjects 
with and without a CI D
Overall Design
This is a multi -centre, randomized, double blind, double dummy , 3-arm parallel group 
study .  Eligible subjects will be randomized in a ratio of 1:1:1 to UMEC/VI inhalation 
powder (62.5/25 mcg once dail y) administered via the ELLIPTA™dry powder inhaler 
(DPI) or UMEC (62.5 mcg once daily ) administered via the ELLIPTA DPI [INVESTIGATOR_645916] 
(50 mcg twice daily (BID)) administered via the DISKUS™DPI.
There will be a total of 5 clinic visits and one follow -up phone call (Visit 6). A pre -
screening visit (Visit 0) may be required in order to administer the informed consent 
before an y changes are made to the subject’s current medication regimen. If no changes 
in medication are required, V0 (pre -screening) and V1 (screening) may  be conducted on 
the same day .Inhaled long -acting muscarinic antagonist (LAMA) or long-acting beta 2-
agonist (LABA) and/or albuterol/salbutamol as needed (rescue medication )are not 
exclusionary  prior to Screening or during the run -in. 
Eligible subjects at Screening Visit [ADDRESS_864791] 6 weeks 
ICS and ICS/LABA free with an FEV 1post-albuterol/salbutamol of ≥30% to ≤80% 
predicted normal and a FEV 1/FVC <0.7 and a CAT score ≥10.  2018N377698_00
2016N277425_03 CONFIDENTIA L
[ADDRESS_864792] withhold thei r morning dose 
prior to Screening spi[INVESTIGATOR_038] . Subjects who meet all other eligibility  criteria at Screening 
will enter a run -in period for 4 weeks. During the run -in period ,subjects will continue 
with their inhaled LAMA orLABA .  In addition, subjects wil l be provided with short 
acting albuterol/salbutamol as needed for relief of COPD sy mptoms (rescue medication) 
throughout the stud y.
Subjects who experience a moderate or severe COPD exacerbation during the run -in 
period will be deemed run- in failures.  Subjects who experience a mild COPD 
exacerbation, defined as worsening of s ymptoms that requires notreatment with 
antibiotics or steroids and is self managed b y the patient by [CONTACT_645993]’s medical monitor.
At the randomization Visit 2 (Day  1),those subjects who successfull y complete the run-
in period ,as well as meet the other pre -defined eligibility  and randomization cr iteria ,will 
be randomized to one of the 3 treatment arms for 24 weeks.
In addition, a subset of subjects (approximately  150 per treatment arm )will undergo 
assessment of their ph ysical activity  measured through a phy sical activit y monitor 
(Actigraph GT9X) worn for 7 day sfrom Screening (Visit 1), for 7 day s from 
Randomisation (Visit 2), [ADDRESS_864793] clinic Visit 
(Visit 5). 
The occurrence of adverse events (AEs) will be evaluated throughout the study  beginning 
at Visit 2 (Day  1) and until the follow -up contact (Visit 6).  Serious adverse events 
(SAEs) will be collected over the same time period as AEs.  However, an y SAEs 
assessed as related to study  participation (e.g., study  treatment, protocol -mandated 
procedures, inv asive tests, or change in existing therapy ) or related to a [COMPANY_004] concomitant 
medication, will be recorded from the time a subject consents to participate in the study  
up to and including an y follow up contact.
All subjects will be given an electronic diary  (eDiary ) for use during the run -in, and the 
treatment period to complete PRO questionnair es, record COPD daily  symptoms and the 
time they  take their COPD medications.  Dail y rescue medication usage (number of 
inhalations taken in the last 24 h) will also b e captured in the eDiary .  In addition, and in 
some countries, rescue medication use will also be captured b y the use of electronic 
metered dose inhaler (eMDI).
At Screening Visit 1, all subjects must be trained on the proper use of their existing 
COPD medications inhalation devices and instructed to strictly  adhere to and record the 
time they  take their COPD medications in the eDiary .
At the randomization Visit 2, all subjects must be trained on the proper use of the 
ELLIPTA and DISKUS inhalation devices a nd instructed to strictly  adhere to and record 
the time they  take their study  medications in the eDiary .
All subjects must be trained on the correct use of the eDiary  and instructed to complete 
the eDiary  during the run -in and treatment period. 2018N377698_00
2016N277425_03 CONFIDENTIA L
[ADDRESS_864794] completed the study  upon completion of the Follow –
Up contact b y telephone.
There are no plans to routinely  provide any  of the study  treatments for compassionate use 
following stud y completion as the study treatment are commerciall yavailable.
Treatment A rms and Duration
Subjects will be stratified based on long-acting bronchodilator usage during the run- in 
(none orone long -acting bronchodilator per day ) and randomized in a ratio of 1:1:1 to 
either 
UMEC/VI  62.5/25 mcg once dail y via ELLIPTA + placebo twice dail y via 
DISKUS
UMEC 62.5 mcg once daily  via ELLIPTA + placebo twice dail y via DISKUS
Salmeterol 50 mcg twice daily  via DI SKUS + placebo once daily  via ELLIPTA 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
15Study schematic
*Subjects may continue the use of inhaled LAMAs or LABAs and/orstudy  provided 
albuterol/salbutamol as needed (rescue medication) during the run-in while adhering to the 
withholding of other COPD medications detailed in the Exclusion Criteria.
Type and Number of Subjects
Approximately  3232 subjects will be screened, such that 2424 subjects will be 
randomized and approximately  2181 evaluable subjects complete the study. 
Analysis
The primary  purpose of this study  is to demonstrate improvements in lung function for 
subjects treated with UMEC/VI  compared with UMEC for 24 weeks.
The primary  endpoint is change from baseline in trough FEV 1at Week 24.
The null hy pothesis is no difference between treatment groups (H0: μT – μS = 0), with 
the alternative h ypothesis that there is a difference between treatment groups (H1: μT –
μS ≠0), where μ T is the mean change from baseline for UMEC/VI and μS is the mean 
change from baseline for UMEC. 
The primary  endpoint of mean chang e from baseline in trough FEV 1at the end of Week 
24 will be anal ysed using Mixed Models repeated Measures (MMRM) analy sis. The 
MMRM analy sis will include measurements at Treatment Weeks 4, 12 and 24. Treatment 
group (a categorical variable) will be fitted as the explanatory  variable with appropriate 
pre-defined variables, stratum (number of bronchodilators per day  during run- in) and 
baseline values, fitted as covariates. Visit (nominal) will be fitted as a categorical variable 
and visit -by-baseline and visit- by-treatment interaction terms will be included to allow 
treatment effects to be estimated at each visit separatel y.  The variance covariance matrix  2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
16will be assumed to be unstructured (based on previous experience no issues are expected 
with fitting mod els with this matrix structure). 
The estimated treatment differences between UMEC/VI versus UMEC for each endpoint 
will be presented with the 95% confidence intervals for the difference and the p -value. 
2. INTRODUCTION
2.1. Stud y Rationale
Chronic obstructive pu lmonary  disease ( COPD) is associated with poor health- related 
quality  of life (HRQoL).  Pharmacologic therap y is used to improve lung function, reduce 
symptoms, frequency  and severit y of exacerbations, and improve patients HRQoL
[GOL D, 2015].  Umeclidinium/Vilanterol (UMEC/VI  62.5/25 mcg) is indicated for the 
maintenance treatment of COPD that contain long- acting muscarinic antagonist (L AMA) 
and long -acting beta 2-agonist (L ABA) bronchodilators.  Umeclidinium (UMEC) is 
indicated as a maintenance bronchodilator treatment to relieve s ymptoms in adult patients 
with COPD .  Salmeterol has long been used for s ymptoms management of COPD.  
However, a direct comparison of these maintenance therapi[INVESTIGATOR_645917].
The primary  purpose of this study  is to demonstrate improvements in lung function for 
subjects treated with UMEC/VI  compared with UMEC for [ADDRESS_864795] of
UMEC/VI , UMEC, and salmeterol with respect to patient HRQoL  measured through 
patient reported outcomes (PROs) questionnaires, sy mptoms and lung function will also 
be evaluated.
2.2. Brief Background
COPD is characterized by [CONTACT_645994], usually  
progressive and accompanied by  a chronic cough, sputum production and dyspnea which 
can be a major cause of disability  and anxiety  associated with the disease [ Maleki -Yazdi , 
2014]
Furthermore, acute exacerbations contribute to the overall severity  of disease as thes e 
epi[INVESTIGATOR_645918] s ymptoms and are associated with increased 
decline in lung function and mortality  [Wedzicha , 2013; Schmidt , 2014].
Pharmacologic therap y is used to improve lung function, reduce s ymptoms, reduce the 
frequency  and severit y of exacerbations, and also to improve health status and exercise 
tolerance.  Maintenance treatment is recommended primarily  through the use of LABAs 
or LAMAs.  COPD treatment guidelines recommend an incremental approach to 
pharmacological treatment as the disease state worsens, involving the use of 
combinations of drug classes with different or complementary  mechanisms [ GOL D, 
2015]. 
UMEC/VI  inhalation powder is a combination of UMEC (umeclidinium bromide), a 
LAMA, and VI (Vilanterol), a LABA, delivered via the ELLIPTA dry  powder inhaler  2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
17(DPI). UMEC/VI at a dose of 62.5/25mcg once- daily  is marketed in the [LOCATION_002] 
(US) and Europe und er the trade name [CONTACT_646039]™ELLIPTA.  
UMEC (62.5 mcg) inhalation powder is marketed in the [LOCATION_002] (US) and Europe 
under the trade name [CONTACT_646040]™ELLIPTA.  UMEC (62.5mcg) is indicated as a 
maintenance bronchodilator treatment to relieve symptoms in adul t patients with COPD.  
UMEC (62.5 mcg) improves forced expi[INVESTIGATOR_131955] (FEV 1), dyspnea 
and HRQoL whether used as monotherap y [Trivedi , 2014; Feldman , 2016] or as an add 
on to fluticasone propi[INVESTIGATOR_645919] (FF/VI) [ Siler , 2015].  Salmetrol (50 mcg) 
DISKUS is a long -acting broncholdilator that has long been used for the maintenance 
treatment of COPD [ Tashkin, 2010].
Clinically  important deterioration (CID) is a novel, exploratory  composite endpoint 
which assesses individual deteriorations in lung function and in patient PROs defined by  
[CONTACT_645995] (MCID), as well as the incidence of 
moderate to severe exacerbations [ Singh , 2016], (Section 7.3.5 ).  CID will be anal ysed to 
determine whether UMEC/VI  (62.5/25mcg) thera py provides greater clinical stability  as 
compared with UMEC and salmeterol monotherapi[INVESTIGATOR_014]. 
3. OBJECTIVE(S) A ND END POINT(S)
Objectives Endpoints
Primary
To compare the effect of UMEC/VI  
(62.5/25 mcg once dail y) with UMEC 
(62.5 mcg once daily ) on lung functi onChange from baseline in trough Forced 
Expi[INVESTIGATOR_645914] 
(FEV 1) at week 24 
Secondary
To compare UMEC/VI (62.5/25 mcg 
once dail y), UMEC (62.5 mcg once 
daily ) with salmeterol (50 mcg twice 
daily ) on patient reported outcomes 
(PROs) Change from baseline in self 
administered computerised (SAC) 
transient dy spnea index (TDI) 
Percentage of TDI responders 
according to SAC TDI score.  A 
responder is defined as a ≥1 unit 
improvement in SAC TDI score 
Assessment of respi[INVESTIGATOR_645915] 24 weeks using 
Evaluating Respi[INVESTIGATOR_244774] -
COPD (E- RS) and its subscales 
(breathlessness, cough and sputum and 
chest sy mptoms) 
Percentage of E -RS responders 
according to E -RS score (defined as 
reduction in E -RS score of  2 or 3.35 
units) from baseli ne 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
18Objectives Endpoints
Change from baseline in St George’s 
Respi[INVESTIGATOR_21606] (SGRQ -C)
Percentage of responders according to 
SGRQ -C total score (defined as a 4 
point or greater reduction from 
baseline) 
Change from baseline in COPD 
assessment test ( CAT)
Percentage of responders according to 
CAT (defined as a 2 unit improvement 
in score from baseline)
Other
To compare UMEC/VI (62.5/25 mcg 
once dail y), UMEC (62.5 mcg once 
daily ) with salmeterol (50 mcg twice 
daily ) on other COPD efficacy  measures Time to first mild , moderate or severe 
exacerbation
Time to moderate or severe 
exacerbation
Time to severe exacerbations
Time to clinically  important 
deterioration (CID) composite endpoint 
Time to clinically  important 
deterioration composite endpoint 
excluding FEV 1
Rescue albuterol/salbutamol use, 
(percentage of rescue- free day s and 
mean number of Inhalations/day ) 
captured b y the electronic diary 
(eDiary ) over 24 weeks
Inspi[INVESTIGATOR_645920] y (IC)
Full Vital capacity  (FVC) 
Change from baseline in trough FEV 1
Change from bas eline in global 
impression of disease severity   2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
19Objectives Endpoints
Safety
To evaluate safet y and tolerability of 
UMEC/VI  (62.5/25 mcg once dail y), 
UMEC (62.5 mcg once daily ) and 
salmeterol 50
mcg twice dail y)Incidence of adverse events
Exploratory
To explore the effect ofUMEC/VI  
(62.5/25 mcg once dail y), UMEC 
(62.5 mcg once daily ) with salmeterol 
(50mcg twice dail y) on rate of COPD 
exacerbationRate of mild, moderate or severe 
exacerbations
Rate of moderate or severe 
exacerbation
To compare albuterol/salbutamol use 
captured in the eDiary  with the 
electronic metered dose inhaler (eMDI) 
device Rescue albuterol/salbutamol use, 
(percentage of rescue- free day s and 
mean number of Inhalations/day ) 
captured b y the eMDI device over 24 
weeks as data allow
To explore the effec t of UMEC/VI  
(62.5/25 mcg once dail y), UMEC (62.5 
mcg once dail y) with salmeterol (50 
mcg twice dail y) on ph ysical activityChange from baseline in phy sical 
activity  
To investigate the CID composite 
endpoint ability  to predict short term 
outcomes To compare ph ysical activity  levels, 
ER-S, rescue medication use, 
exacerbations and mortality  in subjects 
with and without a CI D
4. STUDY DESIGN
4.1. Overall Design
This is a multi -centre, randomized, double blind, double -dummy , 3-arm parallel group 
study .  Eligible subjects will be randomized in a ratio of 1:1:1 to UMEC/VI inhalation 
powder (62.5/25 mcg once dail y) administered via the ELLIPTA™dry powder inhaler, or 
UMEC (62.5 mcg once daily ) administered via the ELLIPTA™or salmeterol (50 mcg 
BID) administered via the DISKUS. 
There will be a total of 5 clinic visits and one follow -up phone call (Visit 6). A pre -
screening visit (Visit 0) may be required in order to administer the informed consent 
before an y changes are made to the subject’s current medication regime n. If no changes 
in medication are required, V0 (pre -screening) and V1 (screening) may  be conducted on 
the same day .Inhaled long -acting muscarinic antagonist (LAMA) orlong-acting beta 2-
agonist (LABA) and/or albuterol/salbutamol as needed (rescue medicati on) are not 
exclusionary  prior to Screening or during the run -in.  2018N377698_00
2016N277425_03 CONFIDENTIA L
[ADDRESS_864796] 6 weeks 
ICS and ICS/LABA free with an FEV 1post-albuterol/salbutamol of ≥30% to ≤80% 
predicted normal and a FEV 1/FVC <0.7 and a CAT score ≥10.
Subjects using inhaled LAMA or LABA medication must withhold their morning dose 
prior to Screening spi[INVESTIGATOR_038] . Subjects who meet all other eligibility  criteria at Screening
will enter a run -in period for 4 weeks. During the run -in period ,subjects will continue 
with their inhaled LAMA orLABA medication .  In addition, subjects will be provided 
with short acting albuterol/salbutamol as needed for relief of COPD sy mptoms (rescue 
medication) throughout the study . 
Subjects who experience a moderate or severe COPD exacerbation during the run -in 
period will be deemed run- in failures.  Subjects who experience a mild COPD 
exacerbation, defined as worsening of s ymptoms that requires notreatment with 
antibiotics or steroids and i sself managed b y the patient by [CONTACT_645996] , (Appendix 5 ), will be able to continue in the study  based on the judgment of 
the investigator and agreement of the sponsor’s medical monitor.
At the randomization Visit 2 (Day  1),those subjects who successfull y complete the run-
in period as well as meet the other pre -defined eligibility  and randomization criteria will 
be randomized to one of the 3 treatment arms for 24 weeks.
In addition, a subset of subjects (approximately  150 per treatment arm )will undergo 
assessment of their ph ysical activity  measured through a phy sical activit y monitor 
(Actigraph GT9X) worn for 7 day sfrom Screening (Visit 1), for 7 day s from 
Randomisation (Visit 2), [ADDRESS_864797] clinic Visit 
(Visit 5).
The occurrence of adverse events (AEs) will be evaluated throughout the study  beginning 
at Visit 2 (Day  1) and until the follow -up contact (Visit 6).  Serious adverse events 
(SAEs) will be collected over the same time period as AEs.  However, an y SAEs 
assessed as related to study  participation (e.g., study  treatment, protocol -mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] concomitant 
medication, will be recorded from the time a subject consents to participate in the study  
up to and including an y follow up contact ( Appendix 4 ). 
All subjects will be given an electronic diary  (eDiary ) for use during the run -in, and the 
treatment period to complete PRO questionnaires, record COPD daily  symptoms, any  
medical problems experienced during the stud y and the time they  take their COPD 
medications.  Daily  rescue medication usage (number of inhalations taken in the last 24h) 
will also be captured in the eDiary.  In addition, and in some countries, rescue medication 
use will also be captured by  [CONTACT_645997] (eMDI).
At Screening Visit 1, all subjects must be trained on the proper use of their existin g 
COPD medications inhalation devices and instructed to strictly  adhere to and record the 
time they  take their COPD medications in the eDiary . 2018N377698_00
2016N277425_03 CONFIDENTIA L
[ADDRESS_864798] completed the study  upon completion of the follow –
up contact b y telephone.
There are no plans to routinely  provide any  of the study  treatments for compassionate use 
following study completion as the study treatment are c ommerciall y available.
The study  design schematic is illustrated in Figure 1
Figure 1 Study  Schematic
*Subjects may continue the use of inhaled LAMAs or LABAs and/or study  provided 
albuterol/salbutamol as needed (rescue medication) during the run-in while adhering to the 
withholding of other COPD medications detailed in the Exclusion Criteria.
4.2. Treatment A rms and Duration
Subjects will be stratified based on long- acting bronchodilator usag e during the run -in 
(none or one long -acting bronchodilator per day ) and randomized in a ratio of 1:1:1 to 
either
UMEC/VI  62.5/25 mcg once dail y via ELLIPTA + placebo twice dail y via 
DISKUS
UMEC 62.5 mcg once daily  via ELLIPTA + placebo twice dail y via DIS KUS
Salmeterol 50 mcg twice daily  via DI SKUS + placebo once daily  via ELLIPTA 2018N377698_00
2016N277425_03 CONFIDENTIA L
[ADDRESS_864799], well -established design 
to evaluate the efficacy  and safet y of an investigational drug.  A salmeterol arm is 
included to allow a comparison to be made between UMEC/VI , UMEC with sa lmeterol, 
a standard practice treatment.
The double -dumm y design is appropriate when drugs are of different appearance or 
different administration regimen which is appropriate in this study  where the inhalers 
used have a different appearance and used once daily  and twice dail y.
The European Medicines Agency  (EMA) COPD Guidelines suggest that duration of 12 to 
24 weeks is considered adequate for assessment of response of COPD sy mptoms to 
treatment intervention with bronchodilators ( EMA COPD guidelines, 2012). 
The primary  endpoint is trough FEV [ADDRESS_864800], well established and an objective means to show the efficacy  of a 
bronchodilator [ Dahl , 2010; Feldman , 2010]. 
Other endpoints such SAC TDI , E-RS, SGRQ -C, CAT, Subject Global Rating of Change 
in global impression of disease severity  are captured to allow responder analy ses and to 
provide comparative data on P ROs between the treatment groups. 
4.5. Dose Justification
This study  is intended to evaluate the efficacy  of marketed doses of UMEC/VI  
(62.5/25mcg once dail y), UMEC (62.5 mcg once daily ) and salmeterol (50mcg twice 
daily ) that are approved for the maintenance treatment of COPD, with respect to PRO 
measures.
4.6. Benefit: Risk A ssessment
Summaries of findings from both clinical and non-clinical studies conducted with 
UMEC/VI  and UMEC can be found in the investigator’s brochures (IB) 
[GlaxoSmithKline Document Number RM2009/[ZIP_CODE]/07] and [GlaxoSmithKline 
Document Number RM2006/[ZIP_CODE]/09] and in the label information sheets. The current 
safet y profile for UMEC (62.5mcg) and the UMEC/VI  (62.5/25mcg) based on data 
available to date, is comparable with other LABAs and LAMAs.  Summary  safet y data 
can also be found in the information sheet for salmeterol [ Serevent product information , 
2003] .The following section outlines the risk assessment and mitigation strategy for this 
protocol:  2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
234.6.1. Risk A ssessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP) [UMEC/VI] 
Seve re milk protein allergy Anoro contains Lactose monohydrate (which contains milk 
protein) as an excipi[INVESTIGATOR_841].Exclusion criteria have been set for subjects with milk 
protein allergy.
Cardiovascular effects such as cardiac arrhythmias e.g.
supraventricular tachycardia and extrasystoles.Class effects associated with LABAs and LAMA containing 
therapy. The clinical significance of these arrhythmias is 
unknown. Clinical experience with UMEC/VI to date in 
completed studies did not show any association with major 
cardiovascular events. 
Data available in the product label for UMEC/VI Exclusion criteria have been set for subjects with 
uncontrolled or severe cardiovascular disease according to 
the principal investigation’s (PI) opi[INVESTIGATOR_645921]. The PI [INVESTIGATOR_645922].  Patients with the 
following abnormalities will be excluded fr om participation:  
atrial fibrillation with rapid ventricular rate >120bpm, 
sustained or nonsustained ventricular tachycardia, or 
second degree heart block Mobitz type II or third degree 
heart block (unless pacemaker or defibrillator had been 
inserted). 
Beta agonists and risk of asthma -related death Long -acting beta agonists such as vilanterol when used 
alone may increase the risk of asthma -related death.  A 
placebo -controlled trial with another LABA (salmeterol) 
showed an increase in asthma -related death s in subjects 
receiving salmeterol.  This finding with salmeterol is 
considered a class effect of all LABAs, including vilanterol. 
Data are not available to determine whether the rate of death 
in patients with COPD is increased by [INVESTIGATOR_140413].Subjects with a cur rent diagnosis of asthma are excluded 
from participation in the study.
Paradoxical bronchospasm As with other inhaled medicines, UMEC/VI can produce 
paradoxical bronchospasm which may be life threatening.If paradoxical bronchospasm occurs following dosin g with 
UMEC/VI, this treatment should be discontinued 
immediately and alternative therapy should be instituted. 
Use in patients with narrow -angle glaucoma or urinary 
retentionNo association has been found to date, in completed studies 
with UMEC/VI or UM EC monotherapy, on glaucoma or 
urinary retention.  However, glaucoma or urinary retention Exclusion criterion states that subjects with medical 
condition s such as narrow -angle glaucoma, prostatic 
hypertrophy, or bladder neck obstruction should only be  
 
 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
24Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
have been observed with other antimuscarinic agents, and 
could potentially be due to the pharmacology.included if, in the opi[INVESTIGATOR_14371], the 
benefit outweighs the risk.
Use of beta blockers Beta-adrenergic blockers may weaken or antag onize the 
effect of beta 2-agonists such as vilanterol.The study permitted medications and non drug therapi[INVESTIGATOR_645923] -
blockers is only permitted if, in the Investigator’s opi[INVESTIGATOR_1649], 
the likely benefit outweigh s the potential risk.
Pregnancy There is no experience to date of pregnancy during the use 
of UMEC/VI.The study inclusion criteria ensures that female subjects of 
child bearing potential must have a negative pregnancy 
test at screening, and agree to a re liable contraceptive 
method, used consistently and correctly (i.e. in accordance 
with the approved product label and the instructions of the 
physician for the duration of the study). Exclusion criteria 
include Pregnancy: Women who are pregnant or lactating
or are planning on becoming pregnant during the study.
Severe hepatic impairment UMEC/VI has not been studied in severe hepatic impairment. Exclusion criterion states that subjects severe hepatic 
impairment should only be included if, in the opi[INVESTIGATOR_1101] t he 
study physician, the benefit outweighs the risk.
Investigational product (IP) [UMEC]
Cardiovascular effects such as cardiac arrhythmia, e.g. 
atrial fibrillation and tachycardiaA potential class effect associated
with anti -muscarinic therapi[INVESTIGATOR_014]. Data a vailable to date in the 
IB for UMEC [GlaxoSmithKline Document Number 
RM2006/[ZIP_CODE]/09Screening electrocardiogram (ECG) criteria to exclude 
subjects potentially at risk 
Narrow -angle glaucoma, urinary retention A class effect associated with anti -muscarinic therapi[INVESTIGATOR_014].
Data available in the IB for UMEC [GlaxoSmithKline 
Document Number RM2006/[ZIP_CODE]/09Exclusion criterion states that subjects with medical 
conditions such as na rrow-angle glaucoma, prostatic 
hypertrophy, or bladder neck obstruction should only be 
included if, in the opi[INVESTIGATOR_9764], the benefit 
outweighs the risk.
Paradoxical bronchospasm that may be life threatening Known effect associated with i nhalation therapy A short -acting inhaled bronchodilator 
(albuterol/salbutamol) will be provided for use as needed 
throughout the study. The investigators will be instructed to 
assess subject’s condition to determine their eligibility to  
 
 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
25Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
continue in the stu dy and the need for alternative therapy.
Severe hepatic impairment UMEC has not been studied in severe hepatic impairment. Exclusion criterion states that subjects with severe hepatic 
impairment should only be included if, in the opi[INVESTIGATOR_564989], the benefit outweighs the risk.
Pregnancy/Lactation There is no experience to date of pregnancy during the use 
of UMEC.The study inclusion criteria ensure that female subjects 
enrolled, who are of Child bearing potential, have a 
negative pregnancy test at screening, and agree to a 
reliable contraceptive method, used consistently and 
correctly (i.e. in accordance with the approved product 
label and the instructions of the physician for the duration 
of the study). Exclusion criteria states -Pregnanc y: 
Women who are pregnant or lactating or are planning on 
becoming pregnant during the study.
Study Procedures
Spi[INVESTIGATOR_645924], changes in pulse rate 
and blood pressure, coughing, wheezing, chest tightness or 
fainting.Subjects will be monitored during the procedure for these 
effects and spi[INVESTIGATOR_645925].
ECG lead placement This may cause skin irritation. It may be necessary to have small patches (about a 
centimetre in diameter) of hair on the chest shaved to 
properly attach electrodes to the chest. 
Blood sampling procedure (optional pharmacogenetic 
blood sample)Giving blood may make subjects feel faint, or experience 
mild pain, bruising, irritation or redness at the site. In rare 
cases, they may get an infectionSubjects will be monitored during the blood draw for these 
effects and should call their study doctor if any of these 
effects do not resolve
Other 
Side effects of rescue albuterol/salbutamol. Adverse 
events seen in clinical studies to date are however 
consistent for the beta 2-adrenergic class of compoundsClass effects associated with short acting beta -agonists 
(SABAs)Subjects should call their study doctor if they experience 
any of these symptoms 
 
 2018N377698_00
2016N277425_03 CONFIDENTIA L
[ADDRESS_864801] to PROs and sy mptoms in the treatment of COPD.
Specific benefits associated with the study  design and procedures include the following:
Subjects will receive treatments approved for the treatment of COPD that have 
been show n to be effective in the population under study
All subjects will receive albuterol/salbutamol for use “as needed” for relief of 
COPD sy mptoms
The combination of study procedures of spi[INVESTIGATOR_038] , CAT, SGRQ, TDI, E-RSwill 
provide the study  subjects with a co mprehensive evaluation of their s ymptoms, 
health status and COPD disease severity . Subjects will also be monitored 
throughout the stud y for any worsening of COPD symptoms or decline in general 
health.  Finall y smoking cessation counselling will also be pro vided.
4.6.3. Overall Benefit: Risk Conclusion
Taking into account the measures taken to minimize risk to subjects participating in this 
study , the potential risks identified in association with UMEC/VI , UMEC, salmeterol and 
with study  procedures are justified by [CONTACT_645998].
5. SELECTION OF STUDY P OPULA TION A ND 
WITHDRA WAL CRITERIA
Specific information regarding warnings, precautions, contraindications, adverse events, 
and other pertinent information on the [COMPANY_004] investigational product or other study  
treatment that may  impact subject eligibility  is provided in the IBs, [ GlaxoSmithKline 
Document Number RM2006/[ZIP_CODE]/09], [ GlaxoSmithKline Document Numbe r 
RM2009/[ZIP_CODE]/0
7] and product labels.
Deviations from inclusion and exclusion criteria are not allowed because they can 
potentially  jeopardize the scientific integrity  of the study , regulatory  acceptability  or 
subject safet y. Therefore, adherence to the criteria as specified in the protocol is essential.
5.1. Inclusion Criteria
French subjects : In [LOCATION_009], a subject will be eligible for inclusion in this study  only if 
either affiliated to or a beneficiary  of a social sec urity  category .
A subject will be eligible for inclusion in this study onl y if all of the following criteria 
apply : 2018N377698_00
2016N277425_03 CONFIDENTIA L
[ADDRESS_864802] AND DIAGNOSI S INC LUDING DISEASE SEVERI TY
2.Outpatient with a di agnosis of COPD in accordance with the definition of the 
American Thoracic Society /European Respi[INVESTIGATOR_21618]  (ATS/ERS) [ Celli , 2004]. 
3.FEV 1: Persistent airflow limitations as indicated by :  A pre and post -
albuterol/ salbutamol FEV 1/FVC ratio of <0.[ADDRESS_864803] -albuterol/salbutamol FEV 1
of ≥30% to ≤80% predicted normal values at Screening Visit 1.  Predicted values 
will be based upon the ERS Global L ung Function I nitiative [ Quanjer , 2012].
4.CAT score :  A CAT score of ≥10 at Screening Visit 1
Smoki ng History
5.Current or former cigarette smokers with a history  of cigarette smoking of 10 
pack -years [number of pack years = (number of cigarettes per day  / 20) x number of 
years smoked (e.g. 20 cigarettes per day  for 10 y ears, or 10 cigarettes per day  for 20 
years both equal 10 pack -years)].  Former smokers are defined as those who have 
stopped smoking for at least 6 months prior to Visit 1.  Pi[INVESTIGATOR_23887]/or cigar use cannot 
be used to calculate pack -year history .
SEX
6.Male and female subjects are eligible to participate in the study
A female subject is eligible to participate if she is not pregnant (as confirmed by  a 
negative urine human chorionic gonadotrophin (hCG) test), not lactating, and at least one 
of the following conditions applies:
a.Non-reproductive potential defined as:
Pre-menopausal females with one of the following:
Documented tubal ligation
Documented h ysteroscopic tubal occlusion procedure with follow -up 
confirmation of bilateral tubal occlusion 
Hysterectomy
Documented Bilateral Oophorectom y
Postmenopausal defined as 12 months of spontaneous amenorrhea.  In questionable cases 
a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels 
consistent with menopause must be tested.  Females on hormone replacement therap y 
(HRT) and whose menopausal status is in doubt will be required to use one of the highl y 
effective contraception methods if they  wish to continue their HRT during the study .   2018N377698_00
2016N277425_03 CONFIDENTIA L
[ADDRESS_864804] of Highl y Effective Methods for Avoiding Pregnancy in Females of 
Reproductive Potential (FRP) ( Appendix 7 ) from [ADDRESS_864805] dose of 
study  medication and until [at least five terminal half- lives OR until any  continuing 
pharmacologic effect has ended, whichever is longer] after the last dose of study  
medication and completion of the follow- up visit.
The investigator is responsible for ensuring that subjects understand how to properl y use 
these methods of contraception.
INFORMED CONSENT
7.Capable of giving signed informed consent prior to study  participation, which 
includes compliance with the requirements and restrictions listed in the consent form 
and in this protocol.
5.2. Exclusion Criteria
A subject will not be eligible for inclusion in this study  if an y of the following criteria 
apply :
CONCURRENT CONDITIONS/MEDI CAL  HISTORY (INCLUDES LIV ER 
FUNCTION 
1. Asthma :  A current diagnosis of asthma.  (Subjects with a prior history  of asthma 
are eligible if they  have a current diagnosis of COPD, which is the primary cause of 
their respi[INVESTIGATOR_23908]).
2. Alpha -antitrypsin deficiency: Subjects with known α1-antitry psin deficiency  as 
the underl ying cause of COPD
3. Other respi[INVESTIGATOR_17744]: Subjects with active tuberculosis are excluded. 
Subjects with other respi[INVESTIGATOR_146456] (e.g. clinically  significant: 
bronchiectasis, sarcoidosis, lung fibrosis, pulmo nary hypertension, interstitial 
lung diseases) are excluded if these conditions are the primary cause of their 
respi[INVESTIGATOR_23908].
4. Unstable liver disease: Current active liver or biliary  disease (with the exception 
of Gilbert’s s yndrome or asymptomatic g allstones or otherwise stable chronic 
liver disease per investigator assessment). 
Stable chronic liver disease should generally  be defined by  [CONTACT_107415], 
encephalopath y, coagulopathy, h ypoalbuminaemia, oesophageal or gastric 
varices, or persis tent jaundice, or cirrhosis.
Chronic stable hepatitis B and C ( e.g., presence of hepatitis B surface antigen 
(HBsAg) or positive hepatitis C antibody  test result or within [ADDRESS_864806] dose of study  treatment) are acceptable if subject otherwise meets entry   2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
29criteria
5. Unstable or life threatening cardiac disease: Investigational Product should be 
used with caution in subjects with severe cardiovascular disease.  In the opi[INVESTIGATOR_8574], use should only  be considered if the benefit is lik ely to 
outweigh the risk in conditions such as:
Myocardial infarction or unstable angina in the last 6 months
Unstable or life threatening cardiac arrh ythmia requiring intervention in the last 3 
months
NYHA Class IV heart failure
6. 12 Lead ECG: The Investiga tor will determine the clinical significance of each 
abnormal ECG finding in relation to the subject’s medical history  and exclude 
subjects who would be at undue risk by  [CONTACT_19212]. Subjects with the 
following abnormalities are excluded fro m participation in the study :
Atrial fibrillation with rapid ventricular rate >120 bpm
Sustained or non -sustained ventricular tach ycardia
Second degree heart block Mobitz ty pe II or third degree heart block (unless 
pacemaker or defibrillator had been inser ted)
7. Antimuscarinic effects:   Subjects with medical conditions such as narrow -angle 
glaucoma, urinary  retention, prostatic hy pertrophy, or bladder neck obstruction 
should be excluded unless, in the opi[INVESTIGATOR_23942], the benefit 
outweighs the risk.
8. Other disease abnormalities: Any subject who is considered unlikel y to survive 
the duration of the stud y period or has an y rapi[INVESTIGATOR_2478] y progressing disease or 
immediate life-threatening illness (e.g. cancer). In addition, any  subject who has 
any other condition (e.g. neurological condition) that is likely  to affect respi[INVESTIGATOR_645926] .
9. Hospi[INVESTIGATOR_059]: Hospi[INVESTIGATOR_645927] 12 weeks prior 
to Visit 1. Pneumonia and/or moderate COPD exacerbation th at has not 
resolved at least [ADDRESS_864807] dose of oral/s ystemic corticosteroids (if applicable). 
10. Inhaled corticosteroids (ICS): Had received ICS or I CS/LABA for the treatment 
of COPD in the 6 w eeks prior to Screening Visit 1
11. Exacerbation: Had >[ADDRESS_864808] 7 days prior to 
Screening V1.
13. Lung Resection: Subjects with lung volume reduction surgery  (including 
procedures such as endobronchial valves) within the 12 months prior to Screening 
V1.
14. Oxygen: Use of long -term oxy gen therap y (LTOT) described as resting oxy gen  2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
30therap y >3L/min at screening required to maintain adequate ox ygenation ( e.g. 
SaO2>90%). (Ox ygen use ≤3L/min flow is not exclusionary , and patients may  
adjust oxy gen levels up or down as needed during the study .)
CONCOMI TANT MEDICATIONS
15. Medications prior to Screening: Use of the following medications according to 
the following define d time intervals prior to Screening (Visit 1) or during the 
study :
Medication No use within the 
following time intervals 
prior to Screening and
thereafter at any time 
during the study
Inhaled corticosteroids (ICS) 6 weeks
Depot corticosteroids 12 weeks
Systemic, oral or parenteral corticosteroidsa 6 weeks
Antibiotics (for lower respi[INVESTIGATOR_1092]) 6 weeks
Phosphodiesterase 4 (PDE 4) Inhibitor ( e.groflumilast) 14 days
LABA/Inhaled Corticosteroid (ICS) combination products 6 weeks
LABA/LAMA c ombination products 2 weeks
Theophyllines 48 hours
Oral beta 2-agonists
     Long- acting
     Short -acting48 hours
12 hours
Inhaled short acting beta 2-agonistsb 4 hours
Inhaled short -acting anticholinergics 4 hours
Inhaled short -acting anticholinergi c/short -acting beta 2-agonist 
combination products4 hours
Any other investigational medication 30 days or within 5 drug 
half-lives (whichever is 
longer)
a- Corticosteroids are allowed for the treatment of COPD exacerbations during the double -blind treatment
phase of the study. Localized corticosteroid injections (e.g., intra -articular and epi[INVESTIGATOR_13873]) are permitted.
b- Use of study provided albuterol/salbutamol is permitted during the study, except in the 4 -hour period prior to 
spi[INVESTIGATOR_68333]
16. Medication prior to spi[INVESTIGATOR_038]: Unable to withhold albuterol/salbutamol for 
the [ADDRESS_864809]’s inhaled LABA or LAMA COPD 
medication prior to spi[INVESTIGATOR_645928] (Visit 1).
17. Maintenance use of short -acting bronchodilators :  Regular use (prescribed for 
daily / regular use, not for as -needed use) of short -acting bronchodilators ( e.g. 
albuterol/salbutamol).
REL EVANT HABITS
18. Drug or alcohol abuse: A known or suspected history  of alcohol or drug abuse 
within [ADDRESS_864810] from completing the study procedures.
CONTRAINDICATIONS 
19. Any history of allergy or hypersensitivity to any anticholinergic/muscarinic 
receptor antagonist, s ympathomimetic, lactose/milk protein or magnesium 
stearate.
DIAGNOSTIC ASSESSMENTS AND OTHER CRI TERIA
20. Pulmonary Rehabilitation program: Participation in the acute phase of a 
pulmonary  rehabilitation p rogram within 4 weeks prior to Screening Visit 1.  
Subjects who are in the maintenance phase of a pulmonary  rehabilitation program 
are not excluded.
21. Affiliation with investigator sites: Is an investigator, sub -investigator, study  
coordinator, emplo yee of a participating investigator or study  site, or immediate 
family  member of the aforementioned that is involved in this study
22. Inability to read: In the opi[INVESTIGATOR_871], any  subject who is unable to 
read and/or would not be able to complete questio nnaires on the electronic diary .
Subjects who fail to meet inclusion and exclusion criteria at the Screening Visit [ADDRESS_864811] fulfilled all inclusion and exclusion criteria 
described in Section 5.1and Section 5.2. In addition to the following:
REQUI RED CRI TERIA FOR RANDOMIZATION AND TREATMENT
1.COPD Exacerbation : Subjects must nothave experienced a moderate or severe 
COPD exacerbation or a lower respi[INVESTIGATOR_626201] -in or at Day  1 
(Visit 2) inclusi ve.  A moderate exacerbation is defined as worsening of s ymptoms of 
COPD requiring the use of antibiotics or sy stemic corticosteroids.  A severe 
exacerbation is defined as worsening sy mptoms of COPD requiring hospi[INVESTIGATOR_059].
2.CAT score :  A CAT score of ≥10at Visit 2
3.Prohibited Medications: No use of an y prohibited medications during the run -in 
period or at Visit 2, including an y ICS or ICS/LABA combination . Subject’s inhaled 
LABA orLAMA medication morning dose must be withheld and discontinued at 
Visit 2.
4.Any change to COPD medications: Including dosage and regimen during the run -in
5.Completion of electronic diary: Must have completed the electronic diary for at 
least 80% of day s during the run- in period 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
32Subjects who do not meet the required criteria for randomization at Visit 2 will not be 
randomized.
5.4. Screening/Baseline/Run-in Failures
Pre-screen, screen and run -in failures are defined as follows: 
Pre-screening failures: A subject, who is assigned a subject number at the Pre -
screening Visit [ADDRESS_864812] an y Screening Visit 1 procedures, will be 
considered a pre -screen failure.
Screening failures: Those subjects that complete at least one Screening Visit 1 
procedure but do not enter the run -in period.
Run-in failures: Those subjects that enter the run-in period but are not randomized 
to any  of the study  treatment arms.
Subjects who are pre -screen, screen and run -in failure will be recorded in the eCRF.  In 
order to ensure transparent reporting of screen failure subjects, meet the Consolidated 
Standa rds of Reporting Trials (CONSORT) publishing requirements, and respond to 
queries from Regulatory  Authorities, a minimal set of screen failure information is 
required to be recorded in eCRF including demograph y, screen failure details, eligibility  
criteria , and serious adverse events (Section 7.4.1 ). 
5.5. Withdrawal/Stoppi[INVESTIGATOR_2121]
5.5.1. Withdrawal from the Study
Subjects may  be withdrawn from the study  at an y time by  [CONTACT_645999] l for them to continue in the study .  Reasons for withdrawal 
from study  treatment can include: an AE, clinically  significant abnormality, lack of 
efficacy , sponsor terminated study , pregnancy , or for any  other reason. 
If a subject withdraws from the study , he/she may request destruction of any  samples 
taken, and the investigator must document this in the site study  records . 
A reason for the withdrawal from the study  must be captured in the electronic case report 
form (eCRF).
Stoppi[INVESTIGATOR_2121]
A subject mu stbe withdrawn from the stud y, in consultation with the medical monitor 
and principal investigator, if any of the following stoppi[INVESTIGATOR_23893]:
Liver Chemistry: Meets any  of the Liver chemistry  stoppi[INVESTIGATOR_3418] (See Section 
5.5.3 )
Note: clinical laboratory  assessments are not required for this study . However, 
laboratory  samples may  be taken for liver event analy sis, if clinicall y indicated b y 
the study  investigator.
Pregnancy:   Positive pregnancy  test ( see Appendix 7 ) 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
33Unstable or life threatening cardiac events :myocardial infarction, hospi[INVESTIGATOR_81076], stroke, and other cardiovascular events considered life -or 
intensively  health -threatening by  [CONTACT_646000].
COPD Exacerbations: Subjects with two moderate or one severe COPD 
exacerbation during the study .
Withdrawal from study treatment requires withdrawal from the study .
Non-Compliance with Study treatment : Subjects’ compliance with stud y trea tment 
will be assessed at each study  visit. Subjects who are non- compliant should be re -
educated on the requirement for treatment compliance. Every  effort will be made to 
keep subjects in the study  and to re -educate those subjects who continue to be non -
compliant.  Subjects who continue to be non -compliant after m ultiple visit 
assessments may  be permanently  discontinued after consultation with the [COMPANY_004] 
clinical team. 
Non-Compliance with eDiar y:  Subjects must be compliant in completing their 
eDiary  betwee n each pair of on-treatment visits.  Subjects who are non- compliant 
should be re -educated on the requirement for dail y diary entry  compliance . Subjects 
who continue to be non -compliant after multiple visit assessments may  be 
permanentl y discontinued after consultation with the [COMPANY_004] clinical team.
Subjects withdrawn from study  treatment will not be replaced. 
The following actions must be taken in relation to a subject who fails to attend the clinic 
for a required stud y visit:
The site must attempt to contact [CONTACT_131993]- schedule the missed visit as 
soon as possible. 
The site must counsel the subject on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the subject wishes to and/or should 
continue in the study . 
In cases where the subject is deemed ‘lost to follow up’, the investigator or 
designee must make every effort to regain contact [CONTACT_1155] (where 
possible, [ADDRESS_864813]’s last 
known mailing address or local equivalent methods). These contact [CONTACT_131994]’s medical record. 
Should the subject continue to be unreachable, only then will he/she be considered 
to have withdrawn from the study  with a primary  reason of “Lost t o Follow -up”. 
5.5.2. Reason for Study  Withdrawal
The primary  reason for study  withdrawal will be recorded in the eCRF. When a subject 
withdraws consent, the investigator must document the reason (if specified by  [CONTACT_1560]) in the eCRF. 
The primary  reason for study  withdrawal may  include:
Adverse event 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
34Lost to follow -up
Withdrew consent
osubject relocated
ofrequency  of visits
oburden of procedures
oother (specify )
Protocol deviation
Lack of efficacy
COPD exacerbation
Study  closed/terminated
Subject reached protocol -defined stoppi[INVESTIGATOR_3418]
Pregnancy
Investigator discretion
5.5.3. Liver Chemistry Stoppi[INVESTIGATOR_131957] y and evaluate liver event etiology (in alignment with the F DA 
premarketing clinical liver safety  guidance). 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf
Phase III -IV Liver Chemistry Increased Monitoring Algorithm with Continued 
Therapy for ALT 3xULN but <8xULN
Cont inue Study Treatm ent   and   Monitor  Liver Chem istry
Discontinue Study Treatment ALT≥5xULN 
but <8xULN
+ bili<2xULN +
no symptoms
NoMust  refer to Liver Safety Requi red Actions and Fol low up Asses smen ts section in the Appendi x
YesALT ≥3xULN 
but <5xULN
+ bili<2xULN  +
no symptomsAble to 
monitor  
weekly 
for  ≥2 
weeksPersists for 
≥2 weeks  
or other  
stoppi[INVESTIGATOR_53099]  ≥4 
weeksPersists for 
≥4 weeks  
or other  
stoppi[INVESTIGATOR_131958] ≥5xULN ALT <5xULN 
Yes Yes
*INR value not applicable to subjects on anticoagulants Must  refer to Liver Safety Requi red Actions and Fol low up Asses sments section in the Appendi x
Repor t as an SAE if possible Hy’sLaw case:  ALT≥3xUL N and  Bilirubin≥2x ULN (>35% direct)  or 
INR>1.5, if measur ed* 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
35Liver Safet y Required Actions and Follow up Assessments Section can be found in 
Appendix 2 .
[IP_ADDRESS]. Study  Treatment Restart or Rechallenge
Study  treatment restart or rechallenge after liver chemistry  stoppi[INVESTIGATOR_109367] m et by 
[CONTACT_428207].
5.6. Follow -up contact
A safet y follow- up contact (Visit 6) should be conducted 7 3days following the 
completion of Visit 5 or the Earl y Withdrawal Visit, if applicable. 
The following procedures wi ll be performed:
AE/SAE assessment
COPD exacerbation assessment
Concomitant medication assessment limited to any  medications used to treat a 
COPD exacerbation or SAE (if applicable)
Pregnancy  information (if applicable)
Subjects who have successfully  compl eted all on -treatment randomized visits will be 
discharged from the study upon completion of the safet y follow- up contact.
5.7. Subject and Study  Completion
A subject will be considered to have completed the study  if he/she receives study  
treatment at Visit 5 ( Week 24) and completes the follow -up contact [CONTACT_4838] 6.
The end of the stud y is defined as the last subject’s last visit. 
6. STUDY TREA TMENT
6.1. Investigational Product and Other Study  Treatment
The term ‘stud y treatment’ is used throughout the protocol to describ e any  combination 
of products received b y the subject as per the protocol design.  Stud y treatment may 
therefore refer to the individual study  treatments or the combination of those study  
treatments.
The contents of the label will be in ac accordance with a ll applicable regulatory  
requirements.
Under normal conditions of handling and administration, investigational product is not 
expected to pose significant safet y risks to site staff.  Take adequate precautions to avoid 
direct ey e or skin contact [CONTACT_646001]. Notify  the monitor of 
any unintentional occupational exposure.  A Material Safet y Data Sheet (MSDS) 
describing the occupational hazards and recommended handling precautions will be  2018N377698_00
2016N277425_03 CONFIDENTIA L
[ADDRESS_864814] 
be dispensed or administered onl y to subjects enrolled in the study  and in accordance 
with the protocol.
GlaxoSmithKline ([COMPANY_004]) will provide the study  treatments for use in this study . 
The following stud y medications will be used in this study :
UMEC/VI  62.5/ 25mcg administered via ELLIPTA
UMEC 62.5 mcg administered via ELLIPTA
Salmeterol 50 mcg administered via DISKUS
Placebo via ELLIPTA
Placebo via DISKUS
Subjects will be instructed to take one dose of medication each morning from the 
ELLIPTA (one inhalation equals one dose), and one dose in the morning and one in the 
evening from the DI SKUS.  Subject instructions and details on how to use the ELLIPTA 
andDISKUS are provided in the stud y reference manual (SRM).
A description of the UMEC/VI  investigational product administered via the ELLIPTA is 
provided below in Table 1. The ELLIPTA will contain two, double -foil, laminate, blister 
strips.  The EL LIPTA will provide a total of 30 doses (60 blisters) and will deliver, when 
actuated, the contents of a single blister simultaneously  from each of the two blister 
strips. 
The DISKUS will provide a total of [ADDRESS_864815] administered via the ELLIPTA is 
provided below in Table 2. A description of placebo inhalation powder via ELLIPTA is 
shown in Table 3.  A description of salmeterol 50mcg and placebo via DISKUS are 
shown in Table 4 and Table 5respectively .
Table 1 Description of UMEC/VI Inhalation Powder via ELLIPTA
Formulation First strip Second strip
Umeclidinium bromide blended with 
lactose monohydrate and 
magnesium stearate1Vilanterol trifenatate blended with 
lactose monohydrate and magnesium 
stearate2
Dosage Form ELLIPTA Inhaler with 30 doses (2 strips with 30 blisters per strip)
Unit Dose Strengths 62.5 mcg 25 mcg
Physical description White powder White powder
Route of Administration Inhaled
1. Magnesium stearate 0.6% w/w of total drug product
2. Magnesium stearate 1.0% w/w of total drug product 2018N377698_00
2016N277425_03 CONFIDENTIA L
[ADDRESS_864816] strip
Umeclidinium bromide blended with lactose monohydrate and 
magnesium stearate1
Dosage Form ELLIPTA Inhal er with 30 doses (1 strip with 30 blisters) 
Unit Dose Strengths 62.5mcg 
Physical description Dry white powder
Route of Administration Inhaled
1. Magnesium stearate 0.6% w/w of total drug product
Table [ADDRESS_864817] strip Second strip
Lactose monohydrate blended with 
magnesium stearate1Lactose monohydrate blended with 
magnesium stearate2
Dosage Form ELLIPTA Inhaler with 30 doses (2 strips with 30 blisters per strip)
Unit Dose Strengths Not applicable Not applicable
Physical description Dry white powder Dry white powder
Route of Administration Inhaled
1. Magnesium stearate 0.6% w/w of total drug product
2. Magnesium stearate 1% w/w of total drug product
Table [ADDRESS_864818] strip
Salmeterol Xinafoate blended with lactose monohydrate
Dosage Form Diskus Inhaler with 60 doses (1 strip with 60 blisters per strip)
Unit Dose Strengths 50 mcg
Physical description White powder
Route of Administration Inhaled
Table 5 Description of Placebo inhalation powder via DISKUS
Formulation Lactose monohydrate 
Dosage Form Diskus Inhaler with 60 doses (1 strip with 60 blisters per strip)
Unit Dose Strengths Not Applicable
Physical description White powder
Route of Administration Inhaled
Albuterol/salbutamol via metered -dose-inhaler (MDI) will be issued for reversibility  
testing at Visit 1.  Albuterol/salbutamol MDI  for as needed (prn) use will be issued 
throughout the study.  Albuterol/salbutamol will be sourced from local commercial stock 
if appropriate.  
6.2. Medical Devices
The eMDI devices are provided by  [CONTACT_646002].  They  have US FDA 510(K) clearance to market (Class  2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
38II device) and EU CE mark eting (Class I device). Description of the eMDI and its use 
will be provided in the SRM .
6.3. Treatment A ssignment
Subjects who meet the randomization criteria will be assigned to one of the [ADDRESS_864819] is 24 weeks.  On the morning of each clinic 
study  visit, subjects will refrain from taking their morning dose of study  treatment until 
instructed to do so by  [CONTACT_6477].  On the other day s during the treatment period 
(i.e. “non- clinic day s”), s ubjects will be instructed to self -administer their study  treatment 
in the morning and evening . Subjects should enter the time they  take their study  treatment 
in the eDiary . 
Subjects will be randomly assigned to one of the blinded study  treatment regimens in 
equal proportion (ratio of 1:1:1):
UMEC/VI  62.5/25 mcg once dail y via ELLIPTA + placebo twice dail y via 
DISKUS
UMEC 62.5 mcg once daily  via ELLIPTA + placebo twice dail y via DISKUS
Salmeterol 50 mcg twice daily  via DI SKUS + placebo once daily  via ELLIPTA
The randomisation will be stratified based on long-acting bronchodilator usage during 
the run- in (none or one long-acting bronchodilator per day ).
Study  treatment/investigational product will be dispensed at Visits 2, [ADDRESS_864820] return to 
clinic within 30 day s from V2 and 60 day s from V3 respectively  (see Time and event 
table Section 7.1). 
Used study  drug and rescue medication will be collected at Visits 3, [ADDRESS_864821] ment is allowed for this study 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
396.5. Blinding
This will be a double- blind double dummy  study  and the following will apply . 
The investigator or treating ph ysician may  unblind a subject’s treatment 
assignment only in the case of an emergency OR in the event of a serious 
medical condition when knowledge of the stud y treatment is essential for the 
appropriate clinical management or welfare of the subject as judged b y the 
investigator. 
Investigators have direct access to the subject’s individual study  treatment. 
Itis preferred (but not required) that the investigator first contacts the Medical 
Monitor or appropriate [COMPANY_004] study  personnel to discuss options before unblinding 
the subject’s treatment assignment. 
If [COMPANY_004] personnel are not contact[CONTACT_222201], the investigator must 
notify  [COMPANY_004] as soon as possible after unblinding, but without revealing the 
treatment assignment of the unblinded subject, unless that information is 
important for the safety  of subjects currently  in the study . 
The date and reason fo r the unblinding must be fully  documented in the eCRF 
A subject will be withdrawn if the subject’s treatment code is unblinded b y the 
investigator or treating phy sician. [COMPANY_004]’s Global Clinical Safety  and Pharmacovigilance 
(GCSP) staff may  unblind the treat ment assignment for any  subject with an SAE. If the 
SAE requires that an expedited regulatory  report be sent to one or more regulatory  
agencies, a cop y of the report, identifying the subject’s treatment assignment, may  be sent 
to investigators in accordanc e with local regulations and/or [COMPANY_004] policy .
6.6. Packaging and Labeling
The contents of the label will be in accordance with all applicable regulatory  
requirements.
6.7. Preparation/Handling/Storage/A ccountability
No special preparation of the study  treatment is req uired.
The investigator or designee must confirm appropriate temperature conditions 
have been maintained during transit for all study  treatment received and any  
discrepancies are reported and resolved before use of the study  treatment.
Only  subjects enroll ed in the study  may  receive study  treatment and onl y 
authorized site staff may  supply  or administer study  treatment.  All study  
treatments must be stored in a secure environmentally  controlled and monitored 
(manual or automated) area in accordance with the labelled storage conditions 
with access limited to the investigator and authorized site staff. 
The investigator, institution, or the head of the medical institution (where 
applicable) is responsible for study  treatment accountability , reconciliation, and
record maintenance (i.e. receipt, reconciliation and final disposition records).   2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
40Further guidance and information for final disposition of unused study  treatment 
are provided in the SRM. 
All ELLIPTA DPI [INVESTIGATOR_645929] 25 C (77 F).  Each 
ELLIPTA DPI [CONTACT_468929] [ADDRESS_864822]. 
Salmeterol DI SKUS should be stored up to 25 C. 
Under normal conditions of handling and administration, study  treatment is not 
expected to pose significant safety risks to site staff .  Take adequate precautions to 
avoid direct ey e or skin contact [CONTACT_23968]. In the case of 
unintentional occupational exposure notify  the monitor, Medical Monitor and/or [COMPANY_004] 
study  contact.
A Material Safety  Data Sheet (MSDS)/equivalent document describing 
occupational hazard s and recommended handling precautions either will be 
provided to the investigator, where this is required by [CONTACT_1207], or is available 
upon request from [COMPANY_004].
6.7.1. Study Treatment Return
All used and unused ELLIPTA and DISKUS inhalers and albuterol/salbutamol will be 
returned to [COMPANY_004] at the end of the study  to be available for disposal.  In some instances 
for sites outside the US, study  supplies will be disposed of locall y either b y the site, the 
country  medical department or third -party vendor.  Detailed instr uctions for the return of 
the study  drug can be found in the SRM.
Study  treatment will be collected at Visit 3, [ADDRESS_864823] and dispense a new 
study  treatment kit from the site’s investigational product supply as instructed by  [CONTACT_646003], any  ELLIPTA that fails to function properly  must be identified and returned 
to [COMPANY_004] for testing. 
6.8. Compliance with Study  Treatment A dministration
When subjects self- administer study  treatment(s) at home , compliance with study  
treatment(s) will be assessed through query ing the subject during the site visits and 
through stud y drug compliance assessed at Visits 2, 3, [ADDRESS_864824] be maintained and reconciled with 
study  treatment and compliance records.  Treatment start and stop dates, including dates 
for treatment delay s if any  will also be recorded in the eCRF. 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
41Compliance with the ELLIPT A inhaler will be determined by  [CONTACT_646004].  Compliance with the study  DISKUS will be determined by  [CONTACT_646005].  Subjects should be ≥80% to ≤120% compliant on 
taking stud y medication between each pair of on -treatment visits.  Subjects who fall 
outside this range should be re -educated on treatment compliance b y their site. This re -
education should be documented in the subject’s source document.  If medication 
compliance repeatedly  falls outside of acceptable ranges, the stud y sponsor/site monitor 
must be contact[CONTACT_646006] .
6.9. Treatment of Study  Treatment Overdose
An overdose is defined as a dose greater than the total doses described in Se ction 6.1and 
Section 6.8which results in clinical signs and s ymptoms.  These should be recorded b y 
the investigator on the AE/SAE pages.  In the event of an overdos e of study  medication, 
the investigator should use clinical judgment in treating the overdose and contact [CONTACT_646007]. 
[COMPANY_004] is not recommending specific treatment guidelines for overdose and toxicity  
management.  The investigator is advised t o refer to the relevant document(s) for detailed 
information regarding warnings, precautions, contraindications, adverse events, and other 
significant data pertaining to the stud y drug being used in this study . Such documents 
may include, but may  not be li mited to, the approved product label for salmeterol 
albuterol, UMEC and UMEC/VI  or equivalent document provided by  [CONTACT_23983].
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_424359].
6.10. Treatment after the End of the Study
Subjects will not receive any additional treatment from [COMPANY_004] after completion of the 
study , since the stud y treatments are commercially available.
The investigator is responsibl e for ensuring that consideration has been given to the post -
study  care of the subject’s medical condition, post
-study  treatment. 
6.11. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_645930] 30 day s prior to Pre -Screening (Visit 0) and onwards 
should be recorded in the eCRF including an y changes in medications.  Beginning at 
Visit [ADDRESS_864825] of the stud y, all medications should be recorded in the 
eCRF including an y changes.  Stud y provided albuterol/salbutamol and double -blinded 
study  drug should notbe recorded in the eCRF.  The minimum requirement includes but 
is not limited to drug name, dose, route and the dates of administration.  Medications 
initiated after completion of Visit 5 or the Earl y Withdrawal Visit will not be recorded in 
the eCRF, with the exception of those used to treat a COPD exacerbation or SAE that 
occurs between Visit 5 (or the Early Withdrawal Visit) and the follow -up contact [CONTACT_293778] 
6. 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
426.11.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_645931] :
Study -provided albuterol/salbutamol for use as relief medication throughout the 
run-in and treatment periods 
Mucoly tics such as acet ylcysteine
Medications for rhinitis (e.g. intranasal corticosteroids, anti histamines, cromoly n, 
nedocromil, nasal decongestants)
Influenza vaccine
pneumococcal vaccine
Antibiotics for short term treatment ( 14 day s) of acute infections including  
COPD exacerbations
Systemic corticosteroids for short term ( 14 consecutive day s)  treatment of 
COPD exacerbations 
As-needed supplemental oxy gen use provided it is ≤3L/min flow at rest at 
screening.  Patients may  adjust oxy gen levels as needed during the stud y.
Pulmonary  rehabilitation program in maintenance phase
Smoking cessation treatment, including a stable regimen of nicotine replacement
Use of positive airway  pressure/non -invasive ventilation for sleep apnea/sleep 
disordered breathing ( e.g. CPAP, BiPAP) 
Localized corticosteroid injections (e.g., intra -articular and epi[INVESTIGATOR_13873])
Oral muscarinic antagonists for the tr eatment of overactive bladder are permitted 
but should be used with caution as they  may  exacerbate medical conditions that 
are contraindicated for anticholinergics (e.g., narrow angle glaucoma and bladder 
outflow obstruction)
Immunotherap y injections
Topic al or ophthalmic corticosteroids
Over -the counter (OTC) cough suppressants
Tricy clic antidepressants and monoamine oxidase inhibitors (MAOI s). Administer 
with caution as they  may potentiate the effect of beta -agonists on the vascular 
system
Diuretics. Caut ion is advised in the co -administration of beta agonists with non-
potassium sparing diuretics
Allergy  vaccination
All medications for other disorders as long as the dose remains constant whenever 
possible and their use would not be expected to affect lung function 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
436.11.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_417438] 6 is not permitted during the study
Table 6 Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_645932], oral or parenteral corticosteroids1
Inhaled corticosteroids (ICS)2
Antibiotics >14 days
LABA/ICS combination products
PDE4 inhibitor (e.g. roflumilast)
Inhaled long acting beta 2-agonists (LABA, e.g. salmeterol, f ormoterol, indacaterol, vilanterol)3
Long -acting muscarinic antagonists (LAMA, e.g. tiotropi[INVESTIGATOR_1890], aclidinium, glycopyrronium, umeclidinium)3
LAMA/LABA combination products except for study drugs
Theophyllines
Oral beta 2-agonists
Inhaled short acting bet a2-agonists4
Inhaled short -acting anticholinergics
Inhaled short -acting anticholinergic/short -acting beta 2-agonist combination products
Any other investigational medication
1 Except for the treatment of COPD exacerbations during the study. Localized cort icosteroid injections (e.g., 
intra-articular and epi[INVESTIGATOR_13873]) are permitted.
2 Except if during the study use of ICS is deemed necessary for the treatment of subjects’ exacerbation. 
3 Except for study drug
4 Use of study provided albuterol /salbutamol is permitted during the study, except in the 4 -hour period prior to 
spi[INVESTIGATOR_68333]. 
The following medications or treatments are also notallowed during the study :
Use of long -term ox ygen therap y (LTOT) described as resting ox ygen therapy 
>3L/min onl y at screenin g. Ox ygen may  be titrated to any  level deemed necessary  
during the stud y.
Regular use (prescribed for daily / regular use, not for as -needed use) of short -
acting bronchodilators ( e.g. albuterol/salbutamol)
Initiation of pulmonary  rehabilitation during the s tudy.
7. STUDY A SSESSMENTS A ND PROCEDURES
Protocol waivers or exemptions are not allowed with the exception of immediate safety  
concerns. Therefore, adherence to the stud y design requirements, including those 
specified in the Time and Events Table Section 7.1, are essential and required for stud y 
conduct.
This section lists the procedures and parameters of each planned study assessment.  The 
exact timing of each assessment is listed in the Time and Events Table Sect ion 7.1 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
447.1. Time and Events Table
Blinded Treatment
VisitPre-
screen1
0Screen/ 
Run-in
1Rando -
mization 
[ADDRESS_864826] 
6
Week -10to -4 -4 0 4 12 24
Day -70to -28 -28 1 28 84 1687 days after V5 or EW 
Visit
Window -7/+2 days -7/+2 days-7/+2 
days-7/+2 days -7/+2 days -7/+2 days 3days
Screen/Baseline
Informed consent X
Demography X
Medical/COPD history X
Smoking h istory/status X
Smoking cessation counselling X
Concomitant medication assessment X X X X X X X X
Height and weight X
Cardiovascular History/family history of premature CV 
disease])X
Screening sp irometry (including post bronchodilator 
testing )3X
CAT questionnaire X X
Verify Inclusion/Exclusion Criteria X
Training on use of inhalers X X
Training on use of eDiary and eMDI X X
Verify randomization Criteria X
Register Visit in InForm X X X X X X X X
Register Visit in RAMOS NG X X X X X X X X 
 
 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
45Blinded Treatment
VisitPre-
screen1
0Screen/ 
Run-in
1Rando -
mization 
[ADDRESS_864827] 
6
Week -10to -4 -4 0 4 12 24
Day -70to -28 -28 1 28 84 1687 days after V5 or EW 
Visit
Window -7/+2 days -7/+2 days-7/+2 
days-7/+2 days -7/+2 days -7/+2 days 3days
Efficacy/HRQoL assessments
Spi[INVESTIGATOR_038], including pre -dose FEV 1, trough  FEV 1and 
inspi[INVESTIGATOR_645933] X X X
SAC BD I questionnaire4 X
SAC TDI questionnaire4 X X X
SGRQ -C questionnaire [ADDRESS_864828]/ER -S: COPD 5
Patient Global Rating of COPD severity X X X X
Patient Global Rating o f Change in COPD X X X
Safety assessments
Adverse events/Serious adverse events6 X X X X X X X X
COPD exacerbation assessment X X X X X X X X
12-Lead ECG X
Urine pregnancy test 7 X X X X
Pharmacogenetic sample8                                             X
Medication/Supplies
Dispense rescue albuterol/slabutamol. Dispense MDI9 X X X X X
Assess COPD medication compliance10 during run -in X
Dispense eDiary X
Assess compliance w ith eDiary during run -in X
Collect rescue albuterol/slabutamol. X X X X X
Collect eDiary X X
Dispense study treatment11 X X X 
 
 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
46Blinded Treatment
VisitPre-
screen1
0Screen/ 
Run-in
1Rando -
mization 
[ADDRESS_864829] 
6
Week -10to -4 -4 0 4 12 24
Day -70to -28 -28 1 28 84 1687 days after V5 or EW 
Visit
Window -7/+2 days -7/+2 days-7/+2 
days-7/+2 days -7/+2 days -7/+2 days 3days
Collect study treatment X X X X
Assess study treatment compliance during treatment10 X X X X
Study sub -set
Physical activity monitor12 X X X X
Collect Physical activity monitor X X
1. Pre-screen Visit [ADDRESS_864830] be completed prior to Screening Visit1. It can be completed 6weeks prior or on the same day of V1, i f no wash out of exclusionary medications is 
required. 
2. Early Withdrawal Visit: Subjects that withdraw should return to the clinic as soon as possible to complete the Early Withdraw al Visit procedures.
3. Spi[INVESTIGATOR_645934] (Section [IP_ADDRESS] ). 
4. SAC BDI, SAC TDI, SGRQ- C, CAT questionnaires will be completed at clinic visits and in the eDiary
5. EXACT/ER -S: COPD is completed daily in the eDiary approximately 2 hours before bed -time, starting on Day 1 of the run -in period.
6. For the start date of collecting AEs and SAEs see ( Appendix 4 )
7. Pregnancy test: for females for child bearing potential only.
8. Pharmacogenetic sample may be drawn at visit [ADDRESS_864831] provide informed 
consent to the study  participant.  Subjects can perform the Pre- screening Visit (Visit 0) 
up to 6weeks prior to or on the same day  as the Screening Visit (Visit 1) if subject does 
not take or has not taken any  protocol excluded medications.
Modification of the subject’s medicati ons prior to study  participation is based on the 
physician’s judgment according to sound medical practice, principles, and each subject’s 
needs.  A subject’s treatment must not be changed merel y for the purpose of enabling the 
subject’s participation in th e study .  A subject number will be assigned at the time the 
informed consent form (ICF) is signed. No study related procedures may be 
performed until the informed consent form document has been signed by [CONTACT_1560].  
Once the informed consent is signed a nd if required, changes can be made to the subject’s 
current medication regimen. The investigator should exercise clinical judgment, and is 
discouraged from changing medications only  for the purpose of the clinical study . 
During the pre -screening Visit 0 , the following information is collected:
Demographic parameters: y ear of birth, gender, race and ethnicity
Concomitant medications review
COPD exacerbation assessment
From the pre -screening visit onwards concomitant medications, exacerbations and SAEs 
(considered as related to study  participation) must be reported
7.2.2. Critical procedures performed at Screening (Visit 1)
The following critical assessments will be conducted at Visit 1:
Cardiovascular medical history /risk factors (as detailed in the eCRF) will be
assessed at screening
Medical history  including COPD (including date of diagnosis and COPD ty pe 
(emphy sema and/or chronic bronchitis), smoking history , COPD exacerbation 
history , smoking status and previous and/or current medical conditions) 
Concomitant medication review (COPD and non COPD medications in the 3 
months prior to Screening).
Height and weight
12-Lead ECG. (Note: ECG is performed at screening Visit [ADDRESS_864832] for eligibility  
only. See Section 7.4.4). 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
48Urine pregnancy  test if applicable
Train subject on the use of eDiary
COPD assessment test (CAT) and patient global rating of COPD severit y in 
eDiary
Pre-and post -albuterol/salbutamol spi[INVESTIGATOR_038]  (reversibility , see Section [IP_ADDRESS] )
Inclusion/Exclusion criteria assessment
Review exacerbations, AEs, (SAEs if related to study  participation)
Train subject on the proper use of their COPD medication inhalation devices
Instruct subject to take their COPD medications a s instructed and to enter the time 
they take their medication in the eDiary
Dispense rescue medication
Medical history will be assessed as related to the inclusion/exclusion criteria listed in 
Section 5.1and Se ction 5.2.
Assessment of subject’s health status will be made at screening using CAT.  PRO 
questionnaires should be completed b y subjects before an y other assessments at a clinic 
visit, in the order specified in Section 7.3.1
[IP_ADDRESS]. Albuterol/Salbutamol Reversibility  Assessment
At Visit 1, both pre -and post -albuterol/salbutamol spi[INVESTIGATOR_645935] .  Reversibility  assessment should be performed as follows:
Perform pre -bronchodilator spi[INVESTIGATOR_645936] 1and FVC
Subject to self -administer 4 Inhalations (4X100 g) of albuterol/salbutamol MDI
Perform post -bronchodilator spi[INVESTIGATOR_645936] 1and FVC approximately  
10 to 30 minutes after albuterol/salbutamol administration
The results of the spi[INVESTIGATOR_645937]/ERS criteria [ Miller , 2005] for 
the subject to continue in the study .
7.2.3. Critical procedures performed at first treatment Visit ( Baseline 
V2)
Review and assess  compliance with subject’s COPD medications during the run -
in period
Review and assess compliance with completing the eDiary during the run -in 
period
Review AEs, SAEs and exacerbations 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
49Urine pregnancy  test, if applicable
Base line dy spnea Index, BDI, patient global rating of COPD severit y, patient 
global rating of change in COPD, SGRQ -C and CAT questionnaires in eDiary
Review randomization criteria (Section 5.3)
Register and randomiz e subject in RAMOS NG
Pre-dose spi[INVESTIGATOR_038] ; IC and FEV 1
Train subject on the proper use of ELLIPTA and DI SKUS inhalers
Dispense study  medication
Dispense rescue medication
Optional pharmacogentic sample can be collected at V2 or an y visit after.
7.3. Efficacy  Assessments
7.3.1. HRQoL assessments: Completion of PRO questionnaires in the 
Electronic Diary
All subjects will be completing PRO questionnaires in the eDiary . 
It is requested that questionnaires are completed before an y procedures are performed on 
the subject. 
All questionnaires will be completed using the eDiary at clinic and at home.  Adequate 
time should be allowed to complete all items of the questionnaires and the questionnaires 
must be reviewed b y the investigator or designated study  staff for completeness and, if 
necessary , the subject must be encouraged to complete any  missing items. Where more 
than one questionnaire is to be completed at a visit the order should be as follows:
1.Baseline d yspnea index (Visit 2) then Transient dy spnea index at subsequent 
visits
2.Patient global rating of COPD severit y and global rating of change in COPD
3.St George’s respi[INVESTIGATOR_645938]
4. COPD Assessment Test 
Instructions for completing the questionnaires can be found in the SRM.
[IP_ADDRESS]. Self A dministered Computerised Baseline Dy spnea Index/Transitional 
Dyspnea Index (SA C BDI/TDI)
The BD I is used to measure the severity of d yspnea in patients at baseline. The TDI 
measures changes in the patient’s dyspnea from baseline.  The self -administered 
computerized version of the BDI/TDI (SAC BDI/TDI)[ Mahler , 2004] is used to measure 
severit y of d yspnea in patients at baseline (SAC BDI) on Day  1 (Visit 2) of treatment and 
change from the baseline (SAC TDI) at Week 4, 12 and 24 (Visits 3, 4 and 5).  The  2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
50scores in both indexes depend on ratings for three different categories: functional 
impairment; magnitude of task, and magnitude of effort. SAC BDI/TDI should be 
completed before performing spi[INVESTIGATOR_038] . 
The SAC BDI/TDI was developed to address issues of pot ential bias in the interviewer 
administered (original) BDI /TDI [ Mahler , 1984].  The SAC BDI/TDI provides a 
standardized approach to the measurement of d yspnea, equivalent to the original 
BDI/TDI with advantages over t he interviewer method for grading d yspnea in patients 
with COPD by  [CONTACT_646008] b y the interviewers when completing the original BDI/TDI. This also 
removes the need for the same investigator to conduct all interviews with a subject based 
on the patient’s responses. SAC TDI  provides a continuous measure of change in dy spnea 
using a visual analogue scale to record responses. 
Details for the completion of the SAC BDI/TDI are provided i n the SRM.
[IP_ADDRESS]. SGRQ -C
The St George’s Respi[INVESTIGATOR_6015] -Chronic Obstructive Pulmonary  Disease 
specific (SGRQ -C) will be completed by  [CONTACT_646009] (V2, Day  1), at Week 
4, 12 and 24.
The SGRQ- C [Meguro , 2007] is a well established, disease -specific questionnaire.  It was 
designed to measure the impact of respi[INVESTIGATOR_496926] a COPD 
patient’s HRQoL.  As well as producing an overall summary score, scores for the 
individual domains of sympt oms, activity  and impacts are also produced.  It has been 
used in studies of COPD subjects and has been translated and validated for use in most 
major languages.  The SGRQ-C is derived from the original SGRQ, and produces scores 
equivalent to the SGRQ inst rument [ Meguro , 2007].  
[IP_ADDRESS]. COPD A ssessment Test (CA T)
The COPD Assessment Test [ Jones, 2009, Jones, 2012] is a validated, short and simple 
patient completed questionnaire which has been developed for use in routine clinical 
practice to measure the health status of patients with COPD.  The CAT is an 8- item 
questionnaire suitable for completion by  [CONTACT_453569].  When 
completing the questionnaire, subjects rate their experience on a 6 -point scale, ranging 
from 0 (no impairment) to 5 (maximum impairment) with a scoring range of [ADDRESS_864833].
The CAT will be completed in the eDiary  by [CONTACT_277935] S creening Visit 1 and 
Randomisation Visit 2 to assess their eligibility  to enter the stud y.  CAT is also 
completed at Weeks 4, 12 and 24 .  Additional instructions for completion of the CAT are 
provided in the SRM. 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
[IP_ADDRESS]. EXACT and the Evaluating Respi[INVESTIGATOR_645939]-COPD (E -RS: 
COPD)
EXACT -PRO is a 14 item patient reported outcome instrument designed to capture 
information on the occurrence, frequency , severity , and duration of exacerbations of 
disease in patients with COPD [ Leidy, 2011].  EXACT captures information on the 
severit y of the respi[INVESTIGATOR_69908] s ystemic manifestations of a COPD exacerbation as 
reported b y the patient.  The instrument is to be completed daily  (typi[INVESTIGATOR_897] 2 hrs before 
bedtime) using the electronic diary .  The daily  recording of information allows an 
assessment of the underlying day  to day  variability  of a patient's s ymptoms and facilitates 
the detection of s ymptom worsening indicative of a COPD exacerbation.  The total score 
for EXACT ranges from 0 -100.  The entire instrument is intended to be completed in 
about 3 minutes or less (typi[INVESTIGATOR_645940] ).
The E- RS: COPD consists of [ADDRESS_864834] instrument [ Leidy, 
2014].  E -RS: COPD is intended to capture information related to the respi[INVESTIGATOR_244853], i.e. breathlessness, cough, sputum production, chest congestion and 
chest tightness.  Th e E-RS: COPD has a scoring range of 0 -40 higher scores indicate 
more severe s ymptoms.
Three subscales of the E -RS are used to describe different s ymptoms; dy spnea, cough and 
sputum and chest sy mptoms.
The EXACT questionnaire will be completed b y subjects i n the eDiary , at home every  
night throughout the entire study , starting from Screening V1 
[IP_ADDRESS]. Subject Global Rating of COPD Severity  and Global Rating of Change 
in COPD
Subjects will complete the Global Rating of COPD Severit y at Randomization Visit 2 
and vis its 3, 4 and 5.  This single global question will ask subjects to rate their severit y of 
COPD on a four point scale (mild, moderate, severe, and very  severe).
This question should be used immediately  before the patient completes other visit 
specific quest ionnaires but after completion of SAC TDI  questionnaire. 
Subjects will also complete a Global Rating of Change in COPD (overall disease) 
question at Visits 3, 4 and 5.  Response options will be on a 7 point L ikert scale ranging 
from much better to much wo rse.  Completing the question at each Visit allows for earl y 
detection of response as well as continued response.
7.3.2. Spi[INVESTIGATOR_645941] o f the ATS [ Miller , 2005]. All sites 
will use standardized spi[INVESTIGATOR_645942].
All subjects will have spi[INVESTIGATOR_645943]  (see Section 
[IP_ADDRESS] ) and at Visits 2, 3, [ADDRESS_864835] 3 acceptable spi[INVESTIGATOR_496921] (with no 
more than 8) should be obtained. Acceptable spi[INVESTIGATOR_496922] a satisfactory  
start of test and end of test (i.e. a plateau in the volume time curve) and be free from 
artifacts due to cough, early  termination, poor effort, obstructed mouthpi[INVESTIGATOR_13959], equipment 
malfunction, or other reasons [ Miller , 2005].
The largest FEV 1and FVC from the 3 acceptable efforts should be recorded, even if they  
do not come from the same effort.
Spi[INVESTIGATOR_645944] 1and FVC assessments that is not obtained as follows will be 
considered a protocol deviation:
Started between 6:00AM and 11:00AM.
After withholding albuterol/salbutamol (all visits) for ≥4 hours
At Screening Visit 1, after wash out of medications as specified in the exclusion 
criteria in Section 5.2(Con comitant Medications).
At Screening Visit 1, before subject’s morning dose of inhaled LABA or LAMA
COPD medication
At Visit 2 after withholding the morning dose of inhaled LABA or LAMA COPD 
medication and prior to administration of study  medication
At Vis it 3, 4 and 5 after withholding the morning dose of study treatment.
Pre dose assessment performed prior to dosing.
Subjects should refrain from smoking for [ADDRESS_864836].
Trough FEV 1measurements for UME C/VI or UMEC on Weeks 4, 12 and 24 (Visits 3, 4 
and 5) should be performed 23 hours and 24 hours after the previous day ’s dose of study  
medication recorded in the eDiary . This will also provide trough FEV 1measurements for 
the evening dose of salmeterol. 
7.3.3. Inspi[INVESTIGATOR_359371]  (IC)
Inspi[INVESTIGATOR_645920] y (IC) is the volume of gas that can be taken into the lungs in a normal 
and full inhalation. Starting from the resting inspi[INVESTIGATOR_645945].  IC has been widel y used to assess static and 
dynamic h yperinflation in patients with COPD.
ICwill be measured b y spi[INVESTIGATOR_645946] -dose at Visits 2 (30 
and 5 min prior to dosing) and at trough at Visits 3, 4, and 5 ([ADDRESS_864837] dosing 
on the pre vious day ). For I C determination the average of at least three acceptable 
manoeuvres should be recorded.  Subjects should be tested while sitting, relaxed and 
wearing a nose clip.  They should be asked to breathe regularl y for several breaths until 
the end- expi[INVESTIGATOR_645947] (this usually  requires at least three tidal 
manoeuvres) then urged to take a deep breath to Total L ung Capacit y (TLC) with no 
hesitation. 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
53Spi[INVESTIGATOR_645948] 1and FVC assessments 
that is not obtained as follows will be considered a protocol deviation:
Started between 6:00AM and 11:00AM.
After withholding albuterol/salbutamol (all visits) ≥4 hours 
At Visit 2 after discontinuation of run -in LABA or LAMA COPD medication and 
prior to administration of study  medication
At Visit 3, 4 and 5 after withholding the morning dose of study  drug 
7.3.4. COPD E xacerbation
A mild exacerbation is defined as worsening of symptoms that require no treatment with 
antibiotics or steroids, and is self managed b y the patient by [CONTACT_646010]. A moderate COPD exacerbation is defined as worsenin g symptoms of 
COPD that require treatment with oral/sy stemic corticosteroids and/or antibiotics. A 
severe exacerbation is defined as worsening s ymptoms of COPD that require in- patient 
hospi[INVESTIGATOR_645949] [ADDRESS_864838] for the patient to withdraw from the stud y.
Signs and s ymptoms of COPD included on the electronic diary  cards will not be 
considered AEs and will not be recorded in the eCRF.
The time period for collection of COPD exacerbations will be from the Pre -Screening 
(Visit 0) until completion of the follow -up contact.  If a subject experiences a COPD 
exacerbation from the time the I CF is signed until randomization, summary  information 
(yes/no status question) will be collected in the eCRF. COPD exacerbations after 
randomization through follow -up will be recorded on the COPD exacerbation page of the 
eCRF.
7.3.5. Clinically  important deterioration (CID)
Clinically  important deterioration (CID) is a composite e ndpoint defined as: 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
54A decrease of  100 mL  from baseline in trough FEV 1
A deterioration in HRQoL defined as 4 units increase from baseline in 
SGRQ
The occurrence of an on -treatment moderate/severe COPD exacerbation
In addition, this study  will explore C AT and TDI  PROs as part of the composite 
endpoint.
7.3.6. Rescue albuter ol/salbutamol use
Subjects will record the number of dail y albuterol/salbutemol puffs they  use in the 
eDiary .  In addition, in some countries and selected sites the number of puffs will be 
collected through the eMDI device (Section 6.2) 
7.3.7. Physical activity monitor (study subset)
Physical activity  limitation is a common feature of COPD and its measures are highl y 
related to the degree of disease seve rity [Watz , 2009]. 
Reduced ph ysical activity  levels in COPD is associated with increased morbidity  and 
mortality , sustained disability , depression, and social and phy sical isolation [ Shu-Yi, 
2014; Gimeno, 2014] 
Improved activity  has been identified as an important factor that may  modify  morbidity  
and mortality  in COPD [ Moy , 2012 ].
The Actigraph GT9X phy sical activity  monitor will be used to measure levels of activity . 
The activity  monitor will be worn by  [CONTACT_422906]  150 subjects per treatment arm 
for 7 day s from Screening (Visit 1), for 7 day s from Randomisation (Visit 2), 7 day s from 
Visit 3 (Week 4) and for 7 day s prior to Week 24 (Visit 5).
There will be [ADDRESS_864839] will be given an activity  
monitor and instruction leaflet at the start of each assessment period. Further details of 
distribution, operation and retrieval of the monitors will be provided in the SRM .
7.4. Safet y
Planned time points for all safety  assessments are listed in the Time and Events Table 
(Section 7.1)
Safety  endpoint includes:
Incidence of adverse events
7.4.1. Adverse Events (A E) and Serious A dverse Events (S AEs)
The definitions of an AE or SAE can be found in Appendix 4 . 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
55The investi gator and their designees are responsible for detecting, documenting and 
reporting events that meet the definition of an AE or SAE. 
[IP_ADDRESS]. Time period and Frequency  for collecting A E and SA E information
Any SAEs assessed as related to study  participation (e.g., protocol -mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] 
product will be recorded from the time a subject consents to participate in the 
study  up to and including any  follow -up contact. 
AEs will be collected from th e start of Study  Treatment until the follow -up 
contact (see Section [IP_ADDRESS] ), at the timepoints specified in the Time and Events 
Table (Section 7.1).
Medical occurren ces that begin prior to the start of study  treatment but after 
obtaining informed consent may  be recorded on the Medical History /Current 
Medical Conditions section of the CRF.
All SAEs will be recorded and reported to [COMPANY_004] within 24 hours, as indicated in 
(Appendix 4 , Section 12.4.6 )
Investigators are not obligated to activel y seek AEs or SAEs in former study 
subjects. However, if the investigator learns of an y SAE, including a death, at any  
time after a subject has been discharged from the study , and he/she considers the 
event reasonabl y related to the study  treatment or study  participation, the 
investigator must promptly  notify  [COMPANY_004].
NOTE: The method of recording, evaluating a nd assessing causality  of AEs and SAEs 
plus procedures for completing and transmitting SAE reports to [COMPANY_004] are provided in 
(Appendix 4 , Section 12.4.4 to Section 12.4.6 )
[IP_ADDRESS]. Method of Detecting AEs and SA Es
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended 
and non-leading verbal questioning of the subject is the preferred method to inquire about 
AE occu rrence.  Appropriate questions include:
“How are you feeling?”
“Have you had an y (other) medical problems since y our last visit/contact
 “Have you taken an y new medicines, other than those provided in this study , 
since y our last visit/contact?
[IP_ADDRESS]. Follo w-up of AEs and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
subject at subsequent visits/contacts.  All SAEs, and non -serious AEs of special interest 
(as defined in Section 4.6.1 ) will be followed until resolution, until the condition 
stabilizes, until the event is otherwise explained, or until the subject is lost to follow -up 
(as defined in Section 5.5).  2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
[IP_ADDRESS]. Pneumonia Events
Investigators will be required to fill out a pneumonia event specific eCRF within one 
week of when the pneumonia AE/SAE(s) is first reported. 
[IP_ADDRESS]. Cardiovascular and Death Events
For an y cardiovascular events detailed in (Section 12.4.3) and all deaths, whether or not 
they are considered SAEs, specific Cardiovascular (CV) and Death sections of the CRF 
will be required to be completed. These sections include questions regarding 
cardiovascular (including sudden cardiac d eath) and non -cardiovascular death. 
The CV CRFs are presented as queries in response to reporting of certain CV MedDRA 
terms. The CV information should be recorded in the specific cardiovascular section of 
the CRF within one week of receipt of a CV Event data query  prompting its completion. 
The Death CRF is provided immediately after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed within one 
week of when the death is reported.
[IP_ADDRESS]. Disease- Relat ed Events and/or Disease -Related Outcomes Not 
Qualify ing as SA Es
The following disease related events (DREs) are common in subjects with COPD and can 
be serious/life threatening:
COPD exacerbation
COPD exacerbations are associated with the disease to be st udied and will not be 
recorded as AEs unless the exacerbation meets the definition of a ‘serious’ AE. 
Exacerbations that meet the definition of ‘serious’ AEs will be recorded on the 
appropriate eCRF section and should be reported to [COMPANY_004] for all subjects re gardless of 
whether or not they  are randomized to study  medication. Signs and s ymptoms of COPD 
included on the electronic diary  will not be considered AEs and will not be recorded in 
the eCRF
[IP_ADDRESS]. Regulatory  Reporting Requirements for SA Es
Prompt notification b y the investigator to [COMPANY_004] of SAEs related to study treatment (even 
for non -interventional post -marketing studies) is essential so that legal obligations and 
ethical responsibilities towards the safet y of subjects and the safety of a product under 
clinical investigation are met. 
[COMPANY_004] has a legal responsibility  to notify  both the local regulatory  authorit y and other 
regulatory  agencies about the safet y of a product under clinical investigation.  [COMPANY_004] will 
comply  with country  specific regulatory  requirements r elating to safet y reporting to the 
regulatory  authorit y, Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) and investigators. 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
57Investigator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local r egulatory  requirements and [COMPANY_004] policy  and are forwarded 
to investigators as necessary .
An investigator who receives an investigator safety report describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from [COMPANY_004] will file it with 
the IB and will notify  the I RB/IEC, if appropriate according to local requirements.
[IP_ADDRESS]. Additional A dverse Event (AE) Reporting Requirements for Canadian 
investigators
Health Canada requires pharmaceutical manufacturers to expeditiously  report domesti c 
cases of unusual failure in efficacy  (UFIE) for new drugs to the Marketed Health 
Products Directorate (MHPD) within [ADDRESS_864840] notification. This regulation applies 
to marketed drugs, and used as directed per the Canadian prescribing information, 
including those drugs used in Phase IV (non CTA filed) clinical trials.  
Adverse event (AE): Any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not 
necessarily  have to have a causal relationship with this treatment. An AE can therefore 
be an y unfavourable and unintended sign (including an abnormal laboratory finding) 
symptom or disease (new or exacerbated) temporally  associated with the use of a 
Medicinal Product. For a marke ted Medicinal Product, this can also include failure 
to produce expected benefits (i.e. lack of efficacy, with or without an adverse event), 
In order for [COMPANY_004] to comply  this Canadian regulatory  requirement, Canadian investigators 
are required to collect, r ecord and report lack of efficacy  events as per the table in 
Appendix 4 Section 12.4.1 .  
All paper forms are required to be faxed to [COMPANY_004] Canada’s Drug Safety  department at 
 within [ADDRESS_864841] awareness.
7.4.2. Pregnancy
Details of all pregnancies in female subjects will be collected after the start of 
Screening and until the follow -up contact. 
If a pregnancy  is reported then the investigator should inform [COMPANY_004] within 2 
weeks of l earning of the pregnancy  and should follow the procedures outlined in 
Appendix 7 .
7.4.3. Medical Device Incidents (Including Malfunctions)
Procedures for documenting medical device incidents are provide
d in Appendix 6 .
7.4.4. Electrocardiogram (ECG)
A Single 12- lead ECG will be obtained at Screening using an ECG machine provided by  
[CONTACT_646011], QRS, 
QT, and QTc intervals. 2018N377698_00
PP
2016N277425_03 CONFIDENTIA L
201749
58The 12 -lead ECG measurement and rh ythm strip (10 seconds) will be obtained before 
spi[INVESTIGATOR_496914]. ECG measurement should be obtained after subjects have rested for 
approximately  [ADDRESS_864842] provide his/her dated signature [CONTACT_24003], attesting to the authenticity  of the ECG machine interpretation. 
7.5. Genetics
Information regarding genetic research is included in Appendix 3
8. DATA MANAG EMENT
For this study  subject data will be entered into [COMPANY_004] defined CRFs, transmitted 
electronically  to [COMPANY_004] or designee and combined with data provided from other 
sources in a validated data sy stem.  
Management of clinical data will be performed in accordance with applicable 
[COMPANY_004] standards and data cleaning procedures to ensure the integrit y of the data, 
e.g., removing errors and inconsistencies in the data.
Adverse events and concomitant medications terms will b e coded using MedDRA 
(Medical Dictionary  for Regulatory  Activities) and an internal validated 
medication dictionary , [COMPANY_004]Drug.  
CRFs (including queries and audit trails) will be retained b y [COMPANY_004], and copi[INVESTIGATOR_645950] e investigator cop y.  Subject initials 
will not be collected or transmitted to [COMPANY_004] according to [COMPANY_004] policy .
9. STATISTICA L CONSIDER ATIONS AND DA TA 
ANALYSES
9.1. Hypotheses
The primary  purpose of this study  is to demonstrate improvements in lung function for 
subjec ts treated with UMEC/VI  compared with UMEC for 24 weeks. 
The primary  endpoint is change from baseline in trough FEV 1at Week 24.
The null hy pothesis is no difference between treatment groups (H0: μT – μS = 0), with 
the alternative h ypothesis that there is a difference between treatment groups (H1: μT –
μS ≠0), where 
μT is the mean change from baseline for UMEC/VI and μS is the mean 
change from baseline for UMEC.  2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
599.2. Sample Size Considerations
The pr imary  endpoint is change from baseline in trough FEV 1at Week 24. As an 
important aim of the study is to compare UMEC/VI, UMEC and salmeterol with respect 
to HRQoL  the sample size has been calculated to provide sufficient power for the 
comparison of the pr imary  and secondary  endpoint TDI , at Week 24.  
The sample size calculations use a two -sided 5% significance level and an estimate of 
between subject standard deviation for TDI of 2.94 units.  The estimate of SD is based on 
DB2113373 [ Donohue , 2013], a study  which consisted of treatment arms of UMEC/VI 
62.5/25, UMEC 62.5 VI (Vilanterol) 25mcg and placebo and is the value at Day  168 in a 
subgroup of subjects who were ICS free at screening.  Based on these data, 727 eva luable 
subjects per treatment arm will be required to provide 90% power to detect a statistically  
significant difference if the true difference is 0.5 units, ½ the MCI D, between UMEC/VI 
and UMEC. The smallest observed effect predicted to result in a statis tically  significant 
difference between treatment groups is 0.[ADDRESS_864843] >99% power 
assuming a true treatment difference of 80mL between UMEC/VI and UMEC for trough 
FEV1 at 24 weeks at the two-sided 5% significance level. This calculation uses a SD for 
trough FEV1 of 240mL, based on prior results for trials comparing dual bronchodilators 
versus single bronchodilators ( Donohue , 2013; Bateman , 2013). The smallest observed 
effect predicted to result in a statistically  significant difference between treatment groups 
is 25mL . 
In order to account a for a 10% withdrawal rate , approximately  [ADDRESS_864844] SDTreatment Difference Power
TDI 2.54 0.5 96%
2.74 0.5 94%
2.94 0.5 90%
3.14 0.5 86%
3.34 0.5 81% 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
609.2.2. Sample Size Re -estimation or A djustment
No sample size re -estimation is planned for this study . 
9.3. Data Analysis Considerations
9.3.1. Analysis Populations
Population Definition / Criteria Analyses Evaluated
All 
Subjects 
Enrolled 
(ASE)All subjects for whom a record exists in the 
study  database, including screen failures and 
any subject who was not screened but 
experienced an SAE between the date of 
informed consent and the planned date of the 
Screening visit. Subject 
Disposition
Reasons for 
withdr awal prior 
to randomisation
Inclusion, 
exclusion and 
randomisation 
criteria deviations
SAEs for non-
randomised 
subjects
Intent -to-
treat (ITT)All randomized subjects, excluding those who 
were randomized in error and received at least 
one dose of stud y med ication. A subject who 
is recorded as a screen or run- in failure and 
also randomized will be considered to be 
randomized in error.  Any other subject who 
receives a randomization number will be 
considered to have been randomized.
Display s will be based on the treatment to 
which the subject was randomized.Study  Population
Efficacy
Safety
Intent -to-
treat ICS 
free (ITT 
ICS free)All subjects in the I TT Population who have 
not received ICS.Study  Population
Efficacy
Safety
9.3.2. Interim A nalysis
No interim an alysis is planned for the stud y.
9.4. Key Elements of A nalysis Plan
Treatment Comparisons
The primary  treatment comparison of UMEC/VI with UMEC will be performed on the 
ITT population. 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
61The other treatment comparisons of UMEC/VI and UMEC with Salmeterol will be 
performed on the ITT population and ITT ICS free population.
9.4.1. Primary  Analyses
The treatment comparison of primary  interest will be UMEC/VI versus UMEC for the 
primary  endpoint of change from baseline in trough FEV 1at Week 24. The primary  
analyses will be performed using a mixed model repeated measures (MMRM) anal ysis 
and will be based on a two -sided hy pothesis testing approach on the ITT Population. 
In order to account for multiplicity  across treatment comparisons and endpoints, a step -
down closed testing procedure will be applied whereby  [CONTACT_646012]. If the primary  comparison is significant i.e. 
the associate d p-value for UMEC/VI versus UMEC for change from baseline in trough 
FEV1 at Week 24 is below 0.05, this will allow inference of treatment comparisons 
(UMEC/VI versus UMEC on all other endpoints, and UMEC/VI versus Salmeterol and 
UMEC versus Salmeterol on all endpoints including the primary  endpoint), which will be 
declared statistically  significant if the associated p -value is below 0.05.  
There will be 2 anal yses one for one for the German Federal Joint Committee (G -BA) 
and one for the rest of the world (ROW).
The step-down closed testing procedure onl y applies to the ROW.  For the G -BA 
statistical inference for secondary  and other endpoints or treatment comparisons will not 
be conditional on achieving statistical significance of the primary  comparison.  
The primary  endpoint of mean change from baseline in trough FEV1 at the end of Week 
24 and secondary  endpoint change from baseline in TDI score at Week 24 will both be 
analysed using MMRM analy sis. The MMRM analy sis for change from baseline in 
trough FEV1 and TDI will include measurements at Treatment Weeks 4, 12 and 24. 
Treatment group (a categorical variable) will be fitted as the explanatory  variable with 
appropriate pre -defined variables, stratum (number of bronchodilators per day  during 
run-in) and ba seline values, fitted as covariates. Visit (nominal) will be fitted as a 
categorical variable and visit- by-baseline and visit -by-treatment interaction terms will be 
included to allow treatment effects to be estimated at each visit separatel y. The variance 
covariance matrix will be assumed to be unstructured (based on previous experience no 
issues are expected with fitting models with this matrix structure). 
While missing data are not explicitly  imputed in the primary  MMRM analyses, there is 
an underl ying assumption that the data are missing at random. 
The estimated treatment differences between UMEC/VI versus UMEC for each endpoint 
will be presented with the 95% confidence intervals for the difference and the p -value. 
Full details of the analy ses to be pe rformed on all primary  endpoints will be given in the 
RAP. 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
629.4.2. Other A nalyses
The MMRM anal ysis will be repeated for the ITT ICS free population. Estimated 
differences between UMEC/VI  or UMEC and Salmeterol will be presented together with 
95% confidence interv als (CI s) for the difference and p- values.
Secondary  and other efficacy  endpoints and treatment comparisons will be adjusted for 
multiplicity  as per Section 9.4.1 .
Full details of the analy ses to be performed on the other efficacy  endpoints will be given 
in the RAP.
Safety Analyses
Adverse events (AEs) will be coded using the standard [COMPANY_004] dictionary , Medical
Dictionary  for Regulatory  Activities (MedDRA), and grouped by  [CONTACT_44749]. The 
number and percentage of s ubjects experiencing at least one AE of an y type, AEs within 
each bod y system and AEs within each preferred term will be presented for each 
treatment group. Separate summaries will be provided for all AEs, drug related AEs, fatal 
AEs, non- fatal SAEs, AESI sand AEs leading to withdrawal. 
Deaths and SAEs will be documented in case narrative format. 
Full details of the analy ses to be performed on all safet y endpoints will be given in the 
RAP.
10. STUDY GOVERNANCE CON SIDERATIONS
10.1. Posting of Information on Publicly Available Clinical Trial 
Registers
Study  information from this protocol will be posted on publicly  available clinical trial 
registers before enrollment of subjects begins.
10.2. Regulatory  and Ethical Considerations, Including the 
Informed Consent Process
Prior to initiation of a site, [COMPANY_004] will obtain favourable opi[INVESTIGATOR_1649]/approval from the 
appropriate regulatory  agency  to conduct the study in accordance with I CH Good Clinical 
Practice (GCP) and applicable country -specific regulatory  requirements.
The study  will b e conducted in accordance with all applicable regulatory  requirements, 
and with [COMPANY_004] policy .
Study  site Investigators will be selected to participate in the 201749 study based upon 
their pulmonology  expertise and knowledge of the protocol defined patient po pulation 
and associated required study  assessments. 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
63The study  will also be conducted in accordance with I CH Good Clinical Practice (GCP), 
all applicable subject privacy  requirements, and the guiding principles of the current 
version of the Declaration of H elsinki.  This includes, but is not limited to, the following:
IRB/IEC review and favorable opi[INVESTIGATOR_1649]/approval of the study  protocol and 
amendments as applicable
Obtaining signed informed consent
Investigator reporting requirements (e.g. reporting of AEs/SAEs/protocol 
deviations to I RB/IEC)
[COMPANY_004] will provide full details of the above procedures, either verball y, in writing, 
or both.
Signed informed consent must be obtained for each subject prior to participation 
in the study
The IEC/I RB, and where applicable t he regulatory authority , approve the clinical 
protocol and all optional assessments, including genetic research.  
Optional assessments (including those in a separate protocol and/or under separate 
informed consent) and the clinical protocol should be conc urrentl y submitted for 
approval unless regulation requires separate submission.  
Approval of the optional assessments may  occur after approval is granted for the 
clinical protocol where required b y regulatory  authorities.  I n this situation, 
written approval of the clinical protocol should state that approval of optional 
assessments is being deferred and the study , with the exception of the optional 
assessments, can be initiated.
10.3. Qualit y Control (Study  Monitoring)
In accordance with applicable regulations including GCP, and [COMPANY_004] procedures, 
[COMPANY_004] monitors will contact [CONTACT_288627], study  requirements, and their responsibilities to satisfy  
regulatory , ethical, and [COMPANY_004] requirements.  
When re viewing data collection procedures, the discussion will also include 
identification, agreement and documentation of data items for which the eCRF
will serve as the source document.
[COMPANY_004] will monitor the study  and site activity  to verify  that the:
Data are a uthentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accordance with the currently  approved protocol and any  
other study  agreements, GCP, and all applicable regulatory  requirements.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents 2018N377698_00
2016N277425_03 CONFIDENTIA L
[PHONE_13419].4. Qualit y Assurance
To ensure compliance with GCP and all applicable regulatory  requirements, [COMPANY_004] 
may conduct a quality  assurance asse ssment and/or audit of the site records, and 
the regulatory  agencies may  conduct a regulatory inspection at any  time during or 
after completion of the study . 
In the event of an assessment, audit or inspection, the investigator (and institution) 
must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to all 
relevant documents and to allocate their time and the time of their staff to discuss 
the conduct of the stud y, any findings/relevant issues and to implement any 
corrective and/or pr eventative actions to address any  findings/issues identified.
10.5. Stud y and Site Closure
Upon completion or premature discontinuation of the study , the [COMPANY_004] monitor will 
conduct site closure activities with the investigator or site staff, as appropriate, in 
accordance with applicable regulations including GCP, and [COMPANY_004] Standard 
Operating Procedures.
[COMPANY_004] reserves the right to temporaril y suspend or prematurel y discontinue this 
study  at an y time for reasons including, but not limited to, safety  or ethical issues 
orsevere non- compliance. For multicenter studies, this can occur at one or more 
or at all sites.  
If [COMPANY_004] determines such action is needed, [COMPANY_004] will discuss the reasons for taking 
such action with the investigator or the head of the medical institution (whe re 
applicable).  When feasible, [COMPANY_004] will provide advance notification to the 
investigator or the head of the medical institution, where applicable, of the 
impending action.
If the study is suspended or prematurely discontinued for safet y reasons, [COMPANY_004] will 
promptly  inform all investigators, heads of the medical institutions (where 
applicable) and/or institution(s) conducting the study . [COMPANY_004] will also promptly  
inform the relevant regulatory authorities of the suspension or premature 
discontinuation of the stud y and the reason(s) for the action.  
If required b y applicable regulations, the investigator or the head of the medical 
institution (where applicable) must inform the I RB/I EC promptl y and provide the 
reason for the suspension or premature discontinuation.
10.6. Records Retention
Following closure of the study , the investigator or the head of the medical 
institution (where applicable) must maintain all site study  records (except for 
those required b y local regulations to be maintained elsewhere), in a safe and 
secure location.  
The records must be maintained to allow eas y and timely  retrieval, when needed 
(e.g., for a [COMPANY_004] audit or regulatory  inspection) and must be available for review 
in conjunction with assessment of the facilit y, supporting s ystems, and releva nt 
site staff.   2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
65Where permitted b y local laws/regulations or institutional policy, some or all of 
these records can be maintained in a format other than hard cop y (e.g., microfiche, 
scanned, electronic); however, caution needs to be exercised before such action is 
taken.  
The investigator must ensure that all reproductions are legible and are a true and 
accurate cop y of the original and meet accessibility and retrieval standards, 
including re -generating a hard cop y, if required.  Furthermore, the investigator 
must ensure there is an acceptable back -up of these reproductions and that an 
acceptable qualit y control process exists for making these reproductions.
[COMPANY_004] will inform the investigator of the time period for retaining these records to 
comply  with all applicable regulatory requirements.  The minimum retention time 
will meet the strictest standard applicable to that site for the study, as dictated by 
[CONTACT_65406], [COMPANY_004] 
standards/procedures, and/or institution al requirements.  
The investigator must notify  [COMPANY_004] of any  changes in the archival arrangements, 
including, but not limited to, archival at an off- site facility  or transfer of 
ownership of the records in the event the investigator is no longer associated w ith 
the site.
10.7. Provision of Study  Results to Investigators, Posting of 
Information on Publically  Available Clinical Trials Registers 
and Publication
Where required b y applicable regulatory  requirements, an investigator signatory  will be 
identified for the a pproval of the clinical study  report.  The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity  to review the complete study  results at a [COMPANY_004] site or other mutually -
agreeable loc ation.
[COMPANY_004] will also provide the investigator with the full summary  of the stud y results.  The 
investigator is encouraged to share the summary  results with the study  subjects, as 
appropriate.
[COMPANY_004] will provide the investigator with the randomization codes f or their site only  after 
completion of the full statistical analy sis.
The procedures and timing for public disclosure of the results summary  and for 
development of a manuscript for publication will be in accordance with [COMPANY_004] Policy .
A manuscript will be pro gressed for publication in the scientific literature if the results 
provide important scientific or medical knowledge. 2018N377698_00
2016N277425_03 CONFIDENTIA L
[PHONE_13420]. REFERENCES
Bateman ED, Ferguson GT, Barnes N et al. Dual bronchodilation with QVA149 versus 
single bronchodilation therap y: The SHINE st udy. Eur Respir J. 2013 Dec; 42:1484 -94
Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: 
a summary  of the ATS/ERS position paper. Eur Respir J. 2004; 23:932 -946.
Chen H, Yu KD, Xu GZ. Association between Variant Y402H in Age-Related Macular 
Degeneration (AMD) Susceptibility  Gene CFH and Treatment Response of AMD: A 
Meta -Anal ysis. PloS ONE 2012; 7: e42464
Dahl R, Chung KF, Buhl R et al. Efficacy  of a new once -daily  long -acting inhaled β2 -
agonist indacaterol versus twice- daily formoterol in COPD. Thorax 2010, 65:473 -479.
Donohue JF, Maleki -Yazdi MR, Kilbride S, et al.  Efficacy  and safet y of once -daily 
umeclindinium/vilanterol 62.5/25mcg in COPD.  Respir Med 201 3; 107: 1538-1546.
European Medicines Agency  (EMA) . Guidelines on clinical investigation of medicinal 
productsin the treatment of chronic obstructive pulmonary  disease (COPD). 
EMA/CHMP/48353572 , 2012.
Feldman G, Maltais F, Khindri S, et al.  A randomized blinded study  to evaluate the 
efficacy  and safet y of umeclidinium 62.5 g compared with tiotropi[INVESTIGATOR_1890] 18 g in patients 
with COPD.  I nternational Journal of COPD 2016; 11: 719 -730
Feldman G, Siler T, Prasad N et al. Efficacy  and safet y of indacaterol 150 μg once -daily 
in COPD: a double -blind, randomised, 12- week study . BMC Pulm Med 2010, 10:11.
Gimeno- Santos E, Frei A, Steurer -Stey C, et al. Determinants and outcomes of phy sical 
activity  in patients with COPD: a sy stematic review. Thorax 2014; 0:1-9
GlaxoSmithKlineDocument Number [RM2006/[ZIP_CODE]/09, Umeclidinium ([COMPANY_004]573719) 
Investigator’s Brochure. Report Date -Aug-2016.
GlaxoSmithKlineDocument Number RM2009/[ZIP_CODE]/07, Umeclidinium + Vilanterol 
Investigator's Brochure. Re port date AUG -2015
GOLD. Global Initiative for Chronic Obstructive Lung Disease [GOLD]. Global Strategy 
for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary  
Disease. Last Updated 2015. http://www.goldcopd.org.
Gorin MB. Genetic ins ights into age -related macular degeneration: Controversies 
addressing risk, causality, and therapeutics. Mol. Asp. Med. 2012; 33: 467 -486.
Hatcher RA, Trussell J, Nelson AL, Cates W Jr, et al, editors. Contraceptive Technology . 
20th revised edition. New Yo rk: Ardent Media, 2011. 2018N377698_00
2016N277425_03 CONFIDENTIA L
[ADDRESS_864845] in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.
Jones, P., Harding, G., Berry , P., Wiklund, I ., Chen, W -H., L eidy, N. Development and 
first validation of the COPD Assessment Test (CAT) Eur Respir J, 2009; 34: 648–654
Jones, P., Harding, G., Wiklund, I ., Berry , P., Tabberer, M., Yu, R., Leidy , N. Tests of 
the Responsiveness of the Chronic Obstructive Pulmonary  Disease (COPD) Assessment 
Test (CAT) Following Acute Exacerbation and Pulmonary  Rehabilitation Chest, 2012, 
142 134 -140
Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Dény P, Gault E.  Quantifi cation 
of Hepatitis Delta Virus RNA in Serum by  [CONTACT_31861] -Time PCR I ndicates 
Different Patterns of Virological Response to Interferon Therap y in Chronically  Infected 
Patients.  J Clin Microbiol. 2005;43(5):2363 –2369. 
Leidy NK, Sexton CC, Jones PW, No tte SM. et al. Measuring respi[INVESTIGATOR_645951]: reliability  and validity  of a daily  diary . Thorax 2014; 69:5 424 -
430
Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S. Standardizing 
measurement of chronic obstructive pu lmonary  disease exacerbations. Reliability  and 
validity  of a patient- reported diary . Am J Respir Crit Care Med 2011; 183:323-[ADDRESS_864846] J, Fierro -Carrion G, et al. Development of self -administered versions 
of modified baseline and transition dy spnea indexes in COPD. J COPD 2004; 165 –[ADDRESS_864847] 1984, 85: 751-758.
Maleki -Yazdi MR, Kael in T, Richard N, Zvarich M, Church A. Efficacy  and safet y of 
umeclidinium/vilanterol 62.5/25 mcg and tiotropi[INVESTIGATOR_1890] 18 mcg in chronic obstructive 
pulmonary  disease: results of a 24- week, randomized, controlled trial. Respi[INVESTIGATOR_645952]. 2014;108:1752-60.
Maltais F, Singh S, Donald AC, Crater G, Church A, Goh AH, Riley  JH. Effects of a 
combination of umeclidinium/vilanterol on exercise endurance in patients with chronic 
obstructive pulmonary  disease: two randomized, double -blind clinical trials. Ther Adv 
Respi r Dis. 2014;8:[ADDRESS_864848]. 
2007;132:456-463 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
68Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coat es A, Crapo R, Enright 
P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacInt yre N, McKay  R, 
Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J.  Standardisation of 
spi[INVESTIGATOR_038] .  Eur Respir J.  2005;26: 319-338.
Moy  ML, Weston NA, Wilson EJ , Hess ML , Richardson CR. A pi[INVESTIGATOR_645953]. Respir Med. 2012;106:1342- 50. 
Quanjer P, Stanojevic S, Cole T, Baur X., Hall G, Enright P, et al. on behalf of the ERS 
Global L ung Function Initiative.  Multi -ethnic reference values for spi[INVESTIGATOR_105221] 3 -
95 year age range: the global lung function 2012 equations. Eur Respir J, 2012; 40: 
1324 –1343.
Schmidt SA, Johansen MB, Olsen M et al. The impact of exacerbation frequency  on 
mortality  following acute exacerba tion of COPD: a registry -based cohort study . B Med J. 
Open. 2014;4: (12): e006720
Serevent product information 2003. Available from 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20236slr028_serevent_lbl.pdf
Shu-Yi Liao, Roberto Benzo et al. Physical Activity  Monitoring in Patients with Chronic 
Obstructive Pulmonary  Disease. Journal of the COPD Foundation 2014; 1: 155 -165
Siler T, Kerwin E, Sousa A, Donald A, Rehan A, Church A, Efficacy  and safet yof 
umeclidinium added to fluticasone furoate/vilan terol in chronic obstructive pulmonary  
disease: Results of two randomized studies.  Respir Med. 2015; 109:1155 -63
Singh D, Maleki -Yazdi MR, Tombs L , Iqbal A, Fah y WA, Naya I. Prevention of 
clinically  important deteriorations in COPD with umeclidinium/vilan terol. Int’l J of 
COPD, 2016; 11:1413 -1424
Tashkin DP, Fabbri LM. Long acting beta -agonists in the management of chronic 
obstructive pulmonary  disease: Current and future agents.  Respir Research, 2010; 11: 
[ADDRESS_864849] N, Mehta R, and Church, A . Umeclidinium in patients with COPD: a 
randomised, placebo -controlled study .  Eur Respir J. 2014; 43: 72–81.
Watz H, Waschki B, Meyer T, Magnussen H: Physical activity  in patients with COPD. 
Eur Respir J 2009, 33:262–272. 
Wedzicha JA, Brill SE, Allinson JP, Donalson GC. Mechanism and impact of the 
frequent exacerbator phenoty pe in chronic obstructive pulmonary  disease. BMC 
Medicine, 2013; 11:181 2018N377698_00
2016N277425_03 CONFIDENTIA L
[PHONE_13421]. APPENDICES
12.1. Appendix 1: A bbreviations and Trademarks
Abbrev iations
AE Adverse Event
ALT Alanine transaminase
AST Aspartate aminotransferase
ATS American Thoracic Society
CAT COPD Assessment Test
CI Confidence Intervals
CID Clinically  important deterioration 
COPD Chronic Obstructive Pulmonary  Disease
CPK Creatine phosphokinase
CRF Case Report Form
CV Card iovascular
DPI [INVESTIGATOR_645954] I nhaler
E-RS Evaluating Respi[INVESTIGATOR_244774] -COPD  To ol
ERS European Respi[INVESTIGATOR_645955] ₁ Forced Expi[INVESTIGATOR_645956] I nitiative for Chronic Obstructive Lung Disease
[COMPANY_004] GlaxoSmithKline
IB Investigator Brochure
ICF Informed Consent Form
ICS Inhaled Corticosteroid
IEC Independent Ethics Committee
IP Investigational product
INR International normalized ratio
IRT Interactive Response Technology
ITT Intent -to-Treat
IUD Intrauterine Device
IUS Intrauterine S ystem
LABA Long Acting Beta -Agonist
LAMA Long -acting Muscarinic Receptor Antagonists
LDH Lactate deh ydrogenase
LTOT Long Term Ox ygen Therapy 2018N377698_00
2016N277425_03 CONFIDENTIA L
[ADDRESS_864850] Upper Limit of Normal
UMEC Umeclidinium ([COMPANY_004]573719)
UMEC/VI Umeclidinium & Vilanterol as a fixed dose combination
VI Vilanterol Trife nate 
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_646013] E-RS
DISKUS EXCACT
ELLIPTA
INCRUSE
SEREVENT 2018N377698_00
2016N277425_03 CONFIDENTIA L
[PHONE_13422].2. Appendix 2: Liver Safety  Required A ctions an d Follow up 
Assessments
Phase III -IV liver chemistry stoppi[INVESTIGATOR_420682] - Liver Stoppi[INVESTIGATOR_53053]- absolute ALT  8xULN
ALT Increase ALT  5xULN but <8xULN  persists for 2 weeks
ALT  3xULN but <5xULN  persists for 4 weeks
Bilirubin1, 2ALT  3xULN andbilirubin 2xULN (>35% direct bilirubin) 
INR2ALT  3xULN andINR>1.5, if INR measured
Cannot 
MonitorALT  5xULN but <8xULN and cannot be monitored weekly for  2 weeks
ALT  3xULN but <5xULN and cannot be monitored weekly for 4 weeks
Symptomatic3ALT   3xULN associated with symptoms (new or worsening) believed to be 
related to  liver injury or hypersensitivity
Required Actions and Follow up Assessments following ANY Liver Stopp ing Event
Actions Follow Up Assessments
Immediately discontinue  study treatment
Report the event to [COMPANY_004] within 24 hours
Complete the liver event CRF and complete 
an SAE data collection tool if the event also 
meets the criteria for an SAE2
Perform liver event follow up assessments 
Monitor the subject until liver chemistries 
resolve , stabilize, or return to within normal 
ranges. baseline (see MONITORING below)
Do not restart/rechallenge subject with 
study treatment. Permanently discontinue 
study treatmen t and may continue subject 
in the study for any protocol specified follow 
up assessments
MONITORING:
For bilirubin or INR criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform Viral hepatitis serology4
Only in those with underlying chron ic 
hepatitis B at study entry (identified by 
[CONTACT_23977] B surface antigen) 
quantitative hepatitis B DNA and hepatitis 
delta antibody5.
Blood sample for pharmacokinetic (PK) 
analysis, obtained within a week after last 
dose6
Serum creatine phosphokin ase (CPK) and 
lactate dehydrogenase (LDH).
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form
Record use of concomitant medications on 
the concomitant medications report form
including acetaminophen, herbal  2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
72Liver Chemistry Stoppi[INVESTIGATOR_2121] - Liver Stoppi[INVESTIGATOR_645957] s within  24 
hrs
Monitor subjects twice weekly until liver 
chemistries resolve, stabilize or return to 
within normal ranges.
A specialist or hepatology consultation is 
recommended
For All other criteria:
Repeat liver chemistries (include ALT, AST, 
alkali ne phosphatase, bilirubin) and perform 
liver event follow up assessments within  24-
72 hrs 
Monitor subjects weekly until liver 
chemistries resolve, stabilize or return to 
within normal ranges.remedies, other over the counter 
medications .
Record alcohol use on the liver event 
alcohol intake case report form
For bi lirubin or INR criteria:
Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti- liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG or gamma 
globulins).
Serum acetaminophen adduct HPLC 
assay (quantifies potential aceta minophen 
contribution to liver injury in subjects with 
definite or likely acetaminophen use in the 
preceding week [ James , 2009]). NOTE: 
not required in China
Liver imaging (ultrasound, magnetic 
resonance, or computerised tomography) 
and /or liver biopsy to evaluate liver 
disease; complete Liver Imaging and/or 
Liver Biopsy CRF forms.
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that subject if ALT 3xULN andbilirubin 2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations a nd suggesting liver injury. 
2. All events of ALT 3xULN andbilirubin  2xULN (>35% direct bilirubin) or ALT 3xULN andINR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR measurement is not required and the threshold value stated 
will not apply to subjects receiving anticoagulants
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)   
4. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody;  Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  Hepatitis E IgM antibody 
5. If hepatitis delta antibody assay cannot be performed,  it can be replaced with a PC R of hepatitis D RNA virus 
(where needed) [ Le Gal , 2005].
6. PK sample may not be required for subjects known to be receiving placebo or non -[COMPANY_004] comparator treatments.  
Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to 
blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the subject’s best 
approximation. If the date/time of the last dose cannot be approximated OR a PK sample can not be collected in 
the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shippi[INVESTIGATOR_131971].   2018N377698_00
2016N277425_03 CONFIDENTIA L
[PHONE_13423].3. Appendix 3: Genetic Research
Genetics –Background
Naturall y occurring genetic variation may  contribute to inter -individual variability in 
response to medicines, as well as an individual's risk of developi[INVESTIGATOR_42259]. 
Genetic factors associated with disease characteristics may  also be associated with 
response to therap y, and could help to explain some clinical study  outcomes. For 
example, genetic variants associated with age- related macular degeneration (AMD) are 
reported to account for much of the risk for the condition [ Gorin , 2012] with certain 
variants reported to in fluence treatment response [ Chen, 2012]. Thus, knowledge of the 
genetic etiology  of disease may  better inform understanding of disease and the 
development of medicines. Additionally , genetic variability  may  impact the 
pharmacokinetics (absorption, distribution, metabolism, and elimination), or 
pharmacod ynamics (relationship between concentration and pharmacologic effects or the 
time course of pharmacologic effects) of a specific medicine and/or clinical outcomes 
(efficac y and/or safet y) observed in a clinical study.
Genetic Research Objectives and A nalyses
The objectives of the genetic research are to investigate the relationship between genetic 
variants and: 
Response to medicine, including an y concomitant medicines;
COP D susceptibility , severity , and progression of related conditions
Genetic data may  be generated while the study  is underway  or following completion of 
the study .  Genetic evaluations may  include focused candidate gene approaches and/or 
examination of a la rge number of genetic variants throughout the genome (whole genome 
analyses). Genetic anal yses will utilize data collected in the study  and will be limited to 
understanding the objectives highlighted above.  Analy ses may  be performed using data 
from multip le clinical studies to investigate these research objectives.
Planned anal yses and results of genetic investigations will be reported either as part of the 
clinical RAP and study  report, or in a separate genetics RAP and report, as appropriate.
Study Popul ation
Any subject who is enrolled in the study  can participate in genetic research.  Any  subject 
who has received an allogeneic bone marrow transplant must be excluded from the 
genetic research.
Study Assessments and Procedures
A key  component of successful genetic research is the collection of samples during 
clinical studies. Collection of samples, even when no a priori hypothesis has been 
identified, may  enable future genetic anal yses to be conducted to help understand 
variability  in disease and medicine response.   2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
74A 6 ml blood sample will be taken for Deox yribonucleic acid (DNA) extraction. 
A blood sample is collected at the baseline visit, after the subject has been 
randomized and provided informed consent for genetic research. Instructions for 
collecti on and shippi[INVESTIGATOR_428121]. The DNA from the blood sample may  undergo quality  control analy ses to 
confirm the integrit y of the sample. If there are concerns regarding the quality  of 
the sample, then the sam ple may  be destroy ed. The blood sample is taken on a 
single occasion unless a duplicate sample is required due to an inabilit y to utilize 
the original sample.  
The genetic sample is labelled (or “coded”) with the same stud y specific number used to 
label o ther samples and data in the study .   This number can be traced or linked back to 
the subject by  [CONTACT_132018]. Coded samples do not carry  personal 
identifiers (such as name [CONTACT_42405]). 
Samples will be stored securel y and may be kept for up to [ADDRESS_864851] 
completes the study , or [COMPANY_004] may  destroy  the samples sooner.  [COMPANY_004] or those working 
with [COMPANY_004] (for example, other researchers) will only use samples collected from the study  
for the purpose stated in this protocol and in the informed consent form.  Samples may  be 
used as part of the development of a companion diagnostic to support the [COMPANY_004] medicinal 
product.
Subjects can request their sample to be destro yed at any  time.
Informed Consent
Subjects who do not w ish to participate in the genetic research may  still participate in the 
study .  Genetic informed consent must be obtained prior to any  blood being taken.
Subject Withdrawal from Study
If a subject who has consented to participate in genetic research withdr aws from the 
clinical study  for any  reason other than being lost to follow -up, the subject will be given a 
choice of one of the following options concerning the genetic sample, if already  
collected:
Continue to participate in the genetic research in which case the genetic DNA 
sample is retained
Discontinue participation in the genetic research and destroy  the genetic DNA 
sample 
If a subject withdraws consent for genetic research or requests sample destruction for an y 
reason, the investigator must complete the appropriate documentation to request sample 
destruction within the timeframe specified b y [COMPANY_004] and maintain the documentation in 
the site study  records . 
Genoty pe data may  be generated during the study  or after completion of the study  and 
may be anal yzed during the study  or stored for future anal ysis.  2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
75If a subject withdraws consent for genetic research and genot ype data has not been 
analyzed, it will not be analy zed or used for future research.  
Genetic data that has been anal yzed at the time of withdr awn consent will 
continue to be stored and used, as appropriate. 
Screen and Baseline Failures
If a sample for genetic research has been collected and it is determined that the subject 
does not meet the entry  criteria for participation in the study , then t he investigator should 
instruct the subject that their genetic sample will be destro yed. No forms are required to 
complete this process as it will be completed as part of the consent and sample 
reconciliation process.  In this instance a sample destruction form will not be available to 
include in the site files.
Provision of Study Results and Confidentiality  of Subject’s Genetic Data
[COMPANY_004] may  summarize the genetic research results in the clinical study  report, or 
separately  and may  publish the results in sci entific journals. 
[COMPANY_004] may  share genetic research data with other scientists to further scientific 
understanding in alignment with the informed consent. [COMPANY_004] does not inform the subject, 
family  members, insurers, or employ ers of individual genoty pi[INVESTIGATOR_124619] s that are not 
known to be relevant to the subject’s medical care at the time of the study , unless 
required b y law. This is due to the fact that the information generated from genetic 
studies is generally preliminary in nature, and therefore the significance and scientific 
validity  of the results are undetermined.  Further, data generated in a research laboratory  
may not meet regulatory  requirements for inclusion in clinical care. 2018N377698_00
2016N277425_03 CONFIDENTIA L
[PHONE_13424].4. Appendix 4: Definition of and Procedures for Recording, 
Evaluating, Follow -Up and Reporting of A dverse Events
12.4.1. Definition of A dverse Events
Adverse Event Definition:
An AE is an y untoward medical occurrence in a patient or clinical investigation 
subject, temporall y associated with the use of a medicinal product, whether or not 
considered related to the medicinal product. Reporting Specific to Canada : For a 
marketed m edicinal product, this can also include failure to produce expected 
benefits (i.e. lack of efficacy , with or without associated signs or s ymptoms or 
clinical sequelae) .
NOTE: An AE can therefore be an yunfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a medicinal product.
Events meeting AE definition include:
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (e.g., ECGs, radiological scans, vital signs 
measurements), including those that worsen from baseline, and felt to be clinically  
significant in the medical and scientific judgement of the investigator.
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y treatment a dministration even 
though it may  have been present prior to the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a conco mitant medication (overdose per se will not be reported as an 
AE/SAE unless this is an intentional overdose taken with possible suicidal/self -
harming intent.  This should be reported regardless of sequelae).
Excluding Canada, "Lack of efficacy " or "failure of expected pharmacological 
action" per se will not be reported as an AE or SAE.  However, the signs and 
symptoms and/or clinical sequelae resulting from lack of efficacy  will be reported if 
they fulfil the definition of an AE or SAE.
Reporting Specific t o Canada: "Lack of efficacy" or "failure of expected 
pharmacological action" will be reported as an AE or SAE as per the table below 2018N377698_00
2016N277425_03 CONFIDENTIA L
[ADDRESS_864852] 
form (eCRF) onlyPaper form only Electronic case 
record form 
(eCRF) + Pape r 
form
Non serious Non drug related lack of 
efficacy  reports with 
associated signs or 
symptoms or clinical 
sequelae Drug related lack of 
efficacy  reports 
without associated 
signs or s ymptoms or 
clinical sequelae.Drug related lack 
of efficacy  with 
assoc iated signs or 
symptoms or 
clinical sequelae  
Serious Non drug related lack of 
efficacy  reports with 
associated signs or 
symptoms or clinical 
sequelae Drug related lack of 
efficacy  reports 
without associated 
signs or s ymptoms or 
clinical sequelae. Drug related lack 
of efficacy  reports 
with associated 
signs or symptoms 
or clinical sequelae
Events NOT meeting definition of an AE include:
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_99479]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more s evere than expected for the subject’s 
condition.
Medical or surgical procedure (e.g., endoscop y, appendectom y): the condition that 
leads to the procedure is an AE.
Situations where an untoward medical occurrence did not occur (social and/or 
convenience adm ission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
12.4.2. Definition of Serious A dverse Events
If an event is not an AE per definition above, th en it cannot be an SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_1080]/sy mptoms of the disease under study , 
death due to progression of disease, etc).
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, 
at an y dose:
a.Results in death
b.Is life -threatening
NOTE: 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
78The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
subject was at risk of death at the time of the event.  I t does not refer to an event, which 
hypothetically  migh t have caused death, if it were more severe.
c.Requires hospi[INVESTIGATOR_23916]:
In general, hospi[INVESTIGATOR_5184] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appropriate in the phy sician’s 
office or out -patient setting.  Complications that occur during hospi[INVESTIGATOR_23918].  If a complication prolongs hospi[INVESTIGATOR_645958], 
the event is serious.  When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen 
from baseli ne is not considered an AE.
d.Results in disability/incapacity
NOTE:
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medica l 
significance such as uncomplicated headache, nausea, vomiting, diarrhea , influenza, 
and accidental trauma (e.g. sprained ankle) which may  interfere or prevent every day 
life functions but do not constitute a substantial disruption
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospit alization but may  jeopardize 
the subject or may  require medical or surgical intervention to prevent one of the 
other outcomes listed in the above definition.  These should also be considered 
serious.
Examples of such events are invasive or malignant cancer s, intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse
g. Is associated with liver injury andimpaired liver fun ction defined as:
ALT 3xULN and total bilirubin*2xUL N (>35% direct), or
ALT 3xULN and INR**> 1.5.
* Serum bilirubin fractionation should be performed if testing is available; if unavailable, 
measure urinary  bilirubin via dipstick.  I f fractionation is unavailable and ALT 3xULN 
and total bilirubin  2xULN, then the event is still to be reported as an SAE.
** INR testing not required per protocol and the threshold value does not apply  to 
subjects receiving anticoagulants.  If INR measurement is obtained, the value is to be 
recorded on the SAE form. 2018N377698_00
2016N277425_03 CONFIDENTIA L
[PHONE_13425].4.3. Definition of Cardiovascular Events
Cardiovascular Events (CV) Definition:
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:
Myocardial inf arction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thromboembolism
Deep venous thrombosis/pulmonary  embolism
Revascularization
12.4.4. Recording of A Es and SA Es
AEs and SAE Recording:
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
relative to the event.
The investigator wi ll then record all relevant information regarding an AE/SAE in 
the electronic CRF and/or paper form as applicable .It is notacceptable for the 
investigator to send photocopi[INVESTIGATOR_9238]’s medical records to [COMPANY_004] in lieu of 
completion of the [COMPANY_004], AE/SA E CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_004].  In this instance, all subject identifiers, with the exception of the 
subject number, will be blinded on the copi[INVESTIGATOR_131976].
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  In such cases, the diagnosis will be 
documented as the AE/SAE and not the individual signs/sy mptoms.
Subje ct-completed Value Evidence and Outcomes questionnaires and the collection 
of AE data are independent components of the study .
Responses to each question in the Value Evidence and Outcomes questionnaire will 
be treated in accordance with standard scoring a nd statistical procedures detailed by  
[CONTACT_227417]’s developer. 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
80The use of a single question from a multidimensional health survey  to designate a 
cause -effect relationship to an AE is inappropriate.
12.4.5. Evaluating AEs and SA Es
Assessment of Intensity
The inves tigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and will assign it to one of the following categories:
Mild:  An event that is easily  tolerated by  [CONTACT_423], causing minimal discomfort 
and not interfering with e veryday activities.
Moderate:  An event that is sufficiently  discomforting to interfere with normal 
every day activities
Severe:  An event that prevents normal every day activities. -an AE that is assessed 
as severe will not be confused with an SAE. Severit y is a category utilized for rating 
the intensity  of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least one of the pre -defined 
outcomes as described in the definition of an SAE.
Assessment o f Causality
The investigator is obligated to assess the relationship between stud y treatment and 
the occurrence of each AE/SAE.
A "reasonable possibility " is meant to convey that there are facts/evidence or 
arguments to suggest a causal relationship, rath er than a relationship cannot be ruled 
out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as natural history  of the underly ing diseases, concomitant 
therap y, other risk factors, and the temporal relatio nship of the event to the study  
treatment will be considered and investigated.
The investigator will also consult the I nvestigator Brochure (IB) and/or Product 
Information, for marketed products, in the determination of his/her assessment.
For each AE/SAE the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations when an SAE has occurred and the investigator has minimal 
information to include in the initial rep ort to [COMPANY_004].  However, it is very important 
that the investigator always make an assessment of causality for every event 
prior to the initial transmission of the SAE data to [COMPANY_004].
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
81information, amending the SAE data collection tool accordingl y.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -up of A Es and SA Es
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as may  be indicated or as requested by  [CONTACT_90648]/or causality  of the AE or SAE.
The investigator is obligated to assist.  This may  include additional labo ratory  tests 
or investigations, histopathological examinations or consultation with other health 
care professionals.
If a subject dies during participation in the study  or during a recognized follow -up 
period, the investigator will provide [COMPANY_004] with a copy  of any  post -mortem findings, 
including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to [COMPANY_004] within the designated 
reporting time frames.
12.4.6. Reporting of SA Es to [COMPANY_004]
SAE reporting to [COMPANY_004] via electronic data collection tool
Primary  mechanism for reporting SAEs to [COMPANY_004] will be the electronic data collection 
tool
Reporting Specific to Canada : For lack of efficacy reports , the paper form will be 
used to submit to [COMPANY_004] as per the table in Section 12.4.1 above. 
If the electronic s ystem is unavailable for greater than 24 hours, the site will use the 
paper SAE data collection tool and fax it to the Medical Monitor
Site will enter the serious ad verse event data into the electronic s ystem as soon as it 
becomes available.
The investigator will be required to confirm review of the SAE causality  by [CONTACT_90649] ‘reviewed’ box at the bottom of the eCRF page within 72 hours of submission of 
the SAE.
After the stud y is completed at a given site, the electronic data collection tool (e.g., 
InForm s ystem) will be taken off- line to prevent the entry  of new data or changes to 
existing data
If a site receives a report of a new SAE from a study  subject or receiv es updated data 
on a previousl y reported SAE after the electronic data collection tool has been taken 
off-line, the site can report this information on a paper SAE form or to the Medical  2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
82Monitor by  [CONTACT_756].
Contacts for SAE receipt can be found at the be ginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774]. 2018N377698_00
2016N277425_03 CONFIDENTIA L
[PHONE_13426].5. Appendix 5: COPD Exacerbation Identification, 
Categorization and Treatment Guidelines
12.5.1. Guidelines for Identifying COPD Exacerbations
The following are s ymptoms used to ascert ain an exacerbation of COPD:
Worsening of two or more of the following major sy mptoms for at least two consecutive 
days:
Dyspnea
Sputum volume
Sputum purulence (color)
OR
Worsening of an y one major symptom together with any  one of the following minor 
symptoms for at least two consecutive day s:
Sore throat
Colds (nasal discharge and/or nasal congestion)
Fever (oral temperature > 37.5 °C) without other cause
Increased cough
Increased wheeze
Subjects who experience worsening COPD symptoms for greater than 24 h ours should: 
Contact [CONTACT_496979]/or research coordinator immediately , and 
report to the study  clinic as required
If the subject is unable to contact [CONTACT_23976] y Investigator and/or research 
coordinator, they  should contact [CONTACT_23975] (or other health care 
practitioner as required) and contact [CONTACT_23976] y site as soon as possible
Continue to record their symptoms and rescue albuterol/salbutamol usage in their 
daily  eDiary  
If the subject seeks emergency /acute care for worsening respi[INVESTIGATOR_23908], 
he/she should request the caring Health Care Provider (HCP) to contact [CONTACT_646014].
Subjects with worsening respi[INVESTIGATOR_496947]:
A mild/moderate/severe exacerbation and/or p neumonia
OR
A Lower Respi[INVESTIGATOR_645959] I nfection (L RTI) 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
84Background variability  of COPD
A non- respi[INVESTIGATOR_23910]
Other respi[INVESTIGATOR_23910]
12.5.2. COPD Exacerbation Severity
Each COPD exacerbation will be categorized based on severit y as follows:
Moderate :  Worsening sy mptoms of COPD that require treatment with 
oral/sy stemic corticosteroids and/or antibiotics.
Severe : Worsening s ymptoms of COPD that require treatment with in -patient 
hospi[INVESTIGATOR_26109] [ADDRESS_864853] X -Ray for pneumonia and/or moderate/severe exacerbation is not mandated but 
can be performed if required b y the investigator as part of standard care of subjects.
Details of an exacerbation should be recorded in the exacerbation page of the eCRF. 
However, exacerbations should not be recorded in the AE section of the eCRF unless 
they meet the definition of an SAE. (Pneumonia must be recorded in the AE or SAE 
section of the eCRF and on the Pneumonia page of the eCRF.)
Use of antibiotics for the treatment of upper or lower respi[INVESTIGATOR_496948] a COPD exacerbation unless the subject experiences worsening s ymptoms 
of COPD which match the definition of an exacerbation as given above.
12.5.3. Treatment of COPD Exacerbations
All medications used for the tr eatment of exacerbations must be recorded in the source 
documents and the exacerbation page of the eCRF.  All sites should follow the protocol 
treatment guidelines (as outlined below), but an y medications deemed medically  
necessary  may  be used to treat a C OPD exacerbation. However, caution is advised in 
using a LABA or LAMA to treat a subject currently taking IP as these additional 
medications may  increase the risk of overdose. If necessary  the PI [INVESTIGATOR_645960]’s IP te mporaril y in order to treat the COPD exacerbation.
12.5.4. Guidelines for Treatment with Corticosteroids
If in the opi[INVESTIGATOR_689]/treating ph ysician the exacerbation is severe enough 
to warrant the need for oral or sy stemic corticosteroids (with or wi thout antibiotics) the 
following guidelines should be used.
The duration of treatment with oral/sy stemic corticosteroids should be 14 day s 
(dose and t ype according to local practice) 
The duration of treatment with oral/sy stemic corticosteroids should no t exceed 14 
days unless approval is given by  [CONTACT_107634]
Any course of oral/s ystemic corticosteroids started within 7 day s of finishing a 
previous course will be considered as treatment for a single exacerbation 2018N377698_00
2016N277425_03 CONFIDENTIA L
[PHONE_13427].5.5. Guidelines for Treatment w ith A ntibiotics
If there is evidence of respi[INVESTIGATOR_645961]:
The duration of treatment with antibiotics should not exceed 14 day s (dose and ty pe 
according to local practice). If first line antibiotic treatment fails and additional 
antibiotics are used, the total duration of antibiotic treatment should not exceed 30 
days unless approval is given by  [CONTACT_646015]
Any course of antibiotics started within [ADDRESS_864854] day  (of at least 2 consecutive day s) of worsening s ymptoms 
of COPD as described in Section 12.5.1.
The date of resolution should be based on when the Investigator and/ or subject 
determines that the COPD sy mptoms have returned to pre -exacerbation levels or to a new 
baseline.  In determining this resolution date, consideration should be given to diary  
recorded s ymptoms and/or study  subject evaluation.
12.5.7. Guideline for assess ing multiple mild exacerbations
Two mild exacerbations can be combined into one, per the Investigator’s judgement, if a 
subject’s diary  reveals that the two mild COPD exacerbations are separated by  [CONTACT_646016] s.
12.5.8. Guideline for a ssessing exacerbations that increase in severity
If an exacerbation starts off as mild, but becomes moderate or severe or starts off as 
moderate and becomes severe, the exacerbation should be captured as one exacerbation 
and classified b y its highest level of severity . 2018N377698_00
2016N277425_03 CONFIDENTIA L
[PHONE_13428].6. Appendix 6: Definition of and Procedures for Documenting 
Medical Device Incidents
12.6.1. Definitions of a Medical Device Incident
The detection and documentation procedures described in this protocol apply  to all [COMPANY_004] 
medical devices provided for use in the study  (see Section 6.2for the list of [COMPANY_004] medical 
devices).
Medical Device Incident Definition:
Incident –Any malfunction or deterioration in the characteristics and/or performance 
of a device, as well as any  inadequacy  in the labeling or the instructions for use 
which, directl y or indirectly , might lead to or might have led to the death of a 
patient/user/other persons or to a serious deterioration in their state of health.
Not all incidents lead to dea th or serious deterioration in health.  The non -occurrence 
of such a result might have been due to other fortunate circumstances or to the 
intervention of health care personnel.
It is sufficient that:
 an incident associated with a device happened and
 the incident was such that, if it occurred again, might lead to death or a serious 
deterioration in health.
 A serious deterioration in state of health can include:
 life-threatening illness
 permanent impairment of body  function or permanent damage to a bod y stru cture
 a condition necessitating medical or surgical intervention to prevent one of the 
above 
 fetal distress, fetal death or an y congenital abnormality  or birth defects
Examples of incidents
a patient, user, care giver or professional is injured as a resul t of a medical device 
failure or its misuse
a patient’s treatment is interrupted or compromised by  a medical device failure
misdiagnosis due to medical device failure leads to inappropriate treatment
a patient’s health deteriorates due to medical device fa ilure 2018N377698_00
2016N277425_03 CONFIDENTIA L
[PHONE_13429].6.2. Documenting Medical Device Incidents
Medical Device Incident Documenting:
Any medical device incident occurring during the study  will be documented in the 
subject’s medical records, in accordance with the investigator’s normal clinical 
practice, and on the appropriate form.
For incidents fulfilling the definition of an AE or an SAE, the appropriate AE/SAE 
CRF page will be completed as described in Appendix 4 .
The form will be completed as thoroughl y as possible and signed b y the investigator 
before transmittal to [COMPANY_004].
It is very  important that the investigator provides his/her assessment of causality  to 
the medical device provided by  [CONTACT_132017], and describes 
any corrective or remedial ac tions taken to prevent recurrence of the incident.
A remedial action is an y action other than routine maintenance or servicing of a 
device where such action is necessary to prevent recurrence of an incident. This 
includes an y amendment to the design to pre vent recurrence. 2018N377698_00
2016N277425_03 CONFIDENTIA L
[PHONE_13430].7. Appendix 7: Modified List of Highly  Effective Methods for 
Avoiding Pregnancy  in FRP and Collection of Pregnancy  
Information
12.7.1. Modified List of Highly Effective Methods for Avoiding Pregnancy  
in Females of Reproductive Potential (FRP)
The lis t does not apply  to FRP with same sex partners or for subjects who are and will 
continue to be abstinent from penile-vaginal intercourse on a long term and persistent 
basis, when this is their preferred and usual lifest yle. Periodic abstinence (e.g. calen dar, 
ovulation, sy mptothermal, post -ovulation methods) and withdrawal are not acceptable 
methods of contraception.
1.Contraceptive subdermal implant
2.Intrauterine device or intrauterine s ystem
3. Combined estrogen and progestogen oral contraceptive [ Hatcher , 2011]
4.Injectable progestogen [ Hatcher , 2011]
5.Contraceptive vaginal ring [ Hatcher , 2011]
6.Percutaneous contraceptive patches [ Hatcher , 2011]
7. Male partner sterilization with documentation of azoospermia prior to the female 
subject's entry  into the study , and this male is the sole partner for that subject 
[Hatcher , 2011]. The documentation on male sterility  can come from the site 
personnel’s: review of subject’s medical records, medical examination and/or semen 
analysis, or medical history  interview provided b y her or her partner.
These allowed methods of contraceptio n are only  effective when used consistently , 
correctly  and in accordance with the product label. The investigator is responsible for 
ensuring that subjects understand how to properl y use these methods of contraception.
12.7.2. Collection of Pregnancy  Information
Investigator will collect pregnancy  information on any  female subject, who becomes 
pregnant while participating in this study
Information will be recorded on the appropriate form and submitted to [COMPANY_004] within [ADDRESS_864855]'s pregnancy .
Subject will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow up information on mother and infant, which will be 
forwarded to [COMPANY_004].  Generall y, follow -up will not be required for longer than 6 to 8 
weeks bey ond the es timated delivery  date. 
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or ele ctive termination of a pregnancy  will be reported as an AE or 
SAE. 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
89A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such.  
Any SAE occurring as a result of a post -study  pregnancy  which is considered 
reasonabl y related to th e study  treatment by  [CONTACT_093], will be reported to [COMPANY_004] 
as described in Appendix [ADDRESS_864856] who becomes pregnant while participating 
will be withdrawn from the study 2018N377698_00
2016N277425_03 CONFIDENTIA L
[PHONE_13431].8. Appendix 8: Country  Specific Requirements
In Canada onl y, additions were made to Section 7.4.1 and Appendix 4 to comply  with 
Health Canada guidelines concerning the require ment of pharmaceutical manufacturers to 
expeditiously  report domestic cases of unusual failure in efficacy  (UFIE) for new drugs 
to the Marketed Health Produ cts Directorate (MHPD) within [ADDRESS_864857] notification. 2018N377698_00
2016N277425_03 CONFIDENTIA L
[PHONE_13432].9. Appendix 9 : Protocol changes
Revision History
2016N277425_00 2016 -SEP-13 Original
2016N277425_01 2017 -FEB-07 Amendment No. 1
2016N277425_02 2017 -FEB-21 Amendment No. 2 Canada 
only
2016N277425_03 2017-APR -18 Amendment No. 3
12.9.1. Protocol A mendment 1
Scope:
This amendment applies to all sites
Protocol Changes for Amendment No.1 are summarised below.
Strike through text refers to deleted text and underlined refers to added text.
Protocol Changes:
Title
Rationale for change:   Correct a t ypographical error in the title: Umeclidi mium to 
Umeclidinium
Regulatory Agency Identifying Number(s):  
Rationale for change:   To correct a t ypographical error of the EudraCT no. and add an 
IND no.
Revised text: Eudra CT no 2016 -002513 -226, 2016 -002513 -22, IND no. 104479 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
92Section 1
Overall Design
Rationale for change: To Correct a t ypographical error in the last paragraph.
Revised text: Salmeterol , salbutamol
“This is a multi -centre, randomized, double blind, double-dum my, 3-arm parallel group 
study .  Eligible subjects will be stratified based on long -acting bronchodilator usage 
during the run- in (none, one or 2 long -acting bronchodilators per day ) and randomized in 
a ratio of 1:1:1 to UMEC/VI  inhalation powder (62.5/25 mcg once dail y) administered 
via the ELLIPTA inhaler, or UMEC (62.5 mcg once dail y) administered via the 
ELLIPTA or salmeterol (50 mcg BID) administered via the DISKUS. 
There will be a total of 5 clinic visits and one follow -up phone call (Visit 6). The P re-
screening Visit (Visit 0) can occur on the same day  as the Screening Visit (Visit 1) if 
subject does not take or has not taken an y excluded protocol medications, but must be 
completed prior to initiating an y Visit [ADDRESS_864858]’s eligibility  for the stud y. During the run-
in period subjects will continue with their inhaled COPD medications (excluding ICS and 
any exclusionary  medications).  I n addition, subjects will be provided with short acting 
albuterol/ salmeterol salbutamol to be used on as needed basis for relief of COPD 
symptoms (rescue medication) throughout the study ”. 
Section 4.4 Design justification: To be consistent with Section [IP_ADDRESS] and Section 7.1 
the wording has been updated.
Rationale for change: Ensure consistency with Section [IP_ADDRESS] and Section 7.1 the 
wording has been changed in paragraph 5.
Revised text: “Other endpoints such SAC TDI , E-RS, S GRQ -C, CAT, Subject Global 
Rating of COPD Severity and Change in Global Rating impression of Change in COPD  
disease severity are captured to allow responder analy ses and to provide comparative data 
on PROs between the treatment groups”. 
Section 7.1 Time and Event table
Rationale for change; to:
Correct an un-intentional deletion of the (“x”) in some cells and confirm that concomitant 
medications should be reviewed at every  clinic visit.
Increase the visit window from 2days to - 7/+2
Ensure consistency of wording between Section 7.2 and T able 7.1. “ Written” was deleted
Include height and weight at Screening and correct errors in foot note no.11
“In order to ensure subjects have sufficient doses of study  treatment, they  must return to 
clinic within 30 da ys from V2 and within 60 and 90 days from V3 and V4 respectivel y” 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
93Blinded Treatment
VisitPre-
screen1
0Screen/ 
Run-in
1Rando -
mization 
[ADDRESS_864859] 
6
Week -6 to -4 -4 0 4 12 24
Day42 2
-7/+2 
days 
prior 
Visit 128 2
-7/+2 days 
prior Visit 
212 -7/+2 
days28 2 -7/+2 
days 84 2 
days168  2 -7/+2 
days723 days after V5 
or EW Visit
Screen/Baseline
Written Informed consent X
Demography X
Medical/COPD history X
Smoking history/status X
Smoking cessation counselling X
Concomitant medication assessment X X X X X X X X
Height and weight X
Cardiovascular History/family history of premature CV 
disease])X
Screening spi[INVESTIGATOR_038] (including post bronchodilator 
testing )3X
CAT questionnaire X X
Verify Inclusion/Exclusion Criteria X
Training on use of inhalers X X
Training on use of eDiary and e MDI X X
Verify randomization Criteria X
Register Visit in InForm X X X X X X X X
Register Visit in RAMOS NG X X X X X X X X 
 
 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
94Blinded Treatment
VisitPre-
screen1
0Screen/ 
Run-in
1Rando -
mization 
[ADDRESS_864860] 
6
Week -6 to -4 -4 0 4 12 24
Day42 2
-7/+2 
days 
prior 
Visit 128 2
-7/+2 days 
prior Visit 
212 -7/+2 
days28 2 -7/+2 
days 84 2 
days168  2 -7/+2 
days723 days after V5 
or EW Visit
Efficacy/HRQoL assessments
Spi[INVESTIGATOR_038], including pre -dose FEV 1, trough  FEV 1and 
inspi[INVESTIGATOR_645933] X X X
SAC BDI questionnaire4 X
SAC TDI questionnaire4 X X X
SGRQ -C questionnaire [ADDRESS_864861]/ER -S: COPD 5
Patient Global Rating of COPD severity X X X X
Patient Global Rating of Change in COPD X X X
Safety assessments
Adverse events/Serious adverse events6 X X X X X X X X
COPD exacerbation assessment X X X X X X X X
12-Lead ECG X
Urine pregnancy test 7 X X X X
Pharm acogenetic sample8                                             X
Medication/Supplies
Dispense rescue albuterol/slabutamol. Dispense MDI9 X X X X X
Assess COPD medication compliance10 during run -in X
Dispense eDiary X
Assess compliance with eDiary during run -in X
Collect rescue albuterol/slabutamol. X X X X X
Collect eDiary X X
Dispense study treatment11 X X X 
 
 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
95Blinded Treatment
VisitPre-
screen1
0Screen/ 
Run-in
1Rando -
mization 
[ADDRESS_864862] 
6
Week -6 to -4 -4 0 4 12 24
Day42 2
-7/+2 
days 
prior 
Visit 128 2
-7/+2 days 
prior Visit 
212 -7/+2 
days28 2 -7/+2 
days 84 2 
days168  2 -7/+2 
days7[ADDRESS_864863] be completed prior to Screening Visit1. It can be completed 2 weeks prior or on the same day of V1, if no wash out of exclusionary medications is 
required. 
2. Early Withdrawal Visit: Subjects that withdraw should return to the clinic as soon as possible to complete the Early Withdraw al Visit procedures.
3. Spi[INVESTIGATOR_645934] (Section [IP_ADDRESS]). 
4. SAC BDI, SAC TDI, SGRQ- C, CAT questionnaires will be completed at clinic visits and in the eDiary
5. EXACT/ER -S: COPD is completed daily in the eDiary approximately 2 hours before bed -time, starting on Day 1 of the run -in period.
6. For the start date of collecting AEs and SAEs see (Appendix 4)
7. Pregnancy test: for females for child bearing potential only.
8. Pharmacogenetic sample may be drawn at visit [ADDRESS_864864] return to clinic within 30 days from V2 and within 60 and 90 days from V3 and V4 respectively.
12. The Actigraph GT9X should be worn for 7 days from Visit 1, for 7 days from Visit 2, for 7 days from Visit 3 and for 7 days prior to Visit 5. 
 
 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
96Section 7.2.2 Critical procedures performed at Screening (Visit 1)
Rationale for change:   To clarify  that height and weight are collected at V1
Revised text: “Height and weight”
Section 7.3.2 Spi[INVESTIGATOR_645962]:  To further clarify  that spi[INVESTIGATOR_645963] [ADDRESS_864865] inhales their usual morning COPD medication(s) a bullet point 
was added. “At Screening Visit 1, before the morning dose of usual COPD medications”
Revised text :
“Spi[INVESTIGATOR_645964] [ Miller , 2005]. All sites 
will use standardized spi[INVESTIGATOR_645942].
All subjects will have spi[INVESTIGATOR_645943]  (see Section 
[IP_ADDRESS]) and at Visits 2, 3, [ADDRESS_864866] 3 acceptable spi[INVESTIGATOR_496921] (with no 
more than 8) should be obtained. Acceptable spi[INVESTIGATOR_496922] a satisfactory  
start of test and end of test (i.e. a plateau in the volume time curve) and be free from 
artifacts due to cough, early  termination, poor effort, obstructed mouthpi[INVESTIGATOR_13959], equipment 
malfunction, or other reasons [ Miller , 2005].
The largest FEV 1and FVC from the 3 acceptable efforts should be recorded, even if they  
do not come from the same effort.
Spi[INVESTIGATOR_645944] 1and FVC assessments that is not obtained as follows will be 
considered a protocol deviation:
Started between 6:00AM and 11:00AM.
After withholding albuterol/salbutamol (all visits) for ≥4 hours
At Screening Visit 1, after wash out of medications as specified in the exclusion 
criteria in Section 5.2 (Concomitant Medications).
At Screening Visit 1, before the morning dose of usual COPD medications
At Visit [ADDRESS_864867] dose 
of study  treatment 
At Visit 3, 4 and 5 after withholding the morning dose of study  treatment.
Pre dose assessment performed prior dosing.
Subjects should refrain from smoking for [ADDRESS_864868].
Trough FEV 1measurements for UMC/VI  or UMEC on Weeks 4, 12 and 24 (Visits 3, 4 
and 5) should be performed 23 hours and 24 hours after the previous day ’s dose of study  
medication recorded in the eDiary . This will also provide trough FEV 1measurements for 
the evening dose of salmeterol”.  2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
978. Physical activity monitor (study subset)
Rationale for changes: Ensure consistency  of the wording bet ween Section 1 and 
Section 4.1 “overall design” and Section 7.3.7.
per treatment arm added to paragraph 4.
Revised Text : 
Physical activity monitor (study subset)
“Phy sical activity  limitation is a common feature of COPD and its measures are highl y 
relate d to the degree of disease severity  [Watz, 2009]. 
Reduced ph ysical activity  levels in COPD is associated with increased morbidity  and 
mortality , sustained disability , depression, and social and phy sical isolation [ Shu-Yi, 
2014; Gimeno, 2014] 
Improved act ivity has been identified as an important factor that may  modify  morbidity  
and mortality  in COPD [ Moy , 2012 ].
The Actigraph GT9X phy sical activity  monitor will be used to measure levels of activity . 
The activity  monitor will be worn by  [CONTACT_422906]  150 subjects per treatment arm 
for 7 day s from Screening (Visit 1), for 7 day s from Randomisation (Visit 2), 7 day s from 
Visit 3 (Week 4) and for 7 day s prior to Week 24 (Visit 5).
There will be [ADDRESS_864869] will be given an activity  
monitor and instruction leaflet at the start of each assessment period. Further details of 
distribution, operation and retrieval of the monitors will b e provided in the SRM” .
12.9.2. Country -specific Protocol A mendment [ADDRESS_864870] be documented and reported.
Strike through text refers to deleted text and underlined refers to added text.
Section 7.4.1 Adverse Events (AE) and serious Adverse Events (SAEs)
Rationale for change : A new Section added to include information related to 
documenting events related to lack of efficacy .
Revised text: 
“[IP_ADDRESS] Additional Adverse Event (AE) Reporting Requirements for Canadian 
investigators
Health Canada requires pharmaceutical manufacturers to expeditiously  report domes tic 
cases of unusual failure in efficacy  (UFIE) for new drugs to the Marketed Health 
Products Directorate (MHPD) within [ADDRESS_864871] notification. This regulation applies 
to marketed drugs, and used as directed per the Canadian prescribing information,
including those drugs used in Phase IV (non CTA filed) clinical trials.  
Adverse event (AE): Any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not 
necessarily  have to have a causal relationship with this treatment. An AE can therefore 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
98be an y unfavourable and unintended sign (including an abnormal laboratory finding) 
symptom or disease (new or exacerbated) temporally  associated with the use of a 
Medicinal Product .For a mar keted Medicinal Product, this can also include failure 
to produce expected benefits (i.e. lack of efficacy, with or without an adverse event), 
In order for [COMPANY_004] to comply  this Canadian regulatory  requirement, Canadian investigators 
are required to collect, record and report lack of efficacy  events as per the table in 
Appendix 4 Section 12.4.1 ”.  
All paper forms are required to be faxed to [COMPANY_004] Canada’s Drug Safety  department at 
 within [ADDRESS_864872] awareness.
Appendix 4, Section 12.4.1 
Rationale for change: To add a small table about reporting of AEs.
Revised text .The table below was added.
Adverse 
Event 
criteriaElectronic case record 
form (eCRF) onlyPaper form only Electronic case 
record form 
(eCRF) + Paper 
form
Non serious Non drug related lack of 
efficacy  reports with 
associated signs or 
symptoms or clinical 
sequelae Drug related lack of 
efficacy  reports 
without associated 
signs or s ymptoms or 
clinical sequelae.Drug related lack 
of efficacy  with 
associated signs or 
symptoms or 
clinical sequelae  
Serious Non drug related lack of 
efficacy  reports with 
associated signs or 
symptoms or clinical 
sequelae Drug related lack of 
efficacy  reports 
without associated 
signs or s ymptoms or 
clinical sequelae. Drug related lack 
of efficacy repo rts 
with associated 
signs or s ymptoms 
or clinical sequelae 
Appendix 4, Section 12.4.4, second bullet point
Revised text: 
The investigator will then record all relevant information regarding an AE/SAE in the 
electronic CRF “and/or paper form as applicab le”.  Added
Section 12.4.6, second bullet point
Revised text: 
“For lack of efficacy  reports the paper form will be used to submit to [COMPANY_004] as per the
table in Section 12.4.1 above ”. Added 2018N377698_00
PP
2016N277425_03 CONFIDENTIA L
[PHONE_13433].9.3. Protocol A mendment 3
Protocol changes for Amendment 03, from protoc ol changes to amendment 02 (21-
Feb-2014)
Scope: This amendment applies to all sites
Amendment [ADDRESS_864873] of Specific Changes
Section 1 Objective(s)/Endpoint( s) and Section 3 Objective(s)/Endpoint(s)
Rationale for change: Rate of COPD exacerbations endpoints from tertiary to 
exploratory due to stoppi[INVESTIGATOR_3418] . 
Revised text :
Exploratory
To explore the effect of UMEC/VI  
(62.5/25 mcg once dail y), UMEC 
(62.5 mcg once daily ) with salmeterol 
(50mcg twice daily) on rate of COPD 
exacerbationRate of mild, moderate or severe 
exacerbations
Rate of moderate or severe 
exacerbation
Section 1. Overall Design
Rationale for change: To clarify  study  design and content of section to agree with 
Section 4.1
Revised text: 
There will be a total of 5 clinic visits and one follow -up phone call (Visit 6). A pre -
screening visit (Visit 0) may  be required in order to administer the informed consent 
before an y changes are made to th e subject’s current medication regimen. If no changes 
in medication are required, V0 (pre -screening) and V1 (screening) may  be conducted on 
the same day .Inhaled long -acting muscarinic antagonist (LAMA) or long -acting beta 2-
agonist (LABA) and/or albuterol/ salbutamol as needed (rescue medication) are not 
exclusionary  prior to Screening or during the run -in.
Eligible subjects at Screening Visit [ADDRESS_864874] 6 weeks 
ICS and ICS/LABA free with an FEV 1post-albuterol/salbutamol of ≥30% to ≤80% 
predicted normal and a FEV 1/FVC <0.7 and a CAT score ≥10. 
Subjects using inhaled LAMA or LABA medication must withhold their morning dose 
prior to Screening spi[INVESTIGATOR_038] . Subjects who meet all other eligibility  criteria at Screening 
will enter a run -in period for 4 weeks. During the run -in period ,subjects will continue 
with their inhaled LAMA or LABA .  In addition, subjects will be provided with short 
acting albuterol/salbutamol as needed for relief of COPD sy mptoms (rescue medication)  2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
100througho ut the study .Eligible subjects at Screening will enter a run -in period for 4 weeks 
during which they  continue taking their inhaled COPD medications (excluding ICS and 
any exclusionary  medications).  I n addition, subjects will be provided with short acting 
albuterol/salbutamol to be used on as needed basis (rescue medication) throughout the 
study .
Subjects who experience a moderate or severe COPD exacerbation during the run -in 
period will be deemed run- in failures.  Subjects who experience a mild COPD 
exacer bation, defined as worsening of s ymptoms that requires notreatment with 
antibiotics or steroids and is self managed b y the patient by [CONTACT_645993]’s medical monitor. Subjects experiencing a mild 
exacerbation, defined as worsening of s ymptoms that requires notreatment with 
antibiotics or steroids and is self managed b y the patient by [CONTACT_646017], will be allowed to continue in the study.
At the randomization Visit 2 (Day  1), those subjects who successfull y complete the run-
in period as well as meet the other pre -defined eligibility  and randomization criteria will 
discontinue their inhaled COPD medications and will be randomized to one of the 
3treatment arms for [ADDRESS_864875] medical problems experienced during the stud y.  
Subjects will be performing slow and forced spi[INVESTIGATOR_645965].
There will be a total of 5 clinic visits and one follow -up phone call (Visit 6).  The total 
duration of subject participation in the study  will be approximately  29 to 31 weeks 
consis ting of 2 weeks pre- screening if necessary , 4 weeks run -in, 24 week treatment and 
one week Follow -Up. 
In addition, a subset of subjects up to 150(approximately  150 per treatment arm) will 
undergo assessment of their phy sical activity  measured through a phy sical activity  
monitor (Actigraph GT9X) worn for 7 day sfrom Screening (Visit 1), for 7 day s from 
Randomisation (Visit 2), [ADDRESS_864876] clinic Visit 
(Visit 5).
The occurrence of adverse events (AEs) will be evaluate d throughout the study  beginning 
at Visit 2 (Day  1) and until the follow -up contact (Visit 6).  Serious adverse events 
(SAEs) will be collected over the same time period as AEs.  However, an y SAEs 
assessed as related to study  participation (e.g., study  treatment, protocol- mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] concomitant 
medication, will be recorded from the time a subject consents to participate in the study  
up to and including an y follow up contact.
All su bjects will be given an electronic diary  (eDiary ) for use during the run -in, and the 
treatment period to complete PRO questionnaires, record COPD daily  symptoms and the 
time they  take their COPD medications.  Dail y rescue medication usage (number of 
inhala tions taken in the last 24 h) will also be captured in the eDiary.  In addition, and in  2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
101some countries, rescue medication use will also be captured b y the use of electronic 
metered dose inhaler (eMDI).
At Screening Visit 1, all subjects must be trained on the proper use of their existing 
COPD medications inhalation devices and instructed to strictly  adhere to and record the 
time they  take their COPD medications in the eDiary .
At the randomization Visit 2, all subjects must be trained on the proper use of th e 
ELLIPTA and DISKUS inhalation devices and instructed to strictly  adhere to and record 
the time they  take their study  medications in the eDiary .
All subjects must be trained on the correct use of the eDiary  and instructed to complete 
the eDiary  during th e run -in and treatment period.
There are no plans to routinely  provide any  of the study  treatments for compassionate use 
following stud y completion as the study treatment are commerciall y available.
Section 1. Treatment Arms and Duration
Rationale for chan ge: clarify  stratification and treatment arms
Revised text: Subjects will be stratified based on long -acting bronchodilator usage 
during the run- in (none or one or 2long-acting bronchodilator sper day ) and randomized 
in a ratio of 1:1:1 to either
UMEC/VI  62.5/25 mcg once dail y via ELLIPTA + placebo twice dail y via 
DISKUS
UMEC 62.5 mcg once daily  via ELLIPTA + placebo twice dail y via DISKUS
Salmeterol 50 mcg twice daily  via DI SKUS + placebo once daily  via ELLIPTA
Rationale for change: Clarify permitted and prohibited Screening and run -in COPD 
medications
Revised text: *Subjects may continue the use of inhaled LAMAs or LABAs and /orstudy 
provided albuterol/salbutamol as needed (rescue medication). Inhaled COPD medications 
including LABAs, LAMAs or LABA/LAMA combination products are allowed in run -in. ICS alone 
or in combination with a bronchodilator or any exclusionary medications are not allowed.
Section 4.1 Study Design
Rationale for change: To clarify  study  design
Revised text:
This is a multi -centre, randomized, double blind, double- dummy , 3-arm parallel group 
study .  Eligible subjects will be stratified based on long- acting bronchodilator usage 
during the run- in (none, one or 2 long -acting bronchodilators per day ) and randomized in 
a ratio of 1:1:1 to UM EC/VI  inhalation powder (62.5/25 mcg once dail y) administered 
via the ELLIPTA™dry powder inhaler, or UMEC (62.5 mcg once daily) administered via 
the ELLIPTA™or salmeterol (50 mcg BID) administered via the DISKUS. 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
102A pre -screening visit (Visit 0) may  be re quired in order to administer the informed 
consent before an y changes are made to the subject’s current medication regimen. If no 
changes in medication are required, V0 (pre- screening) and V1 (screening) may  be 
conducted on the same day .Inhaled long-actin g muscarinic antagonist (LAMA) or long-
acting beta 2-agonist (LABA) medications are not exclusionary  prior to Screening or 
during the run- in. The Pre -screening Visit (Visit 0) can occur on the same day  as the 
Screening Visit (Visit 1) if subject does not ta ke or has not taken an y excluded protocol 
medications, but must be completed prior to initiating an y Visit [ADDRESS_864877] 6 weeks 
ICS and ICS/LABA free with an FEV 1post-albute rol/salbutamol of ≥30% to ≤80% 
predicted normal and a FEV 1/FVC <0.7 and a CAT score ≥10.
Subjects using inhaled LAMA or LABA medication must withhold their morning dose 
prior to Screening spi[INVESTIGATOR_038] . Subjects who meet all other eligibility  criteria at Scre ening 
will enter a run -in period for [ADDRESS_864878]’s 
eligibility  for the study During the run- in period, subjects will continue with their inhaled 
COPD medications (excluding ICS and an y exclusionary  medications) their inhaled 
LAMA or LABA medication .  In addition, subjects will be provided with short acting 
albuterol/salbutamol to be used on as needed basis for relief of COPD s ymptoms (rescue 
medication) throughout the study .
At the randomization Visit 2 (Day  1) those subjects who successfull y complete the run- in 
period as well as meet the other pre -defined eligibility  and randomization criteria will
discontinue their inhaled COPD medications and will be randomized to one of the 3 
treatment arms for 24 weeks.
In addition, a subset of subjects up to 150 (approximately  150 per treatment arm) will 
undergo assessment of their phy sical activity  measured through a ph ysical activity  
monitor (Actigraph GT9X) worn for 7 day sfrom Screening (Visit 1), for 7 day s from 
Randomisatio n (Visit 2), [ADDRESS_864879] clinic Visit 
(Visit 5).
During the run-in and treatment period, subjects will be completing PRO questionnaires 
in the eDiary  and performing slow and forced spi[INVESTIGATOR_645966].
Concurrent use of COPD maintenance medications including LAMAs, LABAs, oral beta -
agonists, theoph yllines, inhaled corticosteroids, inhaled corticosteroids and L ABA 
combination and phosphodiesterase 4 inhibitors will not be allowed during the stud y 
(Section 6.11.2) . 
*Subjects may continue the use of inhaled LAMAs or LABAs and /orstudy  provided 
albuterol/salbutamol as needed (rescue medication) during the run -in while adhering to the 
withholding of other COPD medications detailed in the Exclusion Criteria. Inhaled COPD 
medications including LABAs, LAMAs or LABA/LAMA combination products are allowed in run -in. 
ICS alone or in combination with a bronchodilator or any exclusionary medications are not 
allowed. 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
103Section 4.2 Treatment Arms and Duration
Rationale for change: clarify  stratification and treatment arms
Revised text: Subjects will be stratified based on long -acting bronchodilator usage 
during the run- in (none or one or 2long-acting bronchodilator sper day ) and randomized 
in a ratio of 1:1:1 to either
UMEC/VI  62.5/25 mcg once dail y via ELLIPTA + placebo twice dail y via 
DISKUS
UMEC 62.5 mcg once daily  via ELLIPTA + placebo twice dail y via DISKUS
Salmeterol 50 mcg twice daily  via DI SKUS + placebo once daily  via ELLIPTA
Section 4.2 Type and N umber of Subje cts
Rationale for change: clarify  number of sites
Revised text :
Approximately  3232 will be screened globall y in approximately  240 205 sites such that 
approximately  2424 subjects will be randomized and approximately  2181 evaluable 
subjects complete the stu dy.
Section 5.1 Inclusion Criteria
Rationale for change: Addition of inclusion criterion specific to [LOCATION_009] 
Revised text: French subjects : In [LOCATION_009], a subject will be eligible for inclusion in this 
study  only if either affiliated to or a beneficiary of a social security  category.
Rationale for change: typo
40 years or older at date of signing informed consent at Screening Visit 1
Section 5.2 Exclusion Criteria
Rationale for change: typo 
Revised text: Pneumonia and/or moderate or severe COPD exacerbatio n 
Rationale for change: clarify  prohibited Screening and run -in COPD medications
Revised text:
15. Medications prior to Screening: Use of the following medications according to the 
following defined time intervals prior to Screening (Visit 1) or during th e study :
Medication No use within the 
following time intervals 
prior to Screening and 
thereafter at any time 
during the study
Inhaled corticosteroids (ICS) 6 weeks
Depot corticosteroids 12 weeks
Systemic, oral or parenteral corticosteroidsa 6 weeks
Antibiotics (for lower respi[INVESTIGATOR_1092])b 6 weeks
Phosphodiesterase 4 (PDE 4) Inhibitor ( e.groflumilast) 14 days 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
104LABA/Inhaled Corticosteroid (ICS) combination products 6 weeks
LABA/LAMA combination products 2 weeks
Theophyllines 48 hours
Oral beta 2-agonists
     Long- acting
     Short -acting48 hours
12 hours
Inhaled short acting beta 2-agonistsb 4 hours
Inhaled short -acting anticholinergics 4 hours
Inhaled short -acting anticholinergic/short -acting beta 2-agonist 
combination products4 hours
Any other investigational medication 30 days or within 5 drug 
half-lives (whichever is 
longer)
a- Corticosteroids are allowed for the treatment of COPD exacerbations during the double -blind treatment 
phase of the study. Localized corticosteroid injections (e.g., intra -articular and epi[INVESTIGATOR_13873]) are permitted.
b- Use of study provided albuterol/salbutamol is permitted during the study, except in the 4 -hour period prior to 
spi[INVESTIGATOR_68333]
2. Medication prior to spi[INVESTIGATOR_038]: Unable to withhold albuterol/salbutamo l for the 
[ADDRESS_864880]’s inhaled LABA or LAMA COPD medication prior 
to spi[INVESTIGATOR_645967] (Visit 1). 
Section 5.3 Randomization Criteri a
Rationale for change: clarification of prohibited medications at randomization
Revised text: Prohibited Medications: No use of an y prohibited medications during the 
run-in period or at Visit 2, including an y ICS or ICS/L ABA combination . Subject’s 
inhale d LABA or LAMA medication morning dose must be withheld and discontinued at 
Visit 2.
Section 5.5.1. Withdrawal from the Study
Rationale for change: Clarify  stoppi[INVESTIGATOR_645968]:
Stoppi[INVESTIGATOR_2121]
A subject will also must be withdrawn from the study , in consultation with the medical 
monitor and principal investigator, if an y of the following stoppi[INVESTIGATOR_23893]:
Unstable or life threatening cardiac events : myocardial infarction, hospi[INVESTIGATOR_81076], stroke, an d other cardiovascular events considered life -or 
intensively  health -threatening by  [CONTACT_7536].
COPD Exacerbations: Subjects with two moderate or one severe COPD 
exacerbation during the study .
Withdrawal from study treatment requires withdrawal from the study . 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
105Non-Compliance with Study treatment : Subjects’ compliance with stud y treatment 
will be assessed at each study  visit. Subjects who are non- compliant should be re -
educated on the requirement for treatment compliance. Every effort will be made to 
keep subjects in the study  and to re -educate those subjects who continue to be non -
compliant.  Subjects who continue to be non -compliant after multiple visit 
assessments may  be permanently  discontinued after consultation with the [COMPANY_004] 
clinical team. 
Non-Compliance with eDiary:  Subjects must be compliant in completing their 
eDiary  between each pair of on-treatment visits.  Subjects who are non- compliant 
should be re -educated on the requirement for dail y diary entry  compliance. Sub jects 
who continue to be non -compliant after multiple visit assessments may  be 
permanentl y discontinued after consultation with the [COMPANY_004] clinical team.
Note: Withdrawal from study  treatment requires withdrawal from the study .
Section 5.6. Follow -up contact
[CONTACT_646018]: typo
Revised text: A safet y follow -up contact (Visit 6) should be conducted 7 2 3days
Section 6.3 Treatment Assignment
Rationale for change: clarify  stratification
Revised text: The randomisation will be stratified based on long-acting bronchodilator
usage during the run -in (none or, one or 2long-acting bronchodilator sper day ).
In order to ensure subjects have sufficient doses of study  treatment, they must return to 
clinic within 30 day s from V2 and60 and 90 days from V3 and V4
Section 7.1 Time and Events Table
Rationale for change: clarify  Visit windows and correct ty po concerning Pre -screen 
window
Revised text:
Blinded Treatment
VisitPre-
screen1
0Screen/ Run -in
1Rando -
mization [ADDRESS_864881] 
6
Week -10-6to -4 -4 0 4 12 24
Day-70to -28
42
-7/+2 days 
prior to 
Visit 1-28-7/+2 days 
prior to Visit 21  -7/+2 
days28  -
7/+2 
days84  -
7/+2 
days168  
-7/+2 
days73days 
after V5 or 
EW Visit
Window -7/+2 days -7/+2 days -7/+2 days-7/+2 
days-7/+2 
days-7/+2 
days3 days 2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
106Section 7.1 Time and Events Table
Rationale for change: Correct inconsistency  of pre -screen window to Medication 
withhold periods defined in the Exclusion Criteria
Revised text:
1. Pre-screen Visit [ADDRESS_864882] be completed prior to Screening Visit1. It can be completed 26weeks prior or on the 
same day of V1, if no wash out of exclusionary medications is required. 
Section 7.2.1 Pre -screen Visit
Rationale for change: Correct inconsistency  of pre -screen window to Medication 
withhold periods defined in the Exclusion Criteria
Revised text: Subjects can perform the Pre- screening Visit (Visit 0) up to 2 6weeks 
prior to or on the same day  as the Screening Visit (Visit 1) if subject does not take or has 
not taken an y protocol e xcluded medications.
Section [IP_ADDRESS] SGRQ -C
Rationale for change: typo
Revised text: The St George’s Respi[INVESTIGATOR_21606] -Chronic Obstructive 
Pulmonary  Disease specific (SGRQ -C) will be completed by  [CONTACT_646009] 
(V2, Day  1), at Week 4, 1 2 and 24 or at Early  Withdrawal Visit (Where applicable) . 
Section [IP_ADDRESS]  Subject Global Rating of COPD Severity and Global Rating of 
Change in COPD
Rationale for change: typo
Revised text: Subjects will complete the Global Rating of COPD Severity  at 
Randomization Visit 2 and visits 3, 4 and 5 or Early  Withdrawal Visit.
Subjects will also complete a Global Rating of Change in COPD (overall disease) 
question at Visits 3, 4 and 5 or Earl y Withdrawal Visit .
Section 7.3.2  Spi[INVESTIGATOR_645969]: clarify instructions of COPD medication use prior to Spi[INVESTIGATOR_645970]:
At Screening Visit 1, before thesubject’s morning dose of usual inhaled LABA or 
LAMA COPD medication s
At Visit [ADDRESS_864883] dose of stud y treatment
Section 7.3.3  Inspi[INVESTIGATOR_14008] (IC)
Rationale for change: clarify  instructions of COPD medicati on use prior to I C maneuver  2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
107Revised text:
At Visit 2 after discontinuation of run -in LABA or LAMA COPD medication and 
prior to administration of study  medication
At Visit 3, 4 and 5 after withholding the morning dose of study  drug 
Section 10.2 Regulator y and Ethical Considerations, Including the Informed 
Consent Process
Rationale for change: Clarifications concerning site professional expertise
Revised text: Study  site Investigators will be selected to participate in the 201749 study  
based upon their pulmonology  expertise and knowledge of the protocol defined patient 
population and associated required stud y assessments.
Section 12.4.1 Defining of Adverse Events
Rationale for change: Integration of Canadian Amendment 2 into main protocol
Revised text: Repo rting Specific to Canada : For a marketed medicinal product, this 
can also include failure to produce expected benefits (i.e. lack of efficacy , with or without 
associated signs or s ymptoms or clinical sequelae).
Excluding Canada, "Lack of efficacy " or "fai lure of expected pharmacological 
action" per se will not be reported as an AE or SAE.  However, the signs and 
symptoms and/or clinical sequelae resulting from lack of efficacy  will be reported if 
they fulfil the definition of an AE or SAE.
Reporting Specific to Canada : "Lack of efficacy" or "failure of expected 
pharmacological action" will be reported as an AE or SAE as per the table below
Adverse 
Event 
criteriaElectronic case record 
form (eCRF) onlyPaper form only Electronic case 
record form 
(eCRF) + Pap er 
form
Non serious Non drug related lack of 
efficacy  reports with 
associated signs or 
symptoms or clinical 
sequelae Drug related lack of 
efficacy  reports 
without associated 
signs or s ymptoms or 
clinical sequelae.Drug related lack 
of efficacy  with 
associated signs or 
symptoms or 
clinical sequelae  
Serious Non drug related lack of 
efficacy  reports with 
associated signs or 
symptoms or clinical 
sequelae Drug related lack of 
efficacy  reports 
without associated 
signs or s ymptoms or 
clinical sequelae. Drug related lack 
of efficacy  reports 
with associated 
signs or s ymptoms 
or clinical sequelae  2018N377698_00
2016N277425_03 CONFIDENTIA L
201749
108Section 12.4.6 Reporting of SAEs to [COMPANY_004]
Rationale for change: Integration of Canadian Amendment 2 into main protocol
Revised text: Reporting Specific to Canada : For lack of efficacy  reports, the paper 
form will be used to submit to [COMPANY_004] as per the table in Section 12.4.1 above.
Section 12.5.2 COPD Exacerbation Severity
Rationale for change: clarify  chest x -rays performed in the context of the protocol
Revised text : Every effort should be made to conduct a chest x- ray within [ADDRESS_864884] X -Ray for pneumonia 
and/or moderate/severe exacerbation is not mandated but can be performed if required b y 
the investigator as part of standard care of subjects.
Section 12.8 Appendix 8: Country Specific Requirements
Rationale for change: Integration of Canadian Amendment 2 into main protocol
Revised text: In Canada only , additions were made to Section 7.4.1 and Appendix 4 to
comply  with Health Canada guidelines concerning the requirement of pharmaceutical 
manufacturers to expeditiously  report domestic cases of unusual failure in efficacy  
(UFIE) for new drugs to the Marketed Health Products Directorate (MHPD) within 
15days offirst notification.
No country  specific requirements exist. 2018N377698_00
2016N277425_02 CONFIDENTIA L
The GlaxoSmithKline group of companies 201749
1TITLE PA GE
Division: World wide Development
Information Type: Protocol Amendment
Title: A 24 -week treatment, multi -center, randomized, double- blind, 
double -dummy , parallel group study  to compare 
Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in 
subje cts with chronic obstructive pulmonary  disease (COPD)
Compound Number: [COMPANY_004]2592356
Development Phase:IV
Effective Date: 21-FEB-2017
Protocol Amendment Number:  02
Author (s):  
 
Copy right 2017 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised copy ing or use of this information is prohibited. 2018N377698_00
[COMPANY_003]
2016N277425_02 CONFIDENTIA L
The GlaxoSmithKline group of companies 201749
2Revision Chronology
GlaxoSmith Kline
Document NumberDate Version
2016N277425_00 2016 -SEP-13 Original
2016N277425_01 2017 -FEB-07 Amendment No. 1
This protocol amendment was created to make the following cha nges:
Regulatory  Agency  Identify ing Number(s):  A t ypographical error in the EudraCT no. 
corrected. IND no. added
Section 4.1and Section 4.4: Typographical errors and inconsistencies corrected
Inconsistencies between Section 4.4 , Section [IP_ADDRESS] and Secti on 7.1revised
Section 7.1Time and event table:
Un-intentional deletion of the (“x”) were added to confirm that concomitant medications 
should be reviewed at every  clinic visit was corrected.
Increased the visit window 
Typographical error and inconsistenc ies corrected as described in Appendix 9 , Section 
12.9.
Section 7.2.2 Critical procedures performed at Screening (Visit 1): To clarify  that height 
and weight are collected at V1 “Height and weight” added
Section 7.3.2 Spi[INVESTIGATOR_038]: “At Screening, before th e morning dose of usual COPD 
medication(s)” added.
Section 7.3.7 :  Physical activity  monitor (study  subset)
Inconsistency  between Section 1, Section 4.[ADDRESS_864885] y with Health Canada guidelines . They
require pharmaceutical manufacturers to expeditiously  report domestic cases of unusual 
failure in efficacy  (UFIE) for new drugs to the Marketed Health Products Directorate 
(MHPD) within [ADDRESS_864886] to ensure that site 
staff receives the appropriate information throughout the study . 
Investigator Name:
[CONTACT_132026]:
Investiga tor Phone Number:
Investigator Signature [CONTACT_1782] 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
5TABLE OF CONTENTS
PAGE
1.PROTOCOL SYNOPSIS FO R STUDY 201749 ........................................................ 9
2.INTRODUCTION ................................
.................................................................... 14
2.1. Study Rationale .......................................................................................... 14
2.2. Brief Background ........................................................................................ 14
3.OBJECTIVE(S) AND END POINT(S) ...................................................................... 15
4.STUDY DESIGN .................................................................................................... 17
4.1. Overall Design ............................................................................................ 17
4.2. Treatment Arms and Duration ..................................................................... 19
4.3. Type and Number of Subjects ..................................................................... 20
4.4. Design Justification ..................................................................................... 20
4.5. Dose Justification ........................................................................................ 20
4.6. Benefit: Risk Assessment ........................................................................... 20
4.6.1. Risk Assessment ......................................................................... 21
4.6.2. Benefit Assessment ..................................................................... 24
4.6.3. Overall Benefit: Risk Conclusion .................................................. [ADDRESS_864887] AWAL CRITERIA ............. 24
5.1. Inclusion Criteria ......................................................................................... 24
5.2. Exclusion Criteria ........................................................................................ 26
5.3. Randomization Criter ia............................................................................... 29
5.4. Screening/Baseline/Run -in Failures ............................................................ 29
5.5. Withdrawal/Stoppi[INVESTIGATOR_2121] ....................................................................... 30
5.5.1. Withdrawal from the Study ........................................................... 30
5.5.2. Reason for Study W ithdrawal ....................................................... 31
5.5.3. Liver Chemistry Stoppi[INVESTIGATOR_2121] ................................................ 31
[IP_ADDRESS]. Study Treatment Restart or Rechallenge .................... [ADDRESS_864888] and Other Study Treatment .................................... 33
6.2. Medical Devices .......................................................................................... 35
6.3. Treatment Assignment ................................................................................ 35
6.4. Planned Dose Adjustments ......................................................................... 36
6.5. Blinding ....................................................................................................... 36
6.6. Packaging and Labeling .............................................................................. 37
6.7. Prepara tion/Handling/Storage/Accountability .............................................. 37
6.7.1. Study Treatment Return ............................................................... 38
6.8. Compliance with Study Treatment Administration ....................................... 38
6.9. Treatment of Study Treatment Over dose .................................................... 38
6.10. Treatment after the End of the Study .......................................................... 39
6.11. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_014] .................................... 39
6.11.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014] .......................... 39
6.11.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014] ......................... 40 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
67.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 41
7.1. Time and Events Table ............................................................................... 42
7.2. Scree ning and Critical Baseline Assessments ............................................ 45
7.2.1. Pre-screening Visit ....................................................................... 45
7.2.2. Critical procedures performed at Screening (Visit 1) .................... 45
[IP_ADDRESS]. Albuterol/Salbutamol R eversibility Assessment .......... [ADDRESS_864889] treatment Visit 
(Baseline V2) ............................................................................... 46
7.3. Efficacy Assessments ................................................................................. 47
7.3.1. HRQoL assessments: Compl etion of PRO questionnaires 
in the Electronic Diary .................................................................. 47
[IP_ADDRESS]. Self Administered Computerised Baseline 
Dyspnea Index/Transitional Dyspnea Index 
(SAC BDI/TDI) ............................................................ 47
[IP_ADDRESS]. SGRQ -C..................................................................... 48
[IP_ADDRESS]. COPD Assessment Test (CAT) .................................. 48
[IP_ADDRESS]. EXACT and the Evaluating Respi[INVESTIGATOR_633333] -COPD (E -RS: COPD) .............................. 49
[IP_ADDRESS]. Subject Global Rating of COPD Severity and 
Global Rating of Change in COPD ............................. 49
7.3.2. Spi[INVESTIGATOR_038] ................................................................................... 49
7.3.3. Inspi[INVESTIGATOR_14008] (IC) ............................................................... 50
7.3.4. COPD Exacerbation .................................................................... 51
7.3.5. Clinically important deterioration (CID) ......................................... 51
7.3.6. Rescue albuterl/salbutamol use ................................................... 52
7.3.7. Physical activity monitor (study subset) ....................................... 52
7.4. Safety ......................................................................................................... 52
7.4.1. Adverse Events (AE) and Serious Adverse Events (SAEs) .......... 52
[IP_ADDRESS]. Time period and Frequency for collecting AE 
and SAE information ................................................... 53
[IP_ADDRESS]. Method of Detecting AEs and SAEs ........................... 53
[IP_ADDRESS]. Follow -up of AEs and SAEs ........................................ 53
[IP_ADDRESS]. Pneumonia Events ..................................................... 54
[IP_ADDRESS]. Cardiovascular and Death Events .............................. 54
[IP_ADDRESS]. Disease -Related Events and/or Dise ase-
Related Outcomes Not Qualifying as SAEs ................ 54
[IP_ADDRESS]. Regulatory Reporting Requirements for SAEs ............ 54
[IP_ADDRESS]. Additional Adverse Event (AE) Reporting 
Requirements for Canadian investigators ................... 55
7.4.2. Pregnancy ................................................................................... 55
7.4.3. Medical Device Incidents (Including Malfunctions) ....................... 55
7.4.4. Electrocardiogram (ECG) ............................................................. 55
7.5. Genetics ..................................................................................................... 56
8.DATA MANAGEMENT ........................................................................................... 56
9.STATISTICAL CONSIDER ATIONS AND DATA ANALYSES ................................ .56
9.1. Hypotheses ................................................................................................ .56
9.2. Sample Size Considerations ....................................................................... 57
9.2.1. Sample Size Assumptions ........................................................... 57
9.2.2. Sample Size Sensitivity ................................................................ 57
9.2.3. Sample Size Re- estimation or Adjustment ................................... 58 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
79.3. Data Analysis Considerations ..................................................................... 58
9.3.1. Analysis Populations .................................................................... 58
9.3.2. Interim Analysis ........................................................................... 58
9.4. Key Elements of Analysis Plan ................................................................... 58
9.4.1. Primary Analyses ......................................................................... 59
9.4.2. Other Analyses ............................................................................ 60
10. STUDY GOVERNANCE CON SIDERATIONS ........................................................ 60
10.1. Posting of Information on Publicly Available Clinical Trial Registers ............ 60
10.2. Regulatory and Ethical Considerations, Including the Informed 
Consent Process ........................................................................................ 60
10.3. Quality Control (Study Monitoring) .............................................................. 61
10.4. Quality Assurance ....................................................................................... 61
10.5. Study and Site Closure ............................................................................... 62
10.6. Records Retention ...................................................................................... 62
10.7. Provision of Study Results to Investigators, Posting of Information 
on Publically Available Clinical Trials Registers and Publication ................. 63
11.REFERENCES ....................................................................................................... 64
12.APPENDICES ........................................................................................................ 67
12.1. Appendix 1: Abbreviations and Trademarks ................................................ 67
12.2. Appendix 2: Liver Safety Required Actions and Follow up 
Assessments .............................................................................................. 69
12.3. Appendix 3: Genetic Research ................................................................... 71
12.4. Appendix 4: Definition of and Procedures for Recording, Evaluating, 
Follow -Up and Reporting of Adverse Events ............................................... 74
12.4.1. Definition of Adverse Events ........................................................ 74
12.4.2. Definition of Serious Adverse Events ........................................... 75
12.4.3. Definition of Cardiovascular Events ............................................. 76
12.4.4. Recording of AEs and SAEs ........................................................ 77
12.4.5. Evaluating AEs and SAEs ............................................................ 77
12.4.6. Reporting of SAEs to [COMPANY_004] ........................................................... 79
12.5. Appendix 5: COPD Exacerbation Identification, Categorization and 
Treat ment Guidelines .................................................................................. 80
12.5.1. Guidelines for Identifying COPD Exacerbations ........................... 80
12.5.2. COPD Exacerbation Severity ....................................................... 81
12.5.3. Treatment of COPD Exacerbations .............................................. 81
12.5.4. Guidelines for Treatment with Corticosteroids .............................. 81
12.5.5. Guidelines for Treatment with Antibiotics ..................................... 82
12.5.6. Onset and Resolution of COPD Exacerbations ............................ 82
12.5.7. Guideline for assessing multiple mild exacerbations .................... 82
12.5.8. Guideline for assessing exacerbations that increase in 
severity ........................................................................................ 82
12.6. Appendix 6: Definition of and Pro cedures for Documenting Medical 
Device Incidents ......................................................................................... 83
12.6.1. Definitions of a Medical Device Incident ....................................... 83
12.6.2. Documenting Medical Device Incidents ....................................... 84
12.7. Appendix 7: Modified List of Highly Effective Methods for Avoiding 
Pregnancy in FRP and Collection of Pregnancy Information ....................... [ADDRESS_864890] of Highly Effective Methods for Avoiding 
Pregnancy in Females of Reproductive Potenti al (FRP) .............. 85 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
812.7.2. Collection of Pregnancy Information ............................................ 85
12.8. Appendix 8: Country Specific Requirements ............................................... 87
12.9. Appendix 9: protocol changes ..................................................................... 88 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
91. PROTOCOL SYNOPSIS FOR STUDY 201749
Rationale
The primary  purpose of this study  is to demonstrate improvements in lung function in 
subjects treated with Umeclidinium/Vilanterol (UMEC/VI ) compared with Umeclidinium 
(UMEC) f or [ADDRESS_864891] of
UMC/VI , UMEC, and salmeterol with respect to health- related quality  of life (HRQoL), 
measured through patient reported outcomes (PROs) questionnaires, and lung function .  
Additional assessments to further evaluate other measures of chronic obstructive 
pulmonary  disease (COPD) efficacy  and sy mptoms control will be performed.
Objective(s)/Endpoint(s)
Objectives Endpoints
Primary
To compare the effect of UMEC/VI  
(62.5/25 mcg once dail y) with UMEC 
(62.5 mcg once daily ) on lung functionChange from baseline in trough Forced 
Expi[INVESTIGATOR_645914] 
(FEV 1) at week 24 
Secondary
To compare UMEC/VI (62.5/25 mcg 
once dail y), UMEC (62.5 mcg once 
daily ) with salmeterol (50 mcg twice 
daily ) on patient reported outcomes 
(PROs) Change from baseline in self 
administered computerised (SAC) 
transient dy spnea index (TDI) 
Percentage of TDI responders 
according to SAC TDI score.  A 
responder is defined as a ≥1 unit 
improvement in SAC TDI score 
Assessment of respi[INVESTIGATOR_645915] 24 weeks using 
Evaluating Respi[INVESTIGATOR_244774] -
COPD (E- RS) and its subscales 
(breathlessness, cough and sputum and 
chest sy mptoms) 
Percentage of E -RS responders 
according to E -RS score (defined as 
reduction in E -RS score of  2 or 3.35 
units) from baseline
Change from baseline in St George’s 
Respi[INVESTIGATOR_21606] (SGRQ -C)
Percentage of responders according to 
SGRQ -C total score (defined as a 4 
point or greater reduction from  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
10Objectives Endpoints
baseline) 
Change f rom baseline in COPD 
assessment test ( CAT)
Percentage of responders according to 
CAT (defined as a 2 unit improvement 
in score from baseline)
Other
To compare UMEC/VI (62.5/25 mcg 
once dail y), UMEC (62.5 mcg once 
daily ) with salmeterol (50 mcg twice 
daily) on other COPD efficacy  measures Rate of mild, moderate or severe 
exacerbations
Time to first mild, moderate or severe 
exacerbation
Rate of moderate or severe 
exacerbation
Time to moderate or severe 
exacerbation
Time to severe exacerbations
Time to c linically  important 
deterioration (CID) composite endpoint 
Time to clinically  important 
deterioration composite endpoint 
excluding FEV 1
Rescue albuterol/salbutamol use, 
(percentage of rescue- free day s and 
mean number of Inhalations/day ) 
captured b y the e lectronic diary  
(eDiary ) over 24 weeks
Inspi[INVESTIGATOR_645920] y (IC)
Full Vital capacity  (FVC) 
Change from baseline in trough FEV 1
Change from baseline in global 
impression of disease severity   2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
11Objectives Endpoints
Safety
To evaluate safet y and tolerability 
of UMEC/VI (62.5/25 mcg once 
daily ), UMEC (62.5mcg once dail y) 
and salmeterol 50mcg twice dail y) Incidence of adverse events
Exploratory
To compare albuterol/salbutamol 
use captured in the eDiary  with the 
electronic metered dose inhaler 
(eMDI) device Rescue albuterol/salb utamol use, 
(percentage of rescue- free day s and 
mean number of Inhalations/day ) 
captured b y the eMDI device over 24 
weeks as data allow
To explore the effect of UMEC/VI  
(62.5/25 mcg once dail y), UMEC 
(62.5 mcg once daily ) with 
salmeterol (50 mcg twice dai ly) on 
physical activityChange from baseline in phy sical 
activity  
To investigate the CID composite 
endpoint ability  to predict short 
term outcomes To compare ph ysical activity  levels, 
ER-S, rescue medication use, 
exacerbations and mortality  in subject s 
with and without a CI D
Overall Design
This is a multi -centre, randomized, double blind, double dummy, 3 -arm parallel group 
study .  Eligible subjects will be randomized in a ratio of 1:1:1 to UMEC/VI inhalation 
powder (62.5/25 mcg once dail y) administere d via the ELLIPTA™dry powder inhaler 
(DPI), or UMEC (62.5 mcg once daily ) administered via the ELLIPTA DPI [INVESTIGATOR_645916] 
(50 mcg twice daily (BID)) administered via the DISKUS™DPI.
Eligible subjects at Screening will enter a run -in period for 4 weeks dur ing which they  
continue taking their inhaled COPD medications (excluding ICS and an y exclusionary 
medications).  In addition, subjects will be provided with short acting 
albuterol/salbutamol to be used on as needed basis (rescue medication) throughout the 
study . 
Subjects who experience a moderate or severe COPD exacerbation during the run -in 
period will be deemed run- in failures.  Subjects experiencing a mild exacerbation, 
defined as worsening of symptoms that requires notreatment with antibiotics or ster oids 
and is self managed b y the patient b y an increase of inhaled rescue medication , will be 
allowed to continue in the study .
At the randomization Visit 2 (Day  1) those subjects who successfull y complete the run- in 
period as well as meet the other pre -defined eligibility  and randomization criteria will 
discontinue their inhaled COPD medications and will be randomized to one of the [ADDRESS_864892] medical problems experienced during the stud y.  
Subjects will be performing slow and forced spi[INVESTIGATOR_645965].
In addition, a subset of subjects up to 150 per treatment arm will undergo assessment of 
their phy sical activity  measured through a phy sical activity  monitor (Actigraph GT9X) 
worn for 7 day sfrom Screening (Visit 1), for 7 day s from Randomisation (Visit 2), [ADDRESS_864893] clinic Visit (Visit 5). 
There will be a total of 5 clinic visits and one follow -up phone call (Visit 6).  The total 
duration of subject participation in the study  will be approximately  [ADDRESS_864894] completed the study  upon completion of the Follow –
Up contact b y telephone.
Treatment A rms and Duration
Subjects will be stratified based on long-acting bronchodilator usage during the run- in 
(none, one or 2 long- acting bronchodilators per day ) and randomized in a ratio of 1:1:1 to 
either 
UMEC/VI  inhalation powder (62.5/25 mcg once daily ) administered via the 
ELLIPTA DPI) or 
UMEC (62.5 mcg once daily ) administered via the ELLIPTA DPI [INVESTIGATOR_1660] 
Salmeterol (50 mcg BID) adm inistered via DISKUS  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
13Study schematic
*Inhaled COPD medications including LABAs, LAMAs or LABA/LAMA combination products are 
allowed in run-in. ICS alone or in combination with a bronchodilator or any exclusionary 
medications are not allowed.
Type and N umber of Subjects
Approximately  3232 subjects will be screened, such that 2424 subjects will be 
randomized and approximately  2181 evaluable subjects complete the study. 
Analysis
The primary  purpose of this study  is to demonstrate improvements in lung func tion for 
subjects treated with UMEC/VI  compared with UMEC for 24 weeks.
The primary  endpoint is change from baseline in trough FEV 1at Week 24.
The null hy pothesis is no difference between treatment groups (H0: μT – μS = 0), with 
the alternative h ypothesis that there is a difference between treatment groups (H1: μT –
μS ≠0), where μ T is the mean change from baseline for UMEC/VI and μS is the mean 
change from baseline for UMEC. 
The primary  endpoint of mean chang e from baseline in trough FEV 1at the end of Week 
24 will be anal ysed using Mixed Models repeated Measures (MMRM) analy sis. The 
MMRM analy sis will include measurements at Treatment Weeks 4, 12 and 24. Treatment 
group (a categorical variable) will be fitted as the explanatory  variable with appropriate 
pre-defined variables, stratum (number of bronchodilators per day  during run- in) and 
baseline values, fitted as covariates. Visit (nominal) will be fitted as a categorical variable 
and visit -by-baseline and visit- by-treatment interaction terms will be included to allow 
treatment effects to be estimated at each visit separatel y.  The variance covariance matrix  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
14will be assumed to be unstructured (based on previous experience no issues are expected 
with fitting mod els with this matrix structure). 
The estimated treatment differences between UMEC/VI versus UMEC for each endpoint 
will be presented with the 95% confidence intervals for the difference and the p -value. 
2. INTRODUCTION
2.1. Stud y Rationale
Chronic obstructive pu lmonary  disease ( COPD) is associated with poor health- related 
quality  of life (HRQoL).  Pharmacologic therap y is used to improve lung function, reduce 
symptoms, frequency  and severit y of exacerbations, and improve patients HRQoL
[GOL D, 2015].  Umeclidinium/Vilanterol (UMEC/VI  62.5/25 mcg) is indicated for the 
maintenance treatment of COPD that contain long- acting muscarinic antagonist (L AMA) 
and long -acting beta 2-agonist (L ABA) bronchodilators.  Umeclidinium (UMEC) is 
indicated as a maintenance bronchodilator treatment to relieve s ymptoms in adult patients 
with COPD .  Salmeterol has long been used for s ymptoms management of COPD.  
However, a direct comparison of these maintenance therapi[INVESTIGATOR_645917].
The primary  purpose of this study  is to demonstrate improvements in lung function for 
subjects treated with UMEC/VI  compared with UMEC for [ADDRESS_864895] of
UMC/VI , UMEC, and salmeterol with respect to patient HRQoL  measured through 
patient reported outcomes (PROs) questionnaires, sy mptoms and lung function will also 
be evaluated.
2.2. Brief Background
COPD is characterized by [CONTACT_645994], usually  
progressive and accompanied by  a chronic cough, sputum production and dyspnea which 
can be a major cause of disability  and anxiety  associated with the disease [ Maleki -Yazdi , 
2014]
Furthermore, acute exacerbations contribute to the overall severity  of disease as these
epi[INVESTIGATOR_645918] s ymptoms and are associated with increased 
decline in lung function and mortality  [Wedzicha , 2013; Schmidt , 2014].
Pharmacologic therap y is used to improve lung function, reduce s ymptoms, reduce the 
frequency  and severit y of exacerbations, and also to improve health status and exercise 
tolerance.  Maintenance treatment is recommended primarily  through the use of LABAs 
or LAMAs.  COPD treatme nt guidelines recommend an incremental approach to 
pharmacological treatment as the disease state worsens, involving the use of 
combinations of drug classes with different or complementary  mechanisms [ GOL D, 
2015]. 
UMEC /VI inhalation powder is a combination of UMEC (umeclidinium bromide), a 
LAMA, and VI (Vilanterol), a LABA, delivered via the ELLIPTA dry  powder inhaler  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
15(DPI). UMEC/VI at a dose of 62.5/25mcg once- daily  is marketed in the [LOCATION_002] 
(US) and Europe unde r the trade name [CONTACT_646039]™ELLIPTA.  
UMEC (62.5 mcg) inhalation powder is marketed in the [LOCATION_002] (US) and Europe 
under the trade name [CONTACT_646040]™ELLIPTA.  UMEC (62.5mcg) is indicated as a 
maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.  
UMEC (62.5 mcg) improves forced expi[INVESTIGATOR_131955] (FEV 1), dyspnea 
and HRQoL whether used as monotherap y [Trivedi , 2014; Feldman , 2016] or as an add 
on to fluticasone propi[INVESTIGATOR_645919] (FF/VI) [ Siler , 2015].  Salmetrol (50 mcg) 
DISKUS is a long -
acting broncholdilator that has long been used for the maintenance 
treatment of COPD [ Tashkin, 2010].
Clinically  important deterioration (CID) is a novel, exploratory  composite endpoint 
which assesses individual deteriorations in lung function and in patient PROs defined by  
[CONTACT_646019] e (MCID), as well as the incidence of 
moderate to severe exacerbations [ Singh , 2016], (Section 7.3.5 ).  CID will be anal ysed to 
determine whether UMEC/VI  (62.5/25mcg) therap y provides greater clinical stability  as 
compared with UMEC and salmeterol monotherapi[INVESTIGATOR_014]. 
3. OBJECTIVE(S) A ND END POINT(S)
Objectives Endpoints
Primary
To compare the effect of UMEC/VI  
(62.5/25 mcg once dail y) with UMEC 
(62.5 mcg once daily ) on lung functio nChange from baseline in trough Forced 
Expi[INVESTIGATOR_645914] 
(FEV 1) at week 24 
Secondary
To compare UMEC/VI (62.5/25 mcg 
once dail y), UMEC (62.5 mcg once 
daily ) with salmeterol (50 mcg twice 
daily ) on patient reported outcomes 
(PROs) Change from baseline in self 
administered computerised (SAC) 
transient dy spnea index (TDI) 
Percentage of TDI responders 
according to SAC TDI score.  A 
responder is defined as a ≥1 unit 
improvement in SAC TDI score 
Assessment of respi[INVESTIGATOR_645915] 2 4 weeks using 
Evaluating Respi[INVESTIGATOR_244774] -
COPD (E- RS) and its subscales 
(breathlessness, cough and sputum and 
chest sy mptoms) 
Percentage of E -RS responders 
according to E -RS score (defined as 
reduction in E -RS score of  2 or 3.35 
units) from baselin e 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
16Objectives Endpoints
Change from baseline in St George’s 
Respi[INVESTIGATOR_21606] (SGRQ -C)
Percentage of responders according to 
SGRQ -C total score (defined as a 4 
point or greater reduction from 
baseline) 
Change from baseline in COPD 
assessment test ( CAT)
Percentage of r esponders according to 
CAT (defined as a 2 unit improvement 
in score from baseline)
Other
To compare UMEC/VI (62.5/25 mcg 
once dail y), UMEC (62.5 mcg once 
daily ) with salmeterol (50 mcg twice 
daily ) on other COPD efficacy  measures Rate of mild, moder ate or severe 
exacerbations
Time to first mild, moderate or severe 
exacerbation
Rate of moderate or severe 
exacerbation
Time to moderate or severe 
exacerbation
Time to severe exacerbations
Time to clinically  important 
deterioration (CID) composite endpoint
Time to clinically  important 
deterioration composite endpoint 
excluding FEV 1
Rescue albuterol/salbutamol use, 
(percentage of rescue- free day s and 
mean number of Inhalations/day ) 
captured b y the electronic diary 
(eDiary ) over 24 weeks
Inspi[INVESTIGATOR_270983] (IC)
Full Vital capacity  (FVC)  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
17Objectives Endpoints
Change from baseline in trough FEV 1
Change from baseline in global 
impression of disease severity  
Safety
To evaluate safet y and tolerability 
of UMEC/VI (62.5/25 mcg once 
daily ), UMEC (62.5mcg once dail y) 
and salmeterol (50mcg twice dail y) Incidence of adverse events
Exploratory
To compare albuterol/salbutamol 
use captured in the eDiary  with the 
electronic metered dose inhaler 
(eMDI) device Rescue albuterol/salbutamol use, 
(percentage of rescue- free day s and 
mean number of Inhalations/day ) 
captured b y the eMDI device over 24 
weeks as data allow
To explore the effect of UMEC/VI  
(62.5/25 mcg once dail y), UMEC 
(62.5 mcg once daily ) with 
salmeterol (50 mcg twice daily ) on 
physical activityChange from baseline in phy sical
activity  
To investigate the CID composite 
endpoint ability  to predict short 
term outcomes To compare ph ysical activity  levels, 
ER-S, rescue medication use, 
exacerbations and mortality  in subjects 
with and without a CI D
4. STUDY DESIGN
4.1. Overall Design
This is a multi -centre, randomized, double blind, double -dummy , 3-arm parallel group 
study .  Eligible subjects will be stratified based on long -acting bronchodilator usage 
during the run- in (none, one or 2 long -acting bronchodilators per day ) and randomized in 
a ratio of 1:1:1 to UMEC/VI  inhalation powder (62.5/25 mcg once dail y) administered 
via the ELLIPTA inhaler, or UMEC (62.5 mcg once dail y) administered via the 
ELLIPTA or salmeterol (50 mcg BID) administered via the DISKUS. 
There will be a total of 5 clinic visits and one follow-up phone call (Visit 6). The Pre -
screening Visit (Visit 0) can occur on the same day  as the Screening Visit (Visit 1) if 
subject does not take or has not taken an y excluded protocol medications, but must be 
completed prior to initiating an y Visit [ADDRESS_864896]’s eligibility  for the stud y. During the run-
in period subjects will continue with their inhaled COPD medications (excluding ICS and  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
18any exclusionary  medications).  I n addition, subjects will be provided with short acting 
albuterol/salbutamol to be used on as needed basis for relief of COPD s ymptoms (rescue 
medication) throughout the study . 
Subjects who experience a moderate or severe COPD exacerbation during the run -in 
period will be deemed run- in failures.  Subjects who experience a mild COPD 
exacerbation, defined as worsening of s ymptoms that requires notreatment with 
antibiotics or steroids and is self managed b y the patient by [CONTACT_645996] , (Appendix 5 ), will be able to continue in the study  based on the judgment of 
the investigator and agreement of the sponsor’s m edical monitor.
At the randomization Visit 2 (Day  1) those subjects who successfull y complete the run- in 
period as well as meet the other pre -defined eligibility  and randomization criteria will 
discontinue their inhaled COPD medications and will be randomi zed to one of the 3 
treatment arms for 24 weeks.
During the run-in and treatment period, subjects will be completing PRO questionnaires 
in the eDiary  and performing slow and forced spi[INVESTIGATOR_645966].
In addition, a subset of subjects up to 150 per treatment arm will undergo assessment of 
their phy sical activity  measured through a phy sical activity  monitor (Actigraph GT9X) 
worn for 7 day sfrom Screening (Visit 1), for 7 day s from Randomisation (Visit 2), [ADDRESS_864897] clinic Visit (Visit 5). 
Concurrent use of COPD maintenance medications including LAMAs, LABAs, oral beta -
agonists, theoph yllines, inhaled corticosteroids, inhaled corticosteroids and L ABA 
combination and phosphodiesterase 4 inhibitors will not be allowed during the stud y 
(Section 6.11.2 ) . 
The occurrence of adverse events (AEs) will be evaluated throughout the study  beginning 
at Visit 2 (Day  1) and until the follow -up contact (Visit 6).  Serious adverse events 
(SAEs) will be collected over the same time period as AEs.  However, an y SAEs 
assessed as related to study  participation (e.g., study  treatment, protocol -mandated 
procedures, invasive tests, or change in existing therap y) or related to a GS K concomitant 
medication, will be recorded from the time a subject consents to participate in the study  
up to and including an y follow up contact ( Appendix 4 ). 
All subjects will be given an electronic diary  (eDiary ) for use during the run- in, and the 
treatment period to complete PRO questionnaires, record COPD daily  symptoms, any  
medical problems experienced during the stud y and the time they  take their COPD 
medications.  Daily  rescue medication usage (number of inhala tions taken in the last 24h) 
will also be captured in the eDiary .  In addition, and in some countries, rescue medication 
use will also be captured by  [CONTACT_645997] (eMDI).
At Screening Visit 1, all subjects must be trained on t he proper use of their existing 
COPD medications inhalation devices and instructed to strictly  adhere to and record the 
time they  take their COPD medications in the eDiary . 2018N377698_00
2016N277425_02 CONFIDENTIA L
[ADDRESS_864898] completed the study  upon completion of the follow –
up contact b y telephone.
There are no plans to routinely  provide any  of the study  treatments for compassionate use 
following stud y completio n as the study  treatment are commerciall y available.
The study  design schematic is illustrated in Figure 1
Figure 1 Study  Schematic
*Inhaled COPD medications including LABAs, LAMAs or LABA/LAMA combination products are 
allowed in run-in. ICS alone or in combination with a bronchodilator or any exclusionary 
medications are not allowed.
4.2. Treatment A rms and Duration
Subjects will be stratified based on long- acting bronchodilator usage during the run- in 
(none, one or 2 long- acting bronchodilators per day) and randomized in a ratio of 1:1:1 to 
either
UMEC/VI  inhalation powder (62.5/25 mcg once daily ) administered via the 
ELLIPTA DPI) or 
UMEC (62.5 mcg once daily ) administered via the ELLIPTA DP I or 
Salmeterol (50 mcg BID) administered via DISKUS 2018N377698_00
2016N277425_02 CONFIDENTIA L
[ADDRESS_864899], well- established design 
to evaluate the efficacy  and safet y of an investigational drug.  A salmeterol arm is 
included to allow a comparison to be made between UMEC/VI , UMEC with salmeterol, 
a standard pr actice treatment.
The double -dumm y design is appropriate when drugs are of different appearance or 
different administration regimen which is appropriate in this study  where the inhalers 
used have a different appearance and used once daily  and twice dail y.
The European Medicines Agency  (EMA) COPD Guidelines suggest that duration of 12 to 
24 weeks is considered adequate for assessment of response of COPD sy mptoms to 
treatment intervention with bronchodilators ( EMA COPD guidelines, 2012). 
The primary  endpoint is trough FEV [ADDRESS_864900], well established and an objective means to show the efficacy  of a 
bronchodilator [ Dahl , 2010; Feldman , 2010]. 
Other endpoints such SAC TDI , E-RS, SGRQ -C, CAT, Subject Global Rating of Change 
in global impression of disease severity  are captured to allow responder analy ses and to 
provide comparative data on PROs between the treatme nt groups. 
4.5. Dose Justification
This study  is intended to evaluate the efficacy  of marketed doses of UMEC/VI  
(62.5/25mcg once dail y), UMEC (62.5 mcg once daily ) and salmeterol (50mcg twice 
daily ) that are approved for the maintenance treatment of COPD, with respect to PRO 
measures.
4.6. Benefit: Risk A ssessment
Summaries of findings from both clinical and non-clinical studies conducted with 
UMEC/VI  and UMEC can be found in the investigator’s brochures (IB) 
[GlaxoSmithKline Document Number RM2009/[ZIP_CODE]/07] and [GlaxoSmithKline 
Document Number 
RM2006/[ZIP_CODE]/09] and in the label information sheets. The current 
safet y profile for UMEC (62.5mcg) and the UMEC/VI (62.5/25mcg) based on dat a 
available to date, is comparable with other LABAs and LAMAs.  Summary  safet y data 
can also be found in the information sheet for salmeterol [ Serevent product information , 
2003].The following section outlines the risk assessment and mitigation strategy  for this 
protocol:  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
214.6.1. Risk A ssessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP) [UMEC/VI] 
Severe milk protein allergy Anoro contains Lactose monohydrate (which contains milk 
protein) as an excipi[INVESTIGATOR_841].Exclusion criteria have been set for subjects with milk 
protein allergy.
Cardiovascular effects such as cardiac arrhythmias e.g.
supraventricular tachycardia and extrasysto les.Class effects associated with LABAs and LAMA containing 
therapy. The clinical significance of these arrhythmias is 
unknown. Clinical experience with UMEC/VI to date in 
completed studies did not show any association with major 
cardiovascular events. 
Data available in the product label for UMEC/VI Exclusion criteria have been set for subjects with 
uncontrolled or severe cardiovascular disease according to 
the principal investigation’s (PI) opi[INVESTIGATOR_645921]. T he PI [INVESTIGATOR_645922].  Patients with the 
following abnormalities will be excluded from participation:  
atrial fibrillation with rapid ventricular rate >120bpm, 
sustained or nonsustained ventricular tachycardia, or 
second degree heart block Mobitz type II or third degree 
heart block (unless pacemaker or defibrillator had been 
inserted). 
Beta agonists and risk of asthma -related death Long -acting beta agonists such as vilanterol when used 
alone may increase the risk of asthma -related death.  A 
placebo -controlled trial with another LABA (salmeterol) 
showed an increase in asthma -related deaths in subjects 
receiving salmeterol.  This finding with salmeterol is 
considered a class effect of all LABAs, including vilanterol. 
Data are not available to determine whether the rate of death 
in patients with COPD is increased by [INVESTIGATOR_140413].Subjects with a current diagnosis of asthm a are excluded 
from participation in the study.
Paradoxical bronchospasm As with other inhaled medicines, UMEC/VI can produce 
paradoxical bronchospasm which may be life threatening.If paradoxical bronchospasm occurs following dosing with 
UMEC/VI, this tr eatment should be discontinued 
immediately and alternative therapy should be instituted. 
Use in patients with narrow -angle glaucoma or urinary 
retentionNo association has been found to date, in completed studies 
with UMEC/VI or UMEC monotherapy, on glau coma or 
urinary retention.  However, glaucoma or urinary retention Exclusion criterion states that subjects with medical 
conditions such as narrow -angle glaucoma, prostatic 
hypertrophy, or bladder neck obstruction should only be  
 
 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
22Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
have been observed with other antimuscarinic agents, and 
could potentially be due to the pharmacology.included if, in the opi[INVESTIGATOR_14371], the 
benefit outweighs the risk.
Use of beta blockers Beta-adrenergic blockers may weaken or antagonize the 
effect of bet a2-agonists such as vilanterol.The study permitted medications and non drug therapi[INVESTIGATOR_645923] -
blockers is only permitted if, in the Investigator’s opi[INVESTIGATOR_1649], 
the likely benefit outweighs the potential risk.
Pregnancy There is no experience to date of pregnancy during the use 
of UMEC/VI.The study inclusion criteria ensures that female subjects of 
child bearing potential must have a negative pregnancy 
test at screening, and agree to a reliable contraceptive 
method, used consistently and correctly (i.e. in accordance 
with the approved product label and the instructions of the 
physician for the duration of the study). Exclusion criteria 
include Pregnancy: Women who are pregnant or lactating 
or are planning on becoming pregnant during the study.
Severe hepatic impairment UMEC/VI has not been studied in severe hepatic impairment. Exclusion criterion states that subjects severe hepatic 
impairment should only be included if, in the opi[INVESTIGATOR_564989], the benefit outweighs the risk.
Investigational product (IP) [UMEC]
Cardiovascular effects such as cardiac arrhythmia, e.g. 
atrial fibrillation and tachycardiaA potential class effect associated
with anti -muscarinic therapi[INVESTIGATOR_014]. Data available to date in the
IB for UMEC [GlaxoSmithKline Document Number 
RM2006/[ZIP_CODE]/09Screening electrocardiogram (ECG) criteria to exclude 
subjects potentially at risk 
Narrow -angle glaucoma, urinary retention A class effect associated with anti -muscarinic therapi[INVESTIGATOR_014].
Data available in the IB for UMEC [GlaxoSmithKline 
Document Number RM2006/[ZIP_CODE]/09Exclusion criterion states that subjects with medical 
conditions such as narrow -angle glaucoma, pr ostatic 
hypertrophy, or bladder neck obstruction should only be 
included if, in the opi[INVESTIGATOR_9764], the benefit 
outweighs the risk.
Paradoxical bronchospasm that may be life threatening Known effect associated with inhalation therapy A sho rt-acting inhaled bronchodilator 
(albuterol/salbutamol) will be provided for use as needed 
throughout the study. The investigators will be instructed to 
assess subject’s condition to determine their eligibility to  
 
 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
23Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
continue in the study and the need for alt ernative therapy.
Severe hepatic impairment UMEC has not been studied in severe hepatic impairment. Exclusion criterion states that subjects with severe hepatic 
impairment should only be included if, in the opi[INVESTIGATOR_564989], the benefit outw eighs the risk.
Pregnancy/Lactation There is no experience to date of pregnancy during the use 
of UMEC.The study inclusion criteria ensure that female subjects 
enrolled, who are of Child bearing potential, have a 
negative pregnancy test at screening, and agree to a 
reliable contraceptive method, used consistently and 
correctly (i.e. in accordance with the approved product 
label and the instructions of the physician for the duration 
of the study). Exclusion criteria states -Pregnancy: 
Women who are pregna nt or lactating or are planning on 
becoming pregnant during the study.
Study Procedures
Spi[INVESTIGATOR_645924], changes in pulse rate 
and blood pressure, coughing, wheezing, chest tightness or 
fainting.Subjects will b e monitored during the procedure for these 
effects and spi[INVESTIGATOR_645925].
ECG lead placement This may cause skin irritation. It may be necessary to have small patches (about a 
centimetre in diameter) of hair on the chest s haved to 
properly attach electrodes to the chest. 
Blood sampling procedure (optional pharmacogenetic 
blood sample)Giving blood may make subjects feel faint, or experience 
mild pain, bruising, irritation or redness at the site. In rare 
cases, they may ge t an infectionSubjects will be monitored during the blood draw for these 
effects and should call their study doctor if any of these 
effects do not resolve
Other 
Side effects of rescue albuterol/salbutamol. Adverse 
events seen in clinical studies to dat e are however 
consistent for the beta 2-adrenergic class of compoundsClass effects associated with short acting beta -agonists 
(SABAs)Subjects should call their study doctor if they experience 
any of these symptoms 
 
 2018N377698_00
2016N277425_02 CONFIDENTIA L
[ADDRESS_864901] to PROs and sy mptoms in the treatment of COPD.
Specific benefits associated with the study  design and procedures include the following:
Subjects will receive treatments approved for the treatment of COPD that have 
been shown to be effective in th e population under study
All subjects will receive albuterol/salbutamol for use “as needed” for relief of 
COPD sy mptoms
The combination of study procedures of spi[INVESTIGATOR_038] , CAT, SGRQ, TDI, E-RSwill 
provide the study  subjects with a comprehensive evaluation of their s ymptoms, 
health status and COPD disease severity . Subjects will also be monitored 
throughout the stud y for any worsening of COPD symptoms or decline in general 
health.  Finall y smoking cessation counselling will also be provided.
4.6.3. Overall Benefit: Risk Conclusion
Taking into account the measures taken to minimize risk to subjects participating in this 
study , the potential risks identified in association with UMEC/VI , UMEC, salmeterol and 
with study  procedures are justified by  [CONTACT_646020].
5. SELECTION OF STUDY P OPULA TION A ND 
WITHDRA WAL CRITERIA
Specific information regarding warnings, precautions, contraindications, adverse events, 
and other pertinent information on the [COMPANY_004] investigational product or other study  
treatment that may  impact subject eligibility  is provided in the IBs, [ GlaxoSmithKline 
Document Number RM2006/[ZIP_CODE]/09], [ GlaxoSmithKline Document Number 
RM2009/[ZIP_CODE]/07] and product labels.
Deviations from inclusion and exclusion criteria are not allowed because they can 
potentially  jeopardize the scientific integrity  of the study , regulatory  acceptability  or 
subject safet y. Therefore, adherence to the criteria as specified in the protocol is essential.
5.1. Inclusion Criteria
A subject will be eligible for inclusion in this study onl y if all of the following criteria 
apply :
AGE
1.[ADDRESS_864902] AND DIAGNOSI S INC LUDING DISEASE SEVERI TY
2.Outpatient with a diagnosis of COPD in accordance with the definition of the 
American Thoracic Society /European Respi[INVESTIGATOR_21618]  (ATS/ERS) [ Celli , 2004]. 
3.FEV 1: Persistent airflow limitations as indicated by :  A pre and post -
albuterol/salbutamol FEV 1/FVC ratio of <0.[ADDRESS_864903] -albuterol/salbutamol FEV 1
of ≥30% to ≤80% predicted normal values at Screening Visit 1.  Predicted values 
will be based upon the ERS Global L ung Function I nitiative [ Quanjer , 2012].
4.CAT score :  A CAT score of ≥10 at Screening Visit 1
Smoki ng History
5.Current or former cigarette smokers with a history  of cigarette smoking of 10 
pack -years [number of pack years = (number of cigarettes per day  / 20) x number of 
years smoked (e.g. 20 cigarettes per day  for 10 y ears, or 10 cigarettes per day  for 20 
years both equal 10 pack -years)].  Former smokers are defined as those who have 
stopped smoking for at least 6 months prior to Visit 1.  Pi[INVESTIGATOR_23887]/or cigar use cannot 
be used to calculate pack -year history .
SEX
6.Male and female subjects are eligible to participate in the study
A female subject is eligible to participate if she is not pregnant (as confirmed by  a 
negative urine human chorionic gonadotrophin (hCG) test), not lactating, and at least one 
of the following conditions applies:
a.Non-reproductive potential defined as:
Pre-menopausal females with one of the following:
Documented tubal ligation
Documented h ysteroscopic tubal occlusion procedure with follow -up 
confirmation of bilateral tubal occlusion 
Hysterectomy
Documented Bilateral Oophorectom y
Postmenopausal defined as 12 months of spontaneous amenorrhea.  In questionable cases 
a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels 
consistent with menopause must be tested.  Females on hormone replacement therap y 
(HRT) and whose menopausal status is in doubt will be required to use one of the highl y 
effective contraception methods if they  wish to continue their HRT during the study .  
Otherwise, they  must discontinue HRT to allow confirmation of post -menopausal st atus 
prior to study  enrolment.
b. Reproductive potential and agrees to follow one of the options listed in the Modified 
List of Highl y Effective Methods for Avoiding Pregnancy in Females of  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
26Reproductive Potential (FRP) ( Appendix 7 ) from [ADDRESS_864904] dose of 
study  medication and until [at least five terminal half- lives OR until any  continuing 
pharmacologic effect has ended, whichever is longer] after the last dose of study  
medication and completion of the follow- up visit.
The investigator is responsible for ensuring that subjects understand how to properl y use 
these methods of contraception.
INFORMED CONSENT
7.Capable of giving signed informed consent prior to study  participation, which 
includes compliance with the requirements and restrictions listed in the consent form 
and in this protocol.
5.2. Exclusion Criteria
A subject will not be eligible for inclusion in this study  if an y of the following criteria 
apply :
CONCURRENT CONDITIONS/MEDI CAL  HISTORY (INCLUDES LIV ER 
FUNCTION 
1. Asthma :  A current diagnosis of asthma.  (Subjects with a prior history  of asthma 
are eligible if they  have a current diagnosis of COPD, which is the primary cause of 
their respi[INVESTIGATOR_23908]).
2. Alpha -antitrypsin deficiency: Subjects with known α1-antitry psin deficiency  as 
the underl ying cause of COPD
3. Other respi[INVESTIGATOR_17744]: Subjects with active tuberculosis are excluded. 
Subjects with other respi[INVESTIGATOR_146456] (e.g. clinically  significant: 
bronchiectasis, sarcoidosis, lung fibrosis, pulmo nary hypertension, interstitial 
lung diseases) are excluded if these conditions are the primary cause of their 
respi[INVESTIGATOR_23908].
4. Unstable liver disease: Current active liver or biliary  disease (with the exception 
of Gilbert’s s yndrome or asymptomatic g allstones or otherwise stable chronic 
liver disease per investigator assessment). 
Stable chronic liver disease should generally  be defined by  [CONTACT_107415], 
encephalopath y, coagulopathy, h ypoalbuminaemia, oesophageal or gastric 
varices, or persis tent jaundice, or cirrhosis.
Chronic stable hepatitis B and C ( e.g., presence of hepatitis B surface antigen 
(HBsAg) or positive hepatitis C antibody  test result or within [ADDRESS_864905] dose of study  treatment) are acceptable if subject otherwise meets entry  
criteria
5. Unstable or life threatening cardiac disease: Investigational Product should be 
used with caution in subjects with severe cardiovascular disease.  In the opi[INVESTIGATOR_8574], use should only  be considered if the benefit is lik ely to  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
27outweigh the risk in conditions such as:
Myocardial infarction or unstable angina in the last 6 months
Unstable or life threatening cardiac arrh ythmia requiring intervention in the last 3 
months
NYHA Class IV heart failure
6. 12 Lead ECG: The Investiga tor will determine the clinical significance of each 
abnormal ECG finding in relation to the subject’s medical history  and exclude 
subjects who would be at undue risk by  [CONTACT_19212]. Subjects with the 
following abnormalities are excluded fro m participation in the study :
Atrial fibrillation with rapid ventricular rate >120 bpm
Sustained or non -sustained ventricular tach ycardia
Second degree heart block Mobitz ty pe II or third degree heart block (unless 
pacemaker or defibrillator had been inser ted)
7. Antimuscarinic effects:   Subjects with medical conditions such as narrow -angle 
glaucoma, urinary  retention, prostatic hy pertrophy, or bladder neck obstruction 
should be excluded unless, in the opi[INVESTIGATOR_23942], the benefit 
outweighs the risk.
8. Other disease abnormalities: Any subject who is considered unlikel y to survive 
the duration of the stud y period or has an y rapi[INVESTIGATOR_2478] y progressing disease or 
immediate life-threatening illness (e.g. cancer). In addition, any  subject who has 
any other condition (e.g. neurological condition) that is likely  to affect respi[INVESTIGATOR_645926] .
9. Hospi[INVESTIGATOR_059]: Hospi[INVESTIGATOR_645927] 12 weeks prior 
to Visit 1. Pneumonia and/or moderate or severe COPD exace rbation that has 
not resolved at least [ADDRESS_864906] dose of oral/s ystemic corticosteroids (if applicable). 
10. Inhaled corticosteroids (ICS): Had received ICS or I CS/LABA for the treatment 
of COPD in th e 6 weeks prior to Screening Visit1
11. Exacerbation: Had >[ADDRESS_864907] 7 days prior to 
Screening V1.
13. Lung Resection: Subjects with lung volume reduction surgery  (including 
procedures such as endobronchial valves) within the 12 months prior to Screening 
V1.
14. Oxygen: Use of long -term oxy gen therap y (LTOT) described as resting oxy gen 
therap y >3L/min at screening required to maintain adequate ox ygenation ( e.g. 
SaO2>90%). (Ox ygen use ≤3L/min flow is not exclusionary , and patients may  
adjust oxy gen levels up or down as needed during the study .) 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
28CONCOMI TANT MEDICATIONS
1.Medications prior to Screening: Use of the following medications according to 
the following define d time intervals prior to Screening (Visit 1):
Medication No use within the 
following time intervals 
prior to Screening
Inhaled corticosteroids (ICS) 6 weeks
Depot corticosteroids 12 weeks
Systemic, oral or parenteral corticosteroidsa 6 weeks
Antibioti cs (for lower respi[INVESTIGATOR_1092]) 6 weeks
Phosphodiesterase 4 (PDE 4) Inhibitor ( e.groflumilast) 14 days
LABA/Inhaled Corticosteroid (ICS) combination products 6 weeks
Theophyllines 48 hours
Oral beta 2-agonists
     Long- acting
     Short -acting48 hours
12 hours
Inhaled short acting beta 2-agonistsb 4 hours
Inhaled short -acting anticholinergics 4 hours
Inhaled short -acting anticholinergic/short -acting beta 2-agonist 
combination products4 hours
Any other investigational medication 30 days or within 5 drug 
half-lives (whichever is 
longer)
a- Localized corticosteroid injections (e.g., intra -articular and epi[INVESTIGATOR_13873]) are permitted.
b- Use of study provided albuterol/salbutamol is permitted during the study, except in the 4 -hour period prior to 
spi[INVESTIGATOR_645971]
2.Medication prior to spi[INVESTIGATOR_038]: Unable to withhold albuterol/salbutamol for 
the 4 hour period required prior to spi[INVESTIGATOR_645972].
3.Maintenance use of short -acting bronchodilators :  Regular use (prescribed for 
daily / regul ar use, not for as -needed use) of short -acting bronchodilators ( e.g. 
albuterol/salbutamol).
REL EVANT HABITS
1.Drug or alcohol abuse: A known or suspected history  of alcohol or drug abuse 
within [ADDRESS_864908] from completing the stud y procedures.
CONTRAINDICATIONS 
1.Any history of allergy or hypersensitivity to any anticholinergic/muscarinic 
receptor antagonist, s ympathomimetic, lactose/milk protein or magnesium stearate . 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
29DIAGNOSTIC ASSESSMENTS AND OTHER CRI TERIA
1.Pulmonary Rehabilitation program: Participation in the acute phase of a 
pulmonary  rehabilitation program within 4 weeks prior to Screening Visit 1.  Subjects 
who are in the maintenance phase of a pulmonary  rehabilitation program are not 
excluded.
2.Affiliation with investigator sites: Is an investigator, sub -investigator, study  
coordinator, emplo yee of a participating investigator or study site, or immediate 
family  member of the aforementioned that is involved in this study
3.Inability to read: In the opi[INVESTIGATOR_871], any  subject who is unable to read 
and/or would not be able to complete questionnaires on the electronic diary.
Subjects who fail to meet inclusion and exclusion criteria at the Screening Visit [ADDRESS_864909] fulfilled all inclusion and excl usion criteria 
described in Section 5.1and Section 5.2. In addition to the following:
REQUI RED CRI TERIA FOR RANDOMIZATION AND TREATMENT
1.COPD Exacerbation : Subjects must nothave experienced a moderate or severe 
COPD exacerbation or a lower respi[INVESTIGATOR_626201] -in or at Day  1 
(Visit 2) inclusive.  A moderate exacerbation is defined as worsening of s ymptoms of 
COPD requiring the use of antibiotics or systemic corticosteroids.  A severe 
exacerbation is defined as worsening sy mptoms of COPD requiring hospi[INVESTIGATOR_059].
2.CAT score :  A CAT score of ≥10 at Visit 2
3.Prohibited Medications: No use of an y prohibited medications during the run -in 
period or at Visit 2, including an y ICS or ICS/LABA combination
4.Any change to COPD medications: Including dosage and regimen during the run -in
5.Completion of electronic diary: Must have completed the electronic diary for at 
least 80% of day s during the run- in period
Subjects who do not meet the required criteria for randomization at Visit 2 will not be 
randomized.
5.4. Screening/Baseline/Run-in Failure s
Pre-screen, screen and run -in failures are defined as follows: 
Pre-screening failures: A subject, who is assigned a subject number at the Pre -
screening Visit [ADDRESS_864910] an y Screening Visit 1 procedures, will be 
considered a pre -screen failure. 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
30Screening failures: Those subjects that complete at least one Screening Visit 1 
procedure but do not enter the run -in period.
Run-in failures: Those subjects that enter the run-in period but are not 
randomized to any  of the study  treatment arms.
Subjects w ho are pre -screen, screen and run -in failure will be recorded in the eCRF.  In 
order to ensure transparent reporting of screen failure subjects, meet the Consolidated 
Standards of Reporting Trials (CONSORT) publishing requirements, and respond to 
queries f rom Regulatory  Authorities, a minimal set of screen failure information is 
required to be recorded in eCRF including demograph y, screen failure details, eligibility  
criteria, and serious adverse events (Section 7.4.1 ). 
5.5. Withdrawal/Stoppi[INVESTIGATOR_2121]
5.5.1. Withdrawal from the Study
Subjects may  be withdrawn from the study  at an y time by  [CONTACT_646021] .  Reasons for withdrawal 
from study  treatment c an include: an AE, clinically  significant abnormality, lack of 
efficacy , sponsor terminated study , pregnancy , or for any  other reason. 
If a subject withdraws from the study , he/she may request destruction of any  samples 
taken, and the investigator must do cument this in the site study  records . 
A reason for the withdrawal from the study  must be captured in the electronic case report 
form (eCRF).
A subject will also be withdrawn from the study , in consultation with the medical 
monitor and principal investiga tor, if any  of the following stoppi[INVESTIGATOR_23893]:
Liver Chemistry: Meets any  of the Liver chemistry  stoppi[INVESTIGATOR_3418] (See Section 
5.5.3 )
Note: clinical laboratory  assessments are not required for this st udy. However, 
laboratory  samples may  be taken for liver event analy sis, if clinicall y indicated b y 
the study  investigator.
Pregnancy:   Positive pregnancy  test (see Appendix 7 )
Subjects withdrawn from study  treatment wi ll not be replaced. 
Note: Withdrawal from study  treatment requires withdrawal from the study .
The following actions must be taken in relation to a subject who fails to attend the clinic 
for a required stud y visit:
The site must attempt to contact [CONTACT_646022] -schedule the missed visit as 
soon as possible. 
The site must counsel the subject on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the subject wishes to and/or should 
continue in the study .  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
31In cases wher e the subject is deemed ‘lost to follow up’, the investigator or 
designee must make every effort to regain contact [CONTACT_1155] (where 
possible, [ADDRESS_864911]’s last 
known mailing address or local equivalent methods). These contact [CONTACT_131994]’s medical record. 
Should the subject continue to be unreachable, only then will he/she be considered 
to have withdrawn from the study  with a primary  reason of “Lost to Follow -up”. 
5.5.2. Reason for Study  Withdrawal
The primary  reason for study  withdrawal will be recorded in the eCRF. When a subject 
withdraws consent, the investigator must document the reason (if specified by  [CONTACT_1560]) in the eCRF. 
The primary  reason for study  withdrawal may  include:
Adverse event
Lost to follow -up
Withdrew consent
osubject relocated
ofrequency  of visits
oburden of procedures
oother (specify )
Protocol deviation
Lack of efficacy
COPD exacerbation
Study  closed/terminated
Subject reached protocol -defined stoppi[INVESTIGATOR_645973]
Pregnancy
Investigator discretion
5.5.3. Liver Chemistry Stoppi[INVESTIGATOR_131957] y and evaluate liver event etiology (in alignment with th e FDA 
premarketing clinical liver safety  guidance). 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
32Phase III -IV Liver Chemistry Increased Monitoring Algorithm with Continued 
Therapy for ALT 3xULN but <8xULN
Cont inue Study Treatm ent   and   Monitor  Liver Chem istry
Discontinue Study Treatment ALT≥5xULN 
but <8xULN
+ bili<2xULN +
no symptoms
NoMust  refer to Liver Safety Requi red Actions and Fol low up Asses smen ts section in the Appendi x
YesALT ≥3xULN 
but <5xULN
+ bili<2xULN  +
no symptomsAble to 
monitor  
weekly 
for  ≥2 
weeksPersists for 
≥2 weeks  
or other  
stoppi[INVESTIGATOR_53099]  ≥4 
weeksPersists for 
≥4 weeks  
or other  
stoppi[INVESTIGATOR_131958] ≥5xULN ALT <5xULN 
Yes Yes
*INR value not applicable to subjects on anticoagulants Must  refer to Liver Safety Requi red Actions and Fol low up Asses sments section in the Appendi x
Repor t as an SAE if possible Hy’sLaw case:  ALT≥3xUL N and  Bilirubin≥2x ULN (>35% direct)  or 
INR>1.5, if measur ed*
Liver Safet y Required Actions and Follow up Assessments Section can be found in 
Appendix 2 .
[IP_ADDRESS]. Study  Treatment Restart or Rechallenge
Study  treatment restart or rechallenge after liver chemistry  stoppi[INVESTIGATOR_539093] e met b y 
any subject participating in this study  is not allowed.
5.6. Follow -up contact
A safet y follow- up contact (Visit 6) should be conducted 7 2 day s following the 
completion of Visit 5 or the Earl y Withdrawal Visit, if applicable. 
The following procedures will be performed:
AE/SAE assessment
COPD exacerbation assessment
Concomitant medication assessment limited to any  medications used to treat a 
COPD exacerbation or SAE (if applicable)
Pregnancy  information (if applicable)
Subjects who have successfully  completed all on -treatment randomized visits will be 
discharged from the study upon completion of the safet y follow- up contact. 2018N377698_00
2016N277425_02 CONFIDENTIA L
[ADDRESS_864912] completed the study  if he/she receives study  
treatment at Visit 5 (Week 24) and completes the follow -up contact [CONTACT_4838] 6.
The end of the stud y is defined as the last subject’s last visit. 
6. STUDY TREA TMENT
6.1. Investigational Product and Other Study  Treatment
The term ‘stud y treatment’ is used throughout the protocol to desc ribe any  combination 
of products received b y the subject as per the protocol design.  Stud y treatment may 
therefore refer to the individual study  treatments or the combination of those study  
treatments.
The contents of the label will be in ac accordance wit h all applicable regulatory  
requirements.
Under normal conditions of handling and administration, investigational product is not 
expected to pose significant safet y risks to site staff.  Take adequate precautions to avoid 
direct ey e or skin contact [CONTACT_23968]. Notify  the monitor of 
any unintentional occupational exposure.  A Material Safet y Data Sheet (MSDS) 
describing the occupational hazards and recommended handling precautions will be 
provided to site staff if required by  [CONTACT_339256].
Investigational product must be stored in a secure area under the appropriate phy sical 
conditions for the product.  Access to and administration of the investigational product 
will be limited to the investigator and authorised site staff.  Investigational product must 
be dispensed or administered onl y to subjects enrolled in the study  and in accordance 
with the protocol.
GlaxoSmithKline ([COMPANY_004]) will provide the study treatments for use in this stud y. 
The following stud y medications will be used in this study :
UMEC/VI  62.5/ 25mcg administered via ELLIPTA
UMEC 62.5 mcg administered via ELLIPTA
 Salmeterol 50 mcg administered via DISKUS
 Placebo via ELLIPTA
 Placebo via DISKUS
Subjects will be instructed to take one dose of medication each morning from the 
ELLIPTA (one inhalation equals one dose), and one dose in the morning and one in the 
evening from the DI SKUS).  Subject instructions and details on how to use the ELLIPTA 
andDISKUS are provided in the study  reference manual (SRM). 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
34A description of the UMEC/VI  investigational product administered via the ELLIPTAis 
provided below in Table 1. The ELLIPTA will contain two, double -foil, laminate, blister 
strips.  The ELLIPTA will provide a total of 30 doses (60 blisters) and will deliver, when 
actuated, the contents of a single blister simultaneously  from each of the two blister 
strips. 
The DISKUS will provide a total of [ADDRESS_864913] administered via the ELLIPTA is 
provided below in Table 2. A description of placebo inhalation powder via ELLIPTA is 
shown in Table 3.  A description of salmeterol 50mcg and placebo via DISKUS are 
shown in Table 4 and Table 5respectively .
Table 1 Description of UMEC/VI Inhalation Powder via ELLIPTA
Formulation First strip Second strip
Umeclidinium bromide blended with 
lactose monohydrate and 
magnesium stearate1Vilanterol trifenatate blended with 
lactose monohydrate and magnesium 
stearate2
Dosage Form ELLIPTA Inhaler with 30 doses (2 strips with 30 blisters per strip)
Unit Dose Strengths 62.5 mcg 25 mcg
Physical description White powder White powder
Route of Administration Inhaled
1. Magnesium stearate 0.6% w/w of total drug product
2. Magnesium stearate 1.0% w/w of total drug product
Table [ADDRESS_864914] strip
Umeclidinium bromide blended with lactose monohydrate and 
magnesium stearate1
Dosage Form ELLIPTA I nhaler with 30 doses (1 strip with 30 blisters) 
Unit Dose Strengths 62.5mcg 
Physical description Dry white powder
Route of Administration Inhaled
1. Magnesium stearate 0.6% w/w of total drug product
Table [ADDRESS_864915] strip Second strip
Lactose monohydrate blended with 
magnesium stearate1Lactose monohydrate blended with 
magnesium stearate2
Dosage Form ELLIPTA Inhaler with 30 doses (2 strips with 30 blisters per strip)
Unit Dose Strengths Not applicable Not applicable
Physical description Dry white powder Dry white powder
Route of Administration Inhaled
1. Magnesium stearate 0.6% w/w of total drug product
2. Magnesium stearate 1% w/w of total drug product 2018N377698_00
2016N277425_02 CONFIDENTIA L
[ADDRESS_864916] strip
Salmeterol Xinafoate blended with lactose monohydrate
Dosage Form Diskus Inhaler with 60 doses (1 strip with 60 blisters per strip)
Unit Dose Strengths 50 m cg
Physical description White powder
Route of Administration Inhaled
Table 5 Description of Placebo inhalation powder via DISKUS
Formulation Lactose monohydrate 
Dosage Form Diskus Inhaler with 60 doses (1 strip with 60 blisters per strip)
Unit Dose Strengths Not Applicable
Physical description White powder
Route of Administration Inhaled
Albuterol/salbutamol via metered -dose-inhaler (MDI) will be issued for reversibility  
testing at Visit 1.  Albuterol/salbutamol MDI  for as needed (prn) use will be issued 
throughout the study.  Albuterol/salbutamol will be sourced from local commercial stock 
if appropriate.  
6.2. Medical Devices
The eMDI devices are provided by  [CONTACT_646023].  They  have US FDA 510(K) clearance to market (Class 
II device) and EU CE marking (Class I device). Description of the eMDI and its use will 
be provided in the SRM.
6.3. Treatment A ssignment
Subjects who meet the randomization criteria will be assign ed to one of the [ADDRESS_864917] is 24 weeks.  On the morning of each clinic 
study  visit, subjects will refrain from taking their mornin g dose of study  treatment until 
instructed to do so by  [CONTACT_6477].  On the other day s during the treatment period 
(i.e. “non- clinic day s”), s ubjects will be instructed to self -administer their study  treatment  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
36in the morning and evening. Subjects shou ld enter the time they  take their study  treatment 
in the eDiary . 
Subjects will be randomly assigned to one of the blinded study  treatment regimens in 
equal proportion (ratio of 1:1:1):
UMEC/VI  62.5/25 mcg once dail y via ELLIPTA + placebo twice dail y via 
DISKUS
UMEC 62.5 mcg once daily  via ELLIPTA + placebo twice dail y via DISKUS
Salmeterol 50 mcg twice daily  via DI SKUS + placebo once daily  via ELLIPTA
The randomisation will be stratified based on long-acting bronchodilator usage during 
the run- in (none, on e or 2 long-acting bronchodilators per day ). 
Study  treatment/investigational product will be dispensed at Visits 2, [ADDRESS_864918] return to 
clinic within 30 day s from V2, 60 and 90 day s from V3 and V4 respectively  (see Time 
and event table Section 7.1). 
Used study  drug and rescue medication will be collected at Visits 3, 4 and 5 or at the 
Early Withdrawal Visit. 
6.4. Planned Dose A djustmen ts
No dose adjustment is allowed for this study
6.5. Blinding
This will be a double- blind double dummy  study  and the following will apply . 
The investigator or treating ph ysician may  unblind a subject’s treatment 
assignment only in the case of an emergency OR i n the event of a serious 
medical condition when knowledge of the stud y treatment is essential for the 
appropriate clinical management or welfare of the subject as judged b y the 
investigator. 
Investigators have direct access to the subject’s individual stu dy treatment. 
It is preferred (but not required) that the investigator first contacts the Medical 
Monitor or appropriate [COMPANY_004] study  personnel to discuss options before unblinding 
the subject’s treatment assignment. 
If [COMPANY_004] personnel are not contact[CONTACT_20453] e the unblinding, the investigator must 
notify  [COMPANY_004] as soon as possible after unblinding, but without revealing the 
treatment assignment of the unblinded subject, unless that information is 
important for the safety  of subjects currently  in the study . 
The d ate and reason for the unblinding must be fully  documented in the eCRF  2018N377698_00
2016N277425_02 CONFIDENTIA L
[ADDRESS_864919]’s treatment code is unblinded b y the 
investigator or treating phy sician. [COMPANY_004]’s Global Clinical Safety  and Pharmacovigilance 
(GCSP) staff may  unblind the treatment assignment for an y subject with an SAE. If the 
SAE requires that an expedited regulatory  report be sent to one or more regulatory  
agencies, a cop y of the report, identifying the subject’s treatment assignment, may  be sent 
to investiga tors in accordance with local regulations and/or [COMPANY_004] policy .
6.6. Packaging and Labeling
The contents of the label will be in accordance with all applicable regulatory  
requirements.
6.7. Preparation/Handling/Storage/A ccountability
No special preparation of the study treatment is required.
The investigator or designee must confirm appropriate temperature conditions 
have been maintained during transit for all study  treatment received and any  
discrepancies are reported and resolved before use of the study  treatment.
Only subjects enrolled in the study  may  receive study  treatment and onl y 
authorized site staff may  supply  or administer study  treatment.  All study  
treatments must be stored in a secure environmentally  controlled and monitored 
(manual or automated) area in ac cordance with the labelled storage conditions 
with access limited to the investigator and authorized site staff. 
The investigator, institution, or the head of the medical institution (where 
applicable) is responsible for study  treatment accountability , reconciliation, and 
record maintenance (i.e. receipt, reconciliation and final disposition records).  
Further guidance and information for final disposition of unused study  treatment 
are provided in the SRM. 
All ELLIPTA DPI [INVESTIGATOR_645929] 25C (77F).  Each All 
ELLIPTA DPI [CONTACT_468929] [ADDRESS_864920]. 
Salmeterol DI SKUS should be stored up to 25 C. 
Under normal conditions of handling and administration, study  treatment is not 
expected to pose significant safety risks to site staff .  Take adequate precautions to 
avoid direct ey e or skin contact [CONTACT_23968]. In the case of 
unintentional occupational exposure notify  the monitor, Medical Monitor and/or [COMPANY_004] 
study  contact.
A Material Safety  Data Sheet (MSDS)/equivalent document describin g 
occupational hazards and recommended handling precautions either will be 
provided to the investigator, where this is required by [CONTACT_1207], or is available 
upon request from [COMPANY_004]. 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
386.7.1. Study Treatment Return
All used and unused ELLIPTA and DISKUS inhalers and albuterol/salbutamol will be 
returned to [COMPANY_004] at the end of the study  to be available for disposal.  In some instances 
for sites outside the US, study  supplies will be disposed of locall y either b y the site, the 
country  medical department or third -party vendor.  Detailed instructions for the return of 
the study  drug can be found in the SRM.
Study  treatment will be collected at Visit 3, [ADDRESS_864921] and dispense a new 
study  treatment kit from the site’s investigational product supply  as instructed by  [CONTACT_646003], any  ELLIPTA that fails to function properly  must be identified and returned 
to [COMPANY_004] for testing. 
6.8. Compliance with Study  Treatment A dministration
When subjects self- administer study  treatment(s) at home , compliance with study  
treatment(s) will be assessed through querying the subject during the site visits and 
through stud y drug compliance assessed at Visits 2, 3, [ADDRESS_864922] iance with the ELLIPTA inhaler will be determined by [CONTACT_646004].  Compliance with the study  DISKUS will be determined by  [CONTACT_646005].  Subjects should be ≥80% to ≤120% compliant on 
taking stud y me dication between each pair of on- treatment visits.  Subjects who fall 
outside this range should be re -educated on treatment compliance b y their site. This re -
education should be documented in the subject’s source document.  If medication 
compliance repeate dly falls outside of acceptable ranges, the study  sponsor/site monitor 
must be contact[CONTACT_646006] .
6.9. Treatment of Study  Treatment Overdose
An overdose is defined as a dose greater than the total doses described in Section 6.1and 
Section 6.8which results in clinical signs and s ymptoms.  These should be recorded b y 
the investigator on the AE/SAE pages.  In th e event of an overdose of study  medication, 
the investigator should use clinical judgment in treating the overdose and contact [CONTACT_646007]. 
[COMPANY_004] is not recommending specific treatment guidelines for overdose and toxicity  
management.  The investigator is advised to refer to the relevant document(s) for detailed  2018N377698_00
2016N277425_02 CONFIDENTIA L
[ADDRESS_864923] label for salmeterol 
albuterol, UMEC and UMEC/VI  or equivalent document provided by  [CONTACT_23983].
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_424359].
6.10. Treatment after the End of the Study
Subjects will not receive any additional treatment from [COMPANY_004] after completion of the 
study , since the stud y treatments are commercially available.
The inves tigator is responsible for ensuring that consideration has been given to the post -
study  care of the subject’s medical condition, post- study  treatment. 
6.11. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_645930] 30 day s prior to Pre -Screening (Visit 0) and onwards 
should be recorded in the eCRF including an y changes in medications.  Beginning at 
Visit [ADDRESS_864924] of the stud y, all medications should be recorded in the 
eCRF including an y changes.  Stud y provided albuterol/sa lbutamol and double -blinded 
study  drug should notbe recorded in the eCRF.  The minimum requirement includes but 
is not limited to drug name, dose, route and the dates of administration.  Medications 
initiated after completion of Visit 5 or the Earl y Withd rawal Visit will not be recorded in 
the eCRF, with the exception of those used to treat a COPD exacerbation or SAE that 
occurs between Visit 5 (or the Early Withdrawal Visit) and the follow -up contact [CONTACT_646024] 
6.
6.11.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_645974] :
Study -provided albuterol/salbutamol for use as relief medication throughout the 
run-in and treatment periods 
Mucoly tics such as acet ylcysteine
Medications for rhinitis (e.g. intranasal c orticosteroids, antihistamines, cromoly n, 
nedocromil, nasal decongestants)
Influenza vaccine
pneumococcal vaccine
Antibiotics for short term treatment ( 14 day s) of acute infections including  
COPD exacerbations
Systemic corticosteroids for short term ( 14consecutive day s)  treatment of 
COPD exacerbations  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
40As-needed supplemental oxy gen use provided it is ≤3L/min flow at rest at 
screening.  Patients may  adjust oxy gen levels as needed during the stud y.
Pulmonary  rehabilitation program in maintenance phase
Smoking cessation treatment, including a stable regimen of nicotine replacement
Use of positive airway  pressure/non -invasive ventilation for sleep apnea/sleep 
disordered breathing ( e.g. CPAP, BiPAP) 
Localized corticosteroid injections (e.g., intra -articular and epi[INVESTIGATOR_13873])
Oral muscarinic antagonists for the tr eatment of overactive bladder are permitted 
but should be used with caution as they  may  exacerbate medical conditions that 
are contraindicated for anticholinergics (e.g., narrow angle glaucoma and bladder 
outflow obstruction)
Immunotherap y injections
Topic al or ophthalmic corticosteroids
Over -the counter (OTC) cough suppressants
Tricy clic antidepressants and monoamine oxidase inhibitors (MAOI s). Administer 
with caution as they  may potentiate the effect of beta -agonists on the vascular 
system
Diuretics. Caut ion is advised in the co -administration of beta agonists with non-
potassium sparing diuretics
Allergy  vaccination
All medications for other disorders as long as the dose remains constant whenever 
possible and their use would not be expected to affect lung function
6.11.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_417438] 6 is not permitted during the study 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
41Table 6 Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_645932], oral or parenteral corticosteroids1
Inhaled corticosteroids (ICS)2
Antibiotics >14 days
LABA/ICS combination products
PDE4 inhibitor (e.g. roflumilast)
Inhaled long acting beta 2-agonists (LABA, e.g. salmeterol, f ormoterol, indacaterol, vilanterol)
Long -acting muscarinic antagonists (LAMA, e.g. tiotropi[INVESTIGATOR_1890], aclidinium, glycopyrronium, umeclidinium3)
LAMA/LABA combination products except for study drugs
Theophyllines
Oral beta 2-agonists
Inhaled short acting beta 2-agonists4
Inhaled short -acting anticholinergics
Inhaled short -acting anticholinergic/short -acting beta 2-agonist combination products
Any other investigational medication
1 Except for the treatment of COPD exacerbations during the study. Localized corti costeroid injections (e.g., 
intra-articular and epi[INVESTIGATOR_13873]) are permitted.
2 Except if during the study use of ICS is deemed necessary for the treatment of subjects’ exacerbation. 
[ADDRESS_864925] for study drug
4 Use of study provided albuterol /salbutamol is permitted d uring the study, except in the 4 -hour period prior to 
spi[INVESTIGATOR_68333]. 
The following medications or treatments are also notallowed during the study :
Use of long -term ox ygen therap y (LTOT) described as resting ox ygen therapy 
>3L/min onl y at screening . Oxygen may  be titrated to any  level deemed necessary  
during the stud y.
Regular (prescribed for daily /regular use, not for as- needed use) therap y with 
albuterol/salbutamol.
Initiation of pulmonary  rehabilitation during the study .
7. STUDY A SSESSMENTS A ND PR OCEDURES
Protocol waivers or exemptions are not allowed with the exception of immediate safety  
concerns. Therefore, adherence to the stud y design requirements, including those 
specified in the Time and Events Table Section 7.1, are essential and required for stud y 
conduct.
This section lists the procedures and parameters of each planned study assessment.  The 
exact timing of each assessment is listed in the Time and Events Table Section 7.1 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
427.1. Time and Events Table
Blinded Treatment
VisitPre-
screen1
0Screen/ 
Run-in
1Rando -
mization 
[ADDRESS_864926] 
6
Week -6 to -4 -4 0 4 12 24
Day42 -7/+2 
days 
prior 
Visit 128  -7/+2 
days prior 
Visit 21 -7/+2 
days28  -7/+2 
days 84  -7/+2 
days168  -7/+2 
days73 days after V5 or 
EW Visit
Screen/Baseline
Written informed consent X
Demography X
Medical/COPD history X
Smoking history/statu s X
Smoking cessation counselling X
Concomitant medication assessment X X X X X X X X
Height and weight X
Cardiovascular History/family history of premature CV 
disease])X
Screening spi[INVESTIGATOR_038] (in cluding post bronchodilator 
testing )3X
CAT questionnaire X X
Verify Inclusion/Exclusion Criteria X
Training on use of inhalers X X
Training on use of eDiary and eMDI X X
Verify randomiza tion Criteria X
Register Visit in InForm X X X X X X X X
Register Visit in RAMOS NG X X X X X X X X 
 
 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
43Blinded Treatment
VisitPre-
screen1
0Screen/ 
Run-in
1Rando -
mization 
[ADDRESS_864927] 
6
Week -6 to -4 -4 0 4 12 24
Day42 -7/+2 
days 
prior 
Visit 128  -7/+2 
days prior 
Visit 21 -7/+2 
days28  -7/+2 
days 84  -7/+2 
days168  -7/+2 
days73 days after V5 or 
EW Visit
Efficacy/HRQoL assessments
Spi[INVESTIGATOR_038], including pre -dose FEV 1, trough  FEV 1and 
inspi[INVESTIGATOR_645933] X X X
SAC BDI questionna ire4 X
SAC TDI questionnaire4 X X X
SGRQ -C questionnaire [ADDRESS_864928]/ER -S: COPD 5
Patient Global Rating of COPD severity X X X X
Patient Global Rating of Change in COPD X X X
Safety assessments
Adverse events/Serious adverse events6 X X X X X X X X
COPD exacerbation assessment X X X X X X X X
12-Lead ECG X
Urine pregnancy test 7 X X X X
Pharmacogenetic sample8                                             X
Medication/Supplies
Dispense rescue albuterol/slabutamol. Dispense MDI9 X X X X X
Assess COPD medication compliance10 during run -in X
Dispense eDiary X
Assess compliance with eDiary d uring run -in X
Collect rescue albuterol/slabutamol. X X X X X
Collect eDiary X X
Dispense study treatment11 X X X
Collect study treatment X X X X 
 
 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
44Blinded Treatment
VisitPre-
screen1
0Screen/ 
Run-in
1Rando -
mization 
[ADDRESS_864929] 
6
Week -6 to -4 -4 0 4 12 24
Day42 -7/+2 
days 
prior 
Visit 128  -7/+2 
days prior 
Visit 21 -7/+2 
days28  -7/+2 
days 84  -7/+2 
days168  -7/+2 
days7[ADDRESS_864930] be completed prior to Screening Visit1. It can be completed 2 weeks prior or on the same day of V1, if no wash ou t of exclusionary medications is 
required. 
2. Early Withdrawal Visit: Subjects that withdraw should return to the clinic as soon as possible to complete the Early Withdraw al Visit procedures.
3. Spi[INVESTIGATOR_645934] (Secti on [IP_ADDRESS] ). 
4. SAC BDI, SAC TDI, SGRQ- C, CAT questionnaires will be completed at clinic visits and in the eDiary
5. EXACT/ER -S: COPD is completed daily in the eDiary approximately 2 hours before bed -time, starting o n Day 1 of the run -in period.
6. For the start date of collecting AEs and SAEs see ( Appendix 4 )
7. Pregnancy test: for females for child bearing potential only.
8. Pharmacogenetic sample may be drawn at visit [ADDRESS_864931] provide informed 
consent to the study participant.  Subjects can perform the Pre- screening Visit (Visit 0) 
up to 2 weeks prior to or on the same day  as the Screening Visit (Visit 1) if subject does 
not take or has not taken any  protocol excluded medications.
Modification of the subject’s medications prior to study  participation is based on the 
physician’s judgment according to sound medical practice, principles, and each subject’s 
needs.  A subject’s treatment must not be changed merel y for the purpose of enabling the 
subject’s participation in the study .  A subject number will be assigned at the time the 
informed consent form (ICF) is signed. No study related procedures may be 
performed until the informed consent form document has been signed by [CONTACT_1560].  
Once the informed consent is signed and if requir ed, changes can be made to the subject’s 
current medication regimen. The investigator should exercise clinical judgment, and is 
discouraged from changing medications only  for the purpose of the clinical study . 
During the pre -screening Visit 0, the follow ing information is collected:
Demographic parameters: y ear of birth, gender, race and ethnicity
Concomitant medications review
COPD exacerbation assessment
From the pre -screening visit onwards concomitant medications, exacerbations and SAEs 
(considered as related to study  participation) must be reported
7.2.2. Critical procedures performed at Screening (Visit 1)
The following critical assessments will be conducted at Visit 1:
Cardiovascular medical history /risk factors (as detailed in the eCRF) will be 
assessed at screening
Medical history  including COPD (including date of diagnosis and COPD ty pe 
(emphy sema and/or chronic bronchitis), smoking history , COPD exacerbation 
history , smoking status and previous and/or current medical conditions) 
Concomitant medication r eview (COPD and non COPD medications in the 3 
months prior to Screening).
Height and weight
12-Lead ECG. (Note: ECG is performed at screening Visit [ADDRESS_864932] for eligibility  
only. See Section 7.4.4). 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
46Urine pregn ancy  test if applicable
Train subject on the use of eDiary
COPD assessment test (CAT) and patient global rating of COPD severit y in 
eDiary
Pre-and post -albuterol/salbutamol spi[INVESTIGATOR_038]  (reversibility , see Section [IP_ADDRESS] )
Inclusion/Exclusion criteria assessment
Review exacerbations, AEs, (SAEs if related to study  participation)
Train subject on the proper use of their COPD medication inhalation devices
Instruct subject to take their COPD medications as instructed and to enter the time 
they take their medication in the eDiary
Dispense rescue medication
Medical history will be assessed as related to the inclusion/exclusion criteria listed in 
Section 5.1and Section 5.2.
Assessment of subject’s health status will be made at screening using CAT.  PRO 
questionnaires should be completed b y subjects before an y other assessments at a clinic 
visit, in the order specified in Section 7.3.1
[IP_ADDRESS]. Albuterol/Salbutamol Reversibility  Assessment
At Visit 1, both pre -and post -albuterol/salbutamol spi[INVESTIGATOR_645935] .  Reversibility  assessment should be performed as follows:
Perform pre -bronchodilator spi[INVESTIGATOR_645936] 1and FVC
Subject to self -administer 4 Inhalations (4X100 g) of albuterol/salbutamol MDI
Perform post -bronchodilator spi[INVESTIGATOR_645936] 1and FVC approximately  
10 to 30 minutes after albuterol/salbutamol administration
The results of the spi[INVESTIGATOR_645937]/ERS criteria [ Miller , 2005] for 
the subject to continue in the study .
7.2.3. Critical procedures performed at first treatment Visit (Baseline 
V2)
Review and assess  compliance with subject’s COPD medications during the run -
in period
Review and assess compliance with completing the eDiary during the run -in 
period
Review AEs, SAEs and exacerbations 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
47Urine pregnancy  test, if applicable
Baseline d yspnea Index, BDI, patient global rating of COPD severit y, patient 
global rating of change in COPD, SGRQ -C and CAT questionnaires in eDiary
Review randomization criteria (Section 5.3)
Register and randomize subject in RAMOS NG
Pre-dose spi[INVESTIGATOR_038] ; IC and FEV 1
Train subject on the proper use of ELLIPTA and DI SKUS inhalers
Dispense study  medication
Dispense rescue medication
Optional pharmacogentic sample can be collected at V2 or an y visit after.
7.3. Efficacy  Assessments
7.3.1. HRQoL assessments: Completion of PRO questionnaires in the 
Electronic Diary
All subjects will be completing PRO questionnaires in the eDiary . 
It is requested that questionnaires are completed before an y procedures are performed on 
the subject. 
All questio nnaires will be completed using the eDiary at clinic and at home.  Adequate 
time should be allowed to complete all items of the questionnaires and the questionnaires 
must be reviewed b y the investigator or designated study  staff for completeness and, if 
necessary , the subject must be encouraged to complete any  missing items. Where more 
than one questionnaire is to be completed at a visit the order should be as follows:
1.Baseline d yspnea index (Visit 2) then Transient dy spnea index at subsequent 
visits
2. Patien t global rating of COPD severit y and global rating of change in COPD
3.St George’s respi[INVESTIGATOR_645938]
4. COPD Assessment Test 
Instructions for completing the questionnaires can be found in the SRM.
[IP_ADDRESS]. Self A dministered Computerised Baseline Dy spnea Index/T ransitional 
Dyspnea Index (SA C BDI/TDI)
The BD I is used to measure the severity of d yspnea in patients at baseline. The TDI 
measures changes in the patient’s dyspnea from baseline.  The self -administered 
computerized version of the BDI/TDI (SAC BDI/TDI)[ Mahler , 2004] is used to measure 
severit y of d yspnea in patients at baseline (SAC BDI) on Day  1 (Visit 2) of treatment and 
change from the baseline (SAC TDI) at Week 4, 12 and 24 (Visits 3, 4 and 5).  The  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
48scores in both indexes depend on ratings for three different categories: functional 
impairment; magnitude of task, and magnitude of effort. SAC BDI/TDI should be 
completed before performing spi[INVESTIGATOR_038] . 
The SAC BDI/TDI was developed to address issues of potential bias in the interviewer 
administered (original) BDI /TDI [ Mahler , 1984].  The SAC BDI/TDI provides a 
standardized approach to the measurement of d yspnea, equivalent to the original 
BDI/TDI with advantages over the interview er method for grading d yspnea in patients 
with COPD by  [CONTACT_646008] b y the interviewers when completing the original BDI/TDI. This also 
removes the need for the same investigator to conduct all interviews with a subject based 
on the patient’s responses. SAC TDI  provides a continuous measure of change in dy spnea 
using a visual analogue scale to record responses. 
Details for the completion of the SAC BDI/TDI are provided in the SRM.
[IP_ADDRESS]. SGRQ-C
The St George’s Respi[INVESTIGATOR_6015] -Chronic Obstructive Pulmonary  Disease 
specific (SGRQ -C) will be completed by  [CONTACT_646009] (V2, Day  1), at Week 
4, 12 and 24 or at the Early  Withdrawal Visit (where applicable).
The SGRQ- C [Meguro , 2007] is a well established, disease -specific questionnaire.  It was 
designed to measure the impact of respi[INVESTIGATOR_496926] a COPD 
patient’s HRQoL.  As well as producing an overall summary score, sco res for the 
individual domains of symptoms, activity  and impacts are also produced.  It has been 
used in studies of COPD subjects and has been translated and validated for use in most 
major languages.  The SGRQ- C is derived from the original SGRQ, and prod uces scores 
equivalent to the SGRQ instrument [ Meguro , 2007].  
[IP_ADDRESS]. COPD A ssessment Test (CA T)
The COPD Assessment Test [ Jones, 2009, Jones, 2012] is a validated, short and simple 
patient completed questionnaire which has been developed for use in routine clinical 
practice to measure the health status of patients with COPD.  The CAT is an 8- item 
questionnaire suitable for completion by  [CONTACT_646025].  When 
completing the questionnaire, subjects rate their experience on a 6 -point scale, ranging 
from 0 (no impairment) to 5 (maximum impairment) with a scoring range of [ADDRESS_864933].
The CAT will be c ompleted in the eDiary  by [CONTACT_646026] 1 and 
Randomisation Visit 2 to assess their eligibility  to enter the stud y.  CAT is also 
completed at Weeks 4, 12 and 24 .  Additional instructions for completion of the CAT are 
provided in the SRM. 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
[IP_ADDRESS]. EXACT and the Evaluating Respi[INVESTIGATOR_244774] -COPD (E -RS: 
COPD)
EXACT -PRO is a 14 item patient reported outcome instrument designed to capture 
information on the occurrence, frequency , severity , and duration of exacerbations of 
disease in patients with COPD [ Leidy, 2011].  EXACT captures information on the 
severit y of the respi[INVESTIGATOR_69908] s ystemic manifestations of a COPD exacerbation as 
reported b y the patient.  The instrument is to be completed daily  (typi[INVESTIGATOR_897] 2 hrs before 
bedtime) using the electronic diary .  The daily  recording of information allows an 
assessment of the underlying day  to day  variability  of a patient's s ymptoms and facilitates 
the detection of s ymptom worsening indicative of a COPD exacerbation.  The tot al score 
for EXACT ranges from 0 -100.  The entire instrument is intended to be completed in 
about 3 minutes or less (typi[INVESTIGATOR_645940] ).
The E- RS: COPD consists of [ADDRESS_864934] instrument [ Leidy, 
2014].  E -RS: COPD is intended to capture information related to the respi[INVESTIGATOR_244853], i.e. breathlessness, cough, sputum production, ch est congestion and 
chest tightness.  The E -RS: COPD has a scoring range of 0 -40 higher scores indicate 
more severe s ymptoms.
Three subscales of the E -RS are used to describe different s ymptoms; dy spnea, cough and 
sputum and chest sy mptoms.
The EXACT questi onnaire will be completed b y subjects in the eDiary , at home every  
night throughout the entire study , starting from Screening V1 
[IP_ADDRESS]. Subject Global Rating of COPD Severity  and Global Rating of Change 
in COPD
Subjects will complete the Global Rating of COPD Se verity at Randomization Visit 2 
and visits 3, 4 and 5 or Early  Withdrawal Visit.  This single global question will ask 
subjects to rate their severity  of COPD on a four point scale (mild, moderate, severe, and 
very severe).
This question should be used im mediately  before the patient completes other visit 
specific questionnaires but after completion of SAC TDI  questionnaire. 
Subjects will also complete a Global Rating of Change in COPD (overall disease) 
question at Visits 3, 4 and 5 or Earl y Withdrawal Vis it.  Response options will be on a 7 
point L ikert scale ranging from much better to much worse.  Completing the question at 
each Visit allows for early detection of response as well as continued response.
7.3.2. Spi[INVESTIGATOR_645964] [ Miller , 2005]. All sites 
will use standardized spi[INVESTIGATOR_645942]. 2018N377698_00
2016N277425_02 CONFIDENTIA L
[ADDRESS_864935] spi[INVESTIGATOR_645943]  (see Section 
[IP_ADDRESS] ) and at Visits 2, 3, [ADDRESS_864936] 3 acceptable spi[INVESTIGATOR_496921] (with no 
more than 8) should be obtained. Acceptable spi[INVESTIGATOR_496922] a satisfactory  
start of test and end of test (i.e. a plateau in the volume time curve) and be free from 
artifacts due to cough, early termination, poor effort, obstructed mouthpi[INVESTIGATOR_13959], equipment 
malfunction, or other reasons [ Miller , 2005].
The largest FEV1and FVC from the 3 acceptable efforts should be recorded, even if they  
do not come from the same effort.
Spi[INVESTIGATOR_645944] 1and FVC assessments that is not obtained as follows will be 
considered a protocol deviation:
Started between 6:00AM and 11:00AM.
After withholding albuterol/salbutamol (all visits) for ≥4 hours
At Screening Visit 1, after wash out of medications as specified in the exclusion 
criteria in Section 5.2(Concomitant Medications).
At Screening Visit 1, before the morning dose of usual COPD medications
At Visit [ADDRESS_864937] dose 
of study  treatment 
At Visit 3, 4 and 5 after withholding the morning dose of study  treatment.
Pre dose assessment performed prior dosing.
Subjects should refrain from smoking for [ADDRESS_864938].
Trough FEV 1measure ments for UMC/VI  or UMEC on Weeks 4, 12 and 24 (Visits 3, 4 
and 5) should be performed 23 hours and 24 hours after the previous day ’s dose of study  
medication recorded in the eDiary . This will also provide trough FEV 1measurements for 
the evening dose of s almeterol. 
7.3.3. Inspi[INVESTIGATOR_359371]  (IC)
Inspi[INVESTIGATOR_645920] y (IC) is the volume of gas that can be taken into the lungs in a normal 
and full inhalation. Starting from the resting inspi[INVESTIGATOR_645975].  IC has been widel y used to assess static and 
dynamic h yperinflation in patients with COPD.
IC will be measured b y spi[INVESTIGATOR_645946] -dose at Visits 2 (30 
and 5 min prior to dosing) and at trough at Visits 3, 4, and 5 ([ADDRESS_864939] dosing 
on the previous day ). For I C determination the average of at least three acceptable 
manoeuvres should be recorded.  Subjects should be tested while sitting, relaxed and 
wearing a nose clip.  They should be asked to breathe regularl y for several breaths until 
the end- expi[INVESTIGATOR_645947] (this usually  requires at least three tidal 
manoeuvres) then urged to take a deep breath to Total L ung Capacit y (TLC) with no 
hesitation. 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
51Spi[INVESTIGATOR_645948] 1and FVC assessments 
that is not obtained as follows will be considered a protocol deviation:
Started between 6:00AM and 11:00AM.
After withholding albuterol/salbutamol (all visits) ≥4 hours 
At Visit 2 after discontinuation of run -in medication
At Visit 3, 4 and 5 after withholding the morning dose of study  drug 
7.3.4. COPD Exacerbation
A mild exacerbation is defined as worsening of s ymptoms that require no treatment with 
antibiotics or steroids, and is self managed b y the patient by [CONTACT_646010]. A moderate COPD exacerbation is defined as worsening s ymptoms of 
COPD that require treatment with oral/sy stemic co rticosteroids and/or antibiotics. A 
severe exacerbation is defined as worsening s ymptoms of COPD that require in- patient 
hospi[INVESTIGATOR_645949] [ADDRESS_864940] for the patient to withdraw from the study.
Signs and s ymptoms of COPD included on the electronic diary  cards will not be 
considered AEs and will not be recorded in the eCRF.
The time period for collection of COPD exacerbations will be from the Pre -Screen ing 
(Visit 0) until completion of the follow -up contact.  If a subject experiences a COPD 
exacerbation from the time the I CF is signed until randomization, summary  information 
(yes/no status question) will be collected in the eCRF. COPD exacerbations after
randomization through follow -up will be recorded on the COPD exacerbation page of the 
eCRF.
7.3.5. Clinically  important deterioration (CID)
Clinically  important deterioration (CID) is a composite endpoint defined as:
A decrease of  100 mL  from baseline in trou gh FEV 1 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
52A deterioration in HRQoL defined as 4 units increase from baseline in 
SGRQ
The occurrence of an on -treatment moderate/severe COPD exacerbation
In addition, this study will explore CAT and TDI  PROs as part of the composite 
endpoint.
7.3.6. Rescue albuter l/salbutamol use
Subjects will record the number of dail y albuterol/salbutemol puffs they  use in the 
eDiary .  In addition, in some countries and selected sites the number of puffs will be 
collected through the eMDI device (Section 6.2) 
7.3.7. Physical activity monitor (study subset)
Physical activity  limitation is a common feature of COPD and its measures are highl y 
related to the degree of disease severity  [Watz , 2009]. 
Reduced phy sical activity  levels in COPD is associated with increased morbidity  and 
mortality , sustained disability , depression, and social and phy sical isolation [ Shu-Yi, 
2014; Gimeno, 2014] 
Improved activity  has been identified as an important factor that may  modify  morbidity  
and mortality  in COPD [ Moy , 2012 ].
The Actigraph GT9X phy sical activity  monitor will be used to measure levels of activity . 
The activity  monitor will be worn by  [CONTACT_422906]  150 subjects per treatment arm 
for 7 day s from Screening (Visit 1), for 7 day s from Randomisation (Visit 2), 7 day s from 
Visit 3 (Week 4) and for 7 day s prior to Week 24 (Visit 5).
There will be [ADDRESS_864941] will be given an activity  
monitor and instruction leaflet at the start of each assessment period. Further details of 
distrib ution, operation and retrieval of the monitors will be provided in the SRM .
7.4. Safet y
Planned time points for all safety  assessments are listed in the Time and Events Table 
(Section 7.1)
Safety  endpoint includes:
Incidence of adverse events
7.4.1. Adverse Events (A E) and Serious A dverse Events (S AEs)
The definitions of an AE or SAE can be found in Appendix 4 . 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
53The investigator and their designees are responsible for detecting, documenti ng and 
reporting events that meet the definition of an AE or SAE. 
[IP_ADDRESS]. Time period and Frequency  for collecting A E and SA E information
Any SAEs assessed as related to study  participation (e.g., protocol- mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] 
product will be recorded from the time a subject consents to participate in the 
study  up to and including any  follow -up contact. 
AEs will be collected from the start of Study  Treatment until the follow -up 
contact (see Sectio n 7.4.1. 3), at the timepoints specified in the Time and Events 
Table (Section 7.1).
Medical occurrences that begin prior to the start of study treatment but after 
obtaining informed consent may  be recorded on the Medical History /Current 
Medical Conditions section of the CRF.
All SAEs will be recorded and reported to [COMPANY_004] within 24 hours, as indicated in 
(Appendix 4 , Section 12.4.6 )
Investigators are not obligated to activel y seek AEs or SAEs in former study 
subjects. However, if the investigator learns of an y SAE, including a death, at an y 
time after a subject has been discharged from the study , and he/she considers the 
event reasonabl y related to the study  treatment or study  participation, the 
investigator must promptly  notify  [COMPANY_004].
NOTE: The method of recording, evaluating and assessing causality  of AEs and SAEs 
plus procedures for completing and transmitting SAE reports to [COMPANY_004] are provided in 
(Appendix 4 , Section 12.4.4 to Section 12.4.6 )
[IP_ADDRESS]. Method of Detecting AEs a nd SA Es
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended 
and non-leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrence.  Appropriate questions include:
“How are you feeling?”
“Have you had an y (other) medical problems since y our last visit/contact
 “Have you taken an y new medicines, other than those provided in this study , 
since y our last visit/contact?
[IP_ADDRESS]. Follo w-up of A Es and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
subject at subsequent visits/contacts.  All SAEs, and non -serious AEs of special interest 
(as defined in Section 4.6.1 ) will be followed until resolution, until the condition
stabilizes, until the event is otherwise explained, or until the subject is lost to follow-up 
(as defined in Section 5.5).  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
[IP_ADDRESS]. Pneumonia Events
Investigators will be required to fill out a pneumonia event specific eCRF within one 
week of when the pneumonia AE/SAE(s) is first reported. 
[IP_ADDRESS]. Cardiovascular and Death Events
For an y cardiovascular events detailed in (Section 12.4.3) and all deaths, whether or not 
they are consid ered SAEs, specific Cardiovascular (CV) and Death sections of the CRF 
will be required to be completed. These sections include questions regarding 
cardiovascular (including sudden cardiac death) and non- cardiovascular death. 
The CV CRFs are presented as queries in response to reporting of certain CV MedDRA 
terms. The CV information should be recorded in the specific cardiovascular section of 
the CRF within one week of receipt of a CV Event data query  prompting its completion. 
The Death CRF is provided immediately  after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed within one 
week of when the death is reported.
[IP_ADDRESS]. Disease- Related Events and/or Disease -Related Outcomes Not 
Qualify ing as SA Es
The following disease related events (DREs) are common in subjects with COPD and can 
be serious/life threatening:
COPD exacerbation
COPD exacerbations are associated with the disease to be studied and will not be 
recorded as AEs unless the exacerbation meet s the definition of a ‘serious’ AE. 
Exacerbations that meet the definition of ‘serious’ AEs will be recorded on the 
appropriate eCRF section and should be reported to [COMPANY_004] for all subjects regardless of 
whether or not they  are randomized to study  medication . Signs and s ymptoms of COPD 
included on the electronic diary  will not be considered AEs and will not be recorded in 
the eCRF
[IP_ADDRESS]. Regulatory  Reporting Requirements for SA Es
Prompt notification by  [CONTACT_646027] (even
for non -interventional post -marketing studies) is essential so that legal obligations and 
ethical responsibilities towards the safet y of subjects and the safety of a product under 
clinical investigation are met. 
[COMPANY_004] has a legal responsibility  to notify  both the local regulatory  authorit y and other 
regulatory  agencies about the safet y of a product under clinical investigation.  [COMPANY_004] will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the 
regulatory  authority, Instituti onal Review Board (IRB)/Independent Ethics Committee 
(IEC) and investigators. 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
55Investigator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and [COMPANY_004] policy  and are forwarded 
to investigators as necessary .
An investigator who receives an investigator safety report describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from [COMPANY_004] will file it with 
the IB and will notify  the I RB/IEC, if appropriate accord ing to local requirements.
[IP_ADDRESS]. Additional A dverse Event (AE) Reporting Requirements for Canadian 
investigators
Health Canada requires pharmaceutical manufacturers to expeditiously  report domestic 
cases of unusual failure in efficacy  (UFIE) for new drugs to the Marketed Health 
Products Directorate (MHPD) within [ADDRESS_864942] notification. This regulation applies 
to marketed drugs, and used as directed per the Canadian prescribing information, 
including those drugs used in Phase IV (non CTA filed) clinical tri als.  
Adverse event (AE): Any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not 
necessarily  have to have a causal relationship with this treatment. An AE can therefore 
be any unfavourable and unintended sign (including an abnormal laboratory finding) 
symptom or disease (new or exacerbated) temporally  associated with the use of a 
Medicinal Product. For a marketed Medicinal Product, this can also include failure 
to produce ex pected benefits (i.e. lack of efficacy, with or without an adverse event), 
In order for [COMPANY_004] to comply  this Canadian regulatory  requirement, Canadian investigators 
are required to collect, record and report lack of efficacy events as per the table in 
Appendix 4 Section 12.4.1 .  
All paper forms are required to be faxed to [COMPANY_004] Canada’s Drug Safety  department at 
 within [ADDRESS_864943] awareness.
7.4.2. Pregnancy
Details of all pregnanci es in female subjects will be collected after the start of 
Screening and until the follow -up contact. 
If a pregnancy  is reported then the investigator should inform [COMPANY_004] within 2 
weeks of learning of the pregnancy  and should follow the procedures outlined 
in 
Appendix 7 .
7.4.3. Medical Device Incidents (Including Malfunctions)
Procedures for documenting medical device incidents are provided in Appendix 6 .
7.4.4. Electrocardiogram (ECG)
A Single 12- lead ECG will be obtained at Screening using an ECG machine provided by  
[CONTACT_646011], QRS, 
QT, and QTc intervals. 2018N377698_00
PP
2016N277425_02 CONFIDENTIA L
201749
56The 12- lead ECG measurement and rh ythm strip (10 seconds) will be ob tained before 
spi[INVESTIGATOR_496914]. ECG measurement should be obtained after subjects have rested for 
approximately  [ADDRESS_864944] provide his/her d ated signature [CONTACT_24003], attesting to the authenticity  of the ECG machine interpretation. 
7.5. Genetics
Information regarding genetic research is included in Appendix 3
8. DATA MANAG EMENT
For this study  subject data will be entered into [COMPANY_004] defined CRFs, transmitted 
electronically  to [COMPANY_004] or designee and combined with data provided from other 
sources in a validated data sy stem.  
Management of clinical data will be performed in accordance with applicable 
[COMPANY_004] standards and data cleaning procedures to ensure the integrit y of the data, 
e.g., removing errors and inconsistencies in the data.
Adverse events and concomitant medications terms will be coded using MedDRA 
(Medical Dictionary  for Regulatory  Activities) and an internal validated 
medication dictionary , [COMPANY_004]Drug.  
CRFs (including queries and audit trails) will be retained b y [COMPANY_004], and copi[INVESTIGATOR_131964] y.  Subject initials 
will not be collected or tra nsmitted to [COMPANY_004] according to [COMPANY_004] policy .
9. STATISTICA L CONSIDER ATIONS AND DA TA 
ANALYSES
9.1. Hypotheses
The primary  purpose of this study  is to demonstrate improvements in lung function for 
subjects treated with UMEC/VI  compared with UMEC for 24 weeks. 
The prim ary endpoint is change from baseline in trough FEV 1at Week 24.
The null hy pothesis is no difference between treatment groups (H0: μT – μS = 0), with 
the alternative h ypothesis that there is a difference between treatment groups (H1: μT –
μS ≠0), where μ T is the mean change from baseline for UMEC/VI and μS is the mean 
change from baseline for UMEC.  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
579.2. Sample Size Considerations
The pr imary  endpoint is change from baseline in trough FEV 1at Week 24. As an 
important aim of the study is to compare UMEC/VI, UMEC and salmeterol with respect 
to HRQoL  the sample size has been calculated to provide sufficient power for the 
comparison of the pr imary  and secondary  endpoint TDI , at Week 24.  
The sample size calculations use a two -sided 5% significance level and an estimate of 
between subject standard deviation for TDI of 2.94 units.  The estimate of SD is based on 
DB2113373 [ Donohue , 2013], a study  which consisted of treatment arms of UMEC/VI 
62.5/25, UMEC 62.5 VI (Vilanterol) 25mcg and placebo and is the value at Day  168 in a 
subgroup of subjects who were ICS free at screening.  Based on these data, 727 eva luable 
subjects per treatment arm will be required to provide 90% power to detect a statistically  
significant difference if the true difference is 0.5 units, ½ the MCI D, between UMEC/VI 
and UMEC. The smallest observed effect predicted to result in a statis tically  significant 
difference between treatment groups is 0.[ADDRESS_864945] >99% power 
assuming a true treatment difference of 80mL between UMEC/VI and UMEC for trough 
FEV1 at 24 weeks at the two-sided 5% significance level. This calculation uses a SD for 
trough FEV1 of 240mL, based on prior results for trials comparing dual bronchodilators 
versus single bronchodilators ( Donohue , 2013; Bateman , 2013). The smallest observed 
effect predicted to result in a statistically  significant difference between treatment groups 
is 25mL . 
In order to account a for a 10% withdrawal rate , approximately  [ADDRESS_864946] SDTreatment Difference Power
TDI 2.54 0.5 96%
2.74 0.5 94%
2.94 0.5 90%
3.14 0.5 86%
3.34 0.5 81% 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
589.2.3. Sample Size Re -estimation or A djustment
No sample size re -estimation is planned for this study . 
9.3. Data Analysis Considerations
9.3.1. Analysis Populations
Population Definition / Criteria Analyses Evaluated
All 
Subjects 
Enrolled 
(ASE)All subjects for whom a record exists in the 
study  database, including screen failures and 
any subject who was not screened but 
experienced an SAE between the date of 
informed consent and the planned date of the 
Screening visit. Subject 
Dispos ition
Reasons for 
withdrawal prior 
to randomisation
Inclusion, 
exclusion and 
randomisation 
criteria deviations
SAEs for non-
randomised 
subjects
Intent -to-
treat (ITT)All randomized subjects, excluding those who 
were randomized in error and received at lea st 
one dose of stud y medication. A subject who 
is recorded as a screen or run- in failure and 
also randomized will be considered to be 
randomized in error.  Any other subject who 
receives a randomization number will be 
considered to have been randomized.
Display s will be based on the treatment to 
which the subject was randomized.Study  Population
Efficacy
Safety
Intent -to-
treat ICS 
free (ITT 
ICS free)All subjects in the I TT Population who have 
not received ICS.Study  Population
Efficacy
Safety
9.3.2. Interi m Analysis
No interim anal ysis is planned for the stud y.
9.4. Key Elements of A nalysis Plan
Treatment Comparisons
The primary  treatment comparison of UMEC/VI with UMEC will be performed on the 
ITT population. 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
59The other treatment comparisons of UMEC/VI and UMEC with Salmeterol will be 
performed on the ITT population and ITT ICS free population.
9.4.1. Primary  Analyses
The treatment comparison of primary  interest will be UMEC/VI versus UMEC for the 
primary  endpoint of change from baseline in trough FEV 1at Week 24. The primary  
analyses will be performed using a mixed model repeated measures (MMRM) anal ysis 
and will be based on a two -sided hy pothesis testing approach on the ITT Population. 
In order to account for multiplicity  across treatment comparisons and endpoints, a step-
down closed testing procedure will be applied whereb y inference for secondary and other 
endpoints or treatment comparisons are dependent upon statistical significance having 
been achieved for the primary  comparison. If the primary  comparison is signif icant i.e. 
the associated p-value for UMEC/VI versus UMEC for change from baseline in trough 
FEV1 at Week 24 is below 0.05, this will allow inference of treatment comparisons 
(UMEC/VI versus UMEC on all other endpoints, and UMEC/VI versus Salmeterol and 
UMEC versus Salmeterol on all endpoints including the primary  endpoint), which will be 
declared statistically  significant if the associated p -value is below 0.05.  
There will be 2 anal yses one for one for the German Federal Joint Committee (G -BA) 
and one fo r the rest of the world (ROW).
The step-down closed testing procedure onl y applies to the ROW.  For the G -BA 
statistical inference for secondary  and other endpoints or treatment comparisons will not 
be conditional on achieving statistical significance of t he primary  comparison.  
The primary  endpoint of mean change from baseline in trough FEV1 at the end of Week 
24 and secondary  endpoint change from baseline in TDI score at Week 24 will both be 
analysed using MMRM analy sis. The MMRM analy sis for change from baseline in 
trough FEV1 and TDI will include measurements at Treatment Weeks 4, 12 and 24. 
Treatment group (a categorical variable) will be fitted as the explanatory  variable with 
appropriate pre -defined variables, stratum (number of bronchodilators per d ay during 
run-in) and baseline values, fitted as covariates. Visit (nominal) will be fitted as a 
categorical variable and visit- by-baseline and visit -by-treatment interaction terms will be 
included to allow treatment effects to be estimated at each visit s eparatel y. The variance 
covariance matrix will be assumed to be unstructured (based on previous experience no 
issues are expected with fitting models with this matrix structure). 
While missing data are not explicitly  imputed in the primary  MMRM analy ses, there is 
an underl ying assumption that the data are missing at random. 
The estimated treatment differences between UMEC/VI versus UMEC for each endpoint 
will be presented with the 95% confidence intervals for the difference and the p -value. 
Full details of the analy ses to be performed on all primary  endpoints will be given in the 
RAP. 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
609.4.2. Other A nalyses
The MMRM anal ysis will be repeated for the ITT ICS free population. Estimated 
differences between UMEC/VI  or UMEC and Salmeterol will be presented together wi th 
95% confidence intervals (CI s) for the difference and p- values.
Secondary  and other efficacy  endpoints and treatment comparisons will be adjusted for 
multiplicity  as per Section 9.4.1 .
Full details of the ana lyses to be performed on the other efficacy  endpoints will be given 
in the RAP.
Safety	Analyses
Adverse events (AEs) will be coded using the standard [COMPANY_004] dictionary , Medical
Dictionary  for Regulatory  Activities (MedDRA), and grouped by  [CONTACT_44749]. The 
number and percentage of subjects experiencing at least one AE of an y type, AEs within 
each bod y system and AEs within each preferred term will be presented for each 
treatment group. Separate summaries will be provided for all AEs, drug related AEs, fatal 
AEs, non- fatal SAEs, AESI s and AEs leading to withdrawal. 
Deaths and SAEs will be documented in case narrative format. 
Full details of the analy ses to be performed on all safet y endpoints will be given in the 
RAP.
10. STUDY GOVERNANCE CON SIDERATIONS
10.1. Posting of Information on Publicly  Available Clinical Trial 
Registers
Study  information from this protocol will be posted on publicly  available clinical trial 
registers before enrollment of subjects begins.
10.2. Regulatory  and Ethical Considerations, Including the 
Infor med Consent Process
Prior to initiation of a site, [COMPANY_004] will obtain favourable opi[INVESTIGATOR_1649]/approval from the 
appropriate regulatory  agency  to conduct the study in accordance with I CH Good Clinical 
Practice (GCP) and applicable country -specific regulatory  requir ements.
The study  will be conducted in accordance with all applicable regulatory  requirements, 
and with [COMPANY_004] policy .
The study  will also be conducted in accordance with I CH Good Clinical Practice (GCP), 
all applicable subject privacy  requirements, and the g uiding principles of the current 
version of the Declaration of Helsinki.  This includes, but is not limited to, the following: 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
61IRB/IEC review and favorable opi[INVESTIGATOR_1649]/approval of the study  protocol and 
amendments as applicable
Obtaining signed informed consen t
Investigator reporting requirements (e.g. reporting of AEs/SAEs/protocol 
deviations to I RB/IEC)
[COMPANY_004] will provide full details of the above procedures, either verball y, in writing, 
or both.
Signed informed consent must be obtained for each subject prior t o participation 
in the study
The IEC/I RB, and where applicable the regulatory authority, approve the clinical 
protocol and all optional assessments, including genetic research.  
Optional assessments (including those in a separate protocol and/or under sep arate 
informed consent) and the clinical protocol should be concurrentl y submitted for 
approval unless regulation requires separate submission.  
Approval of the optional assessments may  occur after approval is granted for the 
clinical protocol where required b y regulatory  authorities.  I n this situation, 
written approval of the clinical protocol should state that approval of optional 
assessments is being deferred and the study , with the exception of the optional 
assessments, can be initiated.
10.3. Qualit y Control (Study  Monitoring)
In accordance with applicable regulations including GCP, and [COMPANY_004] procedures, 
[COMPANY_004] monitors will contact [CONTACT_288627], study  requirements, and their responsibilities to satisfy  
regulatory , ethical, and [COMPANY_004] requirements.  
When reviewing data collection procedures, the discussion will also include 
identification, agreement and documentation of data items for which the eCRF
will serve as the source document.
[COMPANY_004] will monitor the study  and site activity  to verify  that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accordance with the currently  approved protocol and any  
other study  agreements, GCP, and all applicable regulatory  requirements.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents
10.4. Qualit y Assurance
To ensure compliance with GCP and all applicable r egulatory  requirements, [COMPANY_004] 
may conduct a quality  assurance assessment and/or audit of the site records, and  2018N377698_00
2016N277425_02 CONFIDENTIA L
[ADDRESS_864947] a regulatory inspection at any  time during or 
after completion of the study . 
In the event of an assessment, au dit or inspection, the investigator (and institution) 
must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to all 
relevant documents and to allocate their time and the time of their staff to discuss 
the conduct of the stud y, any fi ndings/relevant issues and to implement any  
corrective and/or preventative actions to address any  findings/issues identified.
10.5. Stud y and Site Closure
Upon completion or premature discontinuation of the study , the [COMPANY_004] monitor will 
conduct site closure activities with the investigator or site staff, as appropriate, in 
accordance with applicable regulations including GCP, and [COMPANY_004] Standard 
Operating Procedures.
[COMPANY_004] reserves the right to temporaril y suspend or prematurel y discontinue this 
study  at an y time for re asons including, but not limited to, safety  or ethical issues 
or severe non -compliance. For multicenter studies, this can occur at one or more 
or at all sites.  
If [COMPANY_004] determines such action is needed, [COMPANY_004] will discuss the reasons for taking 
such action w ith the investigator or the head of the medical institution (where 
applicable).  When feasible, [COMPANY_004] will provide advance notification to the 
investigator or the head of the medical institution, where applicable, of the 
impending action.
If the stud y is sus pended or prematurely  discontinued for safet y reasons, [COMPANY_004] will 
promptly  inform all investigators, heads of the medical institutions (where 
applicable) and/or institution(s) conducting the study . [COMPANY_004] will also promptly  
inform the relevant regulatory  author ities of the suspension or premature 
discontinuation of the study  and the reason(s) for the action.  
If required b y applicable regulations, the investigator or the head of the medical 
institution (where applicable) must inform the I RB/I EC promptl y and pro vide the 
reason for the suspension or premature discontinuation.
10.6. Records Retention
Following closure of the study , the investigator or the head of the medical 
institution (where applicable) must maintain all site study  records (except for 
those required b ylocal regulations to be maintained elsewhere), in a safe and 
secure location.  
The records must be maintained to allow eas y and timely  retrieval, when needed 
(e.g., for a [COMPANY_004] audit or regulatory  inspection) and must be available for review 
in conjunction with assessment of the facilit y, supporting s ystems, and relevant 
site staff.  
Where permitted b y local laws/regulations or institutional policy, some or all of 
these records can be maintained in a format other than hard cop y (e.g., microfiche,  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
63scanned, electronic); however, caution needs to be exercised before such action is 
taken.  
The investigator must ensure that all reproductions are legible and are a true and 
accurate cop y of the original and meet accessibility and retrieval standards, 
including re -generating a hard cop y, if required.  Furthermore, the investigator 
must ensure there is an acceptable back -up of these reproductions and that an 
acceptable qualit y control process exists for making these reproductions.
[COMPANY_004] will inform the investigator of the time period for retaining these records to 
comply  with all applicable regulatory  requirements.  The minimum retention time 
will meet the strictest standard applicable to that site for the study, as dictated by 
[CONTACT_120095] l aws or regulations, [COMPANY_004] 
standards/procedures, and/or institutional requirements.  
The investigator must notify  [COMPANY_004] of any  changes in the archival arrangements, 
including, but not limited to, archival at an off- site facility  or transfer of 
ownership of the records in the event the investigator is no longer associated with 
the site.
10.7. Provision of Study  Results to Investigators, Posting of 
Information on Publically  Available Clinical Trials Registers 
and Publication
Where required b y applicable regulatory  requ irements, an investigator signatory  will be 
identified for the approval of the clinical study  report.  The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity  to review the comp lete study  results at a [COMPANY_004] site or other mutually -
agreeable location.
[COMPANY_004] will also provide the investigator with the full summary  of the stud y results.  The 
investigator is encouraged to share the summary  results with the study  subjects, as 
appropriate.
[COMPANY_004] will provide the investigator with the randomization codes for their site only  after 
completion of the full statistical analy sis.
The procedures and timing for public disclosure of the results summary  and for 
development of a manuscript for publication will be in accordance with [COMPANY_004] Policy .
A manuscript will be progressed for publication in the scientific literature if the results 
provide important scientific or medical knowledge. 2018N377698_00
2016N277425_02 CONFIDENTIA L
[PHONE_13434]. REFERENCES
Bateman ED, Ferguson GT, Barnes N et al. Dual bronchodilation with QVA149 versus 
single bronchodilation therap y: The SHINE study . Eur Respir J. 2013 Dec; 42:1484 -94
Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: 
a summary  of the ATS/ERS position paper. Eur Respir J. 2004; 23:932 -946.
Chen H, Yu KD, Xu GZ. Association between Variant Y402H in Age- Related Macular 
Degeneration (AMD) Susceptibility  Gene CFH and Treatment Response of AMD: A 
Meta -Anal ysis. PloS ONE 2012; 7: e42464
Dahl R, Chung KF, Buhl R et al. Efficacy  of a new once -daily  long -acting inhaled β2 -
agonist indacaterol versus twice- daily formoterol in COPD. Thorax 2010, 65:473 -479.
Donohue JF, Maleki -Yazdi MR, Kilbride S, et al.  Efficacy  and safet y of once -daily 
umeclindinium/vilanterol 62.5/25mcg in COPD.  Respir Med 201 3; 107: 1538-1546.
European Medicines Agency  (EMA) . Guidelines on clinical investigation of medicinal 
productsin the treatment of chronic obstructive pulmonary  disease (COPD). 
EMA/CHMP/48353572 , 2012.
Feldman G, Maltais F, Khindri S, et al.  A randomized blinded study  to evaluate the 
efficacy  and safet y of umeclidinium 62.5 g compared with tiotropi[INVESTIGATOR_1890] 18 g in patients 
with COPD.  I nternational Journal of COPD 2016; 11: 719 -730
Feldman G, Siler T, Prasad N et al. Efficacy  and safet y of indacaterol 150 μg once -daily 
in COPD: a double -blind, randomised, 12- week study . BMC Pulm Med 2010, 10:11.
Gimeno- Santos E, Frei A, Steurer -Stey C, et al. Determinants and outcomes of phy sical 
activity  in patients with COPD: a sy stematic review. Thorax 2014; 0:1-9
GlaxoSmithKlineDocument Number [RM2006/[ZIP_CODE]/09, Umeclidinium ([COMPANY_004]573719) 
Investigator’s Brochure. Report Date -Aug-2016.
GlaxoSmithKlineDocument Number RM2009/[ZIP_CODE]/07, Umeclidinium + Vilanterol 
Investigator's Brochure. Re port date AUG -2015
GOLD. Global Initiative for Chronic Obstructive Lung Disease [GOLD]. Global Strategy 
for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary  
Disease. Last Updated 2015. http://www.goldcopd.org.
Gorin MB. Genetic ins ights into age -related macular degeneration: Controversies 
addressing risk, causality, and therapeutics. Mol. Asp. Med. 2012; 33: 467 -486.
Hatcher RA, Trussell J, Nelson AL, Cates W Jr, et al, editors. Contraceptive Technology . 
20th revised edition. New Yo rk: Ardent Media, 2011. 2018N377698_00
2016N277425_02 CONFIDENTIA L
[ADDRESS_864948] in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.
Jones, P., Harding, G., Berry , P., Wiklund, I ., Chen, W -H., L eidy, N. Development and 
first validation of the COPD Assessment Test (CAT) Eur Respir J, 2009; 34: 648–654
Jones, P., Harding, G., Wiklund, I ., Berry , P., Tabberer, M., Yu, R., Leidy , N. Tests of 
the Responsiveness of the Chronic Obstructive Pulmonary  Disease (COPD) Assessment 
Test (CAT) Following Acute Exacerbation and Pulmonary  Rehabilitation Chest, 2012, 
142 134 -140
Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Dény P, Gault E.  Quantifi cation 
of Hepatitis Delta Virus RNA in Serum by  [CONTACT_31861] -Time PCR I ndicates 
Different Patterns of Virological Response to Interferon Therap y in Chronically  Infected 
Patients.  J Clin Microbiol. 2005;43(5):2363 –2369. 
Leidy NK, Sexton CC, Jones PW, No tte SM. et al. Measuring respi[INVESTIGATOR_645951]: reliability  and validity  of a daily  diary . Thorax 2014; 69:5 424 -
430
Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S. Standardizing 
measurement of chronic obstructive pu lmonary  disease exacerbations. Reliability  and 
validity  of a patient- reported diary . Am J Respir Crit Care Med 2011; 183:323-[ADDRESS_864949] J, Fierro -Carrion G, et al. Development of self -administered versions 
of modified baseline and transition dy spnea indexes in COPD. J COPD 2004; 165 –[ADDRESS_864950] 1984, 85: 751-758.
Maleki -Yazdi MR, Kael in T, Richard N, Zvarich M, Church A. Efficacy  and safet y of 
umeclidinium/vilanterol 62.5/25 mcg and tiotropi[INVESTIGATOR_1890] 18 mcg in chronic obstructive 
pulmonary  disease: results of a 24- week, randomized, controlled trial. Respi[INVESTIGATOR_645952]. 2014;108:1752-60.
Maltais F, Singh S, Donald AC, Crater G, Church A, Goh AH, Riley  JH. Effects of a 
combination of umeclidinium/vilanterol on exercise endurance in patients with chronic 
obstructive pulmonary  disease: two randomized, double -blind clinical trials. Ther Adv 
Respi r Dis. 2014;8:[ADDRESS_864951]. 
2007;132:456-463
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coat es A, Crapo R, Enright 
P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacInt yre N, McKay  R,  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
66Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J.  Standardisation of 
spi[INVESTIGATOR_038] .  Eur Respir J.  2005;26: 319-338.
Moy  ML, Weston NA, Wilson EJ , Hess ML , Richardson CR. A pi[INVESTIGATOR_645953]. Respir Med. 2012;106:1342- 50. 
Quanjer P, Stanojevic S, Cole T, Baur X., Hall G, Enright P, et al. on behalf of the ERS 
Global L ung Function Initiative.  Multi -ethnic reference values for spi[INVESTIGATOR_105221] 3 -
95 year age range: the global lung function 2012 equations. Eur Respir J, 2012; 40: 
1324 –1343.
Schmidt SA, Johansen MB, Olsen M et al. The impact of exacerbation frequency  on 
mortality  following acute exacerba tion of COPD: a registry -based cohort study . B Med J. 
Open. 2014;4: (12): e006720
Serevent product information 2003. Available from 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20236slr028_serevent_lbl.pdf
Shu-Yi Liao, Roberto Benzo et al. Physical Activity  Monitoring in Patients with Chronic 
Obstructive Pulmonary  Disease. Journal of the COPD Foundation 2014; 1: 155 -165
Siler T, Kerwin E, Sousa A, Donald A, Rehan A, Church A, Efficacy  and safet yof 
umeclidinium added to fluticasone furoate/vilan terol in chronic obstructive pulmonary  
disease: Results of two randomized studies.  Respir Med. 2015; 109:1155 -63
Singh D, Maleki -Yazdi MR, Tombs L , Iqbal A, Fah y WA, Naya I. Prevention of 
clinically  important deteriorations in COPD with umeclidinium/vilan terol. Int’l J of 
COPD, 2016; 11:1413 -1424
Tashkin DP, Fabbri LM. Long acting beta -agonists in the management of chronic 
obstructive pulmonary  disease: Current and future agents.  Respir Research, 2010; 11: 
[ADDRESS_864952] N, Mehta R, and Church, A . Umeclidinium in patients with COPD: a 
randomised, placebo -controlled study .  Eur Respir J. 2014; 43: 72–81.
Watz H, Waschki B, Meyer T, Magnussen H: Physical activity  in patients with COPD. 
Eur Respir J 2009, 33:262–272. 
Wedzicha JA, Brill SE, Allinson JP, Donalson GC. Mechanism and impact of the 
frequent exacerbator phenoty pe in chronic obstructive pulmonary  disease. BMC 
Medicine, 2013; 11:181 2018N377698_00
2016N277425_02 CONFIDENTIA L
[PHONE_13435]. APPENDICES
12.1. Appendix 1: A bbreviations and Trademarks
Abbrev iations
AE Adverse Event
ALT Alanine transaminase
AST Aspartate aminotransferase
ATS American Thoracic Society
CAT COPD Assessment Test
CI Confidence Intervals
CID Clinically  important deterioration 
COPD Chronic Obstructive Pulmonary  Disease
CPK Creatine phosphokinase
CRF Case Report Form
CV Card iovascular
DPI [INVESTIGATOR_645954] I nhaler
E-RS Evaluating Respi[INVESTIGATOR_244774] -COPD  To ol
ERS European Respi[INVESTIGATOR_645955] ₁ Forced Expi[INVESTIGATOR_645956] I nitiative for Chronic Obstructive Lung Disease
[COMPANY_004] GlaxoSmithKline
IB Investigator Brochure
ICF Informed Consent Form
ICS Inhaled Corticosteroid
IEC Independent Ethics Committee
IP Investigational product
INR International normalized ratio
IRT Interactive Response Technology
ITT Intent -to-Treat
IUD Intrauterine Device
IUS Intrauterine S ystem
LABA Long Acting Beta -Agonist
LAMA Long -acting Muscarinic Receptor Antagonists
LDH Lactate deh ydrogenase
LTOT Long Term Ox ygen Therapy 2018N377698_00
2016N277425_02 CONFIDENTIA L
[ADDRESS_864953] Upper Limit of Normal
UMEC Umeclidinium ([COMPANY_004]573719)
UMEC/VI Umeclidinium & Vilanterol as a fixed dose combination
VI Vilanterol Trife nate 
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_646013] E-RS
DISKUS EXCACT
ELLIPTA
INCRUSE
SEREVENT 2018N377698_00
2016N277425_02 CONFIDENTIA L
[PHONE_13421].2. Appendix 2: Liver Safety  Required A ctions an d Follow up 
Assessments
Phase III -IV liver chemistry stoppi[INVESTIGATOR_420682] - Liver Stoppi[INVESTIGATOR_53053]- absolute ALT  8xULN
ALT Increase ALT  5xULN but <8xULN  persists for 2 weeks
ALT  3xULN but <5xULN  persists for 4 weeks
Bilirubin1, 2ALT  3xULN andbilirubin 2xULN (>35% direct bilirubin) 
INR2ALT  3xULN andINR>1.5, if INR measured
Cannot 
MonitorALT  5xULN but <8xULN and cannot be monitored weekly for  2 weeks
ALT  3xULN but <5xULN and cannot be monitored weekly for 4 weeks
Symptomatic3ALT   3xULN associated with symptoms (new or worsening) believed to be 
related to  liver injury or hypersensitivity
Required Actions and Follow up Assessments following ANY Liver Stopp ing Event
Actions Follow Up Assessments
Immediately discontinue  study treatment
Report the event to [COMPANY_004] within 24 hours
Complete the liver event CRF and complete 
an SAE data collection tool if the event also 
meets the criteria for an SAE2
Perform liver event follow up assessments 
Monitor the subject until liver chemistries 
resolve , stabilize, or return to within normal 
ranges. baseline (see MONITORING below)
Do not restart/rechallenge subject with 
study treatment. Permanently discontinue 
study treatmen t and may continue subject 
in the study for any protocol specified follow 
up assessments
MONITORING:
For bilirubin or INR criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform Viral hepatitis serology4
Only in those with underlying chron ic 
hepatitis B at study entry (identified by 
[CONTACT_23977] B surface antigen) 
quantitative hepatitis B DNA and hepatitis 
delta antibody5.
Blood sample for pharmacokinetic (PK) 
analysis, obtained within a week after last 
dose6
Serum creatine phosphokin ase (CPK) and 
lactate dehydrogenase (LDH).
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form
Record use of concomitant medications on 
the concomitant medications report form
including acetaminophen, herbal  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
70Liver Chemistry Stoppi[INVESTIGATOR_2121] - Liver Stoppi[INVESTIGATOR_645957] s within  24 
hrs
Monitor subjects twice weekly until liver 
chemistries resolve, stabilize or return to 
within normal ranges.
A specialist or hepatology consultation is 
recommended
For All other criteria:
Repeat liver chemistries (include ALT, AST, 
alkali ne phosphatase, bilirubin) and perform 
liver event follow up assessments within  24-
72 hrs 
Monitor subjects weekly until liver 
chemistries resolve, stabilize or return to 
within normal ranges.remedies, other over the counter 
medications .
Record alcohol use on the liver event 
alcohol intake case report form
For bi lirubin or INR criteria:
Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti- liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG or gamma 
globulins).
Serum acetaminophen adduct HPLC 
assay (quantifies potential aceta minophen 
contribution to liver injury in subjects with 
definite or likely acetaminophen use in the 
preceding week [ James , 2009]). NOTE: 
not required in China
Liver imaging (ultrasound, magnetic 
resonance, or computerised tomography) 
and /or liver biopsy to evaluate liver 
disease; complete Liver Imaging and/or 
Liver Biopsy CRF forms.
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that subject if ALT 3xULN andbilirubin 2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations a nd suggesting liver injury. 
2. All events of ALT 3xULN andbilirubin  2xULN (>35% direct bilirubin) or ALT 3xULN andINR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR measurement is not required and the threshold value stated 
will not apply to subjects receiving anticoagulants
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)   
4. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody;  Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  Hepatitis E IgM antibody 
5. If hepatitis delta antibody assay cannot be performed,  it can be replaced with a PC R of hepatitis D RNA virus 
(where needed) [ Le Gal , 2005].
6. PK sample may not be required for subjects known to be receiving placebo or non -[COMPANY_004] comparator treatments.  
Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to 
blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the subject’s best 
approximation. If the date/time of the last dose cannot be approximated OR a PK sample can not be collected in 
the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shippi[INVESTIGATOR_131971].   2018N377698_00
2016N277425_02 CONFIDENTIA L
[PHONE_13422].3. Appendix 3: Genetic Research
Genetics –Background
Naturall y occurring genetic variation may  contribute to inter -individual variability in 
response to medicines, as well as an individual's risk of developi[INVESTIGATOR_42259]. 
Genetic factors associated with disease characteristics may  also be associated with 
response to therap y, and could help to explain some clinical study  outcomes. For 
example, genetic variants associated with age- related macular degeneration (AMD) are 
reported to account for much of the risk for the condition [ Gorin , 2012] with certain 
variants reported to in fluence treatment response [ Chen, 2012]. Thus, knowledge of the 
genetic etiology  of disease may  better inform understanding of disease and the 
development of medicines. Additionally , genetic variability  may  impact the 
pharmacokinetics (absorption, distribution, metabolism, and elimination), or 
pharmacod ynamics (relationship between concentration and pharmacologic effects or the 
time course of pharmacologic effects) of a specific medicine and/or clinical outcomes 
(efficac y and/or safet y) observed in a clinical study.
Genetic Research Objectives and A nalyses
The objectives of the genetic research are to investigate the relationship between genetic 
variants and: 
Response to medicine, including an y concomitant medicines;
COP D susceptibility , severity , and progression of related conditions
Genetic data may  be generated while the study  is underway  or following completion of 
the study .  Genetic evaluations may  include focused candidate gene approaches and/or 
examination of a la rge number of genetic variants throughout the genome (whole genome 
analyses). Genetic anal yses will utilize data collected in the study  and will be limited to 
understanding the objectives highlighted above.  Analy ses may  be performed using data 
from multip le clinical studies to investigate these research objectives.
Planned anal yses and results of genetic investigations will be reported either as part of the 
clinical RAP and study  report, or in a separate genetics RAP and report, as appropriate.
Study Popul ation
Any subject who is enrolled in the study  can participate in genetic research.  Any  subject 
who has received an allogeneic bone marrow transplant must be excluded from the 
genetic research.
Study Assessments and Procedures
A key  component of successful genetic research is the collection of samples during 
clinical studies. Collection of samples, even when no a priori hypothesis has been 
identified, may  enable future genetic anal yses to be conducted to help understand 
variability  in disease and medicine response.   2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
72A 6 ml blood sample will be taken for Deox yribonucleic acid (DNA) extraction. 
A blood sample is collected at the baseline visit, after the subject has been 
randomized and provided informed consent for genetic research. Instructions for 
collecti on and shippi[INVESTIGATOR_428121]. The DNA from the blood sample may  undergo quality  control analy ses to 
confirm the integrit y of the sample. If there are concerns regarding the quality  of 
the sample, then the sam ple may  be destroy ed. The blood sample is taken on a 
single occasion unless a duplicate sample is required due to an inabilit y to utilize 
the original sample.  
The genetic sample is labelled (or “coded”) with the same stud y specific number used to 
label o ther samples and data in the study .   This number can be traced or linked back to 
the subject by  [CONTACT_132018]. Coded samples do not carry  personal 
identifiers (such as name [CONTACT_42405]). 
Samples will be stored securel y and may be kept for up to [ADDRESS_864954] 
completes the study , or [COMPANY_004] may  destroy  the samples sooner.  [COMPANY_004] or those working 
with [COMPANY_004] (for example, other researchers) will only use samples collected from the study  
for the purpose stated in this protocol and in the informed consent form.  Samples may  be 
used as part of the development of a companion diagnostic to support the [COMPANY_004] medicinal 
product.
Subjects can request their sample to be destro yed at any  time.
Informed Consent
Subjects who do not w ish to participate in the genetic research may  still participate in the 
study .  Genetic informed consent must be obtained prior to any  blood being taken.
Subject Withdrawal from Study
If a subject who has consented to participate in genetic research withdr aws from the 
clinical study  for any  reason other than being lost to follow -up, the subject will be given a 
choice of one of the following options concerning the genetic sample, if already  
collected:
Continue to participate in the genetic research in which case the genetic DNA 
sample is retained
Discontinue participation in the genetic research and destroy  the genetic DNA 
sample 
If a subject withdraws consent for genetic research or requests sample destruction for an y 
reason, the investigator must complete the appropriate documentation to request sample 
destruction within the timeframe specified b y [COMPANY_004] and maintain the documentation in 
the site study  records . 
Genoty pe data may  be generated during the study  or after completion of the study  and 
may be anal yzed during the study  or stored for future anal ysis.  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
73If a subject withdraws consent for genetic research and genot ype data has not been 
analyzed, it will not be analy zed or used for future research.  
Genetic data that has been anal yzed at the time of withdr awn consent will 
continue to be stored and used, as appropriate. 
Screen and Baseline Failures
If a sample for genetic research has been collected and it is determined that the subject 
does not meet the entry  criteria for participation in the study , then t he investigator should 
instruct the subject that their genetic sample will be destro yed. No forms are required to 
complete this process as it will be completed as part of the consent and sample 
reconciliation process.  In this instance a sample destruction form will not be available to 
include in the site files.
Provision of Study Results and Confidentiality  of Subject’s Genetic Data
[COMPANY_004] may  summarize the genetic research results in the clinical study  report, or 
separately  and may  publish the results in sci entific journals. 
[COMPANY_004] may  share genetic research data with other scientists to further scientific 
understanding in alignment with the informed consent. [COMPANY_004] does not inform the subject, 
family  members, insurers, or employ ers of individual genoty pi[INVESTIGATOR_124619] s that are not 
known to be relevant to the subject’s medical care at the time of the study , unless 
required b y law. This is due to the fact that the information generated from genetic 
studies is generally preliminary in nature, and therefore the significance and scientific 
validity  of the results are undetermined.  Further, data generated in a research laboratory  
may not meet regulatory  requirements for inclusion in clinical care. 2018N377698_00
2016N277425_02 CONFIDENTIA L
[PHONE_13436].4. Appendix 4: Definition of and Procedures for Recording, 
Evaluating, Follow -Up and Reporting of A dverse Events
12.4.1. Definition of A dverse Events
Adverse Event Definition:
An AE is an y untoward medical occurrence in a patient or clinical investigation 
subject, temporall y associated with the use of a medicinal product, whether or not 
considered related to the medicinal product. For a marketed medicinal product, this 
can also include failure to produce expected benefits (i.e. lack of efficacy , with or 
without associated signs or sy mptoms or clinical sequelae).
NOTE: An AE can therefore be anyunfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a medicinal product.
Events meeting AE definition include:
Any abnormal laboratory test result s (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (e.g., ECGs, radiological scans, vital signs 
measurements), including those that worsen from baseline, and felt to be clinically  
significant in the medical and scientific judgeme nt of the investigator.
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y treatment administration even 
though it m ay have been present prior to the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE unless this is an intentional overdose taken with possible suicidal/self -
harming intent.  This should be reported regardless of sequelae).
"Lack of efficacy " or "failure of expected pharmacological action" will be rep orted 
as an AE or SAE as per the table below
Adverse 
Event 
criteriaElectronic case record 
form (eCRF) onlyPaper form only Electronic case 
record form 
(eCRF) + Paper 
form
Non serious Non drug related lack of 
efficacy  reports with 
associated signs or 
symptoms or clinical Drug related lack of 
efficacy  reports 
without associated 
signs or s ymptoms or Drug related lack 
of efficacy  with 
associated signs or 
symptoms or  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
75sequelae clinical sequelae. clinical sequelae  
Serious Non drug related lack of 
efficacy  reports with 
associated signs or 
symptoms or clinical 
sequelae Drug related lack of 
efficacy  reports 
without associated 
signs or s ymptoms or 
clinical sequelae. Drug related lack 
of efficacy  reports 
with associated 
signs or symptoms 
or clinical sequelae
Events NOT meeting definition of an AE include:
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_646028]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s 
condition.
Medical or surgical procedure (e.g., endos copy, appendectom y): the condition that 
leads to the procedure is an AE.
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or co ndition(s) present 
or detected at the start of the study that do not worsen.
12.4.2. Definition of Serious A dverse Events
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_1080]/ symptoms of the disease under study , 
death due to progression of disease, etc).
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, 
at any dose:
a.Results in death
b.Is life -threatening
NOTE:
The term 'life -threatening' in the def inition of 'serious' refers to an event in which the 
subject was at risk of death at the time of the event.  I t does not refer to an event, which 
hypothetically  might have caused death, if it were more severe.
c.Requires hospi[INVESTIGATOR_17127] e xisting hospi[INVESTIGATOR_645976]:
In general, hospi[INVESTIGATOR_5184] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appropriate in the phy sician’s 
office or out -patient setting.  Complications that occur during hospi[INVESTIGATOR_227926]  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
76AEs.  If a complication prolongs hospi[INVESTIGATOR_9236], 
the event is serious.  When in doubt as to whether “hospi[INVESTIGATOR_5186] n” occurred or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen 
from baseline is not considered an AE.
d.Results in disability/incapacity
NOTE:
The term disability  mea ns a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea , influenza, 
and a ccidental trauma (e.g. sprained ankle) which may  interfere or prevent every day 
life functions but do not constitute a substantial disruption
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_23951].  These should also be considered 
serious.
Examples of such events are invasive or malignant cancers, intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse
g. Is associated with liver injury andimpaired liver function defined as:
ALT 3xULN and total bilirubin*2xUL N (>35% direct), or
ALT 3xULN and I NR**> 1.5.
* Serum bilirubin fractionation should be performed if testing is available; if unavailable, 
measure urinary  bilirubin via dipstick.  I f fractionation is unavailable and ALT 3xULN 
and total bilirubin  2xULN, then the event is still to be reported as an SAE.
** INR testing not required per protocol and the threshold value does not apply  to 
subjects receiving anticoagulants.  If INR measurement is obtained, the value is to be 
recorded on the SAE form.
12.4.3. Definition of Cardiovascular Events
Cardiovascular Events (CV) Definition:
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
77Valvulopathy
Pulmonary  hyperte nsion
Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thromboembolism
Deep venous thrombosis/pulmonary  embolism
Revascularization
12.4.4. Recording of A Es and SA Es
AEs and SAE Recording:
When an AE/SAE occurs, it is the responsib ility of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
relative to the event.
The investigator will then record all relevant information regarding an AE/SAE in 
the electronic CRF and/or pa per form as applicable .It is notacceptable for the 
investigator to send photocopi[INVESTIGATOR_9238]’s medical records to [COMPANY_004] in lieu of 
completion of the [COMPANY_004], AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_004].  In this instance, all subject identifiers, with the exception of the 
subject number, will be blinded on the copi[INVESTIGATOR_131976].
The investigator will attempt to establish a diagnosis of the event bas ed on signs, 
symptoms, and/or other clinical information.  In such cases, the diagnosis will be 
documented as the AE/SAE and not the individual signs/sy mptoms.
Subject -completed Value Evidence and Outcomes questionnaires and the collection 
of AE data are i ndependent components of the study .
Responses to each question in the Value Evidence and Outcomes questionnaire will 
be treated in accordance with standard scoring and statistical procedures detailed b y 
the scale’s developer.
The use of a single question f rom a multidimensional health survey  to designate a 
cause -effect relationship to an AE is inappropriate.
12.4.5. Evaluating AEs and SA Es
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and will assign it to one of the following categories: 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
78Mild:  An event that is easily  tolerated by  [CONTACT_423], causing minimal discomfort 
and not interfering with every day activities.
Moderate:  An event that is sufficiently  discomforting to interfere wit h normal 
every day activities
Severe:  An event that prevents normal every day activities. -an AE that is assessed 
as severe will not be confused with an SAE. Severity  is a category  utilized for rating 
the intensity  of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least one of the pre -defined 
outcomes as described in the definition of an SAE.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y treatme nt and 
the occurrence of each AE/SAE.
A "reasonable possibility " is meant to convey that there are facts/evidence or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled 
out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as natural history  of the underly ing diseases, concomitant 
therap y, other risk factors, and the temporal relationship of the event to the study  
treatment will be considered and investigated.
The investig ator will also consult the I nvestigator Brochure (IB) and/or Product 
Information, for marketed products, in the determination of his/her assessment.
For each AE/SAE the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations when an SAE has occurred and the investigator has minimal 
information to include in the initial report to [COMPANY_004].  However, it is very important 
that the investigator always make an assessment of causality for every event 
prior to the initial transmission of the SAE data to [COMPANY_004].
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information, amending the SAE data collection tool accordingl y.
The causality  assessment i s one of the criteria used when determining regulatory  
reporting requirements.
Follow -up of A Es and SA Es
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as may  be indicated or as requested b y [COMPANY_004] to 
elucidate as fully  as possible the nature and/or causality  of the AE or SAE. 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
79The investigator is obligated to assist.  This may  include additional laboratory  tests 
or investigations, histopathological examinations or consultation with other h ealth 
care professionals.
If a subject dies during participation in the study  or during a recognized follow -up 
period, the investigator will provide [COMPANY_004] with a copy  of any  post -mortem findings, 
including histopathology .
New or updated information will be r ecorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to [COMPANY_004] within the designated 
reporting time frames.
12.4.6. Reporting of SA Es to [COMPANY_004]
SAE reporting to [COMPANY_004] via electronic data collection tool
Primary  mechanism for report ing SAEs to [COMPANY_004] will be the electronic data collection 
tool
For lack of efficacy  reports , the paper form will be used to submit to [COMPANY_004] as per the 
table in Section 12.4.1 above. If the electronic s ystem is unavailable for greate r than 
24 hours, the site will use the paper SAE data collection tool and fax it to the 
Medical Monitor
Site will enter the serious adverse event data into the electronic s ystem as soon as it 
becomes available.
The investigator will be required to confirm review of the SAE causality  by [CONTACT_90649] ‘reviewed’ box at the bottom of the eCRF page within 72 hours of submission of 
the SAE.
After the stud y is completed at a given site, the electronic data collection tool (e.g., 
InForm s ystem) will be taken off- line to prevent the entry  of new data or changes to 
existing data
If a site receives a report of a new SAE from a study  subject or receives updated data 
on a previousl y reported SAE after the electronic data collection tool has been taken 
off-line, the site can report this information on a paper SAE form or to the Medical 
Monitor by  [CONTACT_756].
Contacts for SAE receipt can be found at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774]. 2018N377698_00
2016N277425_02 CONFIDENTIA L
[PHONE_13437].5. Appendix 5: COPD Exacerbation Identification, 
Categorization and Treatment Guidelines
12.5.1. Guidelines for Identifying COPD Exacerbations
The following are s ymptoms used to ascertain an exacerbation of COPD:
Worsening of two or more of the following major sy mptoms for at least two consecutive 
days:
Dyspnea
Sputum volume
Sputum purulence (color)
OR
Worsening of an y one major symptom together with any  one of the following minor 
symptoms for at least two consecutive day s:
Sore throat
Colds (nasal discharge and/or nasal congestion)
Fever (oral temperature > 37.5 °C) without other cause
Increased cough
Increased wheeze
Subjects who experience worsening COPD sy mptoms for greater than 24 hours should: 
Contact [CONTACT_496979]/or research coordinator immediately , and 
report to the study  clinic as required
If the subject is unable to contact [CONTACT_23976] y Investigator and/or research 
coordinator, they  should contact [CONTACT_23975] (or other health care 
practitioner as required) and contact [CONTACT_23976] y site as soon as possible
Continue to record their symptoms and rescue albuterol/salbutamol usage in their 
daily  eDiary  
If the subject seeks emergency /acute care for worsening respi[INVESTIGATOR_23908], 
he/she should request the caring Health Care Provider (HCP) to contact [CONTACT_646029] n as possible.
Subjects with worsening respi[INVESTIGATOR_496947]:
A mild/moderate/severe exacerbation and/or pneumonia
OR
A Lower Respi[INVESTIGATOR_645959] I nfection (L RTI) 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
81Background variability  of COPD
A non- respi[INVESTIGATOR_23910]
Other respi[INVESTIGATOR_23910]
12.5.2. COPD Exacerbation Severity
Each COPD exacerbation will be categorized based on severit y as follows:
Moderate :  Worsening sy mptoms of COPD that require treatment with 
oral/sy stemic corticosteroids and/or antibiotics.
Severe : Worsening s ymptoms of COPD that require treatment with in -patient 
hospi[INVESTIGATOR_26109] [ADDRESS_864955] x- ray within 48 hours of 
identification of a moderate or severe exacerbation. Details of an e xacerbation should 
be recorded in the exacerbation page of the eCRF. However, exacerbations should not be 
recorded in the AE section of the eCRF unless they meet the definition of an SAE. 
(Pneumonia must be recorded in the AE or SAE section of the eCRF and on the 
Pneumonia page of the eCRF.)
Use of antibiotics for the treatment of upper or lower respi[INVESTIGATOR_496948] a COPD exacerbation unless the subject experiences worsening s ymptoms 
of COPD which match the definition of an e xacerbation as given above.
12.5.3. Treatment of COPD Exacerbations
All medications used for the treatment of exacerbations must be recorded in the source 
documents and the exacerbation page of the eCRF.  All sites should follow the protocol 
treatment guidelines ( as outlined below), but any  medications deemed medically  
necessary  may  be used to treat a COPD exacerbation. However, caution is advised in 
using a LABA or LAMA to treat a subject currently taking IP as these additional 
medications may  increase the risk of overdose. If necessary  the PI [INVESTIGATOR_645960]’s IP temporaril y in order to treat the COPD exacerbation.
12.5.4. Guidelines for Treatment with Corticosteroids
If in the opi[INVESTIGATOR_689]/treating ph ysician the exacerb ation is severe enough 
to warrant the need for oral or sy stemic corticosteroids (with or without antibiotics) the 
following guidelines should be used.
The duration of treatment with oral/sy stemic corticosteroids should be 14 day s 
(dose and t ype according to local practice) 
The duration of treatment with oral/sy stemic corticosteroids should not exceed 14 
days unless approval is given by  [CONTACT_107634]
Any course of oral/s ystemic corticosteroids started within 7 day s of finishing a 
previous course will be considered as treatment for a single exacerbation 2018N377698_00
2016N277425_02 CONFIDENTIA L
[PHONE_13438].5.5. Guidelines for Treatment with A ntibiotics
If there is evidence of respi[INVESTIGATOR_645977]:
The duration of treatment with antibiotics should not exceed 14 day s (dose and ty pe 
according to local practice). If first line antibiotic treatment fails and additional 
antibiotics are used, the total duration of antibiotic treatment should not exceed 30 
days unless approval is given by  [CONTACT_107634]
Any course of antibiotics started within [ADDRESS_864956] day  (of at least 2 consecutive day s) of worsening s ymptoms 
of COPD as described in Section 12.5.1.
The date of resolution should be based on when the Investigator and/or subject 
determines that the COPD sy mptoms have returned to pre -exacerbation levels or to a new 
baseline.  In determining this resolution date, consideration shoul d be given to diary  
recorded s ymptoms and/or study  subject evaluation.
12.5.7. Guideline for assessing multiple mild exacerbations
Two mild exacerbations can be combined into one, per the Investigator’s judgement, if a 
subject’s diary  reveals that the two mild COP D exacerbations are separated by  [CONTACT_646016] s.
12.5.8. Guideline for assessing exacerbations that increase in severity
If an exacerbation starts off as mild, but becomes moderate or severe or starts off as 
moderate and becomes severe, the exacerbation should be captured as one exacerbation 
and classified b y its highest level of severity. 2018N377698_00
2016N277425_02 CONFIDENTIA L
[PHONE_13426].6. Appendix 6: Definition of and Procedures for Documenting 
Medical Device Incidents
12.6.1. Definitions of a Medical Device Incident
The detection and documentat ion procedures described in this protocol apply  to all [COMPANY_004] 
medical devices provided for use in the stud y (see Section 6.[ADDRESS_864957] of [COMPANY_004] medical 
devices).
Medical Device Incident Definition:
Incident –Any malfunction or deterioration in the characteristics and/or performance 
of a device, as well as any  inadequacy  in the labeling or the instructions for use 
which, directl y or indirectly , might lead to or might have led to the death of a 
patient/user/other pe rsons or to a serious deterioration in their state of health.
Not all incidents lead to death or serious deterioration in health.  The non- occurrence 
of such a result might have been due to other fortunate circumstances or to the 
intervention of health car e personnel.
It is sufficient that:
 an incident associated with a device happened and
 the incident was such that, if it occurred again, might lead to death or a serious 
deterioration in health.
 A serious deterioration in state of health can include:
 life-threatening illness
 permanent impairment of body  function or permanent damage to a bod y structure
 a condition necessitating medical or surgical intervention to prevent one of the 
above 
 fetal distress, fetal death or an y congenital abnormality or birth defe cts
Examples of incidents
a patient, user, care giver or professional is injured as a result of a medical device 
failure or its misuse
a patient’s treatment is interrupted or compromised by  a medical device failure
misdiagnosis due to medical device failur e leads to inappropriate treatment
a patient’s health deteriorates due to medical device failure 2018N377698_00
2016N277425_02 CONFIDENTIA L
[PHONE_13439].6.2. Documenting Medical Device Incidents
Medical Device Incident Documenting:
Any medical device incident occurring during the study  will be documented in the 
subject’s medical records, in accordance with the investigator’s normal clinical 
practice, and on the appropriate form.
For incidents fulfilling the definition of an AE or an SAE, the appropriate AE/SAE 
CRF page will be completed as described in Appendix 4 .
The form will be completed as thoroughl y as possible and signed b y the investigator 
before transmittal to [COMPANY_004].
It is very  important that the investigator provides his/her assessment of causality  to 
the medical device pro vided by  [CONTACT_132017], and describes 
any corrective or remedial actions taken to prevent recurrence of the incident.
A remedial action is an y action other than routine maintenance or servicing of a 
device where such action is neces sary to prevent recurrence of an incident. This 
includes an y amendment to the design to prevent recurrence. 2018N377698_00
2016N277425_02 CONFIDENTIA L
[PHONE_13427].7. Appendix 7: Modified List of Highly  Effective Methods for 
Avoiding Pregnancy  in FRP and Collection of Pregnancy  
Information
12.7.1. Modified List of Highly Effective Methods for Avoiding Pregnancy  
in Females of Reproductive Potential (FRP)
The list does not apply  to FRP with same sex partners or for subjects who are and will 
continue to be abstinent from penile-vaginal intercourse on a long term and persisten t 
basis, when this is their preferred and usual lifest yle. Periodic abstinence (e.g. calendar, 
ovulation, sy mptothermal, post -ovulation methods) and withdrawal are not acceptable 
methods of contraception.
1.Contraceptive subdermal implant
2.Intrauterine devic e or intrauterine s ystem
3. Combined estrogen and progestogen oral contraceptive [ Hatcher , 2011]
4.Injectable progestogen [ Hatcher , 2011]
5.Contraceptive vaginal ring [ Hatcher , 2011]
6.Percutaneous contraceptive patches [ Hatcher , 2011]
7. Male partner sterilization with documentation of azoospermia prior to the female 
subject's entry  into the study , and this mal e is the sole partner for that subject 
[Hatcher , 2011]. The documentation on male sterility  can come from the site 
personnel’s: review of subject’s medical records, medical examination and/or semen 
analysis, or medi cal history  interview provided b y her or her partner.
These allowed methods of contraception are only  effective when used consistently , 
correctly  and in accordance with the product label. The investigator is responsible for 
ensuring that subjects understand how to properl y use these methods of contraception.
12.7.2. Collection of Pregnancy  Information
Investigator will collect pregnancy  information on any  female subject, who becomes 
pregnant while participating in this study
Information will be recorded on the app ropriate form and submitted to [COMPANY_004] within [ADDRESS_864958]'s pregnancy .
Subject will be followed to determine the outcome of the pregnancy . The 
investigator will collect follow up information on mother and infant, which will be 
forwarded to [COMPANY_004].  Generall y, follow -up will not be required for longer than 6 to 8 
weeks bey ond the estimated delivery  date. 
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy will be reported as an AE or 
SAE. 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
86A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such.  
Any SAE o ccurring as a result of a post- study  pregnancy  which is considered 
reasonabl y related to the study  treatment by  [CONTACT_093], will be reported to [COMPANY_004] 
as described in Appendix [ADDRESS_864959] who becomes pregnant while participating 
will be withdrawn from the study 2018N377698_00
2016N277425_02 CONFIDENTIA L
[PHONE_13429].8. Appendix 8: Country  Specific Req uirements
No country -specific requirements exist. 2018N377698_00
2016N277425_02 CONFIDENTIA L
[PHONE_13430].9. Appendix 9: protocol changes
Revision History
2016N277425_00 2016 -SEP-13 Original
2016N277425_01 2017 -FEB-07 Amendment No. 1
2016N277425_02 2017 -FEB-21 Amendment No. 2 Canada 
only
Protocol A mendment 1
Scope:
This amendment applies to all sites
Protocol Changes for Amendment No.1 are summarised below.
Strike through text refers to deleted text and underlined refers to added text.
Protocol Changes:
Title
Rationale for change:   Correct a t ypographical error in the title: Umeclidim ium to 
Umeclidinium
Regulatory Agency Identifying Number(s):  
Rationale for change:   To correct a t ypographical error of the EudraCT no. and add an 
IND no.
Revised text: EudraCT no 2016 -002513 -226, 2016 -002513 -22, IND no. 104479 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
89Section 1
Overall Design
Rationale for change: To Correct a t ypographical error in the last paragraph.
Revised text: Salmeterol , salbutamol
“This is a multi -centre, randomized, double blind, double- dummy , 3-arm parallel group 
study .  Eligible subjects will be stratified based on long -acting bronchodilator usage 
during the run- in (none, one or 2 long -acting bronchodilators per day ) and randomized in 
a ratio of 1:1:1 to UMEC/VI  inhalation powder (62.5/25 mcg once dail y) administered 
via the ELLIPTA inhaler, or UMEC (62.5 mcg once dail y) administered via the 
ELLIPTA or salmeterol (50 mcg BID) administered via the DISKUS. 
There will be a total of 5 clinic visits and one follow -up phone call (Visit 6). The Pre -
screening Visit (Visit 0) can occur on the same day as the Screening Visit (Visit 1) if 
subject does not take or has not taken an y excluded protocol medications, but must be 
completed prior to initiating an y Visit [ADDRESS_864960]’s eligibility  for the stud y. During the run-
in period subjects will continue with their inhaled COPD medications (excluding ICS and 
any exclusionary  medications).  I n addition, subjects will be provided with short acting 
albuterol/ salmeterol salbutamol to be used on as needed basis for relief of COPD 
symptoms (rescue medication) throughout the study ”. 
Section 4.4 Design justification: To be consistent with Section [IP_ADDRESS] and Section 7.1 
the wording has been updated.
Rationale for change: Ensure consistency with Section [IP_ADDRESS] and Section 7.1 the 
wording has been changed in paragraph 5.
Revised text: “Other endpoints such SAC TDI , E-RS, SGRQ -C, CAT, Subject Global 
Rating of COPD Severity and Change in Global Rating impression of Change in COPD  
disease severity are captured to allow responder analy ses and to provide comparative data 
on PROs between the treatment groups”. 
Section 7.1 Time and Event table
Rationale for change; to:
Correct an un-intentional deletion of the (“x”) in some cells and confirm that concomitant 
medications should be reviewed at every  clinic visit.
Increase the visit window from 2days to - 7/+2
Ensure consistency  of w ording between Section 7.2 and T able 7.1. “ Written ”was deleted
Include height and weight at Screening and correct errors in foot note no.11
“In order to ensure subjects have sufficient doses of study  treatment, they  must return to 
clinic within 30 day s from V2 and within 60 and 90 days from V3 and V4 respectivel y” 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
90Blinded Treatment
VisitPre-
screen1
0Screen/ 
Run-in
1Rando -
mization 
[ADDRESS_864961] 
6
Week -6 to -4 -4 0 4 12 24
Day42 2
-7/+2 
days 
prior 
Visit 128 2
-7/+2 days 
prior Visit 
212-7/+2
days28 2-7/+2 
days 84 2 
days168  2-7/+2 
days723 days after V5 
or EW Visit
Screen/Baseline
Written Informed consent X
Demography X
Medical/COPD history X
Smoking history/status X
Smoking cessation counselling X
Concomitant medication assessment X X X X X X X X
Height and weight X
Cardiovascular History/family history of premature CV 
disease])X
Screening spi[INVESTIGATOR_038] (including post bronc hodilator 
testing )3X
CAT questionnaire X X
Verify Inclusion/Exclusion Criteria X
Training on use of inhalers X X
Training on use of eDiary and eMDI X X
Verify randomization Criteria X
Register Visit in InForm X X X X X X X X
Register Visit in RAMOS NG X X X X X X X X 
 
 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
91Blinded Treatment
VisitPre-
screen1
0Screen/ 
Run-in
1Rando -
mization 
[ADDRESS_864962] 
6
Week -6 to -4 -4 0 4 12 24
Day42 2
-7/+2 
days 
prior 
Visit 128 2
-7/+2 days 
prior Visit 
212-7/+2
days28 2-7/+2 
days 84 2 
days168  2-7/+2 
days723 days after V5 
or EW Visit
Efficacy/HRQoL assessments
Spi[INVESTIGATOR_038], including pre -dose FEV 1, trough  FEV 1and 
inspi[INVESTIGATOR_645933] X X X
SAC BDI questionnaire4 X
SAC TDI questionnaire4 X X X
SGRQ -C questionnaire [ADDRESS_864963]/ER -S: COPD 5
Patient Global Rating of COPD severity X X X X
Patient Global Rating of Change in COPD X X X
Safety assessments
Adverse events/Serious adverse events6 X X X X X X X X
COPD exacerbation assessment X X X X X X X X
12-Lead ECG X
Urine pregnancy test 7 X X X X
Pharmacogenetic sample8                                             X
Medication/Supplies
Dispense rescue albuterol/slabutamol. Dispense MDI9 X X X X X
Assess COPD medication compliance10 during run -in X
Dispense eDiary X
Assess compliance with eDiary during run -in X
Collect rescue albuterol/slabutamol. X X X X X
Collect eDiary X X
Dispense study treatment11 X X X 
 
 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
92Blinded Treatment
VisitPre-
screen1
0Screen/ 
Run-in
1Rando -
mization 
[ADDRESS_864964] 
6
Week -6 to -4 -4 0 4 12 24
Day42 2
-7/+2 
days 
prior 
Visit 128 2
-7/+2 days 
prior Visit 
212-7/+2
days28 2-7/+2 
days 84 2 
days168  2-7/+2 
days7[ADDRESS_864965] be completed prior to Screening Visit1. It can be completed 2 weeks prior or on the same day of V1, if no wash out of exclusionary medications is 
required. 
2. Early Withdrawal Visit: Subjects that withdraw should return to the clinic as soon as possible to complete the Early Withdraw al Visit procedures.
3. Spi[INVESTIGATOR_645934] (Section [IP_ADDRESS]). 
4. SAC BDI, SAC TDI, SGRQ -C, CAT questionnaires will be completed at clinic visits and in the eDiary
5. EXACT/ER -S: COPD is completed daily in the eDiary approximately 2 hours before bed -time, starting on Day 1 of the run -in period.
6. For the start date of collecting AEs and SAEs see (Appendix 4)
7. Pregnancy test: for females for child bearing potential only.
8. Pharmacogenetic sample may be drawn at visit [ADDRESS_864966] r eturn to clinic within 30 days from V2 and within 60 and 90 days from V3 and V4 respectively.
12. The Actigraph GT9X should be worn for 7 days from Visit 1, for 7 days from Visit 2, for 7 days from Visit 3 and for 7 days pr ior to Visit 5. 
 
 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
93Section 7.2.2 Criti cal procedures performed at Screening (Visit 1)
Rationale for change:   To clarify  that height and weight are collected at V1
Revised text: “Height and weight”
Section 7.3.2 Spi[INVESTIGATOR_645969]:   To further clarify  that spi[INVESTIGATOR_512020] V isit [ADDRESS_864967] inhales their usual morning COPD medication(s) a bullet point 
was added. “At Screening Visit 1, before the morning dose of usual COPD medications”
Revised text:
“Spi[INVESTIGATOR_645964] [ Miller , 2005]. All sites 
will use standardized spi[INVESTIGATOR_645942].
All subjects will have spi[INVESTIGATOR_645978] g to assess eligibility (see Section 
[IP_ADDRESS]) and at Visits 2, 3, [ADDRESS_864968] 3 acceptable spi[INVESTIGATOR_496921] (with no 
more than 8) should be obtained. Acceptable spi[INVESTIGATOR_496922] a satisfactory  
start of test and end of test (i.e. a plateau in the volume time curve) and be free from 
artifacts due to cough, early  termination, poor effort, obstructed mouthpi[INVESTIGATOR_13959], equipment 
malfunction, or other reasons [ Miller , 2005].
The largest FEV1and FVC from the 3 acceptable efforts should be recorded, even if they  
do not come from the same effort.
Spi[INVESTIGATOR_645944] 1and FVC assessments that is not obtained as follows will be 
considered a protocol deviation:
Started between 6:00AM and 11:00A M.
After withholding albuterol/salbutamol (all visits) for ≥4 hours
At Screening Visit 1, after wash out of medications as specified in the exclusion 
criteria in Section 5.2 (Concomitant Medications).
At Screening Visit 1, before the morning dose of usual COP D medications
At Visit [ADDRESS_864969] dose 
of study  treatment 
At Visit 3, 4 and 5 after withholding the morning dose of study  treatment.
Pre dose assessment performed prior dosing.
Subjects should refrai n from smoking for [ADDRESS_864970].
Trough FEV 1measurements for UMC/VI  or UMEC on Weeks 4, 12 and 24 (Visits 3, 4 
and 5) should be performed 23 hours and 24 hours after the previous day ’s dose of study  
medication recorded in t he eDiary . This will also provide trough FEV 1measurements for 
the evening dose of salmeterol”.  2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
948. Physical activity monitor (study subset)
Rationale for changes: Ensure consistency  of the wording between Section 1 and 
Section 4.1 “overall design” and Sectio n 7.3.7.
per treatment arm added to paragraph 4.
Revised Text : 
Physical activity monitor (study subset)
“Phy sical activity  limitation is a common feature of COPD and its measures are highl y 
related to the degree of disease severity  [Watz, 2009]. 
Reduced physical activity  levels in COPD is associated with increased morbidity  and 
mortality , sustained disability , depression, and social and phy sical isolation [ Shu-Yi, 
2014; Gimeno, 2014] 
Improved activity  has been identified as an important factor that may  modify  morbidity  
and mortality  in COPD [ Moy , 2012 ].
The Actigraph GT9X phy sical activity  monitor will be used to measure levels of activity . 
The activity  monitor will be worn by  [CONTACT_422906]  150 subjects per treatment arm 
for 7 day s from Screening ( Visit 1), for 7 days from Randomisation (Visit 2), 7 day s from 
Visit 3 (Week 4) and for 7 day s prior to Week 24 (Visit 5).
There will be [ADDRESS_864971] will be given an activity  
monitor and instruction leaflet at the start of each assessment period. Further details of 
distribution, operation and retrieval of the monitors will be provided in the SRM” .
Country -specific Protocol A mendmen t [ADDRESS_864972] be documented and reported.
Strike through text refers to deleted text and underlined refers to added text.
Section 7.4.1 Adverse Events (AE) and serious Adverse Events (SAEs)
Rationale for change : A new Section added to include information related to 
documenting events related to lack o f efficacy .
Revised text: 
“[IP_ADDRESS] Additional Adverse Event (AE) Reporting Requirements for Canadian 
investigators
Health Canada requires pharmaceutical manufacturers to expeditiously  report domestic 
cases of unusual failure in efficacy  (UFIE) for new dru gs to the Marketed Health 
Products Directorate (MHPD) within [ADDRESS_864973] notification. This regulation applies 
to marketed drugs, and used as directed per the Canadian prescribing information, 
including those drugs used in Phase IV (non CTA filed) clinical trials.  
Adverse event (AE): Any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not 
necessarily  have to have a causal relationship with this treatment. An AE can there fore 2018N377698_00
2016N277425_02 CONFIDENTIA L
201749
95be an y unfavourable and unintended sign (including an abnormal laboratory finding) 
symptom or disease (new or exacerbated) temporally  associated with the use of a 
Medicinal Product .For a marketed Medicinal Product, this can also include failure 
to produce expected benefits (i.e. lack of efficacy, with or without an adverse event), 
In order for [COMPANY_004] to comply  this Canadian regulatory  requirement, Canadian investigators 
are required to collect, record and report lack of efficacy events as per the table in 
Appendix 4 Section 12.4.1 ”.  
All paper forms are required to be faxed to [COMPANY_004] Canada’s Drug Safety  department at 
 within [ADDRESS_864974] awareness.
Appendix 4, Section 12.4.1 
Rationale for change: To add a small table about reporting of AEs.
Revised text .The table below was added.
Adverse 
Event 
criteriaElectronic case record 
form (eCRF) onlyPaper form only Electronic case 
record form 
(eCRF) + Paper 
form
Non serious Non drug related lack of 
efficacy  reports with 
associated signs or 
symptoms or clinical 
sequelae Drug related lack of 
efficacy  reports 
without associated 
signs or s ymptoms or 
clinical sequelae.Drug related lack 
of efficacy  with 
associated signs or 
symptoms or 
clinical sequelae  
Serious Non drug related lack of 
efficacy reports with 
associated signs or 
symptoms or clinical 
sequelae Drug related lack of 
efficacy  reports 
without associated 
signs or s ymptoms or 
clinical sequelae. Drug related lack 
of efficacy  reports 
with associated 
signs or s ymptoms 
or clinical sequelae 
Appendix 4, Section 12.4.4, second bullet point
Revised text: 
The investigator will then record all relevant information regarding an AE/SAE in the 
electronic CRF “and/or paper form as applicable”.  Added
Section 12.4.6, second bullet point
Revised te xt: 
“For lack of efficacy  reports the paper form will be used to submit to [COMPANY_004] as per the
table in Section 12.4.1 above ”. Added 2018N377698_00
PP
2016N277425_01 CONFIDENTIA L
The GlaxoS mithKline group of companies 201749
1TITLE PA GE
Division: World wide Development
Information Type: Protocol Amendment
Title: A 24 -week treatment, multi -center, randomized, double- blind, 
double -dummy , parallel group study  to compare 
Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in 
subje cts with chronic obstructive pulmonary  disease (COPD)
Compound Number: [COMPANY_004]2592356
Development Phase :IV
Effective Date: 07-FEB-2017
Protocol Amendment Number:  01
Author (s):  
 
Copy right 2017 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised cop ying or use of this information is prohibite d. 2018N377698_00
[COMPANY_003]
2016N277425_01 CONFIDENTIA L
The GlaxoS mithKline group of companies 201749
2Revision Chronology
GlaxoSmith Kline
Document NumberDate Version
2016N277425_00 2016 -SEP-13 Original
2016N277425_01 2017 -FEB-07 Amendment No. 1
This protocol amendment was created to make the following changes:
Regulatory  Agency  Identify ing Number(s) :  A typographical error in the EudraCT no.
corrected. IND no. added
Section 4.1 andSection 4.4 : Typographical error s and inconsistencies corrected
Inconsistencies between Section 4.4 , Section [IP_ADDRESS] and Section 7.1 revised
Section 7.1 Time and event ta ble:
Un-intentional deletion of the ( “x”) were added to confirm that concomitant medications 
should be reviewed at every  clinic visit was corrected .
Increased the visit window 
Typographical error and inconsistencies corrected as described in Appendix 9, S ection 
12.9.
Section 7.2.2 Critical procedures performed at Screening (Visit 1): To clarify  that height 
and weight are collected at V1 “Height and weight” added
Section 7.3.2 Spi[INVESTIGATOR_038]: “At Screening, before the morning dose of usual COPD 
medication(s) ”added .
Section 7.3.7 : Physical activity  monitor (study  subset)
Inconsistency  between Section 1, Section 4.1 and Section 7.3.7 revised 2018N377698_00
 2018N377698_00
[COMPANY_003]
[COMPANY_003]
2016N277425_01 CONFIDENTIA L
201749
4MEDICA L MONITOR/SPONSOR INFOR MATION PA GE
Medical Monitor/SAE Contact [CONTACT_7171]: 
Role Name [CONTACT_387071] -hours 
Phone/Cell/
Pager 
NumberFax 
NumberSite Address
Primary 
Medical 
Monitor Telephone: Cell: Fax: GlaxoSmithKline
Stockley Park 
West, [ADDRESS_864975], 
Heathrow, 
Uxbridge, 
Middlesex, UB11 
1BT, United 
Kingdom
Secondary 
Medical 
MonitorMD
Telphone:Cell:  Fax:  GlaxoSmithKline
Stockley Park 
West, [ADDRESS_864976]  
information Telephone: Cell: Fax: GlaxoSmithKline
Stockley Park 
West, [ADDRESS_864977], 
Heathrow, 
Uxbridge, 
Middlesex, UB11 
1BT, United 
Kingdom
Sponsor Legal Registered Address: 
Glaxo SmithKline Research & Development Limited
[ADDRESS_864978]
Middlesex, TW8 9GS
[LOCATION_006]
In some countries, the clinical trial sponsor may  be the local GlaxoSmithKline Affiliate 
Company  (or designee). If applicable, the details of the alternative Spon sor and contact  2018N377698_00
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2016N277425_01 CONFIDENTIA L
201749
5person in the territory  will be provided to the relevant regulatory  authority  as part of the 
clinical trial application.   
Regulatory  Agency  Identify ing Number(s):  IND no. [ADDRESS_864979] to ensure that site 
staff receives the appropriate informati on throughout the study . 
Investigator Name:
[CONTACT_132026]:
Investigator Phone Number:
Investigator Signature [CONTACT_1782] 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
7TABLE OF CONTENTS
PAGE
1.PROTOCOL SYNOP SIS FOR STUDY 201749 ...................................................... 10
2.INTRODUCTION ................................................................
.................................... 15
2.1. Study Rationale .......................................................................................... 15
2.2. Brief Background ........................................................................................ 15
3.OBJECTIVE(S) AND END POINT(S) ...................................................................... 16
4.STUDY DESIGN .................................................................................................... 18
4.1. Overall Design ............................................................................................ 18
4.2. Treatment Arms and Duration ..................................................................... 20
4.3. Type and Number of Subjects ..................................................................... 21
4.4. Design Justification ..................................................................................... 21
4.5. Dose Justification ........................................................................................ 21
4.6. Benefit: Risk Assessment ........................................................................... 21
4.6.1. Risk Assessment ......................................................................... 22
4.6.2. Benefit Assessm ent..................................................................... 25
4.6.3. Overall Benefit: Risk Conclusion .................................................. [ADDRESS_864980] AWAL CRITERIA ............. 25
5.1. Inclusion Criteria ......................................................................................... 25
5.2. Exclusion Criteria ........................................................................................ 27
5.3. Randomization Criteria ............................................................................... 30
5.4. Screening/Baseline/Run -in Failures ............................................................ 30
5.5. Withdrawal/Stoppi[INVESTIGATOR_2121] ....................................................................... 31
5.5.1. Withdrawal from the Study ........................................................... 31
5.5.2. Reason for Study W ithdrawal ....................................................... 32
5.5.3. Liver Chemistry Stoppi[INVESTIGATOR_2121] ................................................ 32
[IP_ADDRESS]. Study Treatment Restart or Rechallen ge.................... [ADDRESS_864981] and Other Study Treatment .................................... 34
6.2. Medical Devices .......................................................................................... 36
6.3. Treatment Assignment ................................................................................ 36
6.4. Planned Dose Adjustments ......................................................................... 37
6.5. Blinding ....................................................................................................... 37
6.6. Packaging and Labeling .............................................................................. 38
6.7. Preparation/Handling/Storage/Accountability .............................................. 38
6.7.1. Study Treatment Return ............................................................... 39
6.8. Compliance with Study Treatment Adm inistration ....................................... 39
6.9. Treatment of Study Treatment Overdose .................................................... 39
6.10. Treatment after the End of the Study .......................................................... 40
6.11. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_014] .................................... 40
6.11.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014] .......................... 40
6.11.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014] ......................... 41
7.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 42 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
87.1. Time and Events Table ............................................................................... 43
7.2. Screening and Critical Baseline Assessments ............................................ 46
7.2.1. Pre-screening Visit ....................................................................... 46
7.2.2. Critical procedures performed at S creening (Visit 1) .................... 46
[IP_ADDRESS]. Albuterol/Salbutamol Reversibility Assessment .......... [ADDRESS_864982] treatment Visit 
(Baseline V2) ............................................................................... 47
7.3. Efficacy Assessments ................................................................................. 48
7.3.1. HRQoL assessments: Completion of PRO questionnaires 
in the Electronic Diary .................................................................. 48
[IP_ADDRESS]. Self Administered Computerised Baseline 
Dyspnea Index/Transitional Dyspnea Index 
(SAC BDI/TDI) ............................................................ 48
[IP_ADDRESS]. SGRQ -C..................................................................... 49
[IP_ADDRESS]. COPD Assessment Test (CAT) .................................. 49
[IP_ADDRESS]. EXACT and the Evaluating Respi[INVESTIGATOR_633333] -COPD (E -RS: COPD) .............................. 50
[IP_ADDRESS]. Subject Global Rating of COPD Severity and 
Global Rating of Change in COPD ............................. 50
7.3.2. Spi[INVESTIGATOR_038] ................................................................................... 50
7.3.3. Inspi[INVESTIGATOR_14008] (IC) ............................................................... 51
7.3.4. COPD Exacerbation .................................................................... 52
7.3.5. Clinically important deterioration (CID) ......................................... 52
7.3.6. Rescue albuterl/salbutamol use ................................................... 53
7.3.7. Physical activity monitor (study subset) ....................................... 53
7.4. Safety ......................................................................................................... 53
7.4.1. Adverse Events (AE) and Serious Adverse Events (SAEs) .......... 53
[IP_ADDRESS]. Time period and Frequency for collecting AE 
and SAE information ................................................... 54
[IP_ADDRESS]. Method of Detecting AEs and SAEs ........................... 54
[IP_ADDRESS]. Follow -up of AEs and SAEs ........................................ 54
[IP_ADDRESS]. Pneumonia Events ..................................................... 55
[IP_ADDRESS]. Cardiovascular and Death Events .............................. 55
[IP_ADDRESS]. Disease -Related Events and/or Disease-
Related Outcomes Not Qualifying as SAEs ................ 55
[IP_ADDRESS]. Regulatory Reporting Requirements for SAEs ............ 55
7.4.2. Preg nancy ................................................................................... 56
7.4.3. Medical Device Incidents (Including Malfunctions) ....................... 56
7.4.4. Electrocardiogram (ECG) ............................................................. 56
7.5. Genetics ..................................................................................................... 56
8.DATA MANAGEME NT........................................................................................... 56
9.STATISTICAL CONSIDER ATIONS AND DATA ANALYSES ................................ .57
9.1. Hypotheses ................................................................................................ .57
9.2. Sample Size Considerations ....................................................................... 57
9.2.1. Sample Size Assumptions ........................................................... 58
9.2.2. Sample Size Sensitivity ................................................................ 58
9.2.3. Sample Size Re- estimation or Adjustment ................................... 58
9.3. Data Analysis Considerations ..................................................................... 58
9.3.1. Analysis Populations .................................................................... 58
9.3.2. Interim Analysis ........................................................................... 59 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
99.4. Key Elements of Analysis Plan ................................................................... 59
9.4.1. Primary Analyses ......................................................................... 59
9.4.2. Other Analys es............................................................................ 60
10. STUDY GOVERNANCE CON SIDERATIONS ........................................................ 61
10.1. Posting of Information on Publicly Available Clinical Trial Registers ............ 61
10.2. Regulatory and Ethical Considerations, Including the Informed 
Consent Process ........................................................................................ 61
10.3. Quality Control (Study Monitoring) .............................................................. 62
10.4. Quality Assurance ....................................................................................... 62
10.5. Study and Site Closure ............................................................................... 62
10.6. Records Retention ...................................................................................... 63
10.7. Provision of Study Results to Investigators, Posting of Information 
on Publically Available Clinical Trials Registers and Publication ................. 64
11.REFERENCES ....................................................................................................... 65
12.APPENDICES ........................................................................................................ 68
12.1. Appendix 1: Abbreviations and Trademarks ................................................ 68
12.2. Appendix 2: Liver Safety Required Actions and Follow up 
Assessments .............................................................................................. 70
12.3. Appendix 3: Genetic Research ................................................................... 73
12.4. Appendix 4: Definition of and Procedures for Recording, Evaluating, 
Follow -Up and Reporting of Adverse Events ............................................... 76
12.4.1. Definition of Adve rse Events ........................................................ 76
12.4.2. Definition of Serious Adverse Events ........................................... 77
12.4.3. Definition of Cardiovascular Events ............................................. 78
12.4.4. Recording of AEs and SAEs ........................................................ 79
12.4.5. Evaluating AEs and SAEs ............................................................ 79
12.4.6. Reporting of SAEs to [COMPANY_004] ........................................................... 81
12.5. Appendix 5: COPD Exacerbation Identification, Categorization and 
Treatment Guidelines .................................................................................. 82
12.5.1. Guidelines for Identifying COPD Exacerbations ........................... 82
12.5.2. COPD Exacerbation Severity ....................................................... 83
12.5.3. Treatment of COPD Exacerbations .............................................. 83
12.5.4. Guidelines for Treatment with Corticosteroids .............................. 83
12.5.5. Guidelines for Treatment with Antibiotics ..................................... 84
12.5.6. Onset and Resolution of COPD Exacerbations ............................ 84
12.5.7. Guideline for assessing multiple mild exacerbations .................... 84
12.5.8. Guideline for assessing exacerbations that increase in 
severity ........................................................................................ 84
12.6. Appendix 6: Definition of and Procedures for Documenting Medical 
Device Incidents ......................................................................................... 85
12.6.1. Definitions of a Medical Device Incident ....................................... 85
12.6.2. Documenting Medical Device Incidents ....................................... 86
12.7. Appendix 7: Modified List of Highly Effective M ethods for Avoiding 
Pregnancy in FRP and Collection of Pregnancy Information ....................... [ADDRESS_864983] of Highly Effective Methods for Avoiding 
Pregnancy in Females of Reproductive Potential (FRP) .............. 87
12.7.2. Collection of Pregnancy Information ............................................ 87
12.8. Appendix 8: Country Specific Requirements ............................................... 89
12.9. Appendix 9: protocol changes ..................................................................... 90 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
101. PROTOCOL SYNOPSIS FOR STUD Y 201749
Rationale
The primary  purpose of this study  is to demonstrate improvements in lung function in 
subjects treated with Umeclidinium/Vilanterol (UMEC/VI ) compared with Umeclidinium 
(UMEC) for [ADDRESS_864984] of
UMC/VI , UMEC, and salmeterol with respect to health- related quality  of life (HRQoL), 
measured through patient reported outcomes (PROs) questionnaires, and lung function .  
Additional assessments to further evaluate other measures of ch ronic obstructive 
pulmonary  disease (COPD) efficacy  and sy mptoms control will be performed.
Objective(s)/Endpoint(s)
Objectives Endpoints
Primary
To compare the effect of UMEC/VI  
(62.5/25 mcg once dail y) with UMEC 
(62.5 mcg once daily ) on lung functionChange from baseline in trough Forced 
Expi[INVESTIGATOR_645914] 
(FEV 1) at week 24 
Secondary
To compare UMEC/VI (62.5/25 mcg 
once dail y), UMEC (62.5 mcg once 
daily ) with salmeterol (50 mcg twice 
daily ) on patient reported outcomes 
(PROs) Change fro m baseline in self 
administered computerised (SAC) 
transient dy spnea index (TDI) 
Percentage of TDI responders 
according to SAC TDI score.  A 
responder is defined as a ≥1 unit 
improvement in SAC TDI score 
Assessment of respi[INVESTIGATOR_645915] 24 w eeks using 
Evaluating Respi[INVESTIGATOR_244774] -
COPD (E- RS) and its subscales 
(breathlessness, cough and sputum and 
chest sy mptoms) 
Percentage of E -RS responders 
according to E -RS score (defined as 
reduction in E -RS score of  2 or 3.35 
units) from baseline
Change from baseline in St George’s 
Respi[INVESTIGATOR_21606] (SGRQ -C)
Percentage of responders according to 
SGRQ -C total score (defined as a 4 
point or greater reduction from  2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
11Objectives Endpoints
baseline) 
Change from baseline in COPD 
assessment test ( CAT)
Percentage of resp onders according to 
CAT (defined as a 2 unit improvement 
in score from baseline)
Other
To compare UMEC/VI (62.5/25 mcg 
once dail y), UMEC (62.5 mcg once 
daily ) with salmeterol (50 mcg twice 
daily ) on other COPD efficacy  measures Rate of mild, moderate or severe 
exacerbations
Time to first mild, moderate or severe 
exacerbation
Rate of moderate or severe 
exacerbation
Time to moderate or severe 
exacerbation
Time to severe exacerbations
Time to clinically  important 
deterioration (CID) composite endpoint 
Time to clinically  important 
deterioration composite endpoint 
excluding FEV 1
Rescue albuterol/salbutamol use, 
(percentage of rescue- free day s and 
mean number of Inhalations/day ) 
captured b y the electronic diary 
(eDiary ) over 24 weeks
Inspi[INVESTIGATOR_645920] y (IC)
Full Vital capacity  (FVC) 
Change from baseline in trough FEV 1
Change from baseline in global 
impression of disease severity   2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
12Objectives Endpoints
Safety
To evaluate safet y and tolerability 
of UMEC/VI (62.5/25 mcg once 
daily ), UMEC (62.5mcg once dail y) 
and salmeterol 50 mcg twice dail y) Incidence of adverse events
Exploratory
To compare albuterol/salbutamol 
use captured in the eDiary  with the 
electronic metered dose inhaler 
(eMDI) device Rescue albuterol/salbutamol use, 
(percentage of rescue- free day s and 
mean number of Inhalations/day ) 
captured b y the eMDI device over 24 
weeks as data allow
To explore the effect of UMEC/VI  
(62.5/25 mcg once dail y), UMEC 
(62.5 mcg once daily ) with 
salmeterol (50 mcg twice daily ) on 
physical activityChange from baseline in phy sical 
activity 
To investigate the CID composite 
endpoint ability  to predict short 
term outcomes To compare ph ysical activity  levels, 
ER-S, rescue medication use, 
exacerbations and mortality  in subjects 
with and without a CI D
Overall Design
This is a multi -centre, randomized, double blind, double dummy , 3-arm parallel group 
study .  Eligible subjects will be randomized in a ratio of 1:1:1 to UMEC/VI inhalation 
powder (62.5/25 mcg once dail y) administered via the ELLIPTA®dry powder inhaler 
(DPI), or UMEC (62.5 mc g once daily ) administered via the ELLIPTA DPI [INVESTIGATOR_645916] 
(50 mcg twice dail y (BID)) administered via the DI SKUS®DPI.
Eligible subjects at Screening will enter a run -in period for 4 weeks during which they  
continue taking their inhaled COPD medications (excluding ICS and an y exclusionary 
medications).  In addition, subjects will be provided with short acting 
albuterol/sal butamol to be used on as needed basis (rescue medication) throughout the 
study . 
Subjects who experience a moderate or severe COPD exa cerbation during the run -in 
period will be deemed run- in failures.  Subjects experiencing a mild exacerbation, 
defined as worsening of symptoms that requires notreatment with antibiotics or steroids 
and is self managed b y the patient b y an increase of inh aled rescue medication , will be 
allowed to continue in the study .
At the randomization Visit 2 (Day  1) those subjects who successfull y complete the run- in 
period as well as meet the other pre -defined eligibility  and randomization criteria will 
discontinue their inhaled COPD medications and will be randomized to one of the [ADDRESS_864985] medical problems experienced d uring the study .  
Subjects will be performing slow and forced spi[INVESTIGATOR_645965].
In addition, a subset of subjects up to 150 per treatment arm will undergo assessment of 
their phy sical activity  measured through a phy sical activity  monitor (Acti graph GT9X) 
worn for 7 day sfrom Screening (Visit 1), for 7 day s from Randomisation (Visit 2), [ADDRESS_864986] clinic Visit (Visit 5). 
There will be a total of 5 clinic visits and one follow -up phone call (Visit 6).  The total 
duration of subject participation in the study  will be approximately  [ADDRESS_864987] completed the study  upon completion of the Follow –
Up contact b y telephone.
Treatment A rms and Duration
Subjects will be stratified based on long-acting bronchodilator usage during the run- in 
(none, one or 2 long- acting bronchodilators per day ) and randomized in a ratio of 1:1:1 to 
either 
UMEC/VI  inhalation powder (62.5/25 mcg once daily ) administered via the 
ELLIPTA DPI) or 
UMEC (62.5 mcg once daily ) administered via the ELLIPTA DPI [INVESTIGATOR_1660] 
Salmeterol (50 mcg BID) administered via DISKUS  2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
14Study schematic
*Inhaled COPD medications including LABAs, LAMAs or LABA/LAMA combination products are 
allowed in run-in. ICS alone or in combination with a bronchodilator or any exclusionary 
medications are not allowed.
Type and Number of Subjects
Approximately  3232 subjects will be screene d, such that 2424 subjects will be 
randomized and approximately  2181 evaluable subjects complete the study. 
Analysis
The primary  purpose of this study  is to demonstrate improvements in lung function for 
subjects treated with UMEC/VI compared with UMEC for 24 weeks.
The primary  endpoint is change from baseline in trough FEV 1at Week 24.
The null hy pothesis is no difference between treatment groups (H0: μT – μS = 0), with 
the alternative h ypothesis that there is a difference between treatment groups (H1: μT –
μS ≠0), where μ T is the mean change from baseline for UMEC/VI and μS is the mean 
change from baseline for UMEC. 
The primary  endpoint of mean change from baseline in trough FEV 1at the end of Week 
24 will be anal ysed using Mixed Models repeated Measures (MMRM) analy sis. The 
MMRM analy sis will include measurements at Treatment Weeks 4, 12 and 24. Treatment 
group (a categorical variable) will be fitted as the explanatory  variable with appropriate 
pre-defined variables, stratum (number of bronchodilators pe r day  during run- in) and 
baseline values, fitted as covariates. Visit (nominal) will be fitted as a categorical variable 
and visit -by-baseline and visit -by-treatment interaction terms will be included to allow 
treatment effects to be estimated at each visi t separately.  The variance covariance matrix  2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
15will be assumed to be unstructured (based on previous experience no issues are expected 
with fitting models with this matrix structure). 
The estimated treatment differences between UMEC/VI  versus UMEC for each endpoint 
will be presented with the 95% confidence intervals for the difference and the p -value. 
2. INTRODUCTION
2.1. Stud y Rationale
Chronic obstructive pulmonary  disease ( COPD) is associated with poor health- related 
quality  of life (HRQoL).  Pharmacologic ther apy is used to improve lung function, reduce 
symptoms, frequency  and severit y of exacerbations, and improve patients HRQoL
[GOL D, 2015].  Umeclidinium/Vilanterol (UMEC/VI  62.5/25 mcg) is indicated for the 
maintenance tr eatment of COPD that contain long -acting muscarinic antagonist (L AMA) 
and long -acting beta 2-agonist (L ABA) bronchodilators.  Umeclidinium (UMEC) is 
indicated as a maintenance bronchodilator treatment to relieve s ymptoms in adult patients 
with COPD .  Salmet erol has long been used for s ymptoms management of COPD.  
However, a direct comparison of these maintenance therapi[INVESTIGATOR_645917].
The primary  purpose of this study  is to demonstrate improvements in lung function for 
subjec ts treated with UMEC/VI  compared with UMEC for [ADDRESS_864988] of
UMC/VI , UMEC, and salmeterol with respect to patient HRQoL  measured through 
patient reported outcomes (PROs) questionnaires, sy mptoms and lung function will also 
be evaluated.
2.2. Brief Ba ckground
COPD is characterized by [CONTACT_645994], usually  
progressive and accompanied by  a chronic cough, sputum production and dy spnea which 
can be a major cause of disability  and anxiety  associated with the disease [ Maleki -Yazdi , 
2014]
Furthermore, acute exacerbations contribute to the overall severity  of disease as these 
epi[INVESTIGATOR_645918] s ymptoms and are associated with increased 
decline in lung function and mortality  [Wedzicha , 2013; Schmidt , 2014].
Pharmacologic therap y is used to improve lung function, reduce s ymptoms, reduce the 
frequency  and severit y of exacerbations, and also to improve health status and exercise 
tolerance.  Maintenance treatment is recommended primarily  through the use of LABAs 
or LAMAs.  COPD treatment guidelines recommend an incremental approach to 
pharmacological treatment as the disease state worsens, involving the use of 
combinations of drug classes with different or complementary  mechanisms [ GOL D, 
2015]. 
UMEC/VI  inhalation powder is a combination of UMEC (umeclidinium bromide), a 
LAMA, and VI (Vilanterol), a LABA , delivered via the ELLIPTA dry  powder inhaler  2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
16(DPI). UMEC/VI at a dose of 62.5/25mcg once- daily  is marketed in the [LOCATION_002] 
(US) and Europe under the trade name [CONTACT_646039]®ELLIPTA.  
UMEC (62.5 mcg) inhalation powder is marketed in the [LOCATION_002] (US) and Europe 
under the trade name [CONTACT_646040]®ELLIPTA.  UMEC (62.5mcg) is indicated as a 
maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.  
UMEC (62.5 mcg) improves forced expi[INVESTIGATOR_131955] (FEV 1), dyspnea 
and HRQoL whether used as monotherap y [Trivedi , 2014; Feldman , 2016] or as an add 
on to fluticasone propi[INVESTIGATOR_645919] (FF/VI) [ Siler , 2015 ].  Salmetrol (50 mcg) 
DISKUS is a long -acting broncholdilator that has long been used for the maintenance 
treatment of COPD [ Tashkin, 2010].
Clinically  important deterioration (CID) is a novel, exploratory  composite endpoint 
which assesses individual deteriorations in lung function and in patient PROs defined by  
[CONTACT_645995] (MCID), as well as the incidence of 
moderate to severe exacerbations [ Singh , 2016], (Section 7.3.5 ).  CID will be anal ysed to 
determine whether UMEC/VI  (62.5/25mcg) therapy  provides greater clinical stability  as 
compared with UMEC and salmeterol monotherapi[INVESTIGATOR_014]. 
3. OBJECTIVE(S) A ND ENDPOINT(S)
Objectives Endpoints
Primary
To compare the effect of UMEC/VI  
(62.5/25 mcg once dail y) with UMEC 
(62.5 mcg once daily ) on lung functionChange from baseline in trough Forced 
Expi[INVESTIGATOR_645914] 
(FEV 1) at week 24 
Secondary
To compare UMEC/VI (62.5/25 mcg 
once dail y), UMEC (62.5 mcg once 
daily ) with salmeterol (50 mcg twice 
daily ) on patient reported outcomes 
(PROs) Change from baseline in self 
administered computerised (SAC) 
transient dy spnea index (TDI) 
Percentage of TDI responders 
according to SAC TDI score.  A 
responder is defined as a ≥1 unit 
improvement in SAC TDI score 
Assessment of respi[INVESTIGATOR_645915] 24 weeks using 
Evaluating Respi[INVESTIGATOR_244774] -
COPD (E- RS) and its subscales 
(breathlessness, cough and sputum and 
chest sy mptoms) 
Percentage of E -RS responders 
according to E -RS score (defined as 
reduction in E -RS score of  2 or 3.35 
units) from baseline 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
17Objectives Endpoints
Change from baseline in St George’s 
Respi[INVESTIGATOR_21606] (SGRQ -C)
Percentage of responders according to 
SGRQ -C total score (defined as a 4 
point or greater reduction from 
baseline) 
Change from baseline in COPD 
assessment test ( CAT)
Percentage of responders according to 
CAT (defined as a 2 unit improvement 
in score from baseline)
Other
To compare UMEC/VI (62.5/25 mc g 
once dail y), UMEC (62.5 mcg once 
daily ) with salmeterol (50 mcg twice 
daily ) on other COPD efficacy  measures Rate of mild, moderate or severe 
exacerbations
Time to first mild, moderate or severe 
exacerbation
Rate of moderate or severe 
exacerbation
Time to moderate or severe 
exacerbation
Time to severe exacerbations
Time to clinically  important 
deterioration (CID) composite endpoint 
Time to clinically  important 
deterioration composite endpoint 
excluding FEV 1
Rescue albuterol/salbutamol use, 
(percentage ofrescue- free day s and 
mean number of Inhalations/day ) 
captured b y the electronic diary 
(eDiary ) over 24 weeks
Inspi[INVESTIGATOR_645920] y (IC)
Full Vital capacity  (FVC)  2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
18Objectives Endpoints
Change from baseline in trough FEV 1
Change from baseline in global 
impression of disease severity  
Safety
To evaluate safet y and tolerability 
of UMEC/VI (62.5/25 mcg once 
daily ), UMEC (62.5mcg once dail y) 
and salmeterol (50mcg twice dail y) Incidence of adverse events
Exploratory
To compare albuterol/salbutamol 
use captured in the eDiary  with the 
electronic metered dose inhaler 
(eMDI) device Rescue albuterol/salbutamol use, 
(percentage of rescue- free day s and 
mean number of Inhalations/day ) 
captured b y the eMDI device over 24 
weeks as data allow
To explore the effect of UMEC/VI  
(62.5/25 mc g once dail y), UMEC 
(62.5 mcg once daily ) with 
salmeterol (50 mcg twice daily ) on 
physical activityChange from baseline in phy sical 
activity  
To investigate the CID composite 
endpoint ability  to predict short 
term outcomes To compare ph ysical activity  levels, 
ER-S, rescue medication use, 
exacerbations and mortality  in subjects 
with and without a CI D
4. STUDY DESIGN
4.1. Overall Design
This is a multi -centre, randomized, double blind, double -dummy , 3-arm parallel group 
study .  Eligible subjects will be stratifi ed based on long -acting bronchodilator usage 
during the run- in (none, one or 2 long -acting bronchodilators per day ) and randomized in 
a ratio of 1:1:1 to UMEC/VI  inhalation powder (62.5/25 mcg once dail y) administered 
via the ELLIPTA inhaler, or UMEC (62.5 mcg once dail y) administered via the 
ELLIPTA or salmeterol (50 mcg BID) administered via the DISKUS. 
There will be a total of 5 clinic visits and one follow -up phone call (Visit 6). The Pre -
screening Visit (Visit 0) can occur on the same day  as the Scree ning Visit (Visit 1) if 
subject does not take or has not taken an y excluded protocol medications, but must be 
completed prior to initiating an y Visit [ADDRESS_864989]’s eligibility  for the stud y. During the run-
in period subjects will continue with their inhaled COPD medications (excluding ICS and  2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
19any exclusionary  medications).  I n addition, subjects will be provided with short acting 
albuterol/sal butamol to be used on as needed basis for relief of COPD s ymptoms (rescue 
medication) throughout the study . 
Subjects who experience a moderate or severe COPD exacerbation during the run -in 
period will be deemed run-in failur es.  Subjects who experience a mild COPD 
exacerbation, defined as worsening of s ymptoms that requires notreatment with 
antibiotics or steroids and is self managed b y the patient by [CONTACT_645996] , (Appendix 5 ), will be able to continue in the study  based on the judgment of 
the investigator and agreement of the sponsor’s medical monitor.
At the randomization Visit 2 (Day  1) those subjects who successfull y complete the run- in 
period as well as m eet the other pre -defined eligibility  and randomization criteria will 
discontinue their inhaled COPD medications and will be randomized to one of the 3 
treatment arms for 24 weeks.
During the run- in and treatment period, subjects will be completing PRO que stionnaires 
in the eDiary  and performing slow and forced spi[INVESTIGATOR_645966].
In addition, a subset of subjects up to 150 per treatment arm will undergo assessment of 
their phy sical activity  measured through a phy sical activity  monitor (Ac tigraph GT9X) 
worn for 7 day sfrom Screening (Visit 1), for 7 day s from Randomisation (Visit 2), [ADDRESS_864990] clinic Visit (Visit 5). 
Concurrent use of COPD maintenance medications including LAMAs, LABAs, oral beta -
agonists, theophy llines, inhaled corticosteroids, inhaled corticosteroids and L ABA 
combination and phosphodiesterase 4 inhibitors will not be allowed during the stud y 
(Section 6.11.2 ) . 
The occurrence of adverse events (AEs) will be evaluated throughout the study  beginning 
at Visit 2 (Day  1) and until the follow -up contact (Visit 6).  Serious adverse events 
(SAEs) will be collected over the same time period as AEs.  However, an y SAEs 
assessed as related to study  participation (e.g., study  treatment, protocol -mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] concomitant 
medication, will be recorded from the time a subject consents to participate in the study  
up to and including any follow up contact ( Appendix 4 ). 
All subjects will be given an electronic diary  (eDiary ) for use during the run -in, and the 
treatment period to complete PRO questionnaires, record COPD daily  symptoms, any  
medical p roblems experienced during the stud y and the time they  take their COPD 
medications.  Daily  rescue medication usage (number of inhalations taken in the last 24h) 
will also be captured in the eDiary .  In addition, and in some countries, rescue medication 
usewill also be captured by  [CONTACT_645997] (eMDI).
At Screening Visit 1, all subjects must be trained on the proper use of their existing 
COPD medications inhalation devices and instructed to strictly  adhere to and record the 
time they take their COPD medications in the eDiary . 2018N377698_00
2016N277425_01 CONFIDENTIA L
[ADDRESS_864991] completed the study  upon completion of the follow –
up conta ct by [CONTACT_756].
There are no plans to routinely  provide any  of the study  treatments for compassionate use 
following stud y completion as the study treatment are commerciall y available.
The study  design schematic is illustrated in Figure 1
Figure 1 Study  Schematic
*Inhaled COPD medications including LABAs, LAMAs or LABA/LAMA combination products are 
allowed in run-in. ICS alone or in combination with a bronchodilator or any exclusionary 
medications are not allowed.
4.2. Treatment A rms and Duration
Subjects will be stratified based on long-acting bronchodilator usage during the run- in 
(none, one or 2 long- acting bronchodilators per day) and randomized in a ratio of 1:1:1 to 
either
UMEC/VI  inhalat ion powder (62.5/25 mcg once daily) administered via the 
ELLIPTA DPI) or 
UMEC (62.5 mcg once daily ) administered via the ELLIPTA DPI [INVESTIGATOR_1660] 
Salmeterol (50 mcg BID) administered via DISKUS 2018N377698_00
2016N277425_01 CONFIDENTIA L
[ADDRESS_864992], well -established design 
to evaluate the efficacy  and safet y of an inves tigational drug.  A salmeterol arm is 
included to allow a comparison to be made between UMEC/VI , UMEC with salmeterol, 
a standard practice treatment.
The double -dumm y design is appropriate when drugs are of different appearance or 
different administration regimen which is appropriate in this study  where the inhalers 
used have a different appearance and used once daily  and twice dail y.
The European Medicines Agency  (EMA) COPD Guidelines suggest that duration of 12 to 
24 weeks is considered adequate for asses sment of response of COPD sy mptoms to 
treatment intervention with bronchodilators (EMA COPD guidelines, 2012). 
The primary  endpoint is trough FEV [ADDRESS_864993], well e stablished and an objective means to show the efficacy  of a 
bronchodilator [ Dahl , 2010; Feldman , 2010]. 
Other endpoints such SAC TDI , E-RS, SGRQ -C, CAT, Subject Global Rating of Change 
in global impression of disease severity  are captured to allow responder analy ses and to 
provide comparative data on PROs between the treatment groups. 
4.5. Dose Justification
This study  is intended to evaluate the efficacy  of marketed doses of UMEC/VI  
(62.5/25mcg once dail y), UMEC (62.5 mcg once daily ) and salmeterol (50mcg twice 
daily ) that are approved for the maintenance treatment of COPD, with respect to PRO 
measures.
4.6. Benefit: Risk A ssessment
Summaries of findings from both clinical and non- clinical studies conducted with 
UMEC/VI  and UMEC can be found in the investigator’s brochures (IB) 
[GlaxoSmithKline Document Number RM2009/[ZIP_CODE]/07] and [GlaxoSmithKline 
Document Number 
RM2006/[ZIP_CODE]/09] and in the label information sheets. The current 
safet y profile for UMEC (62.5mcg) and the UMEC/VI  (62.5/25mcg) based on data 
available to date, is comparable with other LABAs and LAMAs.  Summary  safet y data 
can also be found in the information sheet for salmeterol [ Serevent product information ,
2003].The following section outlines the risk assessment and mitigation strategy  for this 
protocol:  2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
224.6.1. Risk A ssessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP) [UMEC/VI] 
Severe milk protein allergy Anoro contains Lactose monohydrate (which contains milk 
protein) as an excipi[INVESTIGATOR_841].Exclusion criteria have b een set for subjects with milk 
protein allergy.
Cardiovascular effects such as cardiac arrhythmias e.g.
supraventricular tachycardia and extrasystoles.Class effects associated with LABAs and LAMA containing 
therapy. The clinical significance of these ar rhythmias is 
unknown. Clinical experience with UMEC/VI to date in 
completed studies did not show any association with major 
cardiovascular events. 
Data available in the product label for UMEC/VI Exclusion criteria have been set for subjects with 
uncontrolled or severe cardiovascular disease according to 
the principal investigation’s (PI) opi[INVESTIGATOR_645921]. The PI [INVESTIGATOR_645922].  Patients with the 
following abnormalities will be excluded from participation:  
atrial fibrillation with rapid ventricular rate >120bpm, 
sustained or nonsustained ventricular tachycardia, or 
second degree heart block Mobitz type II or third degree 
heart block (unless pacemaker or defibrillator had been 
inserted). 
Beta agonists and risk of asthma -related death Long -acting beta agonists such as vilanterol when used 
alone may increase the risk o f asthma- related death.  A 
placebo -controlled trial with another LABA (salmeterol) 
showed an increase in asthma -related deaths in subjects 
receiving salmeterol.  This finding with salmeterol is 
considered a class effect of all LABAs, including vilanterol. 
Data are not available to determine whether the rate of death 
in patients with COPD is increased by [INVESTIGATOR_140413].Subjects with a current diagnosis of asthma are excluded 
from participation in the study.
Paradoxical bronchospasm As with other inhaled medicines, U MEC/VI can produce 
paradoxical bronchospasm which may be life threatening.If paradoxical bronchospasm occurs following dosing with 
UMEC/VI, this treatment should be discontinued 
immediately and alternative therapy should be instituted. 
Use in patients w ith narrow -angle glaucoma or urinary 
retentionNo association has been found to date, in completed studies 
with UMEC/VI or UMEC monotherapy, on glaucoma or 
urinary retention.  However, glaucoma or urinary retention Exclusion criterion states that subjects with medical 
conditions such as narrow -angle glaucoma, prostatic 
hypertrophy, or bladder neck obstruction should only be  
 
 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
23Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
have been observed with other antimuscari nic agents, and 
could potentially be due to the pharmacology.included if, in the opi[INVESTIGATOR_1101] t he principal investigator, the 
benefit outweighs the risk.
Use of beta blockers Beta-adrenergic blockers may weaken or antagonize the 
effect of beta 2-agonists such as vilanterol.The study permitted medications and non drug therapi[INVESTIGATOR_645923] -
blockers is only permitted if, in the Investigator’s opi[INVESTIGATOR_1649], 
the likely benefit outweighs the potential risk.
Pregnancy There is no experience to date of pregnancy during the use 
of UMEC/VI.The study inclusion criteri a ensures that female subjects of 
child bearing potential must have a negative pregnancy 
test at screening, and agree to a reliable contraceptive 
method, used consistently and correctly (i.e. in accordance 
with the approved product label and the instructio ns of the 
physician for the duration of the study). Exclusion criteria 
include Pregnancy: Women who are pregnant or lactating 
or are planning on becoming pregnant during the study.
Severe hepatic impairment UMEC/VI has not been studied in severe hepatic i mpairment. Exclusion criterion states that subjects severe hepatic 
impairment should only be included if, in the opi[INVESTIGATOR_564989], the benefit outweighs the risk.
Investigational product (IP) [UMEC]
Cardiovascular effects such as cardiac ar rhythmia, e.g. 
atrial fibrillation and tachycardiaA potential class effect associated
with anti -muscarinic therapi[INVESTIGATOR_014]. Data available to date in the 
IB for UMEC [GlaxoSmithKline Document Number 
RM2006/[ZIP_CODE]/09Screening electrocardiogram (ECG) criteria to exclude 
subjects potentially at risk 
Narrow -angle glaucoma, urinary retention A class effect associated with anti -muscarinic therapi[INVESTIGATOR_014].
Data available in the IB for UMEC [GlaxoSmithKline 
Document Number RM2006/[ZIP_CODE]/09Exclusion criterion states that subjects with medical 
conditions such as narrow -angle glaucoma, prostatic 
hypertrophy, or bladder neck obstruction should only be 
included if, in the opi[INVESTIGATOR_645979], the benefit 
outweighs the risk.
Paradoxical bronchospasm that may be life threatening Known effect associated with inhalation therapy A short -acting inhaled bronchodilator 
(albuterol/salbutamol) will be provided for use as needed 
throughout the study. The investigators will be instructed to 
assess subject’s condition to determine their eligibility to  
 
 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
24Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
continue in the study and the need for alternative therapy.
Severe hepatic impairment UMEC has not been studied in severe hepatic impairment. Exclusi on criterion states that subjects with severe hepatic 
impairment should only be included if, in the opi[INVESTIGATOR_564989], the benefit outweighs the risk.
Pregnancy/Lactation There is no experience to date of pregnancy during the use 
of UMEC.Thestudy inclusion criteria ensure that female subjects 
enrolled, who are of Child bearing potential, have a 
negative pregnancy test at screening, and agree to a 
reliable contraceptive method, used consistently and 
correctly (i.e. in accordance with the appr oved product 
label and the instructions of the physician for the duration 
of the study). Exclusion criteria states -Pregnancy: 
Women who are pregnant or lactating or are planning on 
becoming pregnant during the study.
Study Procedures
Spi[INVESTIGATOR_645980], changes in pulse rate 
and blood pressure, coughing, wheezing, chest tightness or 
fainting.Subjects will be monitored during the procedure for these 
effects and spi[INVESTIGATOR_645925].
ECG lead placement This may cause skin irritation. It may be necessary to have small patches (about a 
centimetre in diameter) of hair on the chest shaved to 
properly attach electrodes to the chest. 
Blood sampling procedure (optional pharmacogenetic 
blood sample)Giving blood may make subjects feel faint, or experience 
mild pain, bruising, irritation or redness at the site. In rare 
cases, they may get an infectionSubjects will be monitored during the blood draw for these 
effects and should call their stud y doctor if any of these 
effects do not resolve
Other 
Side effects of rescue albuterol/salbutamol. Adverse 
events seen in clinical studies to date are however 
consistent for the beta 2-adrenergic class of compoundsClass effects associated with short act ing beta -agonists 
(SABAs)Subjects should call their study doctor if they experience 
any of these symptoms 
 
 2018N377698_00
2016N277425_ [ADDRESS_864994] to PROs and sy mptoms in the treatment of COPD.
Specific benefits associated with the study  design and procedures include the following:
Subjects will receive treatments approved for the treatment of COPD that have 
been shown to be effective in the population under study
All subjects will receive albuterol/salbutamol for use “as needed” for relief of 
COPD sy mptoms
The combination of study procedures of spi[INVESTIGATOR_038] , CAT, SGRQ, TDI, E-RSwill 
provide the study  subjects with a comprehensive evaluation of their s ymptoms, 
health status and COPD disease severity . Subjects will also be monitored 
throughout the s tudy for any  worsening of COPD sy mptoms or decline in general 
health.  Finall y smoking cessation counselling will also be provided.
4.6.3. Overall Benefit: Risk Conclusion
Taking into account the measures taken to minimize risk to subjects participating in this 
study, the potential risks identified in association with UMEC/VI , UMEC, salmeterol and 
with study  procedures are justified by  [CONTACT_645998].
5. SELECTION OF STUDY P OPULA TION A ND 
WITH DRA WAL CRITERIA
Specific information regarding warnings, precautions, contraindications, adverse events, 
and other pertinent information on the [COMPANY_004] investigational product or other study  
treatment that may  impact subject eligibility  is provided in the IBs, [ GlaxoSmithKline 
Document Number RM2006/[ZIP_CODE]/09], [ GlaxoSmithKline Document Number 
RM2009/[ZIP_CODE]/07] and product labels.
Deviations from inclusion and exclusion criteria a re not allowed because they  can 
potentially  jeopardize the scientific integrity  of the study , regulatory  acceptability  or 
subject safet y. Therefore, adherence to the criteria as specified in the protocol is essential.
5.1. Inclusion Criteria
A subject will be e ligible for inclusion in this study  only  if all of the following criteria 
apply :
AGE
1.[ADDRESS_864995] AND DIAGNOSI S INC LUDING DISEASE SEVERI TY
2.Outpatient with a diagnosis of COP Din accordance with the definition of the 
American Thoracic Society /European Respi[INVESTIGATOR_21618]  (ATS/ERS) [ Celli , 2004]. 
3.FEV 1: Persistent airflow limitations as indicated by :  A pre and post -
albuterol/salbutamol FEV 1/FVC ratio of <0.[ADDRESS_864996] -albuterol/salbutamol FEV 1
of ≥30% to ≤80% predicted normal values at Screening Visit 1.  Predicted values 
will be based upon the ERS Global L ung Function I nitiative [ Quanjer , 2012].
4.CAT score :  A CAT score of ≥10 at Screening Visit 1
Smoki ng History
5.Current or former cigarette smokers with a history  of cigarette smoking of 10 
pack -years [number of pack years = (number of cigarettes per day  / 20) x number of 
years smoked (e.g. 20 cigarettes per day  for 10 y ears, or 10 cigarettes per day  for 20 
years both equal 10 pack -years)].  Former smokers are defined as those who have 
stopped smoking for at least 6 months prior to Visit 1.  Pi[INVESTIGATOR_23887]/or cigar use cannot 
be used to calculate pack -year history .
SEX
6.Male and female subjects are eligible to participate in the study
A female subject is eligible to participate if she is not pregnant (as confirmed by  a 
negative urine human chorionic gonadotrophin (hCG) test), not lactating, and at least one 
of the following conditions applies:
a.Non-reproductive potential defined as:
Pre-menopausal females with one of the following:
Documented tubal ligation
Documented h ysteroscopic tubal occlusion procedure with follow -up 
confirmation of bilateral tubal occlusion 
Hysterectomy
Documented Bilateral Oophorectom y
Postmenopausal defined as 12 months of spontaneous amenorrhea.  In questionable cases 
a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels 
consistent with menopause must be tested.  Females on hormone replacement therap y 
(HRT) and whose menopausal status is in doubt will be required to use one of the highl y 
effective contraception methods if they  wish to continue their HRT during the study .  
Otherwise, they  must discontinue HRT to allow confirmation of post -menopausal st atus 
prior to study  enrolment.
b. Reproductive potential and agrees to follow one of the options listed in the Modified 
List of Highl y Effective Methods for Avoiding Pregnancy in Females of  2018N377698_00
2016N277425_ 01 CONFIDENTIA L
201749
27Reproductive Potential (FRP) ( Appendix 7 ) from [ADDRESS_864997] dose of 
study  medication and until [at least five terminal half- lives OR until any  continuing 
pharmacologic effect has ended, whichever is longer] after the last dose of study  
medication and completion of the follow- up visit.
The investigator is responsible for ensuring that subjects understand how to properl y use 
these methods of contraception.
INFORMED CONSENT
7.Capable of giving signed informed consent prior to study  participation, which 
includes compliance with the requirements and restrictions listed in the consent form 
and in this protocol.
5.2. Exclusion Criteria
A subject will not be eligible for inclusion in this study  if an y of the following criteria 
apply :
CONCURRENT CONDITIONS/MEDI CAL  HISTORY (INCLUDES LIV ER 
FUNCTION 
1. Asthma :  A current diagnosis of asthma.  (Subjects with a prior history  of asthma 
are eligible if they  have a current diagnosis of COPD, which is the primary cause of 
their respi[INVESTIGATOR_23908]).
2. Alpha -antitrypsin deficiency: Subjects with known α1-antitry psin deficiency  as 
the underl ying cause of COPD
3. Other respi[INVESTIGATOR_17744]: Subjects with active tuberculosis are excluded. 
Subjects with other respi[INVESTIGATOR_146456] (e.g. clinically  significant: 
bronchiectasis, sarcoidosis, lung fibrosis, pulmo nary hypertension, interstitial 
lung diseases) are excluded if these conditions are the primary cause of their 
respi[INVESTIGATOR_23908].
4. Unstable liver disease: Current active liver or biliary  disease (with the exception 
of Gilbert’s s yndrome or asymptomatic g allstones or otherwise stable chronic 
liver disease per investigator assessment). 
Stable chronic liver disease should generally  be defined by  [CONTACT_107415], 
encephalopath y, coagulopathy, h ypoalbuminaemia, oesophageal or gastric 
varices, or persis tent jaundice, or cirrhosis.
Chronic stable hepatitis B and C ( e.g., presence of hepatitis B surface antigen 
(HBsAg) or positive hepatitis C antibody  test result or within [ADDRESS_864998] dose of study  treatment) are acceptable if subject otherwise meets entry  
criteria
5. Unstable or life threatening cardiac disease: Investigational Product should be 
used with caution in subjects with severe cardiovascular disease.  In the opi[INVESTIGATOR_8574], use should only  be considered if the benefit is lik ely to  2018N377698_00
2016N277425_ 01 CONFIDENTIA L
201749
28outweigh the risk in conditions such as:
Myocardial infarction or unstable angina in the last 6 months
Unstable or life threatening cardiac arrh ythmia requiring intervention in the last 3 
months
NYHA Class IV heart failure
6. 12 Lead ECG: The Investiga tor will determine the clinical significance of each 
abnormal ECG finding in relation to the subject’s medical history  and exclude 
subjects who would be at undue risk by  [CONTACT_19212]. Subjects with the 
following abnormalities are excluded fro m participation in the study :
Atrial fibrillation with rapid ventricular rate >120 bpm
Sustained or non -sustained ventricular tach ycardia
Second degree heart block Mobitz ty pe II or third degree heart block (unless 
pacemaker or defibrillator had been inser ted)
7. Antimuscarinic effects:   Subjects with medical conditions such as narrow -angle 
glaucoma, urinary  retention, prostatic hy pertrophy, or bladder neck obstruction 
should be excluded unless, in the opi[INVESTIGATOR_23942], the benefit 
outweighs the risk.
8. Other disease abnormalities: Any subject who is considered unlikel y to survive 
the duration of the stud y period or has an y rapi[INVESTIGATOR_2478] y progressing disease or 
immediate life-threatening illness (e.g. cancer). In addition, any  subject who has 
any other condition (e.g. neurological condition) that is likely  to affect respi[INVESTIGATOR_645926] .
9. Hospi[INVESTIGATOR_059]: Hospi[INVESTIGATOR_645927] 12 weeks prior 
to Visit 1. Pneumonia and/or moderate or severe COPD exace rbation that has 
not resolved at least [ADDRESS_864999] dose of oral/s ystemic corticosteroids (if applicable). 
10. Inhaled corticosteroids (ICS): Had received ICS or I CS/LABA for the treatment 
of COPD in th e 6 weeks prior to Screening Visit1
11. Exacerbation: Had >[ADDRESS_865000] 7 days prior to 
Screening V1.
13. Lung Resection: Subjects with lung volume reduction surgery  (including 
procedures such as endobronchial valves) within the 12 months prior to Screening 
V1.
14. Oxygen: Use of long -term oxy gen therap y (LTOT) described as resting oxy gen 
therap y >3L/min at screening required to maintain adequate ox ygenation ( e.g. 
SaO2>90%). (Ox ygen use ≤3L/min flow is not exclusionary , and patients may  
adjust oxy gen levels up or down as needed during the study .) 2018N377698_00
2016N277425_ 01 CONFIDENTIA L
201749
29CONCOMI TANT MEDICATIONS
1.Medications prior to Screening: Use of the following medications according to 
the following define d time intervals prior to Screening (Visit 1):
Medication No use within the 
following time intervals 
prior to Screening
Inhaled corticosteroids (ICS) 6 weeks
Depot corticosteroids 12 weeks
Systemic, oral or parenteral corticosteroidsa 6 weeks
Antibioti cs (for lower respi[INVESTIGATOR_1092]) 6 weeks
Phosphodiesterase 4 (PDE 4) Inhibitor ( e.groflumilast) 14 days
LABA/Inhaled Corticosteroid (ICS) combination products 6 weeks
Theophyllines 48 hours
Oral beta 2-agonists
     Long- acting
     Short -acting48 hours
12 hours
Inhaled short acting beta 2-agonistsb 4 hours
Inhaled short -acting anticholinergics 4 hours
Inhaled short -acting anticholinergic/short -acting beta 2-agonist 
combination products4 hours
Any other investigational medication 30 days or within 5 drug 
half-lives (whichever is 
longer)
a- Localized corticosteroid injections (e.g., intra -articular and epi[INVESTIGATOR_13873]) are permitted.
b- Use of study provided albuterol/salbutamol is permitted during the study, except in the 4 -hour period prior to 
spi[INVESTIGATOR_645971]
2.Medication prior to spi[INVESTIGATOR_038]: Unable to withhold albuterol/salbutamol for 
the 4 hour period required prior to spi[INVESTIGATOR_645972].
3.Maintenance use of short -acting bronchodilators :  Regular use (prescribed for 
daily / regul ar use, not for as -needed use) of short -acting bronchodilators ( e.g. 
albuterol/salbutamol).
REL EVANT HABITS
1.Drug or alcohol abuse: A known or suspected history  of alcohol or drug abuse 
within [ADDRESS_865001] from completing the stud y procedures.
CONTRAINDICATIONS 
1.Any history of allergy or hypersensitivity to any anticholinergic/muscarinic 
receptor antagonist, s ympathomimetic, lactose/milk protein or magnesium stearate . 2018N377698_00
2016N277425_ 01 CONFIDENTIA L
201749
30DIAGNOSTIC ASSESSMENTS AND OTHER CRI TERIA
1.Pulmonary Rehabilitation program: Participation in the acute phase of a 
pulmonary  rehabilitation program within 4 weeks prior to Screening Visit 1.  Subjects 
who are in the maintenance phase of a pulmonary  rehabilitation program are not 
excluded.
2.Affiliation with investigator sites: Is an investigator, sub -investigator, study  
coordinator, emplo yee of a participating investigator or study site, or immediate 
family  member of the aforementioned that is involved in this study
3.Inability to read: In the opi[INVESTIGATOR_871], any  subject who is unable to read 
and/or would not be able to complete questionnaires on the electronic diary.
Subjects who fail to meet inclusion and exclusion criteria at the Screening Visit [ADDRESS_865002] fulfilled all inclusion and excl usion criteria 
described in Section 5.1and Section 5.2. In addition to the following:
REQUI RED CRI TERIA FOR RANDOMIZATION AND TREATMENT
1.COPD Exacerbation : Subjects must nothave experienced a moderate or severe 
COPD exacerbation or a lower respi[INVESTIGATOR_626201] -in or at Day  1 
(Visit 2) inclusive.  A moderate exacerbation is defined as worsening of s ymptoms of 
COPD requiring the use of antibiotics or systemic corticosteroids.  A severe 
exacerbation is defined as worsening sy mptoms of COPD requiring hospi[INVESTIGATOR_059].
2.CAT score :  A CAT score of ≥10 at Visit 2
3.Prohibited Medications: No use of an y prohibited medications during the run -in 
period or at Visit 2, including an y ICS or ICS/LABA combination
4.Any change to COPD medications: Including dosage and regimen during the run -in
5.Completion of electronic diary: Must have completed the electronic diary for at 
least 80% of day s during the run- in period
Subjects who do not meet the required criteria for randomization at Visit 2 will not be 
randomized.
5.4. Screening/Baseline/Run-in Failure s
Pre-screen, screen and run -in failures are defined as follows: 
Pre-screening failures: A subject, who is assigned a subject number at the Pre -
screening Visit [ADDRESS_865003] an y Screening Visit 1 procedures, will be 
considered a pre -screen failure. 2018N377698_00
2016N277425_ 01 CONFIDENTIA L
201749
31Screening failures: Those subjects that complete at least one Screening Visit 1 
procedure but do not enter the run -in period.
Run-in failures: Those subjects that enter the run-in period but are not 
randomized to any  of the study  treatment arms.
Subjects w ho are pre -screen, screen and run -in failure will be recorded in the eCRF.  In 
order to ensure transparent reporting of screen failure subjects, meet the Consolidated 
Standards of Reporting Trials (CONSORT) publishing requirements, and respond to 
queries f rom Regulatory  Authorities, a minimal set of screen failure information is 
required to be recorded in eCRF including demograph y, screen failure details, eligibility  
criteria, and serious adverse events (Section 7.4.1 ). 
5.5. Withdrawal/Stoppi[INVESTIGATOR_2121]
5.5.1. Withdrawal from the Study
Subjects may  be withdrawn from the study  at an y time by  [CONTACT_646021] .  Reasons for withdrawal 
from study  treatment c an include: an AE, clinically  significant abnormality, lack of 
efficacy , sponsor terminated study , pregnancy , or for any  other reason. 
If a subject withdraws from the study , he/she may request destruction of any  samples 
taken, and the investigator must do cument this in the site study  records . 
A reason for the withdrawal from the study  must be captured in the electronic case report 
form (eCRF).
A subject will also be withdrawn from the study , in consultation with the medical 
monitor and principal investiga tor, if any  of the following stoppi[INVESTIGATOR_23893]:
Liver Chemistry: Meets any  of the Liver chemistry  stoppi[INVESTIGATOR_3418] (See Section 
5.5.3 )
Note: clinical laboratory  assessments are not required for this st udy. However, 
laboratory  samples may  be taken for liver event analy sis, if clinicall y indicated b y 
the study  investigator.
Pregnancy:   Positive pregnancy  test (see Appendix 7 )
Subjects withdrawn from study  treatment wi ll not be replaced. 
Note: Withdrawal from study  treatment requires withdrawal from the study .
The following actions must be taken in relation to a subject who fails to attend the clinic 
for a required stud y visit:
The site must attempt to contact [CONTACT_646022] -schedule the missed visit as 
soon as possible. 
The site must counsel the subject on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the subject wishes to and/or should 
continue in the study .  2018N377698_00
2016N277425_ 01 CONFIDENTIA L
201749
32In cases wher e the subject is deemed ‘lost to follow up’, the investigator or 
designee must make every effort to regain contact [CONTACT_1155] (where 
possible, [ADDRESS_865004]’s last 
known mailing address or local equivalent methods). These contact [CONTACT_131994]’s medical record. 
Should the subject continue to be unreachable, only then will he/she be considered 
to have withdrawn from the study  with a primary  reason of “Lost to Follow -up”. 
5.5.2. Reason for Study  Withdrawal
The primary  reason for study  withdrawal will be recorded in the eCRF. When a subject 
withdraws consent, the investigator must document the reason (if specified by  [CONTACT_1560]) in the eCRF. 
The primary  reason for study  withdrawal may  include:
Adverse event
Lost to follow -up
Withdrew consent
osubject relocated
ofrequency  of visits
oburden of procedures
oother (specify )
Protocol deviation
Lack of efficacy
COPD exacerbation
Study  closed/terminated
Subject reached protocol -defined stoppi[INVESTIGATOR_645973]
Pregnancy
Investigator discretion
5.5.3. Liver Chemistry Stoppi[INVESTIGATOR_131957] y and evaluate liver event etiology (in alignment with th e FDA 
premarketing clinical liver safety  guidance). 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf 2018N377698_00
2016N277425_ 01 CONFIDENTIA L
201749
33Phase III -IV Liver Chemistry Increased Monitoring Algorithm with Continued 
Therapy for ALT 3xULN but <8xULN
Cont inue Study Treatm ent   and   Monitor  Liver Chem istry
Discontinue Study Treatment ALT≥5xULN 
but <8xULN
+ bili<2xULN +
no symptoms
NoMust  refer to Liver Safety Requi red Actions and Fol low up Asses smen ts section in the Appendi x
YesALT ≥3xULN 
but <5xULN
+ bili<2xULN  +
no symptomsAble to 
monitor  
weekly 
for  ≥2 
weeksPersists for 
≥2 weeks  
or other  
stoppi[INVESTIGATOR_53099]  ≥4 
weeksPersists for 
≥4 weeks  
or other  
stoppi[INVESTIGATOR_131958] ≥5xULN ALT <5xULN 
Yes Yes
*INR value not applicable to subjects on anticoagulants Must  refer to Liver Safety Requi red Actions and Fol low up Asses sments section in the Appendi x
Repor t as an SAE if possible Hy’sLaw case:  ALT≥3xUL N and  Bilirubin≥2x ULN (>35% direct)  or 
INR>1.5, if measur ed*
Liver Safet y Required Actions and Follow up Assessments Section can be found in 
Appendix 2 .
[IP_ADDRESS]. Study  Treatment Restart or Rechallenge
Study  treatment restart or rechallenge after liver chemistry  stoppi[INVESTIGATOR_539093] e met b y 
any subject participating in this study  is not allowed.
5.6. Follow -up contact
A safet y follow- up contact (Visit 6) should be conducted 7 2 day s following the 
completion of Visit 5 or the Earl y Withdrawal Visit, if applicable. 
The following procedures will be performed:
AE/SAE assessment
COPD exacerbation assessment
Concomitant medication assessment limited to any  medications used to treat a 
COPD exacerbation or SAE (if applicable)
Pregnancy  information (if applicable)
Subjects who have successfully  completed all on -treatment randomized visits will be 
discharged from the study upon completion of the safet y follow- up contact. 2018N377698_00
2016N277425_ [ADDRESS_865005] completed the study  if he/she receives study  
treatment at Visit 5 (Week 24) and completes the follow -up contact [CONTACT_4838] 6.
The end of the stud y is defined as the last subject’s last visit. 
6. STUDY TREA TMENT
6.1. Investigational Product and Other Study  Treatment
The term ‘stud y treatment’ is used throughout the protocol to desc ribe any  combination 
of products received b y the subject as per the protocol design.  Stud y treatment may 
therefore refer to the individual study  treatments or the combination of those study  
treatments.
The contents of the label will be in ac accordance wit h all applicable regulatory  
requirements.
Under normal conditions of handling and administration, investigational product is not 
expected to pose significant safet y risks to site staff.  Take adequate precautions to avoid 
direct ey e or skin contact [CONTACT_23968]. Notify  the monitor of 
any unintentional occupational exposure.  A Material Safet y Data Sheet (MSDS) 
describing the occupational hazards and recommended handling precautions will be 
provided to site staff if required by  [CONTACT_339256].
Investigational product must be stored in a secure area under the appropriate phy sical 
conditions for the product.  Access to and administration of the investigational product 
will be limited to the investigator and authorised site staff.  Investigational product must 
be dispensed or administered onl y to subjects enrolled in the study  and in accordance 
with the protocol.
GlaxoSmithKline ([COMPANY_004]) will provide the study treatments for use in this stud y. 
The following stud y medications will be used in this study :
UMEC/VI  62.5/ 25mcg administered via ELLIPTA
UMEC 62.5 mcg administered via ELLIPTA
 Salmeterol 50 mcg administered via DISKUS
 Placebo via ELLIPTA
 Placebo via DISKUS
Subjects will be instructed to take one dose of medication each morning from the 
ELLIPTA (one inhalation equals one dose), and one dose in the morning and one in the 
evening from the DI SKUS).  Subject instructions and details on how to use the ELLIPTA 
andDISKUS are provided in the study  reference manual (SRM). 2018N377698_00
2016N277425_ 01 CONFIDENTIA L
201749
35A description of the UMEC/VI  investigational product administered via the ELLIPTAis 
provided below in Table 1. The ELLIPTA will contain two, double -foil, laminate, blister 
strips.  The ELLIPTA will provide a total of 30 doses (60 blisters) and will deliver, when 
actuated, the contents of a single blister simultaneously  from each of the two blister 
strips. 
The DISKUS will provide a total of [ADDRESS_865006] administered via the ELLIPTA is 
provided below in Table 2. A description of placebo inhalation powder via ELLIPTA is 
shown in Table 3.  A description of salmeterol 50mcg and placebo via DISKUS are 
shown in Table 4 and Table 5respectively .
Table 1 Description of UMEC/VI Inhalation Powder via ELLIPTA
Formulation First strip Second strip
Umeclidinium bromide blended with 
lactose monohydrate and 
magnesium stearate1Vilanterol trifenatate blended with 
lactose monohydrate and magnesium 
stearate2
Dosage Form ELLIPTA Inhaler with 30 doses (2 strips with 30 blisters per strip)
Unit Dose Strengths 62.5 mcg 25 mcg
Physical description White powder White powder
Route of Administration Inhaled
1. Magnesium stearate 0.6% w/w of total drug product
2. Magnesium stearate 1.0% w/w of total drug product
Table [ADDRESS_865007] strip
Umeclidinium bromide blended with lactose 
monohydrate and magnesium stearate1
Dosage Form ELLIPTA I nhaler with 30 doses (1 strip with 30 blisters) 
Unit Dose Strengths 62.5mcg 
Physical description Dry white powder
Route of Administration Inhaled
1. Magnesium stearate 0.6% w/w of total drug product
Table [ADDRESS_865008] strip Second strip
Lactose monohydrate blended with 
magnesium stearate1Lactose monohydrate blended with 
magnesium stearate2
Dosage Form ELLIPTA Inhaler with 30 doses (2 strips with 30 blisters per strip)
Unit Dose Strengths Not applicable Not applicable
Physical description Dry white powder Dry white powder
Route of Administration Inhaled
1. Magnesium stearate 0.6% w/w of total drug product
2. Magnesium stearate 1% w/w of total drug product 2018N377698_00
2016N277425_ [ADDRESS_865009] strip
Salmeterol Xinafoate blended with 
lactose monohydrate
Dosage Form Diskus Inhaler with 60 doses (1 strip 
with 60 blisters per strip)
Unit Dose Strengths 50 m cg
Physical description White powder
Route of Administration Inhaled
Table 5 Description of Placebo inhalation powder via DISKUS
Formulation Lactose monohydrate 
Dosage Form Diskus Inhaler with 60 doses (1 strip 
with 60 blisters per strip)
Unit Dose Strengths Not Applicable
Physical description White powder
Route of Administration Inhaled
Albuterol/salbutamol via metered -dose-inhaler (MDI) will be issued for reversibility  
testing at Visit 1.  Albuterol/salbutamol MDI  for as needed (prn) use will be issued 
throughout the study.  Albuterol/salbutamol will be sourced from local commercial stock 
if appropriate.  
6.2. Medical Devices
The eMDI devices are provided by  [CONTACT_646023].  They  have US FDA 510(K) clearance to market (Class 
II device) and EU CE marking (Class I device). Description of the eMDI and its use will 
be provided in the SRM.
6.3. Treatment A ssignment
Subjects who meet the randomization criteria will be assign ed to one of the [ADDRESS_865010] is 24 weeks.  On the morning of each clinic 
study  visit, subjects will refrain from taking their mornin g dose of study  treatment until  2018N377698_00
2016N277425_ 01 CONFIDENTIA L
201749
37instructed to do so by  [CONTACT_6477].  On the other day s during the treatment period 
(i.e. “non- clinic day s”), s ubjects will be instructed to self -administer their study  treatment 
in the morning and evening. Subjects shou ld enter the time they  take their study  treatment 
in the eDiary . 
Subjects will be randomly assigned to one of the blinded study  treatment regimens in 
equal proportion (ratio of 1:1:1):
UMEC/VI  62.5/25 mcg once dail y via ELLIPTA + placebo twice dail y via 
DISKUS
UMEC 62.5 mcg once daily  via ELLIPTA + placebo twice dail y via DISKUS
Salmeterol 50 mcg twice daily  via DI SKUS + placebo once daily  via ELLIPTA
The randomisation will be stratified based on long-acting bronchodilator usage during 
the run- in (none, on e or 2 long-acting bronchodilators per day ). 
Study  treatment/investigational product will be dispensed at Visits 2, [ADDRESS_865011] return to 
clinic within 30 day s from V2, 60 and 90 day s from V3 and V4 respectively  (see Time 
and event table Section 7.1). 
Used study  drug and rescue medication will be collected at Visits 3, 4 and 5 or at the 
Early Withdrawal Visit. 
6.4. Planned Dose A djustmen ts
No dose adjustment is allowed for this study
6.5. Blinding
This will be a double- blind double dummy  study  and the following will apply . 
The investigator or treating ph ysician may  unblind a subject’s treatment 
assignment only in the case of an emergency OR i n the event of a serious 
medical condition when knowledge of the stud y treatment is essential for the 
appropriate clinical management or welfare of the subject as judged b y the 
investigator. 
Investigators have direct access to the subject’s individual stu dy treatment. 
It is preferred (but not required) that the investigator first contacts the Medical 
Monitor or appropriate [COMPANY_004] study  personnel to discuss options before unblinding 
the subject’s treatment assignment. 
If [COMPANY_004] personnel are not contact[CONTACT_20453] e the unblinding, the investigator must 
notify  [COMPANY_004] as soon as possible after unblinding, but without revealing the 
treatment assignment of the unblinded subject, unless that information is 
important for the safety  of subjects currently  in the study .  2018N377698_00
2016N277425_ 01 CONFIDENTIA L
201749
38The d ate and reason for the unblinding must be fully  documented in the eCRF 
A subject will be withdrawn if the subject’s treatment code is unblinded b y the 
investigator or treating phy sician. [COMPANY_004]’s Global Clinical Safety  and Pharmacovigilance 
(GCSP) staff may  unblind the treatment assignment for an y subject with an SAE. If the 
SAE requires that an expedited regulatory  report be sent to one or more regulatory  
agencies, a cop y of the report, identifying the subject’s treatment assignment, may  be sent 
to investiga tors in accordance with local regulations and/or [COMPANY_004] policy .
6.6. Packaging and Labeling
The contents of the label will be in accordance with all applicable regulatory  
requirements.
6.7. Preparation/Handling/Storage/A ccountability
No special preparation of the study treatment is required.
The investigator or designee must confirm appropriate temperature conditions 
have been maintained during transit for all study  treatment received and any  
discrepancies are reported and resolved before use of the study  treatment.
Only subjects enrolled in the study  may  receive study  treatment and onl y 
authorized site staff may  supply  or administer study  treatment.  All study  
treatments must be stored in a secure environmentally  controlled and monitored 
(manual or automated) area in ac cordance with the labelled storage conditions 
with access limited to the investigator and authorized site staff. 
The investigator, institution, or the head of the medical institution (where 
applicable) is responsible for study  treatment accountability , reconciliation, and 
record maintenance (i.e. receipt, reconciliation and final disposition records).  
Further guidance and information for final disposition of unused study  treatment 
are provided in the SRM. 
All ELLIPTA DPI [INVESTIGATOR_645929] 25C (77F).  Each All 
ELLIPTA DPI [CONTACT_468929] [ADDRESS_865012]. 
Salmeterol DI SKUS should be stored up to 25 C. 
Under normal conditions of handling and administration, study  treatment is not 
expected to pose significant safety risks to site staff .  Take adequate precautions to 
avoid direct ey e or skin contact [CONTACT_23968]. In the case of 
unintentional occupational exposure notify  the monitor, Medical Monitor and/or [COMPANY_004] 
study  contact.
A Material Safety  Data Sheet (MSDS)/equivalent document describin g 
occupational hazards and recommended handling precautions either will be  2018N377698_00
2016N277425_ [ADDRESS_865013] from [COMPANY_004].
6.7.1. Study Treatment Return
All used and unused ELLIPTA and DISKUS inhalers and albuterol/salbutamol will be 
returned to [COMPANY_004] at the end of the study  to be available for disposal.  In some instances 
for sites outside the US, study  supplies will be disposed of locall y either b y the site, the 
country  medical department or third -party vendor.  Detailed instructions for the return of 
the study  drug can be found in the SRM.
Study  treatment will be collected at Visit 3, [ADDRESS_865014] and dispense a new 
study  treatment kit from the site’s investigational product supply  as instructed by  [CONTACT_646003], any  ELLIPTA that fails to function properly  must be identified and returned 
to [COMPANY_004] for testing. 
6.8. Compliance with Study  Treatment A dministration
When subjects self- administer study  treatment(s) at home , compliance with study  
treatment(s) will be assessed through querying the subject during the site visits and 
through stud y drug compliance assessed at Visits 2, 3, [ADDRESS_865015] iance with the ELLIPTA inhaler will be determined by [CONTACT_646004].  Compliance with the study  DISKUS will be determined by  [CONTACT_646005].  Subjects should be ≥80% to ≤120% compliant on 
taking stud y me dication between each pair of on- treatment visits.  Subjects who fall 
outside this range should be re -educated on treatment compliance b y their site. This re -
education should be documented in the subject’s source document.  If medication 
compliance repeate dly falls outside of acceptable ranges, the study  sponsor/site monitor 
must be contact[CONTACT_646006] .
6.9. Treatment of Study  Treatment Overdose
An overdose is defined as a dose greater than the total doses described in Section 6.1and 
Section 6.8which results in clinical signs and s ymptoms.  These should be recorded b y 
the investigator on the AE/SAE pages.  In th e event of an overdose of study  medication, 
the investigator should use clinical judgment in treating the overdose and contact [CONTACT_646007].  2018N377698_00
2016N277425_ 01 CONFIDENTIA L
201749
40[COMPANY_004] is not recommending specific treatment guidelines for overdose and toxicity  
management.  The investigator is advised to refer to the relevant document(s) for detailed 
information regarding warnings, precautions, contraindications, adverse events, and other 
significant data pertaining to the stud y drug being used in this study . Such documents 
may inclu de, but may  not be limited to, the approved product label for salmeterol 
albuterol, UMEC and UMEC/VI  or equivalent document provided by  [CONTACT_23983].
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_424359].
6.10. Treatment after the End of the Study
Subjects will not receive any additional treatment from [COMPANY_004] after completion of the 
study , since the stud y treatments are commercially available.
The inves tigator is responsible for ensuring that consideration has been given to the post -
study  care of the subject’s medical condition, post- study  treatment. 
6.11. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_645930] 30 day s prior to Pre -Screening (Visit 0) and onwards 
should be recorded in the eCRF including an y changes in medications.  Beginning at 
Visit [ADDRESS_865016] of the stud y, all medications should be recorded in the 
eCRF including an y changes.  Stud y provided albuterol/sa lbutamol and double -blinded 
study  drug should notbe recorded in the eCRF.  The minimum requirement includes but 
is not limited to drug name, dose, route and the dates of administration.  Medications 
initiated after completion of Visit 5 or the Earl y Withd rawal Visit will not be recorded in 
the eCRF, with the exception of those used to treat a COPD exacerbation or SAE that 
occurs between Visit 5 (or the Early Withdrawal Visit) and the follow -up contact [CONTACT_646024] 
6.
6.11.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_645974] :
Study -provided albuterol/salbutamol for use as relief medication throughout the 
run-in and treatment periods 
Mucoly tics such as acet ylcysteine
Medications for rhinitis (e.g. intranasal c orticosteroids, antihistamines, cromoly n, 
nedocromil, nasal decongestants)
Influenza vaccine
pneumococcal vaccine
Antibiotics for short term treatment ( 14 day s) of acute infections including  
COPD exacerbations
Systemic corticosteroids for short term ( 14consecutive day s)  treatment of 
COPD exacerbations  2018N377698_00
2016N277425_ 01 CONFIDENTIA L
201749
41As-needed supplemental oxy gen use provided it is ≤3L/min flow at rest at 
screening.  Patients may  adjust oxy gen levels as needed during the stud y.
Pulmonary  rehabilitation program in maintenance phase
Smoking cessation treatment, including a stable regimen of nicotine replacement
Use of positive airway  pressure/non -invasive ventilation for sleep apnea/sleep 
disordered breathing ( e.g. CPAP, BiPAP) 
Localized corticosteroid injections (e.g., intra -articular and epi[INVESTIGATOR_13873])
Oral muscarinic antagonists for the tr eatment of overactive bladder are permitted 
but should be used with caution as they  may  exacerbate medical conditions that 
are contraindicated for anticholinergics (e.g., narrow angle glaucoma and bladder 
outflow obstruction)
Immunotherap y injections
Topic al or ophthalmic corticosteroids
Over -the counter (OTC) cough suppressants
Tricy clic antidepressants and monoamine oxidase inhibitors (MAOI s). Administer 
with caution as they  may potentiate the effect of beta -agonists on the vascular 
system
Diuretics. Caut ion is advised in the co -administration of beta agonists with non-
potassium sparing diuretics
Allergy  vaccination
All medications for other disorders as long as the dose remains constant whenever 
possible and their use would not be expected to affect lung function
6.11.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_417438] 6 is not permitted during the study 2018N377698_00
2016N277425_ 01 CONFIDENTIA L
201749
42Table 6 Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_645932], oral or parenteral corticosteroids1
Inhaled corticosteroids (ICS)2
Antibiotics >14 days
LABA/ICS combination products
PDE4 inhibitor (e.g. roflumilast)
Inhaled long acting beta 2-agonists (LABA, e.g. salmeterol, f ormoterol, indacaterol, vilanterol)
Long -acting muscarinic antagonists (LAMA, e.g. tiotropi[INVESTIGATOR_1890], aclidinium, glycopyrronium, umeclidinium3)
LAMA/LABA combination products except for study drugs
Theophyllines
Oral beta 2-agonists
Inhaled short acting beta 2-agonists4
Inhaled short -acting anticholinergics
Inhaled short -acting anticholinergic/short -acting beta 2-agonist combination products
Any other investigational medication
1 Except for the treatment of COPD exacerbations during the study. Localized corti costeroid injections (e.g., 
intra-articular and epi[INVESTIGATOR_13873]) are permitted.
2 Except if during the study use of ICS is deemed necessary for the treatment of subjects’ exacerbation. 
[ADDRESS_865017] for study drug
4 Use of study provided albuterol /salbutamol is permitted d uring the study, except in the 4 -hour period prior to 
spi[INVESTIGATOR_68333]. 
The following medications or treatments are also notallowed during the study :
Use of long -term ox ygen therap y (LTOT) described as resting ox ygen therapy 
>3L/min onl y at screening . Oxygen may  be titrated to any  level deemed necessary  
during the stud y.
Regular (prescribed for daily /regular use, not for as- needed use) therap y with 
albuterol/salbutamol.
Initiation of pulmonary  rehabilitation during the study .
7. STUDY A SSESSMENTS A ND PR OCEDURES
Protocol waivers or exemptions are not allowed with the exception of immediate safety  
concerns. Therefore, adherence to the stud y design requirements, including those 
specified in the Time and Events Table Section 7.1, are essential and required for stud y 
conduct.
This section lists the procedures and parameters of each planned study assessment.  The 
exact timing of each assessment is listed in the Time and Events Table Section 7.1 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
437.1. Time and Events Table
Blinded Treatment
VisitPre-
screen1
0Screen/ 
Run-in
1Rando -
mization 
[ADDRESS_865018] 
6
Week -6 to -4 -4 0 4 12 24
Day42 -7/+2
days 
prior 
Visit 128 -7/+2 
days prior 
Visit 21-7/+2 
days28-7/+2 
days 84 -7/+2 
days168 -7/+2
days73days after V5 or 
EW Visit
Screen/Baseline
Written informed consent X
Demography X
Medical/COPD history X
Smoking history/statu s X
Smoking cessation counselling X
Concomitant medication assessment X X X X X X X X
Height and weight X
Cardiovascular History/family history of premature CV 
disease])X
Screening spi[INVESTIGATOR_038] (in cluding post bronchodilator 
testing )3X
CAT questionnaire X X
Verify Inclusion/Exclusion Criteria X
Training on use of inhalers X X
Training on use of eDiary and eMDI X X
Verify randomiza tion Criteria X
Register Visit in InForm X X X X X X X X
Register Visit in RAMOS NG X X X X X X X X 
 
 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
44Blinded Treatment
VisitPre-
screen1
0Screen/ 
Run-in
1Rando -
mization 
[ADDRESS_865019] 
6
Week -6 to -4 -4 0 4 12 24
Day42 -7/+2
days 
prior 
Visit 128 -7/+2 
days prior 
Visit 21-7/+2 
days28-7/+2 
days 84 -7/+2 
days168 -7/+2
days73days after V5 or 
EW Visit
Efficacy/HRQoL assessments
Spi[INVESTIGATOR_038], including pre -dose FEV 1, trough  FEV 1and 
inspi[INVESTIGATOR_645933] X X X
SAC BDI questionna ire4 X
SAC TDI questionnaire4 X X X
SGRQ -C questionnaire [ADDRESS_865020]/ER -S: COPD 5
Patient Global Rating of COPD severity X X X X
Patient Global Rating of Change in COPD X X X
Safety assessments
Adverse events/Serious adverse events6 X X X X X X X X
COPD exacerbation assessment X X X X X X X X
12-Lead ECG X
Urine pregnancy test 7 X X X X
Pharmacogenetic sample8                                             X
Medication/Supplies
Dispense rescue albuterol/slabutamol. Dispense MDI9 X X X X X
Assess COPD medication compliance10 during run -in X
Dispense eDiary X
Assess compliance with eDiary d uring run -in X
Collect rescue albuterol/slabutamol. X X X X X
Collect eDiary X X
Dispense study treatment11 X X X
Collect study treatment X X X X 
 
 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
45Blinded Treatment
VisitPre-
screen1
0Screen/ 
Run-in
1Rando -
mization 
[ADDRESS_865021] 
6
Week -6 to -4 -4 0 4 12 24
Day42 -7/+2
days 
prior 
Visit 128 -7/+2 
days prior 
Visit 21-7/+2 
days28-7/+2 
days 84 -7/+2 
days168 -7/+2
days73days after V5 or 
EW Visit
Assess study treatment compliance during treatment10 X X X X
Study sub -set
Physical activity monitor12 X X X X
Collect Physical activity monitor X X
1. Pre-screen Visit [ADDRESS_865022] be completed prior to Screening Visit1. It can be completed 2 weeks prior or on the same day of V1, if no wash ou t of exclusionary medications is 
required. 
2. Early Withdrawal Visit: Subjects that withdraw should return to the clinic as soon as possible to complete the Early Withdraw al Visit procedures.
3. Spi[INVESTIGATOR_645934] (Secti on [IP_ADDRESS] ). 
4. SAC BDI, SAC TDI, SGRQ- C, CAT questionnaires will be completed at clinic visits and in the eDiary
5. EXACT/ER -S: COPD is completed daily in the eDiary approximately 2 hours before bed -time, starting o n Day 1 of the run -in period.
6. For the start date of collecting AEs and SAEs see ( Appendix 4 )
7. Pregnancy test: for females for child bearing potential only.
8. Pharmacogenetic sample may be drawn at visit [ADDRESS_865023] provide informed 
consent to the study participant.  Subjects can perform the Pre- screening Visit (Visit 0) 
up to 2 weeks prior to or on the same day  as the Screening Visit (Visit 1) if subject does 
not take or has not taken any  protocol excluded medications.
Modification of the subject’s medications prior to study  participation is based on the 
physician’s judgment according to sound medical practice, principles, and each subject’s 
needs.  A subject’s treatment must not be changed merel y for the purpose of enabling the 
subject’s participation in the study .  A subject number will be assigned at the time the 
informed consent form (ICF) is signed. No study related procedures may be 
performed until the informed consent form document has been signed by [CONTACT_1560].  
Once the informed consent is signed and if requir ed, changes can be made to the subject’s 
current medication regimen. The investigator should exercise clinical judgment, and is 
discouraged from changing medications only  for the purpose of the clinical study . 
During the pre -screening Visit 0, the follow ing information is collected:
Demographic parameters: y ear of birth, gender, race and ethnicity
Concomitant medications review
COPD exacerbation assessment
From the pre -screening visit onwards concomitant medications, exacerbations and SAEs 
(considered as related to study  participation) must be reported
7.2.2. Critical procedures performed at Screening (Visit 1)
The following critical assessments will be conducted at Visit 1:
Cardiovascular medical history /risk factors (as detailed in the eCRF) will be 
assessed at screening
Medical history  including COPD (including date of diagnosis and COPD ty pe 
(emphy sema and/or chronic bronchitis), smoking history , COPD exacerbation 
history , smoking status and previous and/or current medical conditions) 
Concomitant medication r eview (COPD and non COPD medications in the 3 
months prior to Screening).
Height and weight
12-Lead ECG. (Note: ECG is performed at screening Visit [ADDRESS_865024] for eligibility  
only. See Section 7.4.4). 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
47Urine pregn ancy  test if applicable
Train subject on the use of eDiary
COPD assessment test (CAT) and patient global rating of COPD severit y in 
eDiary
Pre-and post -albuterol/salbutamol spi[INVESTIGATOR_038]  (reversibility , see Section [IP_ADDRESS] )
Inclusion/Exclusion criteria assessment
Review exacerbations, AEs, (SAEs if related to study  participation)
Train subject on the proper use of their COPD medication inhalation devices
Instruct subject to take their COPD medications as instructed and to enter the time 
they take their medication in the eDiary
Dispense rescue medication
Medical history will be assessed as related to the inclusion/exclusion criteria listed in 
Section 5.1and Section 5.2.
Assessment of subject’s health status will be made at screening using CAT.  PRO 
questionnaires should be completed b y subjects before an y other assessments at a clinic 
visit, in the order specified in Section 7.3.1
[IP_ADDRESS]. Albuterol/Salbutamol Reversibility  Assessment
At Visit 1, both pre -and post -albuterol/salbutamol spi[INVESTIGATOR_645935] .  Reversibility  assessment should be performed as follows:
Perform pre -bronchodilator spi[INVESTIGATOR_645936] 1and FVC
Subject to self -administer 4 Inhalations (4X100 g) of albuterol/salbutamol MDI
Perform post -bronchodilator spi[INVESTIGATOR_645936] 1and FVC approximately  
10 to 30 minutes after albuterol/salbutamol administration
The results of the spi[INVESTIGATOR_645937]/ERS criteria [ Miller , 2005] for 
the subject to continue in the study .
7.2.3. Critical procedures performed at first treatment Visit (Baseline 
V2)
Review and assess  compliance with subject’s COPD medications during the run -
in period
Review and assess compliance with completing the eDiary during the run -in 
period
Review AEs, SAEs and exacerbations 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
48Urine pregnancy  test, if applicable
Baseline d yspnea Index, BDI, patient global rating of COPD severit y, patient 
global rating of change in COPD, SGRQ -C and CAT questionnaires in eDiary
Review randomization criteria (Section 5.3)
Register and randomize subject in RAMOS NG
Pre-dose spi[INVESTIGATOR_038] ; IC and FEV 1
Train subject on the proper use of ELLIPTA and DI SKUS inhalers
Dispense study  medication
Dispense rescue medication
Optional pharmacogentic sample can be collected at V2 or an y visit after.
7.3. Efficacy  Assessments
7.3.1. HRQoL assessments: Completion of PRO questionnaires in the 
Electronic Diary
All subjects will be completing PRO questionnaires in the eDiary . 
It is requested that questionnaires are completed before an y procedures are performed on 
the subject. 
All questio nnaires will be completed using the eDiary at clinic and at home.  Adequate 
time should be allowed to complete all items of the questionnaires and the questionnaires 
must be reviewed b y the investigator or designated study  staff for completeness and, if 
necessary , the subject must be encouraged to complete any  missing items. Where more 
than one questionnaire is to be completed at a visit the order should be as follows:
1.Baseline d yspnea index (Visit 2) then Transient dy spnea index at subsequent 
visits
2. Patien t global rating of COPD severit y and global rating of change in COPD
3.St George’s respi[INVESTIGATOR_645938]
4. COPD Assessment Test 
Instructions for completing the questionnaires can be found in the SRM.
[IP_ADDRESS]. Self A dministered Computerised Baseline Dy spnea Index/T ransitional 
Dyspnea Index (SA C BDI/TDI)
The BD I is used to measure the severity of d yspnea in patients at baseline. The TDI 
measures changes in the patient’s dyspnea from baseline.  The self -administered 
computerized version of the BDI/TDI (SAC BDI/TDI)[ Mahler , 2004] is used to measure 
severit y of d yspnea in patients at baseline (SAC BDI) on Day  1 (Visit 2) of treatment and 
change from the baseline (SAC TDI) at Week 4, 12 and 24 (Visits 3, 4 and 5).  The  2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
49scores in both indexes depend on ratings for three different categories: functional 
impairment; magnitude of task, and magnitude of effort. SAC BDI/TDI should be 
completed before performing spi[INVESTIGATOR_038] . 
The SAC BDI/TDI was developed to address issues of potential bias in the interviewer 
administered (original) BDI /TDI [ Mahler , 1984].  The SAC BDI/TDI provides a 
standardized approach to the measurement of d yspnea, equivalent to the original 
BDI/TDI with advantages over the interview er method for grading d yspnea in patients 
with COPD by  [CONTACT_646008] b y the interviewers when completing the original BDI/TDI. This also 
removes the need for the same investigator to conduct all interviews with a subject based 
on the patient’s responses. SAC TDI  provides a continuous measure of change in dy spnea 
using a visual analogue scale to record responses. 
Details for the completion of the SAC BDI/TDI are provided in the SRM.
[IP_ADDRESS]. SGRQ-C
The St George’s Respi[INVESTIGATOR_6015] -Chronic Obstructive Pulmonary  Disease 
specific (SGRQ -C) will be completed by  [CONTACT_646009] (V2, Day  1), at Week 
4, 12 and 24 or at the Early  Withdrawal Visit (where applicable).
The SGRQ- C [Meguro , 2007] is a well established, disease -specific questionnaire.  It was 
designed to measure the impact of respi[INVESTIGATOR_496926] a COPD 
patient’s HRQoL.  As well as producing an overall summary score, sco res for the 
individual domains of symptoms, activity  and impacts are also produced.  It has been 
used in studies of COPD subjects and has been translated and validated for use in most 
major languages.  The SGRQ- C is derived from the original SGRQ, and prod uces scores 
equivalent to the SGRQ instrument [ Meguro , 2007].  
[IP_ADDRESS]. COPD A ssessment Test (CA T)
The COPD Assessment Test [ Jones, 2009, Jones, 2012] is a validated, short and simple 
patient completed questionnaire which has been developed for use in routine clinical 
practice to measure the health status of patients with COPD.  The CAT is an 8- item 
questionnaire suitable for completion by  [CONTACT_646025].  When 
completing the questionnaire, subjects rate their experience on a 6 -point scale, ranging 
from 0 (no impairment) to 5 (maximum impairment) with a scoring range of [ADDRESS_865025].
The CAT will be c ompleted in the eDiary  by [CONTACT_646026] 1 and 
Randomisation Visit 2 to assess their eligibility  to enter the stud y.  CAT is also 
completed at Weeks 4, 12 and 24 .  Additional instructions for completion of the CAT are 
provided in the SRM. 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
[IP_ADDRESS]. EXACT and the Evaluating Respi[INVESTIGATOR_244774] -COPD (E -RS: 
COPD)
EXACT -PRO is a 14 item patient reported outcome instrument designed to capture 
information on the occurrence, frequency , severity , and duration of exacerbations of 
disease in patients with COPD [ Leidy, 2011].  EXACT captures information on the 
severit y of the respi[INVESTIGATOR_69908] s ystemic manifestations of a COPD exacerbation as 
reported b y the patient.  The instrument is to be completed daily  (typi[INVESTIGATOR_897] 2 hrs before 
bedtime) using the electronic diary .  The daily  recording of information allows an 
assessment of the underlying day  to day  variability  of a patient's s ymptoms and facilitates 
the detection of s ymptom worsening indicative of a COPD exacerbation.  The tot al score 
for EXACT ranges from 0 -100.  The entire instrument is intended to be completed in 
about 3 minutes or less (typi[INVESTIGATOR_645940] ).
The E- RS: COPD consists of [ADDRESS_865026] instrument [ Leidy, 
2014].  E -RS: COPD is intended to capture information related to the respi[INVESTIGATOR_244853], i.e. breathlessness, cough, sputum production, ch est congestion and 
chest tightness.  The E -RS: COPD has a scoring range of 0 -40 higher scores indicate 
more severe s ymptoms.
Three subscales of the E -RS are used to describe different s ymptoms; dy spnea, cough and 
sputum and chest sy mptoms.
The EXACT questi onnaire will be completed b y subjects in the eDiary , at home every  
night throughout the entire study , starting from Screening V1 
[IP_ADDRESS]. Subject Global Rating of COPD Severity  and Global Rating of Change 
in COPD
Subjects will complete the Global Rating of COPD Se verity at Randomization Visit 2 
and visits 3, 4 and 5 or Early  Withdrawal Visit.  This single global question will ask 
subjects to rate their severity  of COPD on a four point scale (mild, moderate, severe, and 
very severe).
This question should be used im mediately  before the patient completes other visit 
specific questionnaires but after completion of SAC TDI  questionnaire. 
Subjects will also complete a Global Rating of Change in COPD (overall disease) 
question at Visits 3, 4 and 5 or Earl y Withdrawal Vis it.  Response options will be on a 7 
point L ikert scale ranging from much better to much worse.  Completing the question at 
each Visit allows for early detection of response as well as continued response.
7.3.2. Spi[INVESTIGATOR_645964] [ Miller , 2005]. All sites 
will use standardized spi[INVESTIGATOR_645942]. 2018N377698_00
2016N277425_01 CONFIDENTIA L
[ADDRESS_865027] spi[INVESTIGATOR_645943]  (see Section 
[IP_ADDRESS] ) and at Visits 2, 3, [ADDRESS_865028] 3 acceptable spi[INVESTIGATOR_496921] (with no 
more than 8) should be obtained. Acceptable spi[INVESTIGATOR_496922] a satisfactory  
start of test and end of test (i.e. a plateau in the volume time curve) and be free from 
artifacts due to cough, early termination, poor effort, obstructed mouthpi[INVESTIGATOR_13959], equipment 
malfunction, or other reasons [ Miller , 2005].
The largest FEV1and FVC from the 3 acceptable efforts should be recorded, even if they  
do not come from the same effort.
Spi[INVESTIGATOR_645944] 1and FVC assessments that is not obtained as follows will be 
considered a protocol deviation:
Started between 6:00AM and 11:00AM.
After withholding albuterol/salbutamol (all visits) for ≥4 hours
At Screening Visit 1, after wash out of medications as specified in the exclusion 
criteria in Section 5.2(Concomitant Medications).
At Screening Visit 1, before the morning dose of usual COPD medications
At Visit [ADDRESS_865029] dose 
of study  treatment 
At Visit 3, 4 and 5 after withholding the morning dose of study  treatment.
Pre dose assessment performed prior dosing.
Subjects should refrain from smoking for [ADDRESS_865030].
Trough FEV 1measure ments for UMC/VI  or UMEC on Weeks 4, 12 and 24 (Visits 3, 4 
and 5) should be performed 23 hours and 24 hours after the previous day ’s dose of study  
medication recorded in the eDiary . This will also provide trough FEV 1measurements for 
the evening dose of s almeterol. 
7.3.3. Inspi[INVESTIGATOR_359371]  (IC)
Inspi[INVESTIGATOR_645920] y (IC) is the volume of gas that can be taken into the lungs in a normal 
and full inhalation. Starting from the resting inspi[INVESTIGATOR_645975].  IC has been widel y used to assess static and 
dynamic h yperinflation in patients with COPD.
IC will be measured b y spi[INVESTIGATOR_645946] -dose at Visits 2 (30 
and 5 min prior to dosing) and at trough at Visits 3, 4, and 5 ([ADDRESS_865031] dosing 
on the previous day ). For I C determination the average of at least three acceptable 
manoeuvres should be recorded.  Subjects should be tested while sitting, relaxed and 
wearing a nose clip.  They should be asked to breathe regularl y for several breaths until 
the end- expi[INVESTIGATOR_645947] (this usually  requires at least three tidal 
manoeuvres) then urged to take a deep breath to Total L ung Capacit y (TLC) with no 
hesitation. 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
52Spi[INVESTIGATOR_645948] 1and FVC assessments 
that is not obtained as follows will be considered a protocol deviation:
Started between 6:00AM and 11:00AM.
After withholding albuterol/salbutamol (all visits) ≥4 hours 
At Visit 2 after discontinuation of run -in medication
At Visit 3, 4 and 5 after withholding the morning dose of study  drug 
7.3.4. COPD Exacerbation
A mild exacerbation is defined as worsening of s ymptoms that require no treatment with 
antibiotics or steroids, and is self managed b y the patient by [CONTACT_646010]. A moderate COPD exacerbation is defined as worsening s ymptoms of 
COPD that require treatment with oral/sy stemic co rticosteroids and/or antibiotics. A 
severe exacerbation is defined as worsening s ymptoms of COPD that require in- patient 
hospi[INVESTIGATOR_645949] [ADDRESS_865032] for the patient to withdraw from the study.
Signs and s ymptoms of COPD included on the electronic diary  cards will not be 
considered AEs and will not be recorded in the eCRF.
The time period for collection of COPD exacerbations will be from the Pre -Screen ing 
(Visit 0) until completion of the follow -up contact.  If a subject experiences a COPD 
exacerbation from the time the I CF is signed until randomization, summary  information 
(yes/no status question) will be collected in the eCRF. COPD exacerbations after
randomization through follow -up will be recorded on the COPD exacerbation page of the 
eCRF.
7.3.5. Clinically  important deterioration (CID)
Clinically  important deterioration (CID) is a composite endpoint defined as:
A decrease of  100 mL  from baseline in trou gh FEV 1 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
53A deterioration in HRQoL defined as 4 units increase from baseline in 
SGRQ
The occurrence of an on -treatment moderate/severe COPD exacerbation
In addition, this study will explore CAT and TDI  PROs as part of the composite 
endpoint.
7.3.6. Rescue albuter l/salbutamol use
Subjects will record the number of dail y albuterol/salbutemol puffs they  use in the 
eDiary .  In addition, in some countries and selected sites the number of puffs will be 
collected through the eMDI device (Section 6.2) 
7.3.7. Physical activity monitor (study subset)
Physical activity  limitation is a common feature of COPD and its measures are highl y 
related to the degree of disease severity  [Watz , 2009]. 
Reduced phy sical activity  levels in COPD is associated with increased morbidity  and 
mortality , sustained disability , depression, and social and phy sical isolation [ Shu-Yi, 
2014; Gimeno, 2014] 
Improved activity  has been identified as an important factor that may  modify  morbidity  
and mortality  in COPD [ Moy , 2012 ].
The Actigraph GT9X phy sical activity  monitor will be used to measure levels of activity . 
The activity  monitor will be worn by  [CONTACT_422906]  150 subjects per treatment arm
for 7 day s from Screening (Visit 1), for 7 day s from Randomisation (Visit 2), 7 day s from 
Visit 3 (Week 4) and for 7 day s prior to Week 24 (Visit 5).
There will be [ADDRESS_865033] will be given an activity  
monitor and instruction leaflet at the start of each assessment period. Further details of 
distrib ution, operation and retrieval of the monitors will be provided in the SRM .
7.4. Safet y
Planned time points for all safety  assessments are listed in the Time and Events Table 
(Section 7.1)
Safety  endpoint includes:
Incidence of adverse events
7.4.1. Adverse Events (A E) and Serious A dverse Events (S AEs)
The definitions of an AE or SAE can be found in Appendix 4 . 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
54The investigator and their designees are responsible for detecting, documenti ng and 
reporting events that meet the definition of an AE or SAE. 
[IP_ADDRESS]. Time period and Frequency  for collecting A E and SA E information
Any SAEs assessed as related to study  participation (e.g., protocol- mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] 
product will be recorded from the time a subject consents to participate in the 
study  up to and including any  follow -up contact. 
AEs will be collected from the start of Study  Treatment until the follow -up 
contact (see Sectio n [IP_ADDRESS] ), at the timepoints specified in the Time and Events 
Table (Section 7.1).
Medical occurrences that begin prior to the start of study treatment but after 
obtaining informed consent may  be recorded on the Medical History /Current 
Medical Conditions section of the CRF.
All SAEs will be recorded and reported to [COMPANY_004] within 24 hours, as indicated in 
(Appendix 4 , Section 12.4.6 )
Investigators are not obligated to activel y seek AEs or SAEs in former study 
subjects. However, if the investigator learns of an y SAE, including a death, at an y 
time after a subject has been discharged from the study , and he/she considers the 
event reasonabl y related to the study  treatment or study  participation, the 
investigator must promptly  notify  [COMPANY_004].
NOTE: The method of recording, evaluating and assessing causality  of AEs and SAEs 
plus procedures for completing and transmitting SAE reports to [COMPANY_004] are provided in 
(Appendix 4 , Section 12.4.4 to Section 12.4.6 )
[IP_ADDRESS]. Method of Detecting AEs a nd SA Es
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended 
and non-leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrence.  Appropriate questions include:
“How are you feeling?”
“Have you had an y (other) medical problems since y our last visit/contact
 “Have you taken an y new medicines, other than those provided in this study , 
since y our last visit/contact?
[IP_ADDRESS]. Follo w-up of A Es and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
subject at subsequent visits/contacts.  All SAEs, and non -serious AEs of special interest 
(as defined in Section 4.6.1 ) will be followed until resolution, until the condition
stabilizes, until the event is otherwise explained, or until the subject is lost to follow-up 
(as defined in Section 5.5).  2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
[IP_ADDRESS]. Pneumonia Events
Investigators will be required to fill out a pneumonia event specific eCRF within one 
week of when the pneumonia AE/SAE(s) is first reported. 
[IP_ADDRESS]. Cardiovascular and Death Events
For an y cardiovascular events detailed in (Section 12.4.3) and all deaths, whether or not 
they are consid ered SAEs, specific Cardiovascular (CV) and Death sections of the CRF 
will be required to be completed. These sections include questions regarding 
cardiovascular (including sudden cardiac death) and non- cardiovascular death. 
The CV CRFs are presented as queries in response to reporting of certain CV MedDRA 
terms. The CV information should be recorded in the specific cardiovascular section of 
the CRF within one week of receipt of a CV Event data query  prompting its completion. 
The Death CRF is provided immediately  after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed within one 
week of when the death is reported.
[IP_ADDRESS]. Disease- Related Events and/or Disease -Related Outcomes Not 
Qualify ing as SA Es
The following disease related events (DREs) are common in subjects with COPD and can 
be serious/life threatening:
COPD exacerbation
COPD exacerbations are associated with the disease to be studied and will not be 
recorded as AEs unless the exacerbation meet s the definition of a ‘serious’ AE. 
Exacerbations that meet the definition of ‘serious’ AEs will be recorded on the 
appropriate eCRF section and should be reported to [COMPANY_004] for all subjects regardless of 
whether or not they  are randomized to study  medication . Signs and s ymptoms of COPD 
included on the electronic diary  will not be considered AEs and will not be recorded in 
the eCRF
[IP_ADDRESS]. Regulatory  Reporting Requirements for SA Es
Prompt notification by  [CONTACT_646027] (even
for non -interventional post -marketing studies) is essential so that legal obligations and 
ethical responsibilities towards the safet y of subjects and the safety of a product under 
clinical investigation are met. 
[COMPANY_004] has a legal responsibility  to notify  both the local regulatory  authorit y and other 
regulatory  agencies about the safet y of a product under clinical investigation.  [COMPANY_004] will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the 
regulatory  authority, Instituti onal Review Board (IRB)/Independent Ethics Committee 
(IEC) and investigators. 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
56Investigator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and [COMPANY_004] policy  and are forwarded 
to investigators as necessary .
An investigator who receives an investigator safety report describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from [COMPANY_004] will file it with 
the IB and will notify  the I RB/IEC, if appropriate accord ing to local requirements.
7.4.2. Pregnancy
Details of all pregnancies in female subjects will be collected after the start of 
Screening and until the follow -up contact. 
If a pregnancy  is reported then the investigator should inform [COMPANY_004] within 2 
weeks of learnin g of the pregnancy  and should follow the procedures outlined in 
Appendix 7 .
7.4.3. Medical Device Incidents (Including Malfunctions)
Procedures for documenting medical device incidents are provided in Appendix 6 .
7.4.4. Electrocardiogram (ECG)
A Single 12- lead ECG will be obtained at Screening using an ECG machine provided by  
[CONTACT_646011], QRS, 
QT, and QTc intervals.
The 12- lead ECG measurement and rh ythm strip (10 seconds) will be obtained before 
spi[INVESTIGATOR_496914]. ECG measurement should be obtained after subjects have rested for 
approximately  [ADDRESS_865034] provide his/her dated signature [CONTACT_24003], attesting to the authenticity  of the ECG machine interpretation. 
7.5. Genetics
Information regarding genetic research is included in Appendix 3
8. DATA MANAG EMENT
For this study  subject data will be entered into [COMPANY_004] defined CRFs, transmitted 
electronically  to [COMPANY_004] or designee and combined with data provided from other 
sources in a validated data sy stem.  
Management of cl inical data will be performed in accordance with applicable 
[COMPANY_004] standards and data cleaning procedures to ensure the integrit y of the data, 
e.g., removing errors and inconsistencies in the data. 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
57Adverse events and concomitant medications terms will be code d using MedDRA 
(Medical Dictionary  for Regulatory  Activities) and an internal validated 
medication dictionary , [COMPANY_004]Drug.  
CRFs (including queries and audit trails) will be retained b y [COMPANY_004], and copi[INVESTIGATOR_645981] y.  Subject initials 
will not be collected or transmitted to [COMPANY_004] according to [COMPANY_004] policy .
9. STATISTICA L CONSIDER ATIONS AND DA TA 
ANALYSES
9.1. Hypotheses
The primary  purpose of this study  is to demonstrate improvements in lung function for 
subjects tre ated with UMEC/VI  compared with UMEC for 24 weeks. 
The primary  endpoint is change from baseline in trough FEV 1at Week 24.
The null hy pothesis is no difference between treatment groups (H0: μT – μS = 0), with 
the alternative h ypothesis that there is a difference between treatment groups (H1: μT –
μS ≠0), where μ T is the mean change from baseline for UMEC/VI and μS is the mean 
change from baseline for UMEC. 
9.2. Sample Size Considerations
The pr imary  endpoint is change from baseline in trough FEV 1at Week 24. As an 
important aim of the study is to compare UMEC/VI, UMEC and salmeterol with respect 
to HRQoL  the sample size has been calculated to provide sufficient power for the 
comparison of the pr imary  and secondary  endpoint TDI , at Week 24.  
The sample size calculations use a two -sided 5% significance level and an estimate of 
between subject standard deviation for TDI of 2.94 units.  The estimate of SD is based on 
DB2113373 [ Donohue , 2013], a study  which consisted of treatment arms of UMEC/VI 
62.5/25, UMEC 62.5 VI (Vilanterol) 25mcg and placebo and is the value at Day  168 in a 
subgroup of subjects who were ICS free at screening.  Based on these data, 727 eva luable 
subjects per treatment arm will be required to provide 90% power to detect a statistically  
significant difference if the true difference is 0.5 units, ½ the MCI D, between UMEC/VI 
and UMEC. The smallest observed effect predicted to result in a statis tically  significant 
difference between treatment groups is 0.[ADDRESS_865035] >99% power 
assuming a true treatment difference of 80mL between UMEC/VI and UMEC for trough 
FEV1 at 24 weeks at the two-sided 5% significance level. This calculation uses a SD for 
trough FEV1 of 240mL, based on prior results for trials comparing dual bronchodilators 
versus single bronchodilators ( Donohue , 2013; Bateman , 2013). The smallest observed 
effect predicted to result in a statistically  significant difference between treatment groups 
is 25mL .  2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
58In order to account a for a 10% withdrawal rate , approximately  [ADDRESS_865036] SDTreatment Difference Power
TDI 2.54 0.5 96%
2.74 0.5 94%
2.94 0.5 90%
3.14 0.5 86%
3.34 0.5 81%
9.2.3. Sample Size Re -estimation or A djustment
No sample size re -estimation is planned for this study . 
9.3. Data Analysis Considerations
9.3.1. Analysis Populations
Population Definition / Criteria Analyses Evaluated
All 
Subjects 
Enrolled 
(ASE)All subjects for whom a record exists in the 
study  database, including screen failures and 
any subject who was not screened but 
experienced an SAE between the date of 
informed consent and the planned date of the 
Screening visit. Subject 
Disposition
Reasons for 
withdrawal prior 
to randomisation
Inclusion, 
exclusion and 
randomisation 
criteria deviations
SAEs for non-
randomised  2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
59Population Definition / Criteria Analyses Evaluated
subjects
Intent -to-
treat (ITT)All randomized subjects, excluding those who 
were randomized in error and received at least 
one dose of stud y medication. A subject who 
is recorded as a screen or run- in failure and 
also randomized will be considered to be 
randomized in error.  Any other subject who 
receives a randomization number will be 
considered to have been randomized.
Display s will be based on the treatment to 
which the subject was randomized.Study  Population
Efficacy
Safety
Intent -to-
treat ICS 
free (ITT 
ICS free)All subjects in the I TT Population who have 
not received ICS.Study  Population
Efficacy
Safety
9.3.2. Interim Analy sis
No interim anal ysis is planned for the stud y.
9.4. Key Elements of A nalysis Plan
Treatment Comparisons
The primary  treatment comparison of UMEC/VI with UMEC will be performed on the 
ITT population.
The other treatment comparisons of UMEC/VI and UMEC with Salmeterol will be 
performed on the ITT population and ITT ICS free population.
9.4.1. Primary  Analyses
The treatment comparison of primary  interest will be UMEC/VI versus UMEC for the 
primary  endpoint of change from baseline in trough FEV 1at Week 24. The primary  
analyses will be performed using a mixed model repeated measures (MMRM) anal ysis 
and will be based on a two -sided hy pothesis testing approach on the ITT Population. 
In order to account for multiplicity  across treatment comparisons and endpoints, a step-
down closed testing procedure will be applied whereb y inference for secondary and other 
endpoints or treatment comparisons are dependent upon statistical significance having 
been achieved for the primary  comparison. If the primary  comparison is signi ficant i.e. 
the associated p-value for UMEC/VI versus UMEC for change from baseline in trough 
FEV1 at Week 24 is below 0.05, this will allow inference of treatment comparisons 
(UMEC/VI versus UMEC on all other endpoints, and UMEC/VI versus Salmeterol and 
UMEC versus Salmeterol on all endpoints including the primary  endpoint), which will be 
declared statistically  significant if the associated p -value is below 0.05.   2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
60There will be 2 anal yses one for one for the German Federal Joint Committee (G -BA) 
and one f or the rest of the world (ROW).
The step-down closed testing procedure onl y applies to the ROW.  For the G -BA 
statistical inference for secondary  and other endpoints or treatment comparisons will not 
be conditional on achieving statistical significance of the primary  comparison.  
The primary  endpoint of mean change from baseline in trough FEV1 at the end of Week 
24 and secondary  endpoint change from baseline in TDI score at Week 24 will both be 
analysed using MMRM analy sis. The MMRM analy sis for change fro m baseline in 
trough FEV1 and TDI will include measurements at Treatment Weeks 4, 12 and 24. 
Treatment group (a categorical variable) will be fitted as the explanatory  variable with 
appropriate pre -defined variables, stratum (number of bronchodilators per day during 
run-in) and baseline values, fitted as covariates. Visit (nominal) will be fitted as a 
categorical variable and visit- by-baseline and visit -by-treatment interaction terms will be 
included to allow treatment effects to be estimated at each visit separatel y. The variance 
covariance matrix will be assumed to be unstructured (based on previous experience no 
issues are expected with fitting models with this matrix structure). 
While missing data are not explicitly  imputed in the primary  MMRM analy ses,there is 
an underl ying assumption that the data are missing at random. 
The estimated treatment differences between UMEC/VI versus UMEC for each endpoint 
will be presented with the 95% confidence intervals for the difference and the p -value. 
Full details of the analy ses to be performed on all primary  endpoints will be given in the 
RAP.
9.4.2. Other A nalyses
The MMRM anal ysis will be repeated for the ITT ICS free population. Estimated 
differences between UMEC/VI  or UMEC and Salmeterol will be presented together w ith 
95% confidence intervals (CI s) for the difference and p- values.
Secondary  and other efficacy  endpoints and treatment comparisons will be adjusted for 
multiplicity  as per Section 9.4.1 .
Full details of the an alyses to be performed on the other efficacy  endpoints will be given 
in the RAP.
Safety Analyses
Adverse events (AEs) will be coded using the standard [COMPANY_004] dictionary , Medical
Dictionary  for Regulatory  Activities (MedDRA), and grouped by  [CONTACT_44749]. The 
number and percentage of subjects experiencing at least one AE of an y type, AEs within 
each bod y system and AEs within each preferred term will be presented for each 
treatment group. Separate summaries will be provided for all AEs, drug related AEs, fatal 
AEs, non -fatal SAEs, AESI s and AEs leading to withdrawal.  2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
61Deaths and SAEs will be documented in case narrative format. 
Full details of the analy ses to be performed on all safet y endpoints will be given in the 
RAP.
10. STUDY GOVERNANCE CON SIDERATIONS
10.1. Posting o f Information on Publicly  Available Clinical Trial 
Registers
Study  information from this protocol will be posted on publicly  available clinical trial 
registers before enrollment of subjects begins.
10.2. Regulatory  and Ethical Considerations, Including the 
Informed Consent Process
Prior to initiation of a site, [COMPANY_004] will obtain favourable opi[INVESTIGATOR_1649]/approval from the 
appropriate regulatory  agency  to conduct the study in accordance with I CH Good Clinical 
Practice (GCP) and applicable country -specific regulatory requirements.
The study  will be conducted in accordance with all applicable regulatory  requirements, 
and with [COMPANY_004] policy .
The study  will also be conducted in accordance with I CH Good Clinical Practice (GCP), 
all applicable subject privacy  requirements, and the guiding principles of the current 
version of the Declaration of Helsinki.  This includes, but is not limited to, the following:
IRB/IEC review and favorable opi[INVESTIGATOR_1649]/approval of the study  protocol and 
amendments as applicable
Obtaining signed informed conse nt
Investigator reporting requirements (e.g. reporting of AEs/SAEs/protocol 
deviations to I RB/IEC)
[COMPANY_004] will provide full details of the above procedures, either verball y, in writing, 
or both.
Signed informed consent must be obtained for each subject prior to participation 
in the study
The IEC/I RB, and where applicable the regulatory authority, approve the clinical 
protocol and all optional assessments, including genetic research.  
Optional assessments (including those in a separate protocol and/or under se parate 
informed consent) and the clinical protocol should be concurrentl y submitted for 
approval unless regulation requires separate submission.  
Approval of the optional assessments may  occur after approval is granted for the 
clinical protocol where requ ired b y regulatory  authorities.  I n this situation, 
written approval of the clinical protocol should state that approval of optional  2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
62assessments is being deferred and the study , with the exception of the optional 
assessments, can be initiated.
10.3. Qualit y Control (Study  Monitoring)
In accordance with applicable regulations including GCP, and [COMPANY_004] procedures, 
[COMPANY_004] monitors will contact [CONTACT_288627], study  requirements, and their responsibilitie s to satisfy  
regulatory , ethical, and [COMPANY_004] requirements.  
When reviewing data collection procedures, the discussion will also include 
identification, agreement and documentation of data items for which the eCRF
will serve as the source document.
[COMPANY_004] will m onitor the study  and site activity  to verify  that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accordance with the currently  approved protocol and any  
other study  agreements, GCP, and all applicable regulatory  requirements.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents
10.4. Qualit y Assurance
To ensure compliance with GCP and all applicable regulatory  requirements, [COMPANY_004] 
may conduct a quality  assurance assessment and/or audit of the site records, and 
the regulatory  agencies may  conduct a regulatory inspection at any  time during or 
after completion of the study . 
In the event of an assessment, a udit or inspection, the investigator (and institution) 
must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to all 
relevant documents and to allocate their time and the time of their staff to discuss 
the conduct of the stud y, any f indings/relevant issues and to implement any  
corrective and/or preventative actions to address any  findings/issues identified.
10.5. Stud y and Site Closure
Upon completion or premature discontinuation of the study , the [COMPANY_004] monitor will 
conduct site closure activ ities with the investigator or site staff, as appropriate, in 
accordance with applicable regulations including GCP, and [COMPANY_004] Standard 
Operating Procedures.
[COMPANY_004] reserves the right to temporaril y suspend or prematurel y discontinue this 
study  at an y time for r easons including, but not limited to, safety  or ethical issues 
or severe non -compliance. For multicenter studies, this can occur at one or more 
or at all sites.  
If [COMPANY_004] determines such action is needed, [COMPANY_004] will discuss the reasons for taking 
such action with the investigator or the head of the medical institution (where  2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
63applicable).  When feasible, [COMPANY_004] will provide advance notification to the 
investigator or the head of the medical institution, where applicable, of the 
impending action.
If the stud y is su spended or prematurely  discontinued for safet y reasons, [COMPANY_004] will 
promptly  inform all investigators, heads of the medical institutions (where 
applicable) and/or institution(s) conducting the study . [COMPANY_004] will also promptly  
inform the relevant regulatory  autho rities of the suspension or premature 
discontinuation of the study  and the reason(s) for the action.  
If required b y applicable regulations, the investigator or the head of the medical 
institution (where applicable) must inform the I RB/I EC promptl y and provide the 
reason for the suspension or premature discontinuation.
10.6. Records Retention
Following closure of the study , the investigator or the head of the medical 
institution (where applicable) must maintain all site study  records (except for 
those required b y local regulations to be maintained elsewhere), in a safe and 
secure location.  
The records must be maintained to allow eas y and timely  retrieval, when needed 
(e.g., for a [COMPANY_004] audit or regulatory  inspection) and must be available for review 
in conjunctio n with assessment of the facilit y, supporting s ystems, and relevant 
site staff.  
Where permitted b y local laws/regulations or institutional policy, some or all of 
these records can be maintained in a format other than hard cop y (e.g., microfiche, 
scanned, electronic); however, caution needs to be exercised before such action is 
taken.  
The investigator must ensure that all reproductions are legible and are a true and 
accurate cop y of the original and meet accessibility and retrieval standards, 
including r e-generating a hard cop y, if required.  Furthermore, the investigator 
must ensure there is an acceptable back -up of these reproductions and that an 
acceptable qualit y control process exists for making these reproductions.
[COMPANY_004] will inform the investigator o f the time period for retaining these records to 
comply  with all applicable regulatory  requirements.  The minimum retention time 
will meet the strictest standard applicable to that site for the study, as dictated by 
[CONTACT_65406], [COMPANY_004] 
standards/procedures, and/or institutional requirements.  
The investigator must notify  [COMPANY_004] of any  changes in the archival arrangements, 
including, but not limited to, archival at an off- site facility  or transfer of 
ownership of th e records in the event the investigator is no longer associated with 
the site. 2018N377698_00
2016N277425_01 CONFIDENTIA L
[PHONE_13419].7. Provision of Study  Results to Investigators, Posting of 
Information on Publically  Available Clinical Trials Registers 
and Publication
Where required b y applicable regulatory  requirements, an investigator signatory  will be 
identified for the approval of the clinical study  report.  The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity  to review the com plete study  results at a [COMPANY_004] site or other mutually -
agreeable location.
[COMPANY_004] will also provide the investigator with the full summary  of the stud y results.  The 
investigator is encouraged to share the summary  results with the study  subjects, as 
appropriate.
[COMPANY_004] will provide the investigator with the randomization codes for their site only  after 
completion of the full statistical analy sis.
The procedures and timing for public disclosure of the results summary  and for 
development of a manuscript for publicatio n will be in accordance with [COMPANY_004] Policy .
A manuscript will be progressed for publication in the scientific literature if the results 
provide important scientific or medical knowledge. 2018N377698_00
2016N277425_01 CONFIDENTIA L
[PHONE_13440]. REFERENCES
Bateman ED, Ferguson GT, Barnes N et al. Dual bronchodilatio n with QVA149 versus 
single bronchodilation therap y: The SHINE study . Eur Respir J. 2013 Dec; 42:1484 -94
Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: 
a summary  of the ATS/ERS position paper. Eur Respir J. 2004; 23:93 2-946.
Chen H, Yu KD, Xu GZ. Association between Variant Y402H in Age- Related Macular 
Degeneration (AMD) Susceptibility  Gene CFH and Treatment Response of AMD: A 
Meta -Anal ysis. PloS ONE 2012; 7: e42464
Dahl R, Chung KF, Buhl R et al. Efficacy  of a new once -daily  long -acting inhaled β2 -
agonist indacaterol versus twice- daily formoterol in COPD. Thorax 2010, 65:473 -479.
Donohue JF, Maleki -Yazdi MR, Kilbride S, et al.  Efficacy  and safet y of once -daily 
umeclindinium/vilanterol 62.5/25mcg in COPD.  Respir Med 20 13; 107: 1538-1546.
European Medicines Agency  (EMA) . Guidelines on clinical investigation of medicinal 
productsin the treatment of chronic obstructive pulmonary  disease (COPD). 
EMA/CHMP/48353572 , 2012.
Feldman G, Maltais F, Khindri S, et al.  A randomized blinded study  to evaluate the 
efficacy  and safet y of umeclidinium 62.5 g compared with tiotropi[INVESTIGATOR_1890] 18 g in patients 
with COPD.  I nternational Journal of COPD 2016; 11: 719 -730
Feldman G, Siler T, Prasad N et al. Efficacy  and safet y of indacaterol 150 μg once -daily 
in COPD: a double -blind, randomised, 12- week study . BMC Pulm Med 2010, 10:11.
Gimeno- Santos E, Frei A, Steurer -Stey C, et al. Determinants and outcomes of phy sical 
activity  in patients with COPD: a sy stematic review. Thorax 2014; 0:1-9
GlaxoSmithKlineDocument Number [RM2006/[ZIP_CODE]/09, Umeclidinium ([COMPANY_004]573719) 
Investigator’s Brochure. Report Date -Aug-2016.
GlaxoSmithKlineDocument Number RM2009/[ZIP_CODE]/07, Umeclidinium + Vilanterol 
Investigator's Brochure. Re port date AUG -2015
GOLD. Global Initiative for Chronic Obstructive Lung Disease [GOLD]. Global Strategy 
for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary  
Disease. Last Updated 2015. http://www.goldcopd.org.
Gorin MB. Genetic ins ights into age -related macular degeneration: Controversies 
addressing risk, causality, and therapeutics. Mol. Asp. Med. 2012; 33: 467 -486.
Hatcher RA, Trussell J, Nelson AL, Cates W Jr, et al, editors. Contraceptive Technology . 
20th revised edition. New Yo rk: Ardent Media, 2011. 2018N377698_00
2016N277425_01 CONFIDENTIA L
[ADDRESS_865037] in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.
Jones, P., Harding, G., Berry , P., Wiklund, I ., Chen, W -H., L eidy, N. Development and 
first validation of the COPD Assessment Test (CAT) Eur Respir J, 2009; 34: 648–654
Jones, P., Harding, G., Wiklund, I ., Berry , P., Tabberer, M., Yu, R., Leidy , N. Tests of 
the Responsiveness of the Chronic Obstructive Pulmonary  Disease (COPD) Assessment 
Test (CAT) Following Acute Exacerbation and Pulmonary  Rehabilitation Chest, 2012, 
142 134 -140
Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Dény  P, Gault E.  Quantifi cation 
of Hepatitis Delta Virus RNA in Serum by  [CONTACT_31861] -Time PCR I ndicates 
Different Patterns of Virological Response to Interferon Therap y in Chronically  Infected 
Patients.  J Clin Microbiol. 2005;43(5):2363– 2369. 
Leidy NK, Sexton CC, Jones PW, No tte SM. et al. Measuring respi[INVESTIGATOR_645951]: reliability  and validity  of a daily  diary . Thorax 2014; 69:5 424 -
430
Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S. Standardizing 
measurement of chronic obstructive pu lmonary  disease exacerbations. Reliability  and 
validity  of a patient- reported diary . Am J Respir Crit Care Med 2011; 183:323-[ADDRESS_865038] J, Fierro -Carrion G, et al. Development of self -administered versions 
of modified baseline and transition dy spnea indexes in COPD. J COPD 2004; 165 –[ADDRESS_865039] 1984, 85: 751-758.
Maleki -Yazdi MR, Kael in T, Richard N, Zvarich M, Church A. Efficacy  and safet y of 
umeclidinium/vilanterol 62.5/25 mcg and tiotropi[INVESTIGATOR_1890] 18 mcg in chronic obstructive 
pulmonary  disease: results of a 24- week, randomized, controlled trial. Respi[INVESTIGATOR_645952]. 2014;108:1752-60.
Maltais F, Singh S, Donald AC, Crater G, Church A, Goh AH, Riley  JH. Effects of a 
combination of umeclidinium/vilanterol on exercise endurance in patients with chronic 
obstructive pulmonary  disease: two randomized, double -blind clinical trials. Ther Adv 
Respi r Dis. 2014;8:[ADDRESS_865040]. 
2007;132:456-463
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coat es A, Crapo R, Enright 
P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacInt yre N, McKay  R,  2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
67Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J.  Standardisation of 
spi[INVESTIGATOR_038] .  Eur Respir J.  2005;26: 319-338.
Moy  ML, Weston NA, Wilson EJ , Hess ML , Richardson CR. A pi[INVESTIGATOR_645953]. Respir Med. 2012;106:1342- 50. 
Quanjer P, Stanojevic S, Cole T, Baur X., Hall G, Enright P, et al. on behalf of the ERS 
Global L ung Function Initiative.  Multi -ethnic reference values for spi[INVESTIGATOR_105221] 3 -
95 year age range: the global lung function 2012 equations. Eur Respir J, 2012; 40: 
1324 –1343.
Schmidt SA, Johansen MB, Olsen M et al. The impact of exacerbation frequency  on 
mortality  following acute exacerba tion of COPD: a registry -based cohort study . B Med J. 
Open. 2014;4: (12): e006720
Serevent product information 2003. Available from 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20236slr028_serevent_lbl.pdf
Shu-Yi Liao, Roberto Benzo et al. Physical Activity  Monitoring in Patients with Chronic 
Obstructive Pulmonary  Disease. Journal of the COPD Foundation 2014; 1: 155 -165
Siler T, Kerwin E, Sousa A, Donald A, Rehan A, Church A, Efficacy  and safet yof 
umeclidinium added to fluticasone furoate/vilan terol in chronic obstructive pulmonary  
disease: Results of two randomized studies.  Respir Med. 2015; 109:1155 -63
Singh D, Maleki -Yazdi MR, Tombs L , Iqbal A, Fah y WA, Naya I. Prevention of 
clinically  important deteriorations in COPD with umeclidinium/vilan terol. Int’l J of 
COPD, 2016; 11:1413 -1424
Tashkin DP, Fabbri LM. Long acting beta -agonists in the management of chronic 
obstructive pulmonary  disease: Current and future agents.  Respir Research, 2010; 11: 
[ADDRESS_865041] N, Mehta R, and Church, A . Umeclidinium in patients with COPD: a 
randomised, placebo -controlled study .  Eur Respir J. 2014; 43: 72–81.
Watz H, Waschki B, Meyer T, Magnussen H: Physical activity  in patients with COPD. 
Eur Respir J 2009, 33:262–272.
Wedzicha JA, Brill SE, Allinson JP, Donalson GC. Mechanism and impact of the 
frequent exacerbator phenoty pe in chronic obstructive pulmonary  disease. BMC 
Medicine, 2013; 11:181 2018N377698_00
2016N277425_01 CONFIDENTIA L
[PHONE_13441]. APPENDICES
12.1. Appendix 1: A bbreviations and Trademarks
Abbrev iations
AE Adverse Event
ALT Alanine transaminase
AST Aspartate aminotransferase
ATS American Thoracic Society
CAT COPD Assessment Test
CI Confidence Intervals
CID Clinically  important deterioration 
COPD Chronic Obstructive Pulmonary  Disease
CPK Creatine phosphokinase
CRF Case Report Form
CV Card iovascular
DPI [INVESTIGATOR_645954] I nhaler
E-RS Evaluating Respi[INVESTIGATOR_244774] -COPD  To ol
ERS European Respi[INVESTIGATOR_645955] ₁ Forced Expi[INVESTIGATOR_645956] I nitiative for Chronic Obstructive Lung Disease
[COMPANY_004] GlaxoSmithKline
IB Investigator Brochure
ICF Informed Consent Form
ICS Inhaled Corticosteroid
IEC Independent Ethics Committee
IP Investigational product
INR International normalized ratio
IRT Interactive Response Technology
ITT Intent -to-Treat
IUD Intrauterine Device
IUS Intrauterine S ystem
LABA Long Acting Beta -Agonist
LAMA Long -acting Muscarinic Receptor Antagonists
LDH Lactate deh ydrogenase
LTOT Long Term Ox ygen Therapy 2018N377698_00
2016N277425_01 CONFIDENTIA L
[ADDRESS_865042] Upper Limit of Normal
UMEC Umeclidinium ([COMPANY_004]573719)
UMEC/VI Umeclidinium & Vilanterol as a fixed dose combination
VI Vilanterol Trife nate 
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_646013] E-RS
DISKUS EXCACT
ELLIPTA
INCRUSE
SEREVENT 2018N377698_00
2016N277425_01 CONFIDENTIA L
[PHONE_13442].2. Appendix 2: Liver Safety  Required A ctions an d Follow up 
Assessments
Phase III -IV liver chemistry stoppi[INVESTIGATOR_420682] - Liver Stoppi[INVESTIGATOR_53053]- absolute ALT  8xULN
ALT Increase ALT  5xULN but <8xULN  persists for 2 weeks
ALT  3xULN but <5xULN  persists for 4 weeks
Bilirubin1, 2ALT  3xULN andbilirubin 2xULN (>35% direct bilirubin) 
INR2ALT  3xULN andINR>1.5, if INR measured
Cannot 
MonitorALT  5xULN but <8xULN and cannot be monitored weekly for  2 weeks
ALT  3xULN but <5xULN and cannot be monitored weekly for 4 weeks
Symptomatic3ALT   3xULN associated with symptoms (new or worsening) believed to be 
related to  liver injury or hypersensitivity
Required Actions and Follow up Assessments following ANY Liver Stopp ing Event
Actions Follow Up Assessments
Immediately discontinue  study treatment
Report the event to [COMPANY_004] within 24 hours
Complete the liver event CRF and complete 
an SAE data collection tool if the event also 
meets the criteria for an SAE2
Perform liver event follow up assessments 
Monitor the subject until liver chemistries 
resolve , stabilize, or return to within normal 
ranges. baseline (see MONITORING below)
Do not restart/rechallenge subject with 
study treatment. Permanently discontinue 
study treatmen t and may continue subject 
in the study for any protocol specified follow 
up assessmentsViral hepatitis serology4
Only in those with underlying chron ic 
hepatitis B at study entry (identified by 
[CONTACT_23977] B surface antigen) 
quantitative hepatitis B DNA and hepatitis 
delta antibody5.
Blood sample for pharmacokinetic (PK) 
analysis, obtained within a week after last 
dose6
Serum creatine phosphokin ase (CPK) and 
lactate dehydrogenase (LDH).
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury, or  2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
71Liver Chemistry Stoppi[INVESTIGATOR_2121] - Liver Stoppi[INVESTIGATOR_131970]:
For bilirubin or INR criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessment s within  24 
hrs
Monitor subjects twice weekly until liver 
chemistries resolve, stabilize or return to 
within normal ranges.
A specialist or hepatology consultation is 
recommended
For All other criteria:
Repeat liver chemistries (include ALT, AST, 
alkali ne phosphatase, bilirubin) and perform 
liver event follow up assessments within  24-
72 hrs 
Monitor subjects weekly until liver 
chemistries resolve, stabilize or return to 
within normal ranges.hypersensitivity, on the AE report form
Record use of concomitant medications on 
the concomitant medications report form
including acetaminophen, herbal 
remedies, other over the counter 
medications .
Record alcohol use on the liver event 
alcohol intake case report form
For bi lirubin or INR criteria:
Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti- liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG or gamma 
globulins).
Serum acetaminophen adduct HPLC 
assay (quantifies potential aceta minophen 
contribution to liver injury in subjects with 
definite or likely acetaminophen use in the 
preceding week [ James , 2009]). NOTE: 
not required in China
Liver imaging (ultrasound, magnetic 
resonance, or computerised tomography) 
and /or liver biopsy to evaluate liver 
disease; complete Liver Imaging and/or 
Liver Biopsy CRF forms.
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that subject if ALT 3xULN andbilirubin 2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations a nd suggesting liver injury. 
2. All events of ALT 3xULN andbilirubin  2xULN (>35% direct bilirubin) or ALT 3xULN andINR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR measurement is not required and the threshold value stated 
will not apply to subjects receiving anticoagulants
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)   
4. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody;  Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  Hepatitis E IgM antibody 
5. If hepatitis delta antibody assay cannot be performed,  it can be replaced with a PC R of hepatitis D RNA virus 
(where needed) [ Le Gal , 2005].
6. PK sample may not be required for subjects known to be receiving placebo or non -[COMPANY_004] comparator treatments.  
Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to 
blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the subject’s best  2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
72approximation. If the date/time of the last dose cannot be approximated OR a PK sample can not be collected in 
the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shippi[INVESTIGATOR_131971].   2018N377698_00
2016N277425_01 CONFIDENTIA L
[PHONE_13423].3. Appendix 3: Genetic Research
Genetics –Background
Naturall y occurring genetic variation may  contribute to inter -individual variability in 
response to medicines, as well as an individual's risk of developi[INVESTIGATOR_42259]. 
Genetic factors associated with disease characteristics may  also be associated with 
response to therap y, and could help to explain some clinical study  outcomes. For 
example, genetic variants associated with age- related macular degeneration (AMD) are 
reported to account for much of the risk for the condition [ Gorin , 2012] with certain 
variants reported to in fluence treatment response [ Chen, 2012]. Thus, knowledge of the 
genetic etiology  of disease may  better inform understanding of disease and the 
development of medicines. Additionally , genetic variability  may  impact the 
pharmacokinetics (absorption, distribution, metabolism, and elimination), or 
pharmacod ynamics (relationship between concentration and pharmacologic effects or the 
time course of pharmacologic effects) of a specific medicine and/or clinical outcomes 
(efficac y and/or safet y) observed in a clinical study.
Genetic Research Objectives and A nalyses
The objectives of the genetic research are to investigate the relationship between genetic 
variants and: 
Response to medicine, including an y concomitant medicines;
COP D susceptibility , severity , and progression of related conditions
Genetic data may  be generated while the study  is underway  or following completion of 
the study .  Genetic evaluations may  include focused candidate gene approaches and/or 
examination of a la rge number of genetic variants throughout the genome (whole genome 
analyses). Genetic anal yses will utilize data collected in the study  and will be limited to 
understanding the objectives highlighted above.  Analy ses may  be performed using data 
from multip le clinical studies to investigate these research objectives.
Planned anal yses and results of genetic investigations will be reported either as part of the 
clinical RAP and study  report, or in a separate genetics RAP and report, as appropriate.
Study Popul ation
Any subject who is enrolled in the study  can participate in genetic research.  Any  subject 
who has received an allogeneic bone marrow transplant must be excluded from the 
genetic research.
Study Assessments and Procedures
A key  component of successful genetic research is the collection of samples during 
clinical studies. Collection of samples, even when no a priori hypothesis has been 
identified, may  enable future genetic anal yses to be conducted to help understand 
variability  in disease and medicine response.   2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
74A 6 ml blood sample will be taken for Deox yribonucleic acid (DNA) extraction. 
A blood sample is collected at the baseline visit, after the subject has been 
randomized and provided informed consent for genetic research. Instructions for 
collecti on and shippi[INVESTIGATOR_428121]. The DNA from the blood sample may  undergo quality  control analy ses to 
confirm the integrit y of the sample. If there are concerns regarding the quality  of 
the sample, then the sam ple may  be destroy ed. The blood sample is taken on a 
single occasion unless a duplicate sample is required due to an inabilit y to utilize 
the original sample.  
The genetic sample is labelled (or “coded”) with the same stud y specific number used to 
label o ther samples and data in the study .   This number can be traced or linked back to 
the subject by  [CONTACT_132018]. Coded samples do not carry  personal 
identifiers (such as name [CONTACT_42405]). 
Samples will be stored securel y and may be kept for up to [ADDRESS_865043] 
completes the study , or [COMPANY_004] may  destroy  the samples sooner.  [COMPANY_004] or those working 
with [COMPANY_004] (for example, other researchers) will only use samples collected from the study  
for the purpose stated in this protocol and in the informed consent form.  Samples may  be 
used as part of the development of a companion diagnostic to support the [COMPANY_004] medicinal 
product.
Subjects can request their sample to be destro yed at any  time.
Informed Consent
Subjects who do not w ish to participate in the genetic research may  still participate in the 
study .  Genetic informed consent must be obtained prior to any  blood being taken.
Subject Withdrawal from Study
If a subject who has consented to participate in genetic research withdr aws from the 
clinical study  for any  reason other than being lost to follow -up, the subject will be given a 
choice of one of the following options concerning the genetic sample, if already  
collected:
Continue to participate in the genetic research in which case the genetic DNA 
sample is retained
Discontinue participation in the genetic research and destroy  the genetic DNA 
sample 
If a subject withdraws consent for genetic research or requests sample destruction for an y 
reason, the investigator must complete the appropriate documentation to request sample 
destruction within the timeframe specified b y [COMPANY_004] and maintain the documentation in 
the site study  records . 
Genoty pe data may  be generated during the study  or after completion of the study  and 
may be anal yzed during the study  or stored for future anal ysis.  2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
75If a subject withdraws consent for genetic research and genot ype data has not been 
analyzed, it will not be analy zed or used for future research.  
Genetic data that has been anal yzed at the time of withdr awn consent will 
continue to be stored and used, as appropriate. 
Screen and Baseline Failures
If a sample for genetic research has been collected and it is determined that the subject 
does not meet the entry  criteria for participation in the study , then t he investigator should 
instruct the subject that their genetic sample will be destro yed. No forms are required to 
complete this process as it will be completed as part of the consent and sample 
reconciliation process.  In this instance a sample destruction form will not be available to 
include in the site files.
Provision of Study Results and Confidentiality  of Subject’s Genetic Data
[COMPANY_004] may  summarize the genetic research results in the clinical study  report, or 
separately  and may  publish the results in sci entific journals. 
[COMPANY_004] may  share genetic research data with other scientists to further scientific 
understanding in alignment with the informed consent. [COMPANY_004] does not inform the subject, 
family  members, insurers, or employ ers of individual genoty pi[INVESTIGATOR_124619] s that are not 
known to be relevant to the subject’s medical care at the time of the study , unless 
required b y law. This is due to the fact that the information generated from genetic 
studies is generally preliminary in nature, and therefore the significance and scientific 
validity  of the results are undetermined.  Further, data generated in a research laboratory  
may not meet regulatory  requirements for inclusion in clinical care. 2018N377698_00
2016N277425_01 CONFIDENTIA L
[PHONE_13424].4. Appendix 4: Definition of and Procedures for Recording, 
Evaluating, Follow -Up and Reporting of A dverse Events
12.4.1. Definition of A dverse Events
Adverse Event Definition:
An AE is an y untoward medical occurrence in a patient or clinical investigation 
subject, temporall y associated with the use of a medicinal product, whether or not 
considered related to the medicinal product.
NOTE: An AE can therefore be an yunfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a medicinal product.
Events meeting AE definition include:
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (e.g., ECGs, radiological scans, vital signs 
measurements), including those that worsen from baseline, and felt to be clinically  
significant in the medical and scientific judgement of the investigator.
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions dete cted or diagnosed after study  treatment administration even 
though it may  have been present prior to the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected over dose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE unless this is an intentional overdose taken with possible suicidal/self -
harming intent.  This should be reported regardless of sequelae).
"Lack o f efficacy " or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE.  However, the signs and sy mptoms and/or clinical 
sequelae resulting from lack of efficacy  will be reported if they  fulfil the definition 
of an AE or SA E.
Events NOT meeting definition of an AE include:
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_646030]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s  2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
77condition.
Medical or surgical procedure (e.g., end oscopy , appendectom y): the condition that 
leads to the procedure is an AE.
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
12.4.2. Definition of Serious A dverse Events
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_428193] s/symptoms of the disease under study , 
death due to progression of disease, etc).
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, 
at any dose:
a.Results in death
b.Is life -threatening
NOTE:
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
subject was at risk of death at the time of the event.  I t does not refer to an event, which 
hypothetically  might have caused death, if it were more severe.
c.Requires hospi[INVESTIGATOR_23916]:
In general, hospi[INVESTIGATOR_5184] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appropriate in the phy sician’s 
office or out -patient setting.  Complications that occur during hospi[INVESTIGATOR_23918].  If a complication prolongs hospi[INVESTIGATOR_9236], 
the event is serious.  When in doubt as to whether “hospi[INVESTIGATOR_3094]” occurred or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen 
from baseline is not considered an AE.
d.Results in disability/incapacity
NOTE:
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions. 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
78This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea , influenza, 
andaccidental trauma (e.g. sprained ankle) which may  interfere or prevent every day 
life functions but do not constitute a substantial disruption
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in de ciding whether reporting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_23951].  These should also be considered 
serious.
Examples of such events are invasive or malignant cancers, intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood d yscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse
g. Is associated with liver injury andimpaired liver function defined as:
ALT 3xULN and total bilirubin*2xUL N (>35% direct), or
ALT 3xULN and INR**> 1.5.
* Serum bilirubin fractionation should be performed if testing is available; if unavailable, 
measure urinary  bilirubin via dipstick.  I f fractionation is unavailable and ALT 3xULN 
and total bilirubin  2xULN, then the event is still to be reported as an SAE.
** INR testing not required per protocol and the threshold value does not apply  to 
subjects receiving anticoagulants.  If INR measurement is obtained, the value is to be 
recorded on the SAE form.
12.4.3. Definition of Cardiovascular Events
Cardiovascular Events (CV) Definition:
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
79Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thromboembolism
Deep venous thrombosis/pulmonary  embolism
Revascularization
12.4.4. Recording of A Es and SA Es
AEs and SAE Recording:
When an AE/SAE occurs, it is the respons ibility  of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
relative to the event.
The investigator will then record all relevant information regarding an AE/SAE in 
the CRF
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_9238]’s medical 
records to [COMPANY_004] in lieu of completion of the [COMPANY_004], AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_004].  In this instance, all subj ect identifiers, with the exception of the 
subject number, will be blinded on the copi[INVESTIGATOR_131976].
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinic al information.  I n such cases, the diagnosis will be 
documented as the AE/SAE and not the individual signs/sy mptoms.
Subject -completed Value Evidence and Outcomes questionnaires and the collection 
of AE data are independent components of the study .
Respon ses to each question in the Value Evidence and Outcomes questionnaire will 
be treated in accordance with standard scoring and statistical procedures detailed b y 
the scale’s developer.
The use of a single question from a multidimensional health survey  to de signate a 
cause -effect relationship to an AE is inappropriate.
12.4.5. Evaluating AEs and SA Es
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and will assign it to one of the following categories:
Mild:  An event that is easily  tolerated by  [CONTACT_423], causing minimal discomfort 
and not interfering with every day activities. 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
80Moderate:  An event that is sufficiently  discomforting to interfere with normal 
every day activities
Severe:  An e vent that prevents normal every day activities. -an AE that is assessed 
as severe will not be confused with an SAE. Severity  is a category  utilized for rating 
the intensity  of an event; and both AEs and SAEs can be assessed as severe.
An event is defined a s ‘serious’ when it meets at least one of the pre- defined 
outcomes as described in the definition of an SAE.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y treatment and 
the occurrence of each AE/SAE.
A "reasonable possibility " is meant to convey that there are facts/evidence or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled 
out.
The investigator will use clinical judgment to determine the relationship.
Alternative ca uses, such as natural history  of the underly ing diseases, concomitant 
therap y, other risk factors, and the temporal relationship of the event to the study  
treatment will be considered and investigated.
The investigator will also consult the I nvestigator Br ochure (IB) and/or Product 
Information, for marketed products, in the determination of his/her assessment.
For each AE/SAE the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations when an SAE has occurred and the investigator has minimal 
information to include in the initial report to [COMPANY_004].  However, it is very important 
that the investigator always make an assessment of causality for every event 
prior to the initial transmission of the SAE data to [COMPANY_004].
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information, amending the SAE data collection tool accordingl y.
The causality  assessment is one of the criteria used when determinin g regulatory  
reporting requirements.
Follow -up of A Es and SA Es
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as may  be indicated or as requested by  [CONTACT_646031]/or causality  of the AE or SAE.
The investigator is obligated to assist.  This may  include additional laboratory  tests 
or investigations, histopathological examinations or consultation with other health  2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
81care professionals.
If a subject die s during participation in the study  or during a recognized follow -up 
period, the investigator will provide [COMPANY_004] with a copy  of any  post -mortem findings, 
including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to [COMPANY_004] within the designated 
reporting time frames.
12.4.6. Reporting of SA Es to [COMPANY_004]
SAE reporting to [COMPANY_004] via electronic data collection tool
Primary  mechanism for reporting SAEs to [COMPANY_004] will be the electronic dat a collection 
tool
If the electronic s ystem is unavailable for greater than 24 hours, the site will use the 
paper SAE data collection tool and fax it to the Medical Monitor
Site will enter the serious adverse event data into the electronic s ystem as soon as it 
becomes available.
The investigator will be required to confirm review of the SAE causality  by [CONTACT_90649] ‘reviewed’ box at the bottom of the eCRF page within 72 hours of submission of 
the SAE.
After the stud y is completed at a given site, the electro nic data collection tool (e.g., 
InForm s ystem) will be taken off- line to prevent the entry  of new data or changes to 
existing data
If a site receives a report of a new SAE from a study  subject or receives updated data 
on a previousl y reported SAE after the electronic data collection tool has been taken 
off-line, the site can report this information on a paper SAE form or to the Medical 
Monitor by  [CONTACT_756].
Contacts for SAE receipt can be found at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774]. 2018N377698_00
2016N277425_01 CONFIDENTIA L
[PHONE_13438].5. Appendix 5: COPD Exacerbation Identification, 
Categorization and Treatment Guidelines
12.5.1. Guidelines for Identifying COPD Exacerbations
The following are s ymptoms used to ascertain an exacerbation of COPD:
Worsening of two or more of the following major sy mptoms for at least two consecutive 
days:
Dyspnea
Sputum volume
Sputum purulence (color)
OR
Worsening of an y one major symptom together with any  one of the following minor 
symptoms for at least two consecutive day s:
Sore throat
Colds (nasal discharge and/or nasal congestion)
Fever (oral temperature > 37.5 °C) without other cause
Increased cough
Increased wheeze
Subjects who experience worsening COPD sy mptoms for greater than 24 hours should: 
Contact [CONTACT_496979]/or research coordinator immediately , and 
report to the study  clinic as required
If the subject is unable to contact [CONTACT_23976] y Investigator and/or research 
coordinator, they  should contact [CONTACT_23975] (or other health care 
practitioner as re quired) and contact [CONTACT_496981]
Continue to record their symptoms and rescue albuterol/salbutamol usage in their 
daily  eDiary  
If the subject seeks emergency /acute care for worsening respi[INVESTIGATOR_23908], 
he/she should request the caring Health Care Provider (HCP) to contact [CONTACT_646014].
Subjects with worsening respi[INVESTIGATOR_496947]:
A mild/moderate/severe exacerbation and/or pneumonia
OR
A Lower Respi[INVESTIGATOR_645959] I nfection (L RTI) 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
83Background variability  of COPD
A non- respi[INVESTIGATOR_23910]
Other respi[INVESTIGATOR_23910]
12.5.2. COPD Exacerbation Severity
Each COPD exacerbation will be categorized based on severit y as follows:
Moderate :  Worsening sy mptoms of COPD that require treat ment with 
oral/sy stemic corticosteroids and/or antibiotics.
Severe : Worsening s ymptoms of COPD that require treatment with in -patient 
hospi[INVESTIGATOR_26109] [ADDRESS_865044] x- ray within 48 hours of 
identification of a moderate or severe exacerbation. Details of an exacerbation should 
be recorded in the exacerbation page of the eCRF. However, exacerbations should not be 
recorded in the AE section of the eCRF unless they meet the definition of an SAE. 
(Pneumonia must be recorded in the AE or SAE section of the eCRF and on the 
Pneumonia page of the eCRF.)
Use of antibiotics for the treatment of upper or lower respi[INVESTIGATOR_496948] a COPD exacerbation unless the subject exper iences worsening s ymptoms 
of COPD which match the definition of an exacerbation as given above.
12.5.3. Treatment of COPD Exacerbations
All medications used for the treatment of exacerbations must be recorded in the source 
documents and the exacerbation page of th e eCRF.  All sites should follow the protocol 
treatment guidelines (as outlined below), but an y medications deemed medically  
necessary  may  be used to treat a COPD exacerbation. However, caution is advised in 
using a LABA or LAMA to treat a subject currentl y taking IP as these additional 
medications may  increase the risk of overdose. If necessary  the PI [INVESTIGATOR_645960]’s IP temporaril y in order to treat the COPD exacerbation.
12.5.4. Guidelines for Treatment with Corticosteroids
If in the opi[INVESTIGATOR_689]/treating ph ysician the exacerbation is severe enough 
to warrant the need for oral or sy stemic corticosteroids (with or without antibiotics) the 
following guidelines should be used.
The duration of treatment with oral/s ystemic corticosteroids should be 14 day s 
(dose and t ype according to local practice) 
The duration of treatment with oral/sy stemic corticosteroids should not exceed 14 
days unless approval is given by  [CONTACT_107634]
Any course of oral/s ystemic corticosteroids started within 7 day s of finishing a 
previous course will be considered as treatment for a single exacerbation 2018N377698_00
2016N277425_01 CONFIDENTIA L
[PHONE_13439].5.5. Guidelines for Treatment with A ntibiotics
If there is evidence of respi[INVESTIGATOR_645982]:
The duration of treatment with antibiotics should not exceed 14 day s (dose and ty pe 
according to local practice). If first line antibiotic treatment f ails and additional 
antibiotics are used, the total duration of antibiotic treatment should not exceed 30 
days unless approval is given by  [CONTACT_107634]
Any course of antibiotics started within [ADDRESS_865045] day  (of at least 2 consecutive day s) of worsening s ymptoms 
of COPD as described in Section 12.5.1.
The date of resolution should be based on when the Investigator and/or subject 
determines that the COPD sy mptoms have returned to pre -exacerbation levels or to a new
baseline.  In determining this resolution date, consideration should be given to diary  
recorded s ymptoms and/or study  subject evaluation.
12.5.7. Guideline for assessing multiple mild exacerbations
Two mild exacerbations can be combined into one, per the Investig ator’s judgement, if a 
subject’s diary  reveals that the two mild COPD exacerbations are separated by  [CONTACT_646016] s.
12.5.8. Guideline for assessing exacerbations that increase in severity
If an exacerbation starts off as mild, but becom es moderate or severe or starts off as 
moderate and becomes severe, the exacerbation should be captured as one exacerbation 
and classified b y its highest level of severity. 2018N377698_00
2016N277425_01 CONFIDENTIA L
[PHONE_13427].6. Appendix 6: Definition of and Procedures for Documenting 
Medical Device Incidents
12.6.1. Definitions of a Medical Device Incident
The detection and documentation procedures described in this protocol apply  to all [COMPANY_004] 
medical devices provided for use in the stud y (see Section 6.[ADDRESS_865046] of [COMPANY_004] m edical 
devices).
Medical Device Incident Definition:
Incident –Any malfunction or deterioration in the characteristics and/or performance 
of a device, as well as any  inadequacy  in the labeling or the instructions for use 
which, directl y or indirectly , mig ht lead to or might have led to the death of a 
patient/user/other persons or to a serious deterioration in their state of health.
Not all incidents lead to death or serious deterioration in health.  The non- occurrence 
of such a result might have been due t o other fortunate circumstances or to the 
intervention of health care personnel.
It is sufficient that:
 an incident associated with a device happened and
 the incident was such that, if it occurred again, might lead to death or a serious 
deterioration in he alth.
 A serious deterioration in state of health can include:
 life-threatening illness
 permanent impairment of body  function or permanent damage to a bod y structure
 a condition necessitating medical or surgical intervention to prevent one of the 
above 
 fetal distress, fetal death or any  congenital abnormality  or birth defects
Examples of incidents
a patient, user, care giver or professional is injured as a result of a medical device 
failure or its misuse
a patient’s treatment is interrupted or compromised b y a medical device failure
misdiagnosis due to medical device failure leads to inappropriate treatment
a patient’s health deteriorates due to medical device failure 2018N377698_00
2016N277425_01 CONFIDENTIA L
[PHONE_13428].6.2. Documenting Medical Device Incidents
Medical Device Incident Documenting:
Any medical devic e incident occurring during the study  will be documented in the 
subject’s medical records, in accordance with the investigator’s normal clinical 
practice, and on the appropriate form.
For incidents fulfilling the definition of an AE or an SAE, the appropri ate AE/SAE 
CRF page will be completed as described in Appendix 4 .
The form will be completed as thoroughl y as possible and signed b y the investigator 
before transmittal to [COMPANY_004].
It is very  important that the investigato r provides his/her assessment of causality  to 
the medical device provided by  [CONTACT_132017], and describes 
any corrective or remedial actions taken to prevent recurrence of the incident.
A remedial action is an y action other than rou tine maintenance or servicing of a 
device where such action is necessary to prevent recurrence of an incident. This 
includes an y amendment to the design to prevent recurrence. 2018N377698_00
2016N277425_01 CONFIDENTIA L
[PHONE_13429].7. Appendix 7: Modified List of Highly  Effective Methods for 
Avoiding Pregnancy  in FRP and Collection of Pregnancy  
Information
12.7.1. Modified List of Highly Effective Methods for Avoiding Pregnancy  
in Females of Reproductive Potential (FRP)
The list does not apply  to FRP with same sex partners or for subjects who are and will 
continue to be ab stinent from penile -vaginal intercourse on a long term and persistent 
basis, when this is their preferred and usual lifest yle. Periodic abstinence (e.g. calendar, 
ovulation, sy mptothermal, post -ovulation methods) and withdrawal are not acceptable 
methods of contraception.
1.Contraceptive subdermal implant
2.Intrauterine device or intrauterine s ystem
3. Combined estrogen and progestogen oral contraceptive [ Hatcher , 2011]
4.Injectable progestogen [ Hatcher , 2011]
5.Contraceptive vaginal ring [ Hatcher , 2011]
6.Percutaneous contraceptive patches [ Hatcher , 2011]
7.Male partner sterilization with documentation of azoosper mia prior to the female 
subject's entry  into the study , and this male is the sole partner for that subject 
[Hatcher , 2011]. The documentation on male sterility  can come from the site 
personnel’s: review of subject’s medical records, medical examination and/or semen 
analysis, or medical history  interview provided b y her or her partner.
These allowed methods of contraception are only  effective when used consistently , 
correctly  and in accordance with the product label. The investigator is responsible for 
ensuring that subjects understand how to properl y use these methods of contraception.
12.7.2. Collection of Pregnancy  Information
Investigator will collect pregnancy  information on any  female subject, who becomes 
pregnant while participating in this study
Information will be recorded on the appropriate form and submitted to [COMPANY_004] within [ADDRESS_865047]'s pregnancy .
Subject will be followed to determine the outcome of the pregnancy . The 
investigator will collect fo llow up information on mother and infant, which will be 
forwarded to [COMPANY_004].  Generall y, follow -up will not be required for longer than 6 to 8 
weeks bey ond the estimated delivery  date. 
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy will be reported as an AE or 
SAE. 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
88A spontaneous abortion is alwa ys considered to be an SAE and will be reported as 
such.  
Any SAE occurring as a result of a post -study  pregnancy  which is considered 
reasonabl y related to the study  treatment by  [CONTACT_093], will be reported to [COMPANY_004] 
as described in Appendix [ADDRESS_865048] who becomes pregnant while participating
will be withdrawn from the study 2018N377698_00
2016N277425_01 CONFIDENTIA L
[PHONE_13443].8. Appendix 8: Country  Specific Requirements
No country -specific requirements exist. 2018N377698_00
2016N277425_01 CONFIDENTIA L
[PHONE_13431].9. Appendix 9: protocol changes
Scope:
This amendment applies to all sites
Protocol Changes for Amendment No.1 are summarised below.
Strike t hrough text refers to deleted text and underlined refers to added text.
Protocol Changes:
Title
Rationale for change:   Correct a t ypographical error in the title: Umeclidi mium to 
Umeclidinium
Regulatory Agency Identifying Number(s):  
Rationale for change :  To correct a t ypographical error of the EudraCT no. and add an 
IND no.
Revised text: EudraCT no 2016 -002513 -226, 2016 -002513 -22, IND no.104479 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
91Section 1
Overall Design
Rationale for change: To Correct a t ypographical error in the last paragraph.
Revis ed text: Salmeterol , salbutamol
“This is a multi -centre, randomized, double blind, double- dummy , 3-arm parallel group 
study .  Eligible subjects will be stratified based on long -acting bronchodilator usage 
during the run- in (none, one or 2 long -acting bronc hodilators per day ) and randomized in 
a ratio of 1:1:1 to UMEC/VI  inhalation powder (62.5/25 mcg once dail y) administered 
via the ELLIPTA inhaler, or UMEC (62.5 mcg once dail y) administered via the 
ELLIPTA or salmeterol (50 mcg BID) administered via the DI SKUS. 
There will be a total of 5 clinic visits and one follow -up phone call (Visit 6). The Pre -
screening Visit (Visit 0) can occur on the same day  as the Screening Visit (Visit 1) if 
subject does not take or has not taken an y excluded protocol medications , but must be 
completed prior to initiating an y Visit [ADDRESS_865049]’s eligibility  for the stud y. During the run-
in period subjects will continue with their inhaled COPD medications (excluding ICS and 
any exclusionary  medications).  I n addition, subjects will be provided with short acting 
albuterol/ salmeterol salbutamol to be used on as needed basis for relief of CO PD 
symptoms (rescue medication) throughout the study ”. 
Section 4.4 Design justification: To be consistent with Section [IP_ADDRESS] and Section 7.1 
the wording has been updated.
Rationale for change: Ensure consistency with Section [IP_ADDRESS] and Section 7.1 the 
wording has been changed in paragraph 5.
Revised text: “Other endpoints such SAC TDI , E-RS, SGRQ -C, CAT, Subject Global 
Rating of COPD Severity and Change in Global Rating impression of Change in COPD  
disease severity are captured to allow responder analy ses and to provide comparative data 
on PROs between the treatment groups ”. 
Section 7.1 Time and Event table
Rationale for change; to:
Correct an un-intentional deletion of the ( “x”) in some cells and confirm that concomitant 
medications should be reviewe d at every  clinic visit.
Increase the visit window from 2days to - 7/+2
Ensure consistency  of wording between Section 7.2 and table 7.1. “ Written ”was deleted
Include height and weight at Screening andcorrect errors in foot note no.11
“In order to ensu re subjects have sufficient doses of study  treatment, they  must return to 
clinic within 30 day s from V2 and within 60 and 90 days from V3 and V4 respectivel y” 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
92Blinded Treatment
VisitPre-
screen1
0Screen/ 
Run-in
1Rando -
mization 
[ADDRESS_865050] 
6
Week -6 to -4 -4 0 4 12 24
Day42 2
-7/+2 
days 
prior 
Visit 128 2
-7/+2 days 
prior Visit 
212-7/+2 
days28 2-7/+2 
days 84 2 
days168  2-7/+2 
days723 days after V5 
or EW Visit
Screen/Baseline
Written Informed consent X
Demography X
Medical/COPD history X
Smoking history/status X
Smoking cessation counselling X
Concomitant medication assessment X X X X X X X X
Height and weight X
Cardiovascular History/family history of premature CV 
disease])X
Screening spi[INVESTIGATOR_038] (including post bronchodilator 
testing )3X
CAT questionnaire X X
Verify Inclusion/Exclusion Criteria X
Training on use of inhalers X X
Training on use of eDiary and eMDI X X
Verify randomization Criteria X
Register Visit in InForm X X X X X X X X
Register Visit in RAMOS NG X X X X X X X X 
 
 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
93Blinded Treatment
VisitPre-
screen1
0Screen/ 
Run-in
1Rando -
mization 
[ADDRESS_865051] 
6
Week -6 to -4 -4 0 4 12 24
Day42 2
-7/+2 
days 
prior 
Visit 128 2
-7/+2 days 
prior Visit 
212-7/+2 
days28 2-7/+2 
days 84 2 
days168  2-7/+2 
days723 days after V5 
or EW Visit
Efficacy /HRQoL assessments
Spi[INVESTIGATOR_038], including pre -dose FEV 1, trough  FEV 1and 
inspi[INVESTIGATOR_645933] X X X
SAC BDI questionnaire4 X
SAC TDI questionnaire4 X X X
SGRQ -C questionnaire [ADDRESS_865052]/ER -S: COPD 5
Patient Global Rating of COPD severity X X X X
Patient Global Rating of Change in COPD X X X
Safety assessments
Adverse events/Serious adverse events6 X X X X X X X X
COPD exacerbation assessmen t X X X X X X X X
12-Lead ECG X
Urine pregnancy test 7 X X X X
Pharmacogenetic sample8                                             X
Medication/Supplies
Dispense rescue albuterol/slabutamol. Dispense MDI9 X X X X X
Assess COPD medication compliance10 during run -in X
Dispense eDiary X
Assess compliance with eDiary during run -in X
Collect rescue albuterol/slabutamol. X X X X X
Collect eDiary X X
Dispense study treatment11 X X X 
 
 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
94Blinded Treatment
VisitPre-
screen1
0Screen/ 
Run-in
1Rando -
mization 
[ADDRESS_865053] 
6
Week -6 to -4 -4 0 4 12 24
Day42 2
-7/+2 
days 
prior 
Visit 128 2
-7/+2 days 
prior Visit 
212-7/+2 
days28 2-7/+2 
days 84 2 
days168  2-7/+2 
days7[ADDRESS_865054] be completed prior to Screening Visit1. It can be completed 2 weeks prior or on the same day of V1, if no wa sh out of exclusionary medications is 
required. 
2. Early Withdrawal Visit: Subjects that withdraw should return to the clinic as soon as possible to complete the Early Withdraw al Visit procedures.
3. Spi[INVESTIGATOR_645934] (Section [IP_ADDRESS]). 
4. SAC BDI, SAC TDI, SGRQ- C, CAT questionnaires will be completed at clinic visits and in the eDiary
5. EXACT/ER -S: COPD is completed daily in the eDiary approximately 2 hours before bed -time, starting on Day 1 of the run -in period.
6. For the start date of collecting AEs and SAEs see (Appendix 4)
7. Pregnancy test: for females for child bearing potential only.
8. Pharmacogenetic sample may be drawn at visit [ADDRESS_865055] return to clinic within 30 days from V2 and within 60 and 90 days from V3 and V4 respectively.
12. The Actigraph GT9X should be worn for 7 days from Visit 1, for 7 days from Visit 2, for 7 days from Visit 3 and for 7 days pr ior to Visit 5. 
 
 2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
95Section 7.2.2 Critical procedures performed a t Screening (Visit 1)
Rationale for change:   To clarify  that height and weight are collected at V1
Revised text: “Height and weight”
Section 7.3.2 Spi[INVESTIGATOR_645969]:   To further clarify  that spi[INVESTIGATOR_645963] [ADDRESS_865056] inhales their usual morning COPD medication(s) a bullet point 
was added. “At Screening Visit 1, before the morning dose of usual COPD medications”
Revised text:
“Spi[INVESTIGATOR_645964] [ Miller , 2005]. All sites 
will use standardized spi[INVESTIGATOR_645942].
All subjects will have spi[INVESTIGATOR_645943]  (see Section 
[IP_ADDRESS]) and at Visits 2, 3, [ADDRESS_865057] 3 acceptable spi[INVESTIGATOR_496921] (with no 
more than 8) should be obtained. Acceptable spi[INVESTIGATOR_496922] a satisfactory  
start of test and end of test (i.e. a plateau in the volume time curve) and be free from 
artifacts due to cough, early  termination, poor effort, obstructed mouthpi[INVESTIGATOR_13959], equipment 
malfunction, or other reasons [ Miller , 2005].
The largest FEV1and FVC from the 3 ac ceptable efforts should be recorded, even if they  
do not come from the same effort.
Spi[INVESTIGATOR_645944] 1and FVC assessments that is not obtained as follows will be 
considered a protocol deviation:
Started between 6:00AM and 11:00AM.
After withholding albuterol/salbutamol (all visits) for ≥4 hours
At Screening Visit 1, after wash out of medications as specified in the exclusion 
criteria in Section 5.2 (Concomitant Medications).
At Screening Visit 1, before the morning dose of usual COPD medications
At Visit [ADDRESS_865058] dose 
of study  treatment 
At Visit 3, 4 and 5 after withholding the morning dose of study  treatment.
Pre dose assessment performed prior dosing.
Subjects should refrain from smoking for [ADDRESS_865059].
Trough FEV 1measurements for UMC/VI  or UMEC on Weeks 4, 12 and 24 (Visits 3, 4 
and 5) should be performed 23 hours and 24 hours after the previous day ’s dose of study   2018N377698_00
2016N277425_01 CONFIDENTIA L
201749
96medication recorded in the eDiary . This will al so provide trough FEV 1measurements for 
the evening dose of salmeterol”. 
7.3.7 Physical activity monitor (study subset)
Rationale for changes: Ensure consistency  of the wording between Section 1 and 
Section 4.1 “overall design” and Section 7.3.7.
per treatment arm added to paragraph 4.
Revised Text : 
Physical activity monitor (study subset)
“Phy sical activity  limitation is a common feature of COPD and its measures are highl y 
related to the degree of disease severity  [Watz, 2009]. 
Reduced ph ysical activity  leve ls in COPD is associated with increased morbidity  and 
mortality , sustained disability , depression, and social and phy sical isolation [ Shu-Yi, 
2014; Gimeno, 2014] 
Improved activity  has been identified as an important factor that may  modify  morbidity  
and mortality  in COPD [ Moy , 2012 ].
The Actigraph GT9X phy sical activity  monitor will be used to measure levels of activity . 
The activity  monitor will be worn by  [CONTACT_422906]  150 subjects per treatment arm 
for 7 day s from Screening (Visit 1), for 7 day s from Randomisation (Visit 2), 7 day s from 
Visit 3 (Week 4) and for 7 day s prior to Week 24 (Visit 5).
There will be [ADDRESS_865060] will be given an activity  
monitor and instruction leaflet at the start of each assessment period. Further details of 
distribution, operation and retrieval of the monitors will be provided in the SRM” . 2018N377698_00
2016N277425_00 CONFIDENTIA L
GlaxoSmithKline group of companies 201749
1TITLE PA GE
Division:   Worldwide Development
Information Type: Clinical Protocol
Title: A 24 -week treatment, multi -center, randomized, double- blind , 
double -dummy , parallel group study  to compare 
Umeclidinium/Vilanterol, Umeclidimium, and Salmeterol in 
subje cts with chronic obstructive pulmonary  disease (COPD)
Compound Number: [COMPANY_004]2592356
Development Phase IV
Effective Date: 13-SEP-2016
Author(s):  
 
Copy right 2016 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthoris edcopying or use of this information is prohibited. 2018N377698_00
[COMPANY_003]
 2018N377698_00
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2016N277425_00 CONFIDENTIA L
201749
3MEDICA L MONITOR /SPONSOR INFORM ATION PA GE
Medical Monitor /SAE Contact [CONTACT_7171]:
Role Name [CONTACT_387071] -hours 
Phone/Cell/
Pager 
NumberFax 
NumberSite Address
Primary 
Medical 
Monitor Telephone: Cell: Fax: GlaxoSmithKline
Stockley Park 
West, [ADDRESS_865061], 
Heathrow, 
Uxbridge, 
Middlesex, UB11 
1BT, United 
Kingdom
Secondary 
Medical 
Monito rMD
Telphone:Cell:  Fax:  GlaxoSmithKline
Stockley Park 
West, [ADDRESS_865062]  
information Telephone : Cell: Fax: GlaxoSmithKline
Stockley Park 
West, [ADDRESS_865063], 
Heathrow, 
Uxbridge, 
Middl esex, UB11 
1BT, United 
Kingdom
Sponsor Legal Registered Address:
GlaxoSmithKline Research & Development Limited
[ADDRESS_865064]
Middlesex, TW8 9GS
[LOCATION_006]
In some countries, the clinical trial sponsor may  be the local GlaxoSmithKline Affiliate 
Company (or designee). If applicable, the details of the alternative Sponsor and contact  2018N377698_00
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2016N277425_00 CONFIDENTIA L
201749
4person in the territory  will be provided to the relevant regulatory  authority  as part of the 
clinical trial application.    
Regulatory  Agency  Identify ing Number(s): INDno.[ADDRESS_865065] no. 2016 -
002513 -226 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
5INVESTIGA TOR PROTOCOL A GREEMENT PA GE
I confirm agreement to conduct the study  in compliance with the protocol.
I acknowledge that I am responsible for overall study  conduct. I agree to 
personall y conduct or sup ervise the described study .
I agree to ensure that all associates, colleagues and employ ees assisting in the 
conduct of the stud y are informed about their obligations. Mechanisms are in 
place to ensure that site staff receive sthe appropriate information t hroughout the 
study .
Investigator Name:  ______________ __________ ______
Investigator Signature [CONTACT_1782] 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
6TABLE OF CONTENTS
PAGE
1.PROTOCOL SYNOPSIS FO R STUDY 201749 ........................................................ 9
2.INTRODUCTION ................................
.................................................................... 15
2.1. Study Rationale .......................................................................................... 15
2.2. Brief Background ........................................................................................ 15
3.OBJECTIVE(S) AND END POINT(S) ...................................................................... 16
4.STUDY DESIGN .................................................................................................... 18
4.1. Overall Design ............................................................................................ 18
4.2. Treatment Arms and Duration ..................................................................... 20
4.3. Type and Number of Subjects ..................................................................... 21
4.4. Design Justification ..................................................................................... 21
4.5. Dose Justification ........................................................................................ 21
4.6. Benefit: Risk Assessment ........................................................................... 21
4.6.1. Risk Assessment ......................................................................... 22
4.6.2. Benefit Assessment ..................................................................... 25
4.6.3. Overall Benefit: Risk Conclusion .................................................. [ADDRESS_865066] AWAL CRITERIA ............. 25
5.1. Inclusion Criteria ......................................................................................... 25
5.2. Exclusion Criteria ........................................................................................ 27
5.3. Randomization Criteria ............................................................................... 30
5.4. Screening/Baseline/Run -in Failures ............................................................ 30
5.5. Withdrawal/Stoppi[INVESTIGATOR_2121] ....................................................................... 31
5.5.1. Withdrawal from the Study ........................................................... 31
5.5.2. Reason for Study W ithdrawal ....................................................... 32
5.5.3. Liver Chemistry Stoppi[INVESTIGATOR_2121] ................................................ 32
[IP_ADDRESS]. Study Treatment Restart or Rechallenge .................... [ADDRESS_865067] and Other Study Treatment .................................... 34
6.2. Medical Devices .......................................................................................... 36
6.3. Treatment Assignment ................................................................................ 36
6.4. Planned Dose Adjustments ......................................................................... 37
6.5. Blinding ....................................................................................................... 37
6.6. Packaging andLabeling .............................................................................. 38
6.7. Preparation/Handling/Storage/Accountability .............................................. 38
6.7.1. Study Treatment Return ............................................................... 39
6.8. Compliance with Study Treatment Administration ....................................... 39
6.9. Treatment of Study Treatment Overdose .................................................... 39
6.10. Treatment after the End of the Study .......................................................... 40
6.11. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_014] .................................... 40
6.11.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014] .......................... 40
6.11.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014] ......................... 41
7.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 42 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
77.1. Time an d Events Table ............................................................................... 43
7.2. Screening and Critical Baseline Assessments ............................................ 46
7.2.1. Pre-screening Visit ....................................................................... 46
7.2.2. Critical procedures performed at Screening (Visit 1) .................... 46
[IP_ADDRESS]. Albuterol/Salbutamol Reversibility Assessment .......... [ADDRESS_865068] treatment Visit 
(Baseline V2) ............................................................................... 47
7.3. Efficacy Assessments ................................................................................. 48
7.3.1. HRQoL assessments: Completion of PRO questionnaires 
in the Electronic Diary .................................................................. 48
[IP_ADDRESS]. Self Administered Computerised Baseline 
Dyspnea Index/Transitional Dyspnea Index 
(SAC BDI/TDI) ............................................................ 48
[IP_ADDRESS]. SGRQ -C..................................................................... 49
[IP_ADDRESS]. COPD Assessment Test (CAT) .................................. 49
[IP_ADDRESS]. EXACT and the Evaluating Respi[INVESTIGATOR_633333] -COPD (E -RS: COPD) .............................. 49
[IP_ADDRESS] .Subject Global Rating of COPD Severity and 
Global Rating of Change in COPD ............................. 50
7.3.2. Spi[INVESTIGATOR_038] ................................................................................... 50
7.3.3. Inspi[INVESTIGATOR_14008] (IC) ............................................................... 51
7.3.4. COPD Exacerbation .................................................................... 52
7.3.5. Clinically important deterioration (CID) ......................................... 52
7.3.6. Rescue albuterl/salbutamol use ................................................... 53
7.3.7. Physical activity monitor (study subset) ....................................... 53
7.4. Safety ......................................................................................................... 53
7.4.1. Adverse Events (AE) and Serious Adverse Events (SAEs) .......... 53
[IP_ADDRESS]. Time period and Frequency for collecting AE 
and SAE information ................................................... 53
[IP_ADDRESS]. Method of Detecting AEs and SAEs ........................... 54
[IP_ADDRESS]. Follow -up of AEs and SAEs ........................................ 54
[IP_ADDRESS]. Pneumonia Events ..................................................... 54
[IP_ADDRESS]. Cardiovascular and Death Events .............................. 55
[IP_ADDRESS]. Disease -Related Events and/or Disease-
Related Outcomes Not Qualifying as SAEs ................ 55
[IP_ADDRESS]. Regulatory Reporting Requirements for SAEs ............ 55
7.4.2. Pregnancy ................................................................................... 56
7.4.3. Medical Device Incidents (Including Malfunctions) ....................... 56
7.4.4. Electrocardiogram (ECG) ............................................................. 56
7.5. Genetics ..................................................................................................... 56
8.DATA MANAGEMENT ........................................................................................... 56
9.STATISTICAL CONSIDER ATIONS AND DATA ANALYSES ................................ .57
9.1. Hypotheses ................................................................................................ .57
9.2. Sample Size Considerations ....................................................................... 57
9.2.1. Sample Size Assumptions ........................................................... 58
9.2.2. Sample Size Sensitivity ................................................................ 58
9.2.3. Sample Size Re- estimation or Adjustment ................................... 58
9.3. Data Analysis Considerations ..................................................................... 58
9.3.1. Analysis Populations .................................................................... 58
9.3.2. Interim Analysis ........................................................................... 59 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
89.4. Key Elements of Analysis Plan ................................................................... 59
9.4.1. Primary Analyses ......................................................................... 59
9.4.2. Other Analyses ............................................................................ 60
10. STUDY GOVERNANCE CON SIDERATIONS ........................................................ 61
10.1. Posting of Information on Publicly Available Clinical Trial Registers ............ 61
10.2. Regulatory and Ethical Considerations, Including the Informed
Consent Process ........................................................................................ 61
10.3. Quality Control (Study Monitoring) .............................................................. 62
10.4. Quality Assurance ....................................................................................... 62
10.5. Study and Site Closure ............................................................................... 62
10.6. Records Retention ...................................................................................... 63
10.7. Provision of Study Results to Investigators, Posting of Information 
on Publically Available Clinical Trials Registers and Publication ................. 64
11.REFERENCES ....................................................................................................... 65
12.APPENDICES ........................................................................................................ 68
12.1. Appendix 1: Abbreviations and Trademarks ................................................ 68
12.2. Appendix 2: Liver Safety Required Actions and Follow up 
Assessments .............................................................................................. 70
12.3. Append ix 3: Genetic Research ................................................................... 73
12.4. Appendix 4: Definition of and Procedures for Recording, Evaluating, 
Follow -Up and Reporting of Adverse Events ............................................... 76
12.4.1. Definition of Adverse Events ........................................................ 76
12.4.2. Definition of Serious Adverse Events ........................................... 77
12.4.3. Definition of Cardiovascular Events ............................................. 78
12.4.4. Recording of AEs and SAEs ........................................................ 79
12.4.5. Evaluat ing AEs and SAEs ............................................................ 79
12.4.6. Reporting of SAEs to [COMPANY_004] ........................................................... 81
12.5. Appendix 5: COPD Exacerbation Identification, Categorization and 
Treatment Guidelines .................................................................................. 82
12.5.1. Guideli nes for Identifying COPD Exacerbations ........................... 82
12.5.2. COPD Exacerbation Severity ....................................................... 83
12.5.3. Treatment of COPD Exacerbations .............................................. 83
12.5.4. Guidelines for Treatment with Corti costeroids .............................. 83
12.5.5. Guidelines for Treatment with Antibiotics ..................................... 84
12.5.6. Onset and Resolution of COPD Exacerbations ............................ 84
12.5.7. Guideline for assessing multiple mild exacerbations .................... 84
12.5.8. Guideline for assessing exacerbations that increase in 
severity ........................................................................................ 84
12.6. Appendix 6: Definition of and Procedures for Documenting Medical 
Device Incidents ......................................................................................... 85
12.6.1. Definitions of a Medical Device Incident ....................................... 85
12.6.2. Documenting Medical Device Incidents ....................................... 86
12.7. Appendix 7: Modified List of Highly Effective Methods for Avoiding 
Pregn ancy in FRP and Collection of Pregnancy Information ....................... [ADDRESS_865069] of Highly Effective Methods for Avoiding 
Pregnancy in Females of Reproductive Potential (FRP) .............. 87
12.7.2. Collection of Pregnancy Information ............................................ 87
12.8. Appendix 8: Country Specific Requirements ............................................... 89 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
91. PROTOCOL SYNOPSIS FOR STUDY 201749
Rationale
The primary  purpose of this study  is to demonstrate improvements in lung function in 
subjects treated with Umeclidinium/Vilanterol ( UMEC/VI ) compared with Umeclidinium 
(UMEC )for [ADDRESS_865070] of
UMC/VI , UMEC, and salmeterol with respect to health- related quality  of life ( HRQoL ),
measured through patient reported outcomes (PROs) questionnaires, and lung function .  
Additional assessments to further evaluate other measures of chronic obstructive 
pulmonary  disease (COPD )efficacy and symptom scontrol will be performed.
Objective(s)/Endpoint(s)
Objectives Endpoints
Primary
To compare the effect of UMEC/VI  
(62.5/25 mcg once dail y)with UMEC 
(62.5 mcg once daily )on lung functionChange from baseline in trough Forced 
Expi[INVESTIGATOR_645914] 
(FEV 1)at week 24 
Seco ndary
To compare UMEC/VI (62.5/25 mcg 
once dail y), UMEC (62.5 mcg once 
daily )with salmeterol (50 mcg twice 
daily )on patient reported outcomes 
(PROs) Change from baseline in self 
administered computerised (SAC) 
transient dy spnea index (TDI) 
Percentage of TDI responders 
according to SAC TDI score.  A 
responder is defined as a ≥1 unit 
improvement in SAC TDI score 
Assessment of respi[INVESTIGATOR_645915] 24 weeks using 
Evaluating Respi[INVESTIGATOR_244774] -
COPD (E- RS) and its subscales 
(breathlessness, cough and sputum and 
chest sy mptoms) 
Percentage of E -RS responders 
according to E -RS score (defined as 
reduction in E-RS score of 2 or 3.35 
units) from baseline
Change from baseline in St George’s 
Respi[INVESTIGATOR_21606] (SGRQ -C)
Percentage of responders acco rding to 
SGRQ -C total score (defined as a 4 
point or greater reduction from  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
10Objectives Endpoints
baseline) 
Change from baseline in COPD 
assessment test ( CAT)
Percentage of responders according to 
CAT (defined as a 2 unit improvement 
in score from baseline)
Other
To compar e UMEC/VI ( 62.5/25 mcg 
once dail y), UMEC (62.5 mcg once 
daily )with salmeterol (50 mcg twice 
daily )on other COPD efficacy  measures Rate of mild, moderate or severe 
exacerbations
Time to first mild, moderate or severe 
exacerbation
Rate of moderate or sev ere 
exacerbation
Time to moderate or severe 
exacerbation
Time to severe exacerbations
Time to clinically  important 
deterioration (CID) composite endpoint 
Time to clinically  important 
deterioration composite endpoint 
excluding FEV 1
Rescue albuterol/salbutamol use, 
(percentage of rescue- free day s and 
mean number of Inhalations/day ) 
captured b y the electronic diary 
(eDiary ) over 24 weeks
Inspi[INVESTIGATOR_645920] y (IC)
Full Vital capacity  (FVC) 
Change from baseline in trough FEV 1
Change from baseline in global 
impression of disease severity   2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
11Objectives Endpoints
Safety
To evaluate safet y and tolerability 
of UMEC/VI ( 62.5/25 mcg once 
daily ), UMEC (62.5mcg once dail y)
and salmeterol 50mcg twice dail y) Incidence of adverse events
Exploratory
To compare albuterol/salbutamol 
use captured in the eDiary  with the 
electronic metered dose inhaler 
(eMDI) device Rescue albuterol/salbutamol use, 
(percentage of rescue- free day s and 
mean number of Inhalations/day ) 
captured b y the eMDI device over 24 
weeks as data allow
To explore the effect of UMEC/VI  
(62.5/25 mcg once dail y), UMEC 
(62.5 mcg once daily ) with 
salmeterol (50 mcg twice daily ) on 
physical activityChange from baseline in phy sical 
activity  
To investigate the CIDcomposite 
endpoint ability  to predict short 
term outcomes To compar e physical activity  levels, 
ER-S, rescue medication use, 
exacerbations and mortality  in subject s 
with and without a CI D
Overall Design
This is a multi -centre, randomized, double blind, double dummy, 3 -arm parallel group 
study .  Eligible subjects will be r andomized in a ratio of 1:1:1 to UMEC/VI inhalation 
powder (62.5/25 mcg once dail y) administered via the ELLIPTA®dry powder inhaler
(DPI) , or UMEC ( 62.5 mcg once daily ) administered via the ELLIPTA DPI [INVESTIGATOR_645916] 
(50 mcg twice dail y (BID) ) administered via the DI SKUS®DPI.
Eligible subjects at Screening will enter a run- in period for 4 weeks during which they
continue taking their inhaled COPD medications (excluding ICS and any exclusionary 
medications) .  In addition ,subjects will be provided with shor t acting 
albuterol/salmeterol to be used on as needed basis (rescue medication) throughout the 
study . 
Subjects who experience a moderate or severe COPD exacerbation during the run- in 
period will be deemed run- in failures. Subjects experiencing a mild exa cerbation, 
defined as worsening of symptoms that require snotreatment with antibiotics or steroids 
and is self managed b y the patient b y an increase of inhaled rescue medication , will be 
allowed to continue in the study .
At the randomization Visit 2 (Day  1) those subjects who successfull y complete the run- in 
period as well as meet the other pre -defined eligibility  and randomization criteria will 
discontinue their inhaled COPD medications and will be randomized to one of the [ADDRESS_865071] medical problems experienced during the stud y.  
Subjects will be performing slow and forced spi[INVESTIGATOR_645965].
In addi tion, a subset of subjects up to 150 per treatment arm will undergo assessment of 
their phy sical activity  measured through a phy sical activity  monitor ( Actigraph GT9X) 
worn for 7 day sfrom Screening (Visit 1), for 7 day s from Randomisation (Visit 2) , [ADDRESS_865072] clinic Visit (Visit 5). 
There will be a total of 5 clinic visits and one follow -up phone call ( Visit 6).  The total 
duration of subject participation in the study  will be approximately  29to 31weeks 
consistin g of [ADDRESS_865073] completed the study  upon completion of the Follow –
Up contact b y telephone.
Treatment A rms and Duration
Subjects will be stratified based on long -acting bronchodilator usage during the run- in 
(none, one or 2 long- acting bronchodilators per day ) and randomized in a ratio of 1:1:1 to 
either
UMEC/VI  inhalation powder (62.5/25 mcg once daily ) administered via the 
ELLIPTA DPI) or 
UMEC (62.5 mcg once daily ) administered via the ELLIPTA DPI [INVESTIGATOR_1660] 
Salmeterol (50 mcg BID) administered via DISKUS  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
13Study schematic
*Inhaled COPD medications including LABAs, LAMAs or LABA/LAMA combination products are 
allowed in run-in. ICS alone or in combination with a bronchodilator or any exclusionary 
medications are not allowed.
Type and Number of Subjects
Approximately  3232 subjects will be screened, such that 2424 subjects will be 
randomized and approximately  2181 evaluable subjects complete the stud y. 
Analysis
The primary  purpose of this study  is to demonstrate improvements in lung function for 
subjects treated with UMEC/VI  compared with UMEC for 24 weeks.
The primary  endpoint is change from baseline in trough FEV 1at Week 24.
The null hypothesis is no difference between treatment groups (H0: μT – μS = 0), with 
the alternative h ypothesis that there is a difference between treatment groups (H1: μT –
μS ≠0), where μ T is the mean change from baseline for UMEC/VI and μS is the mean 
change from baseline for UMEC. 
The primary  endpoint of mean change from baseline in trough FEV 1at the end of Week 
24 will be anal ysed using Mixed Models repeated Measures ( MMRM) analysis. The 
MMRM analy sis will include measurements at Treatment Weeks 4, 12 and 24. Treatment 
group (a categorical variable) will be fitted as the explanatory  variable with appropriate 
pre-defined variables, stratum (number of bronchodilators per day  during run- in) and 
baseline values, fitted as covariates. Visit (nominal) will be fit ted as a categorical variable 
and visit -by-baseline and visit -by-treatment interaction terms will be included to allow 
treatment effects to be estimated at each visit separatel y. The variance covariance matrix  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
14will be assumed to be unstructured (based on previous experience no issues are expected 
with fitting models with this matrix structure). 
The estimated treatment differences between UMEC/VI versus UMEC for each endpoint 
will be presented with the 95% confidence intervals for the difference and the p -value.  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
152. INTRODUCTION
2.1. Stud y Rationale
Chronic obstructive pulmonary  disease (COPD) is associated with poor health- related 
quality  of life (HRQoL).  Pharmacologic therap y is used to improve lung function, reduce 
symptoms, frequency  and severit y of exacerbati ons, and improve patients HRQoL
[GOL D, 2015]. Umeclidinium/Vilanterol (UMEC/VI 62.5/25 mcg )is indicated for the 
maintenance treatment of COPD that contain long- acting muscarinic antagonist (L AMA) 
and long -acting beta 2-agonist (L ABA) bronchodilators. Umeclidinium (UME C)is 
indicated as a maintenance bronchodilator treatment to relieve s ymptoms in adult patients 
with COPD . Salmeterol has long been used fo r symptoms management of COPD. 
However, a direct comparison of these maintenance therapi[INVESTIGATOR_645917] .
The primary  purpose of this study  is to demonstrate improvements in lung function for 
subjects treated with UMEC/VI  compared with UMEC for [ADDRESS_865074] of
UMC/VI , UMEC, and s almeterol with respect to patient HRQoL  measured through 
patient reported outcomes (PRO s)questionnaires, sy mptoms and lung function will also 
be evaluated.
2.2. Brief Background
COPD is characterized by [CONTACT_645994], usua lly 
progressive and accompanied by  a chronic cough, sputum production and dy spnea which 
can be a major cause of disability  and anxiety  associated with the disease [ Maleki -Yazdi ,
2014]
Furthermore, acute exacerbat ions contribute to the overall severity  of disease as these 
epi[INVESTIGATOR_645918] s ymptoms and are associated with increased 
decline in lung function and mortality [Wedzicha ,
2013;Schmidt , 2014 ].
Pharmacologic therap y is used to improve lung function, reduce s ymptoms, reduce the 
frequency  and severit y of exacerbations, and also to improve health status and exercise 
tolerance.  Maintenance treatment is recommended primarily  through the use of LABAs
or LAMAs .COPD treatment guidelines recommend an incremental approach to 
pharmacological treatment as the disease state worsens, involving the use of 
combinations of drug classes with different or comp lementary  mechanisms [ GOL D, 
2015]. 
UMEC/VI inhalation p owder is a combination of UMEC (umeclidinium bromide) , a 
LAMA, and VI (V ilanterol) , a LABA, delivered via the ELLIPTA®dry powder inhaler 
(DPI). UMEC/VI at a dose of 62.5/25mcg once- daily  is marketed in the [LOCATION_002] 
(US) and Europe under the trade name [CONTACT_646039]®ELLIPTA®.
UMEC (62.5 mcg) inhalation powder is marketed in the [LOCATION_002] (US) and Europe 
under the trade name [CONTACT_646040]®ELLIPTA®.  UMEC (62.5mcg) is indicated as a 
maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD .
UMEC (62.5 mcg) improves forced expi[INVESTIGATOR_131955] (FEV 1), dyspnea  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
16andHRQoL whether used as monotherap y [Trivedi , 2014; Feldman , 2016] or as an add 
on to fluticasone propi[INVESTIGATOR_645919] (FF/VI ) [Siler , 2015]. Salmetrol (50 mcg)
DISKUS®is a long -acting broncholdilator that has long been used for the maintenance 
treatment of COPD [ Tashkin, 2010].
Clinically  important deterioration (CID) is a novel, exploratory composite endpoint 
which assesses individual deteriorations in lung function and in patient PROs defined b y 
the accepted minimal clinically  important difference ( MCID ),as well as the incidence of 
moderate to se vere exacerbations [ Singh , 2016], (Section 7.3.5 ).CID wi ll be analysedto 
determine whether UMEC/VI (62.5/25mcg) therapy  provides greater clinical stability  as 
compared with UMEC and salmeterol monotherapi[INVESTIGATOR_014] .
3. OBJECTIVE(S) AND ENDPOINT(S)
Objectives Endpoints
Primary
To compare the effect of UMEC/VI  
(62.5/25 mcg once dail y) with UMEC 
(62.5 mcg once daily ) on lung functionChange from baseline in trough Forced 
Expi[INVESTIGATOR_645914] 
(FEV 1) at week 24 
Secondary
To compare UMEC/VI (62.5/25 mcg 
once dail y), UMEC (62.5 mcg once 
daily ) with salmeterol (5 0 mcg twice 
daily ) on patient reported outcomes 
(PROs) Change from baseline in self 
administered computerised (SAC) 
transient dy spnea index (TDI) 
Percentage of TDI responders 
according to SAC TDI score.  A 
responder is defined as a ≥1 unit 
improvement in SAC TDI score 
Assessment of respi[INVESTIGATOR_645915] 24 weeks using 
Evaluating Respi[INVESTIGATOR_244774] -
COPD (E- RS) and its subscales 
(breathlessness, cough and sputum and 
chest sy mptoms) 
Percentage of E -RS responders 
according to E -RS score (defined as 
reduction in E -RS score of  2 or 3.35 
units) from baseline
Change from baseline in St George’s 
Respi[INVESTIGATOR_21606] (SGRQ -C)
Percentage of responders according to 
SGRQ -C total score (defined as a 4 
point or greater reduction from  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
17Objectives Endpoints
baseline) 
Change from baseline in COPD 
assessment test ( CAT)
Percentage of responders according to 
CAT (defined as a 2 unit improvement 
in score from baseline)
Other
To compare UMEC/VI (62.5/25 mcg 
once dail y), UMEC (62.5 mcg once 
daily ) with salmeterol (50 mcg twice 
daily ) on other COPD efficacy  measures Rate of mild, moderate or severe 
exacerbations
Time to first mild, moderate or severe 
exacerbation
Rate of moderate or severe 
exacerbation
Time t o moderate or severe 
exacerbation
Time to severe exacerbations
Time to clinically  important 
deterioration (CID) composite endpoint 
Time to clinically  important 
deterioration composite endpoint 
excluding FEV 1
Rescue albuterol/salbutamol use, 
(percentage o f rescue- free day s and 
mean number of Inhalations/day ) 
captured b y the electronic diary 
(eDiary ) over 24 weeks
Inspi[INVESTIGATOR_645920] y (IC)
Full Vital capacity  (FVC) 
Change from baseline in trough FEV 1
Change from baseline in global 
impression of disease se verity   2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
18Objectives Endpoints
Safety
To evaluate safet y and tolerability 
of UMEC/VI ( 62.5/25 mcg once 
daily ), UMEC (62.5mcg once dail y)
and salmeterol (50mcg twice dail y) Incidence of adverse events
Exploratory
To compare albuterol/salbutamol 
use captured in the eDiary  with the 
electronic metered dose inhaler 
(eMDI) device Rescue albuterol/salbutamol use, 
(percentage of rescue- free day s and 
mean number of Inhalations/day ) 
captured b y the eMDI device over 24 
weeks as data allow
To explore the effect of UMEC/VI  
(62.5/25 mcg once dail y), UMEC 
(62.5 mcg once daily ) with 
salmeterol (50 mcg twice daily ) on 
physical activityChange from baseline in phy sical 
activity  
To investigate the CID composite 
endpoint ability  to predict short 
term outcomes To compare ph ysical activity  levels, 
ER-S, rescue medication use, 
exacerbations and mortality  in subject s 
with and without a CI D
4. STUDY DESIGN
4.1. Overall Design
This is a multi -centre, r andomized, double blind, double -dummy , 3-arm parallel group 
study .  Eligible subjects will be stratified based on long -acting bronchodilator usage 
during the run- in (none, one or 2 long -acting bronchodilators per day ) and randomized in 
a ratio of 1:1:1 to UMEC/VI  inhalation powder (62.5/25 mcg once daily) administered 
via the ELLIPTA inhaler, or UMEC (62.5 m cg once dail y) administered via the 
ELLIPTA or salmeterol (50 mcg BID) administered via the D ISKUS.
There will be a total of 5 clinic visits and one follow -up phone call (Visit 6). The Pre -
screening Visit (Visit 0) can occur on the same day  as the Screeni ng Visit (Visit 1) if 
subject does not take or has not taken an y excluded protocol medications , but must be 
completed prior to initiating an y Visit [ADDRESS_865075]’s eligibility  for the stud y. During the run-
in period subjects will continue with their inhaled COPD medications (excluding ICS and 
any exclusionary medications) . In addition ,subjects will be provided wi th short acting 
albuterol/salmeterol to be used on as needed basis for relief of COPD s ymptoms (rescue 
medication) throughout the study .  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
19Subjects who experience a moderate or severe COPD exacerbation during the run- in 
period will be deemed run-in failures . Subjects who experience a mild COPD 
exacerbation, defined as worsening of s ymptoms that require s notreatment with 
antibiotics or steroids and is self managed b y the patient by [CONTACT_645996] , (Appendix 5), will be able to continue in the study based on the judgment of 
the investigator and agreement of the sponsor ’smedical monitor .
At the randomization Visit 2 ( Day 1) those subjects who successfull y complete the run- in 
period as well as mee t the other pre -defined eligibility  and randomization criteria will 
discontinue the ir inhaled COPD medications and will be randomized to one of the 3 
treatment arms for 24 weeks.
During the run- inand treatment period , subjects will be completing PRO questionnaires
in the eDiary  and performing slow and forced spi[INVESTIGATOR_645983] .
In addition, a subset of subjects up to 150 per treatment arm will undergo assessment of 
their phy sical activity  measured through a phy sical activity  monitor (Acti graph GT9X) 
worn for 7 day sfrom Screening (Visit 1), for 7 day s from Randomisation (Visit 2), [ADDRESS_865076] clinic Visit (Visit 5). 
Concurrent use of COPD maintenance medications including LAMAs, LABAs, oral beta -
agon ists, theophy llines, inhaled corticosteroids, inhaled corticosteroids and L ABA 
combination and phosphodiesterase 4 inhibitors will not be allowed during the stud y
(Section 6.11.2 ) . 
The occurrence of adverse ev ents(AEs) will be evaluated throughout the study  beginning 
at Visit 2 (Day 1) and until the f ollow -up contact (Visit 6).  Serious adverse events 
(SAEs) will be collected over the same time period as AEs. However, an y SAEs 
assessed as related to study  participation (e.g., study  treatment, protocol -mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] concomitant 
medication, will be recorded from the time a subject consents to participate in the study  
up to and including an y follow up contact ( Appendix 4). 
All subjects will be given an electronic diary  (eDiary ) for use during the run -in, and the 
treatment period to complete PRO questionnaires, record COPD daily  symptom s,any 
medical pro blems experienced during the study and the time they  take their COPD 
medications. Daily  rescue medication usage (number of inhalations taken in the last 24h)
will also be captured in the eDiary . In addition, and in some countries, rescue medication 
use w ill also be captured by [CONTACT_645997] (eMDI).
At Screening V isit 1,all subjects must be trained on the proper use of their existing 
COPD medications inhalation devices and instructed to strictly  adhere to and record the 
time t hey take their COPD medications in the eD iary.
At the randomization Visit [ADDRESS_865077] completed the study  upon completion of the follow –
up contact [CONTACT_107461].
There are no plans to routinely  provide any  of the study  treatments for compassionate use 
following stud y completion as the study  treatment are commerciall y available .
The study  design schematic is illustrated in Figure 1
Figure 1 Study  Schematic
*Inhaled COPD medications including LABAs, LAMAs or LABA/LAMA combination products are 
allowed in run-in. ICS alone or in combination with a bronchodilator or any exclusionary 
medications are not allowed.
4.2. Treatment A rms and Duration
Subjects will be stratified based on long-acting bronchodilator usage during the run- in 
(none, one or 2 long- acting bronchodilators per day ) and randomized in a ratio of 1:1:1 to 
either
UMEC/VI  inhalatio n powder (62.5/25 mcg once daily ) administered via the 
ELLIPTA DPI )or 
UMEC ( 62.5 mcg once daily )administered via the ELLIPTA DPI[INVESTIGATOR_1660] 
Salmeterol (50 mcg BID)administered via D ISKUS
The total duration of subject participation in the study  will be approx imately  [ADDRESS_865078], well -established design 
to evaluate the efficacy  and safet y of an investi gational drug. A salmeterol arm is 
included to allow a comparison to be made between UMEC/VI , UMEC with salmeterol, 
a standard practice treatment.
The double -dumm y design is appropriate when drugs are of different appearance or 
different administration regimen which is appropriate in this study  where the inhalers 
used have a different appearance and used once daily  and twice dail y.
The European Medicines Agency  (EMA )COPD Guidelines suggest that duration of 12 to 
24 weeks is considered adequate for assessm ent of response of COPD sy mptoms to 
treatment intervention with bronchodilators (EMA COPD guidelines, 2012).
The primary  endpoint is trough FEV [ADDRESS_865079] ablished and an objective means to show the efficacy  of a 
bronchodilator [ Dahl , 2010; Feldman , 2010].
Other endpoints such SAC TDI , E-RS,SGRQ -C,CAT ,Subject Global Rating of Ch ange 
in global impression of disease severity are captured to allow responder analy ses and to 
provide comparative data on PROs between the treatment groups. 
4.5. Dose Justification
This study  is intended to evaluate the efficacy  of marketed doses of UMEC/VI  
(62.5/25mcg once dail y), UMEC ( 62.5 mcg once daily )andsalmeterol (50mcg twice 
daily ) that are approved for the maintenance treatment of COPD, with respect to PRO
measures.
4.6. Benefit: Risk Assessment
Summaries of findings from both clinical and non- clinical studies conducted with 
UMEC/VI  and UMEC can be found in the investigator’s brochures (IB)
[GlaxoSmithKline Document Number RM2009/[ZIP_CODE]/07] and [GlaxoSmithKline 
Document Number RM2006/[ZIP_CODE]/09 ] and in the label information sheet s. The current 
safet y profile for UMEC (62.5mcg) and the UMEC/VI (62.5/25mcg) based on data 
available to date, is comparable with other LABAs and LAMAs.  Summary  safet y data 
can also be found in the i nformation sheet for salmetero l [Serevent product information
2003 ].The following section outlines the risk assessment and mitigati on strategy  for this 
protocol: 6 2018N377698_00
I2016N277425_00 CONFIDENTIA L
201749
224.6.1. Risk A ssessment
Potential Risk of Clinical Signific ance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP) [UMEC/VI] 
Severe milk protein allergy Anoro contains Lactose monohydrate (which contains milk 
protein) as an excipi[INVESTIGATOR_841].Exclusion criteria have been set for subje cts with milk 
protein allergy.
Cardiovascular effects such as cardiac arrhythmias e.g.
supraventricular tachycardia and extrasystoles.Class effects associated with LABAs and LAMA containing 
therapy. The clinical significance of these arrhythmias is 
unkn own. Clinical experience with UMEC/VI to date in 
completed studies did not show any association with major 
cardiovascular events. 
Data available in the product label for UMEC/VI Exclusion criteria have been set for subjects with 
uncontrolled or severe cardiovascular disease according to 
the principal investigation’s (PI) opi[INVESTIGATOR_645921]. The PI [INVESTIGATOR_645984].  Patients with the 
following abnormalities will be excluded from participation:  
atrial fibrillation with rapid ventricular rate >120bpm, 
sustained or nonsustained ventricular tachycardia, or 
second degree heart block Mobitz type II or third degree 
heart block (unless pacemaker or defibrillator had been 
inserted). 
Beta agonists and risk of asthma -related death Long -acting beta agonists such as vilanterol when used 
alone may increase the risk of asthma -related death.  A 
placebo -controlled trial with another LABA (salmeterol) 
showed an increase in asthma -related deaths in subjects 
receiving salmeterol.  This finding with salmeterol is 
considered a class effect of all LABAs, including vilanterol. 
Data are not avai lable to determine whether the rate of death 
in patients with COPD is increased by [INVESTIGATOR_140413].Subjects with a current diagnosis of asthma are excluded 
from participation in the study.
Paradoxical bronchospasm As with other inhaled medicines, UMEC/VI can produc e 
paradoxical bronchospasm which may be life threatening.If paradoxical bronchospasm occurs following dosing with 
UMEC/VI, this treatment should be discontinued 
immediately and alternative therapy should be instituted. 
Use in patients with narrow -angle glaucoma or urinary 
retentionNo association has been found to date, in completed studies 
with UMEC/VI or UMEC monotherapy, on glaucoma or 
urinary retention.  However, glaucoma or urinary retention Exclusion criterion states that subjects with medical 
conditions such as narrow -angle glaucoma, prostatic 
hypertrophy, or bladder neck obstruction should only be  
 
 2018N377698_00
I2016N277425_00 CONFIDENTIA L
201749
23Potential Risk of Clinical Signific ance Summary of Data/Rationale for Risk Mitigation Strategy
have been observed with other antimuscarinic agents, and 
could potentially be due to the pharmacology.included if, in the opi[INVESTIGATOR_497326], the 
benefit outweighs the risk.
Use of beta blockers Beta-adrenergic blockers may weaken or antagonize the 
effect of beta 2-agonists such as vilanterol.The study permitted medications and non drug therapi[INVESTIGATOR_645985] -
blockers is only permitted if, in the Investigator’s opi[INVESTIGATOR_1649], 
the likely benefit outweighs the potential risk.
Pregnancy There is no experience to date of pregnancy during the use 
of UMEC/VI.The study inclusion criteria ensures that fe male subjects of 
child bearing potential must have a negative pregnancy 
test at screening, and agree to a reliable contraceptive 
method, used consistently and correctly (i.e. in accordance 
with the approved product label and the instructions of the 
physici an for the duration of the study). Exclusion criteria 
include Pregnancy: Women who are pregnant or lactating 
or are planning on becoming pregnant during the study.
Severe hepatic impairment UMEC/VI has not been studied in severe hepatic impairment. Exclus ion criterion states that subjects severe hepatic 
impairment should only be included if, in the opi[INVESTIGATOR_564989], the benefit outweighs the risk.
Investigational product (IP) [UMEC]
Cardiovascular effects such as cardiac arrhythmia, e.g.
atrial fibrillation and tachycardiaA potential class effect associated
with anti -muscarinic therapi[INVESTIGATOR_014]. Data available to date in the 
IB for UMEC [GlaxoSmithKline Document Number 
RM2006/[ZIP_CODE]/09Screening electrocard iogram (ECG) criteria to exclude 
subjects potentially at risk 
Narrow -angle glaucoma, urinary retention A class effect associated with anti -muscarinic therapi[INVESTIGATOR_014].
Data available in the IB for UMEC [GlaxoSmithKline
Document Number RM2006/[ZIP_CODE]/09Exclusion criterion states that subjects with medical 
conditions such as narrow -angle glaucoma, prostatic 
hypertrophy, or bladder neck obstruction should only be 
included if, in the opi[INVESTIGATOR_9764], the benef it 
outweighs the risk.
Paradoxical bronchospasm that may be life threatening Known effect associated with inhalation therapy A short -acting inhaled bronchodilator 
(albuterol/salbutamol) will be provided for use as needed 
throughout the study. The investig ators will be instructed to 
assess subject’s condition to determine their eligibility to  
 
 2018N377698_00
I2016N277425_00 CONFIDENTIA L
201749
24Potential Risk of Clinical Signific ance Summary of Data/Rationale for Risk Mitigation Strategy
continue in the study and the need for alternative therapy.
Severe hepatic impairment UMEC has not been studied in severe hepatic impairment. Exclusion criterion stat es that subjects with severe hepatic 
impairment should only be included if, in the opi[INVESTIGATOR_564989], the benefit outweighs the risk.
Pregnancy/Lactation There is no experience to date of pregnancy during the use 
of UMEC.The study inclusion criteria ensure that female subjects 
enrolled, who are of Child bearing potential, have a 
negative pregnancy test at screening, and agree to a 
reliable contraceptive method, used consistently and 
correctly (i.e. in accordance with the approved product 
label and the instructions of the physician for the duration 
of the study). Exclusion criteria states -Pregnancy: 
Women who are pregnant or lactating or are planning on 
becoming pregnant during the study.
Study Procedures
Spi[INVESTIGATOR_645986], changes in pulse rate 
and blood pressure, coughing, wheezing, chest tightness or 
fainting.Subjects will be monitored during the procedure for these 
effects and spi[INVESTIGATOR_645925].
ECG lead placemen t This may cause skin irritation. It may be necessary to have small patches (about a 
centimetre in diameter) of hair on the chest shaved to 
properly attach electrodes to the chest. 
Blood sampling procedure (optional pharmacogen etic 
blood sample)Giving blood may make subjects feel faint, or experience 
mild pain, bruising, irritation or redness at the site. In rare 
cases, they may get an infectionSubjects will be monitored during the blood draw for these 
effects and should call their study doctor if any o f these 
effects do not resolve
Other 
Side effects of rescue albuterol/salbutamol. Adverse 
events seen in clinical studies to date are however 
consistent for the beta 2-adrenergic class of compoundsClass effects associated with short acting beta -agonists
(SABAs)Subjects should call their study doctor if they experience 
any of these symptoms 
 
 2018N377698_00
2016N277425_00 CONFIDENTIA L
[ADDRESS_865080] to PROs and sy mptoms in thetreatment of COPD.
Specific benefits associated with the study  design and procedures in clude the following:
Subjects will receive treatments approved for the treatment of COPD that have 
been shown to be effective in the population under study
All subjects will receive albuterol /salbutamol for use “as needed” for relief of 
COPD sy mptoms
The c ombination of study  procedures of spi[INVESTIGATOR_038] , CAT, SGRQ, TDI , E-RSwill 
provide the study  subjects with a comprehensive evaluation of their symptoms,
health status and COPD disease severity . Subjects will also be monitored 
throughout the stud y for any  worsening of COPD sy mptoms or decline in general 
health. Finall y smoking cessation counselling will also be provided.
4.6.3. Overall Benefit: Risk Conclusion
Taking into account the measures taken to minimize risk to subjects participating in this 
study , the potenti al risks identified in association with UMEC/VI , UMEC, salmeterol and 
with study  procedures are justified by  [CONTACT_645998] .
5. SELECTION OF STUDY POPULA TION AND 
WITHDRA WAL CRITERIA
Specific information regarding warnings, precautions, contraindications, adverse events, 
and other pertinent information on the [COMPANY_004] investigational product or other study  
treatment that may  impact subject eligibility  is provided in the IBs, [GlaxoSmithKline
Document Number RM2006/[ZIP_CODE]/09], [GlaxoSmithKline Document Number 
RM2009/[ZIP_CODE]/07] and product labels.
Deviations from inclusion and exclusion criteria are not allowed be cause they  can 
potentially  jeopardize the scientific integrity  of the study , regulatory  acceptability  or 
subject safet y. Therefore, adherence to the criteria as specified in the protocol is essential.
5.1. Inclusion Criteria
A subject will be eligible for inclu sion in this study  only  if all of the following criteria 
apply :
AGE
1.[ADDRESS_865081] AND DIAGNOSI S INC LUDING DISEASE SEVERI TY
2.Outpatient with a diagnosis of COPD in accordance w ith the definition of the 
American Thoracic Society /European Respi[INVESTIGATOR_21618]  (ATS/ERS) [ Celli , 2004]. 
3.FEV 1: Persistent airflow limitations as indicated by :  A pre and post -
albuterol/salbutamol FEV 1/FVC ratio of <0.[ADDRESS_865082] -albuterol/salbutamol FEV 1
of ≥30% to ≤80% predicted normal values at Screening Visit 1.  Predicted values 
will be based upon the ERS Global L ung Function I nitiative [ Quanjer , 2012].
4.CAT score :  A CAT score of ≥
10 at Screening Visit 1
Smoki ng History
5.Current or former cigarette smokers with a history  of cigarette smoking of 10 
pack -years [number of pack years = (number of cigarettes per day  / 20) x number of 
years smoked (e.g. 20 cigarettes per day  for 10 y ears, or 10 cigarettes per day  for 20 
years both equal 10 pack -years)].  Former smokers are defined as those who have 
stopped smoking for at least 6 months prior to Visit 1.  Pi[INVESTIGATOR_23887]/or cigar use cannot 
be used to calculate pack -year history .
SEX
6.Male and female subjects are eligible to participate in the study
A female subject is eligible to participate if she is not pregnant (as confirmed by  a 
negative urine human chorionic gonadotrophin (hCG) test), not lactating, and at least one 
of the following conditions applies:
a.Non-reproductive potential defined as:
Pre-menopausal females with one of the following:
Documented tubal ligation
Documented h ysteroscopic tubal occlusion procedure with follow -up 
confirmation of bilateral tubal occlusion 
Hysterectomy
Documented Bilateral Oophorectom y
Postmenopausal defined as 12 months of spontaneous amenorrhea.  In questionable cases 
a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels 
consistent with menopause must be tested .  Females on hormone replacement therap y 
(HRT) and whose menopausal status is in doubt will be required to use one of the highl y 
effective contraception methods if they  wish to continue their HRT during the study .  
Otherwise, they  must discontinue HRT to allow confirmation of post -menopausal st atus 
prior to study  enrolment.
b. Reproductive potential and agrees to follow one of the options listed in the Modified 
List of Highl y Effective Methods for Avoiding Pregnancy in Females of  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
27Reproductive Potential (FRP) (Appendix 7)from [ADDRESS_865083] dose of 
study  medication and until [at least five terminal half- lives OR until any  continuing 
pharmacologic effect has ended, whichever is longer] after the last dose of study  
medication and completion of the follow- up visit.
The investigator is responsible for ensuring that subjects understand how to properl y use 
these methods of contraception.
INFORMED CONSENT
7.Capable of giving signed informed consent prior to study  participation, which 
includes compliance with the requirements and restrictions listed in the consent form 
and in this protocol.
5.2. Exclusion Criteria
A subject will not be eligible for inclusion in this study  if an y of the following criteria 
apply :
CONCURRENT CONDITIONS/MEDI CAL  HISTORY (INCLUDES LIV ER 
FUNCTION 
1. Asthma :  A current diagnosis of asthma.  (Subjects with a prior history  of asthma 
are eligible if they  have a current diagnosis of COPD, which is the primary cause of 
their respi[INVESTIGATOR_23908]).
2. Alpha -antitrypsin deficiency: Subjects with known α1-antitry psin deficiency  as 
the underl ying cause of COPD
3. Other respi[INVESTIGATOR_17744]: Subjects with active tuberculosis are excluded. 
Subjects with other respi[INVESTIGATOR_146456] (e.g. clinically  significant: 
bronchiectasis, sarcoidosis, lung fibrosis, pulmo nary hypertension, interstitial 
lung diseases) are excluded if these conditions are the primary cause of their 
respi[INVESTIGATOR_23908].
4. Unstable liver disease: Current active liver or biliary  disease (with the exception 
of Gilbert’s s yndrome or asymptomatic g allstones or otherwise stable chronic 
liver disease per investigator assessment). 
Stable chronic liver disease should generally  be defined by  [CONTACT_107415], 
encephalopath y, coagulopathy, h ypoalbuminaemia, oesophageal or gastric 
varices, or persis tent jaundice, or cirrhosis.
Chronic stable hepatitis B and C ( e.g., presence of hepatitis B surface antigen 
(HBsAg) or positive hepatitis C antibody  test result or within [ADDRESS_865084] dose of study  treatment) are acceptable if subject otherwise meets entry  
criteria
5. Unstable or life threatening cardiac disease: Investigational Product should be 
used with caution in subjects with severe cardiovascular disease.  In the opi[INVESTIGATOR_8574], use should only  be considered if the benefit is lik ely to  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
28outweigh the risk in conditions such as:
Myocardial infarction or unstable angina in the last 6 months
Unstable or life threatening cardiac arrh ythmia requiring intervention in the last 3 
months
NYHA Class IV heart failure
6. 12 Lead ECG: The Investiga tor will determine the clinical significance of each 
abnormal ECG finding in relation to the subject’s medical history  and exclude 
subjects who would be at undue risk by  [CONTACT_19212]. Subjects with the 
following abnormalities are excluded fro m participation in the study :
Atrial fibrillation with rapid ventricular rate >120 bpm
Sustained or non -sustained ventricular tach ycardia
Second degree heart block Mobitz ty pe II or third degree heart block (unless 
pacemaker or defibrillator had been inser ted)
7. Antimuscarinic effects: Subjects with medical conditions such as narrow -angle 
glaucoma, urinary  retention, prostatic hy pertrophy, or bladder neck obstruction 
should be excluded unless, in the opi[INVESTIGATOR_23942], the benefit 
outweighs the risk.
8. Other disease abnormalities: Any subject who is considered unlikel y to survive 
the duration of the stud y period or has an y rapi[INVESTIGATOR_2478] y progressing disease or 
immediate life-threatening illness (e.g. cancer). In addition, any  subject who has 
any other condition (e.g. neurological condition) that is likely  to affect respi[INVESTIGATOR_645926] .
9. Hospi[INVESTIGATOR_059]: Hospi[INVESTIGATOR_645927] 12 weeks prior 
to Visit 1. Pneumonia and/or moderate or severe COPD exace rbation that has 
not resolved at least [ADDRESS_865085] dose of oral/s ystemic corticosteroids (if applicable). 
10. Inhaled corticosteroids (ICS) :Had received ICS or ICS/LABA for the treatment 
of COPD in th e 6 weeks prior to S creening Visit1
11. Exacerbation: Had >[ADDRESS_865086] 7 days prior to 
Screening V1.
13. Lung Resection: Subjects with lung volume reduction surgery  (including 
procedures such as endobronchial valves) within the 12 months prior to Screening 
V1.
14. Oxygen: Use of long -term oxy gen therap y (LTOT) described as resting oxy gen 
therap y >3L/min at screening required to maintain adequate ox ygenation ( e.g.
SaO2>90%) . (Ox ygen use ≤3L/min flow is not exclusionary , and patients may  
adjust oxy gen levels up or down as needed during the study .) 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
29CONCOMI TANT MEDICATIONS
1.Medications prior to Screening: Use of the following medications according to 
the following defined time intervals prior to Screening (Visit 1):
Medication No use within the 
following time intervals 
prior to Screening
Inhaled corticosteroids ( ICS) 6 weeks
Depot corticosteroids 12 weeks
Systemic, oral or parenteral corticosteroidsa 6 weeks
Antibiotics (fo r lower respi[INVESTIGATOR_1092]) 6 weeks
Phosphodiesterase 4 (PDE 4) Inhibitor ( e.groflumilast) 14 days
LABA/Inhaled Corticosteroid (ICS) combination products 6 weeks
Theophyllines 48 hours
Oral beta 2-agonists
     Long- acting
     Short -acting48 hours
12 hours
Inhaled short acting beta 2-agonistsb 4 hours
Inhaled short -acting anticholinergics 4 hours
Inhaled short -acting anticholinergic/short -acting beta 2-agonist 
combination products4 hours
Any other investigational medication 30 days or wit hin 5 drug 
half-lives (whichever is 
longer)
a- Localized corticosteroid injections (e.g., intra -articular and epi[INVESTIGATOR_13873]) are permitted.
b- Use of study provided albuterol/salbutamol is permitted during the study, except in the 4 -hour period prior to 
spi[INVESTIGATOR_68333]
2.Medication prior to spi[INVESTIGATOR_038]: Unable to withhold albuterol/salbutamol for 
the 4 hour period required prior to spi[INVESTIGATOR_645972].
3.Maintenance use of short -acting bronchodilators :  Regular use (prescribed for 
daily / regular use , not for as- needed use) of short -acting bronchodilators ( e.g. 
albuterol/salbutamol).
REL EVANT HABITS
1.Drug or alcohol abuse: A known or suspected history  of alcohol or drug abuse 
within [ADDRESS_865087] from completing the stud y procedures.
CONTRAINDICATIONS 
1.Any history of allergy or hypersensitivity to any anticholinergic/muscarinic 
receptor antagonist, s ympathomimetic, lactose/milk protein or magnesium stearate. 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
30DIAGNOSTIC ASSESSMENTS AND OTHER CRI TERIA
1.Pulmonary Rehabilitation program: Participation in the acute phase of a 
pulmonary  rehabilitation program within 4 weeks prior to Screening Visit 1.  Subjects 
who are in the maintenance phase of a pulmonary rehabil itation program are not 
excluded.
2.Affiliation with investigator sites: Is an investigator, sub -investigator, study  
coordinator, emplo yee of a participating investigator or study site, or immediate 
family  member of the aforementioned that is involved in thi s study
3.Inability to read: In the opi[INVESTIGATOR_871], any  subject who is unable to read 
and/or would not be able to complete questionnaires on the electronic diary.
Subjects who fail to meet inclusion and exclusion criteria at the Screening Visit 1will be 
considered screen failures and cannot be re-screened.
5.3. Randomization Criteria
In order to be randomized to one of the [ADDRESS_865088] fulfilled all inclusion and exclusion criteria 
described in Section 5.1and Section 5.2. In addition to the following:
REQUI RED CRI TERIA FOR RANDOMIZATION AND TREATMENT
1.COPD Exacerbation : Subjects must nothave experienced a moderate or severe 
COPD exacerbation or a lower respi[INVESTIGATOR_626201] -in or at Day  1 
(Visit 2) inclusive.  A moderate exacerbation is defined as worsening of s ymptoms of 
COPD requiring the use of antibiotics or sy stem ic corticosteroids.  A severe 
exacerbation is defined as worsening sy mptoms of COPD requiring hospi[INVESTIGATOR_059].
2.CAT score :  A CAT score of ≥10 at Visit 2
3.Prohibited Medications: No use of an y prohibited medications during the run -in 
period or at Visit 2, including an y ICS or ICS/LABA combination
4.Any change to COPD medications :Including dosage and regimen during the run -in
5.Completion of electronic diary: Must have completed the electronic diary for at 
least 80% of day s during the run- in period
Subjects who do not meet the required criteria for randomization at Visit 2 will not be 
randomized.
5.4. Screening/Baseline/Run-in Failure s
Pre-screen, screen and run- in failures are defined as follows: 
Pre-screening failures: A subject ,who is assigned a subject number at the Pre -
screening Visit [ADDRESS_865089] any  Screening Visit 1 procedures ,will be 
considered a pre -screen failure. 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
31Screening failures: Those subjects that complete at least one Screening Visit 1 
procedure but do not enter the run -in period.
Run-in failures: Those subjects that enter the run- in period but are not 
randomized to any  of the study  treatment arms.
Subjects w ho are pre -screen, screen and run -in failure will be recorded in the eCRF.  In 
order to ensure transparent reporting of screen failure subjects, meet the Consolidated 
Standards of Reporting Trials (CONSORT) publishing requirements, and respond to 
queries f rom Regulatory  Authorities, a minimal set of screen failure information is 
required to be recorded in eCRF including demograph y, screen failure details, eligibility  
criteria, and serious adverse events (Section 7.4.1 ). 
5.5. Withdrawal/Stoppi[INVESTIGATOR_2121]
5.5.1. Withdrawal from the Study
Subjects may  be withdrawn from thestudy  at an y time by  [CONTACT_646021] .  Reasons for withdrawal 
from study  treatment c an include: an AE, clinically  significant abnormality , lack of 
efficacy , sponsor terminated study , pregnancy , or for any  other reason. 
If a subject withdraws from the study , he/she may request destruction of any  samples 
taken, and the investigator must do cument this in the site study  records . 
A reason for the withdrawal from the study  must be captured in the electronic case report 
form ( eCRF ).
A subject will also be withdrawn from the study , in consultation with the medical 
monitor and principal investiga tor, if any  of the following stoppi[INVESTIGATOR_23893]:
Liver Chemistry: Meets any  of the Liver chemistry  stoppi[INVESTIGATOR_3418] (See Section 
5.5.3 )
Note: clinical laboratory  assessments are not required for this st udy. However, 
laboratory  samples may  be taken for liver event analy sis, if clinicall y indicated b y 
the study  investigator.
Pregnancy: Positive pregnancy  test (see Appendix 7)
Subjects withdrawn from study  treatment wi ll not be replaced.
Note: Withdrawal from study  treatment requires withdrawal from the study .
The following actions must be taken in relation to a subject who fails to attend the clinic 
for a required stud y visit:
The site must attempt to contact [CONTACT_646022] -schedule the missed visit as 
soon as possible. 
The site must counsel the subject on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the subject wishes to and/or should 
continue in the study .  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
32In cases wher e the subject is deemed ‘lost to follow up’, the investigator or 
designee must make every effort to regain contact [CONTACT_1155] (where 
possible, [ADDRESS_865090]’s last 
known mailing address or local equivalent methods). These contact [CONTACT_131994]’s medical record. 
Should the subject continue to be unreachable, only then will he/she be considered 
to have withdrawn from the study  with a primary  reason of “Lost to Follow -up”. 
5.5.2. Reason for Study  Withdrawal
The primary  reason for study  withdrawal will be recorded in the eCRF. When a subject 
withdraws consent, the investigator must document the reason (if specified by  [CONTACT_1560]) in the eCRF. 
The primary  reason for study  withdrawal may  include :
Adverse event
Lost to follow -up
Withdrew consent
osubject relocated
ofrequency  of visits
oburden of procedures
oother (specify )
Protocol deviation
Lack of efficacy
COPD exacerbation
Study  closed/terminated
Subject reached protocol -defined stoppi[INVESTIGATOR_645987]
Investigator discretion
5.5.3. Liver Chemistry Stoppi[INVESTIGATOR_131957] y and evaluate liver event etiology (in alignment with t he FDA 
premarketing cl inical liver safety  guidance). 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
33Phase III -IV Liver Chemistry Increased Monitoring Algorithm with Continued 
Therapy for ALT 3xULN but <[ADDRESS_865091]
Cont inue Study Treatm ent   and   Monitor  Liver Chem istry
Discontinue Study Treatment ALT≥5xULN 
but <8xULN
+ bili<2xULN +
no symptoms
NoMust  refer to Liver Safety Requi red Actions and Fol low up Asses smen ts section in the Appendi x
YesALT ≥3xULN 
but <5xULN
+ bili<2xULN  +
no symptomsAble to 
monitor  
weekly 
for  ≥2 
weeksPersists for 
≥2 weeks  
or other  
stoppi[INVESTIGATOR_53099]  ≥4 
weeksPersists for 
≥4 weeks  
or other  
stoppi[INVESTIGATOR_131958] ≥5xULN ALT <5xULN 
Yes Yes
*INR value not applicable to subjects on anticoagulants Must  refer to Liver Safety Requi red Actions and Fol low up Asses sments section in the Appendi x
Repor t as an SAE if possible Hy’sLaw case:  ALT≥3xUL N and  Bilirubin≥2x ULN (>35% direct)  or 
INR>1.5, if measur ed*
Liver Safet y Required Actions and Follow up Assessments Section can be found in 
Appendix 2.
[IP_ADDRESS]. Study  Treatment Restart or Rechallenge
Study  treatment restart or rechallenge after liver chemistry  stoppi[INVESTIGATOR_3418] a re met b y 
any subject participating in this study  is not allowed.
5.6. Follow -up contact
A safet y follow- up contact (Visit 6) should be conducted 7 2days following the 
completion of Visit 5 or the Earl y Withdrawal Visit, if applicable. 
The following procedure s will be performed:
AE/SAE assessment
COPD exacerbation assessment
Concomitant medication assessment limited to any  medications used to treat a 
COPD exacerbation or SAE (if applicable)
Pregnancy  information (if applicable)
Subjects who have successfully  completed all on -treatment randomized visits will be 
discharged from the study upon completion of the safet y follow- up contact. 2018N377698_00
2016N277425_00 CONFIDENTIA L
[ADDRESS_865092] completed the study  if he/she receives study  
treatment at Visit 5(Week 24) and completes the follow -up contact [CONTACT_4838] [ADDRESS_865093]’s last visit .
6. STUDY TREA TMENT
6.1. Investigational Product and Other Study  Treatment
The term ‘stud y treatment’ is used throughout the protocol to des cribe an y combination 
of products received b y the subject as per the protocol design. Study  treatment may  
therefore refer to the individual study  treatments or the combination of those study  
treatments.
The contents of the label will be in ac accordance wi th all applicable regulatory  
requirements.
Under normal conditions of handling and administration, investigational product is not 
expected to pose significant safet y risks to site staff.  Take adequate precautions to avoid 
direct ey e or skin contact [CONTACT_23968]. Notify the monitor of 
any unintentional occupational exposure.  A Material Safet y Data Sheet (MSDS) 
describing the occupational hazards and recommended handling precautions will be 
provided to site staff if required by  [CONTACT_339256].
Investigational product must be stored in a secure area under the appropriate phy sical 
conditions for the product.  Access to and administration of the investigational product 
will be limited t o the investigator and authorised site staff.  Investigational product must 
be dispensed or administered onl y to subjects enrolled in the study  and in accordance 
with the protocol.
GlaxoSmithKline ([COMPANY_004]) will provide the study  treatments for use in this stu dy. 
The following stud y medications will be used in this study :
UMEC/VI  62.5/ 25mcg administered via ELLIPTA
UMEC 62.5 mcg administered via ELLIPTA
 Salmeterol 50 mcg administered via DISKUS
 Placebo via ELLIPTA
 Placebo via D ISKUS
Subjects will be instructe d to take one dose of medication each morning from the 
ELLIPTA (one inhalation equals one dose) ,and one dose in the morning and one in the 
evening from the DI SKUS ). Subject instructions and details on how to use the ELLIPTA
andDISKUS are provided in the study  reference manual ( SRM). 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
35A description of the UMEC/VI  investigational product administered via the ELLIPTAis 
provided below in Table 1. The ELLIPTA will contain two, double -foil, laminate, blister 
strips.  The ELLIPTA will provide a total of 30 doses (60 blisters) and will deliver, when 
actuated, the contents of a single blister simultaneously  from each of the two blister 
strips. 
The DISKUS will provide a total of [ADDRESS_865094] administered via the ELLIPTA is 
provided below in Table 2.A description of placebo inhalation powder via ELLIPTA is 
shown in Table 3. A description of salmeterol 50mcg and placebo via DISKUS are 
shown in Table 4 and Table 5respectively .
Table 1 Description of UMEC/VI Inhalation Powder via ELLIPTA
Formulation First strip Second strip
Umeclidinium bromide blended with 
lactose monohydrate and 
magnesium stearate1Vilanterol trifenatate blended with 
lactose monohydrate and magnesium 
stearate2
Dosage Form ELLIPTA Inhaler with 30 doses (2 strips with 30 blisters per strip)
Unit Dose Strengths 62.5 mcg 25 mcg
Physical description White powder White powder
Route of Administration Inhaled
1. Magnesium stearate 0.6% w/w of total drug product
2. Magnesium stearate 1.0% w/w of total drug product
Table [ADDRESS_865095] strip
Umeclidinium bromide blended with lactose 
monohydrate and magnesium stearate1
Dosage Form ELLIPTA Inhaler with 30 doses (1 strip with 30 blisters) 
Unit Dose Strengths 62.5mcg 
Physical description Dry white powder
Route of Administration Inhaled
1. Magnesium stearate 0.6% w/w of total drug product
Table [ADDRESS_865096] strip Second strip
Lactose monohydrate blended with 
magnesium stearate1Lactose monohydrate blended with 
magnesium stearate2
Dosage Form ELLIPTA Inhaler with 30 doses (2 strips with 30 blisters per strip )
Unit Dose Strengths Not applicable Not applicable
Physical description Dry white powder Dry white powder
Route of Administration Inhaled
1. Magnesium stearate 0.6% w/w of total drug product
2. Magnesium stearate 1% w/w of total drug product 2018N377698_00
2016N277425_00 CONFIDENTIA L
[ADDRESS_865097] strip
Salmeterol Xinafoate blended with 
lactose monohydrate
Dosage Form Diskus Inhaler with 60 doses (1 strip 
with 60 blisters per strip)
Unit Dose Strengths 50 mcg
Physical description White powder
Route of Administration Inhaled
Table 5 Descriptio n of Placebo inhalation powder v iaDISKUS
Formulation Lactose monohydrate 
Dosage Form Diskus Inhaler with 60 doses (1 strip 
with 60 blister s per strip)
Unit Dose Strengths Not Applicable
Physical description White powder
Route of Administration Inhaled
Albuterol/salbutamol via metered -dose-inhaler (MDI) will be issued for reversibility  
testing at Visit 1.  Albuterol/salbutamol MDI  for as needed (prn) use will be issued 
throughout the study.  Albuterol/salbutamol will be sourced from local commercial stock 
if appropriate.  
6.2. Medical Devices
The eMDI devices are provided by  [CONTACT_646032].  They  have US FDA 510(K) clearance to market (Class 
II device) and EU CE marking (Class I device). Description of the eMDI and its use will 
be provided in the SRM.
6.3. Treatment A ssignment
Subjects who meet the randomization criteria will be assig ned to one of the [ADDRESS_865098] is 24 weeks.  On the morning of each clinic 
study  visit, subjects will refrain from taking their morni ng dose of study  treatment until  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
37instructed to do so by  [CONTACT_6477].  On the other day s during the treatment period 
(i.e. “non- clinic day s”), s ubjects will be instructed to self -administer their study  treatment 
in the morning and evening .Subjects should enter the time they  take their study  treat ment 
in the e Diary .
Subjects will be randomly assigned to one of the blinded study  treatment regimens in 
equal proportion (ratio of 1:1:1) :
UMEC/VI  62.5/25 mcg once dail y via ELLIPTA + placebo twice dail y via 
DISKUS
UMEC 62.5 mcg once daily  via ELLIPTA + placebo twice dail y via DISKUS
Salmeter ol 50 mcg twice daily  via DI SKUS +placebo once daily  via ELLIPTA
The randomisation will be stratified based on long-acting bronchodilator usage during 
the run- in (none, one or 2 long-acting bronchodilators per day ). 
Study  treatment/investigational product will be dispensed at Visits 2, [ADDRESS_865099] return to 
clinic within 30 day s from V2, 60 and 90 day s from V3 and V4 respectively  (see Time 
and event table Section 7.1). 
Used study  drug and rescue medication will be collected at Visits 3, 4 and5or at the 
Early Withdrawal Visit .
6.4. Planned Dose A djustme nts
No dose adjustment is allowed for this study
6.5. Blinding
This will be a double -blind double dummy study and the following will apply . 
The investigator or treating ph ysician may  unblind a subject’s treatment 
assignment only in the case of an emergency ORin the event of a serious 
medical condition when knowledge of the stud y treatment is essential for the 
appropriate clinical management or welfare of the subject as judged b y the 
investigator. 
Investigators have direct access to the subject’s individual st udy treatment. 
It is preferred (but not required) that the investigator first contact [CONTACT_646033]’s treatment assignment. 
If [COMPANY_004] personnel are not contact[CONTACT_646034], the investigator must 
notify  [COMPANY_004] as soon as possible after unblinding, but without revealing the 
treatment assignment of the unblinded subject, unless that information is 
important for the safety  of subjects currently  in the study .  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
38The date and reason for the unblinding m ust be fully  documented in the eCRF
A subject will be withdrawn if the subject’s treatment code is unblinded b y the 
investigator or treating phy sician. [COMPANY_004]’s Global Clinical Safety  and Pharmacovigilance 
(GCSP) staff may unblind the treatment assignment for an y subject with an SAE. If the 
SAE requires that an expedited regulatory  report be sent to one or more regulatory  
agencies, a cop y of the report, identifying the subject’s treatment assignment, may  be sent 
to investig ators in accordance with local regulations and/or [COMPANY_004] policy .
6.6. Packaging and Labeling
The contents of the label will be in accordance with all applicable regulatory  
requirements.
6.7. Preparation/Handling/Storage/A ccountability
No special preparation of the stud y treatment is required.
The investigator or designee must confirm appropriate temperature conditions 
have been maintained during transit for all study  treatment received and any  
discrepancies are reported and resolved before use of the study  treatment.
Only subjects enrolled in the study  may  receive study  treatment and onl y 
authorized site staff may  supply  or administer study  treatment.  All study  
treatments must be stored in a secure environmentally  controlled and monitored 
(manual or automated) area in a ccordance with the labelled storage conditions 
with access limited to the investigator and authorized site staff. 
The investigator, institution, or the head of the medical institution (where 
applicable) is responsible for study  treatment accountability , reconciliation, and 
record maintenance (i.e. receipt, reconciliation and final disposition records).  
Further guidance and information for final disposition of unused study  treatment 
are provided in the SRM .
All ELLIPTA DPI [INVESTIGATOR_645988] d up to 25C (77F).  Each All 
ELLIPTA DPI [CONTACT_468929] [ADDRESS_865100]. 
Salmeterol D ISKUS should be stored up to 25 C. 
Under normal conditions of handling and administration, study  treatment is not 
expected to pose significant safety risks to site staff .  Take adequate precaution s to 
avoid direct ey e or skin contact [CONTACT_23968]. In the case of 
unintentional occupational exposure notify  the monitor, Medical M onitor and/or [COMPANY_004]
study  contact .
A Material Safety  Data Sheet (MSDS)/equivalent document describi ng 
occupational hazards and recommended handling precautions either will be  2018N377698_00
2016N277425_00 CONFIDENTIA L
[ADDRESS_865101] from [COMPANY_004].
6.7.1. Study Treatment Return
All used and unused ELLIPTA and D ISKUS inhalers an d albuterol/salbutamol will be 
returned to [COMPANY_004] at the end of the study  to be available for disposal.  In some instances 
for sites outside the US, study  supplies will be disposed of locall y either b y the site, the 
country  medical department or third -party vendor.  Detailed instructions for the return of 
the study  drug can be found in the SRM.
Study treatment will be collected at Visit 3, [ADDRESS_865102] and dispense a new 
study  treatment kit from the site’s investigational product supply  as instructed by  [CONTACT_646003], any  ELLIPTA that fails to function properly  must be identified and returned 
to [COMPANY_004] for testing. 
6.8. Compliance with Study  Treatment A dministration
When subjects self- administer study  treatment(s) at home , com pliance with study  
treatment(s) will be assessed through querying the subject during the site visits and
through study  drug compliance assessed at Visits2,3, [ADDRESS_865103] be maintained and reconciled with 
study  treatment and compliance records.  Treatment start and stop dates, including dates 
for treatment delay sif any will also be recorded in the eCRF.
Comp liance with the ELLIPTA inhaler will be determined by  [CONTACT_646004]. Compliance with the study  DISKUS will be determined by  [CONTACT_646035] D ISKUS .  Subjects should be ≥80% to ≤120% compliant on 
taking stud y medication between each pair of on -treatment visits. Subjects who fall 
outside this range should be re -educated on treatment compliance b y their site. This re -
education should be documented in the subject’s source document. If medication 
compliance repeat edly falls outside of acceptable ranges, the study  sponsor/site monitor 
must be contact[CONTACT_646006] .
6.9. Treatment of Study  Treatment Overdose
An overdose is defined as a dose greater than the total doses described in Section 6.1and
Section 6.8which results in clinical signs and s ymptoms.  These should be recorded b y 
the investigator on the AE/SAE pages.  In the event of an overdose of study  medication, 
the investigator should use clinical judgment in treating the overdose and contact [CONTACT_646007] .  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
40[COMPANY_004] is not recommending specific treatment guidelines for overdose and toxicity  
management.  The inv estigator is advised to refer to the relevant document(s) for detailed 
information regarding warnings, precautions, contraindications, adverse events, and other 
significant data pertaining to the stud y drug being used in this study . Such documents 
may include, but may  not be limited to, the approved product label for salmeterol 
albuterol, UMEC and UMEC/VI  or equivalent document provided by  [CONTACT_23983].
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_424359].
6.10. Treatment after the End of the Study
Subjects will not receive any additional treatment from [COMPANY_004] after completion of the 
study , since the stud y treatment sare commercially  available.
The inve stigator is responsible for ensuring that consideration has been given to the post -
study  care of the subject’s medical condition, post-study  treatment.
6.11. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_645930] 30 day s prior to Pre -Screening (Visit 0) and onwards 
should be recorded in the eCRF including an y changes in medications. Beginning at 
Visit [ADDRESS_865104] of the stud y, all medications should be recorded in the 
eCRF including an y changes. Study  provided albuterol/s albutamol and double -blinded 
study  drug should notbe recorded in the eCRF. The minimum requirement includes but 
is not limited to drug name, dose, route and the dates of administration. Medications 
initiated after completion of V isit 5or the Earl y With drawal Visit will not be recorded in 
the eCRF, with the exception of those used to treat a COPD exacerbation or SAE that 
occurs between Visit 5(or the Earl y Withdrawal Visit) and the follow -up contact [CONTACT_646024] 
6.
6.11.1. Permitted Medications and Non -Drug Therapie s
The following relevant medications are permitted during this study :
Study -provided albuterol/salbutamol for use as relief medication throughout the 
run-in and treatment periods 
Mucoly tics such as acet ylcysteine
Medications for rhinitis (e.g. intranasal corticosteroids, antihistamines, cromoly n, 
nedocromil, nasal decongestants)
Influenza vaccine
pneumococcal vaccine
Antibiotics for short term treatment ( 14 day s) of acute infections including  
COPD exacerbations
Systemic corticosteroids for short term ( 14 consecutive day s)  treatment of 
COPD exacerbations  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
41As-needed supplemental oxygen use provided it is ≤3L /min flow at rest at 
screening .Patients may  adjust oxy gen levels as needed during the stud y.
Pulmonary  rehabilitation program in maintenance phase
Smoking cessation treatment, including a stable regimen of nicotine replacement
Use of po sitive airway  pressure /non-invasive ventilation for sleep apnea /sleep 
disordered breathing ( e.g. CPAP, BiPAP)
Localized corticosteroid injections (e.g., intra -articular and epi[INVESTIGATOR_13873])
Oral muscarinic antagonists for the treatment of overactive bladder are permitted 
but should be used with caution as they  may  exacerbate medical conditions that 
are contraindicated for anticholinergics (e.g., narrow angle glaucoma and bladder 
outflow obstruction)
Immunotherap y injections
Topi[INVESTIGATOR_645989]
Over-the counter (OTC) cough suppressants
Tricy clic antidepressants and monoamine oxidase inhibitors (MAOI s). Administer 
with caution as they  may potentiate the effect of beta -agonists on the vascular 
system
Diuretics. Caution is advised in the co -administr ation of beta agonists with non-
potassium sparing diuretics
Allergy  vaccination
All medications for other disorders as long as the dose remains constant whenever 
possible and their use would not be expected to affect lung function
6.11.2. Prohibited Medications an d Non -Drug Therapi[INVESTIGATOR_417438] 6 is not permitted during the study 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
42Table 6 Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_645990], oral or parenteral corticosteroids1
Inhaled corticosteroids (ICS)2
Antibiotics >14 days
LABA/ICS combination products
PDE4 inhibitor (e.g. roflumilast)
Inhaled long acting beta 2-agonists (LABA, e.g. salmeterol , formoterol, indacaterol, vilanterol )
Long -acting muscarinic antagonists (LAMA, e.g. tiotropi[INVESTIGATOR_1890], aclidinium, glycopyrronium, umeclidinium3)
LAMA/LABA combination products except for study drugs
Theophyllines
Oral beta 2-agonists
Inhaled short acting beta 2-agonists4
Inhaled short -acting anticholinergics
Inhaled short -acting anticholinergic/short -acting beta 2-agonist combination products
Any other investigational medication
1 Except for the treatment of COPD exacerbations during the study. Localized corticosteroid injections (e.g., 
intra-articular and epi[INVESTIGATOR_13873]) are permitted.
2 Except if during the study use of ICS is deemed necessary for the treatment of subjects’ exacerbation .
[ADDRESS_865105] for study drug
4 Use of study provided albuter ol/salbutamol is permitted during the study, except in the 4 -hour period prior to 
spi[INVESTIGATOR_68333]. 
The following medications or treatments are also notallowed during the study :
Use of long -term ox ygen therap y (LTOT) described as resting ox ygen therapy 
>3L/min only at screening. Ox ygen may  be titrated to any  level deemed necessary  
during the stud y.
Regular (prescribed for daily /regular use, not for as- needed use) therap y with 
albuterol/salbutamol.
Initiation of pulmonary  rehabilitation during the study .
7. STUDY A SSESSMENTS A ND PROCEDURES
Protocol waivers or exemptions are not allowed with the exception of immediate safety  
concerns. Therefore, adherence to the stud y design requirements, including those 
specified in the Time and Events Table Section 7.1, are essential and required for stud y 
conduct.
This section lists the procedures and parameters of each planned study assessment.  The 
exact timing of each assessment is listed in the Time and Events Table Section 7.1 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
437.1. Time and Events Table
Blinded Treatment
VisitPre-
screen1
0Screen/ 
Run-in
1Rando -
mizatio
n [ADDRESS_865106] 
6
Week -6 to -4 -4 0 4 12 24
Day42 2
days 
prior 
Visit 128 2days 
prior Visit 212
days28 2
days 84 2
days168  2
days72days after V5 or 
EW Visit
Screen/Baseline
Written informed consent X
Demography X
Medical/COPD history X
Smoking history/status X
Smoking cessation counselling X
Concomitant medication assessment X X
Cardiovascular History/family history of premature CV 
disease])X
Screening spi[INVESTIGATOR_038] (including post bronchodilator testing )3X
CAT questionnaire X X
Verify Inclusion/Exclusion Criteria X
Training on use of inhalers X X
Training on use of eDiary and eMDI X X
Verify randomization Criteria X
Register Visit in InForm X X X X X X X X
Register Visit in RAMOS NG X X X X X X X X 
 
 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
44Blinded Treatment
VisitPre-
screen1
0Screen/ 
Run-in
1Rando -
mizatio
n [ADDRESS_865107] 
6
Week -6 to -4 -4 0 4 12 24
Day42 2
days 
prior 
Visit 128 2days 
prior Visit 212
days28 2
days 84 2
days168  2
days72days after V5 or 
EW Visit
Efficacy/HRQoL assessments
Spi[INVESTIGATOR_038], including pre -dose FEV 1, trough  FEV 1and 
inspi[INVESTIGATOR_645933] X X X
SAC BDI questionnaire4 X
SAC TDI questionnaire4 X X X
SGRQ -C questionnaire [ADDRESS_865108]/ER -S: COPD 5
Patient Global Rating of COPD severity X X X X
Patient Global Rating of Change in COPD X X X
Safety assessments
Adverse events/Serious adverse events6 X X X X X X X X
COPD exacerbation assessment X X X X X X X X
12-Lead ECG X
Urine pregnancy test 7 X X X X
Pharmacogenetic sample8                                             X
Medication/Supplies
Dispense rescue albuterol/slabu tamol. Dispens eMDI9 X X X X X
Assess COPD medication compliance10during run -in X
Dispense eDiary X
Assess compliance with eDiary during run -in X
Collect rescue albuterol/slabutamol. X X X X X
Collect eDiary X X
Dispense study treatment11 X X X
Collect study treatment X X X X 
 
 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
45Blinded Treatment
VisitPre-
screen1
0Screen/ 
Run-in
1Rando -
mizatio
n [ADDRESS_865109] 
6
Week -6 to -4 -4 0 4 12 24
Day42 2
days 
prior 
Visit 128 2days 
prior Visit 212
days28 2
days 84 2
days168  2
days72days after V5 or 
EW Visit
Assess study treatment compliance during treatment10 X X X X
Study sub -set
Physical activity monitor12 X X X X
Collect Physic al activity monitor X X
1. Pre-screen Visit [ADDRESS_865110] be completed prior to Screening Visit1. It can be completed 2 weeks prior or on the same day of V1, if no wash out of exclusionary medications is 
required. 
2. Early Withdrawal Visit: Subjects that withd raw should return to the clinic as soon as possible to complete the Early Withdrawal Visit procedures.
3. Spi[INVESTIGATOR_645934] (Section [IP_ADDRESS] ). 
4. SAC BDI, SAC TDI, SGRQ- C, CA T questionnaires will be completed at clinic visits andin the eDiary
5. EXACT/ER -S: COPD is completed daily in the eDiary approximately 2 hours before bed -time, starting on Day 1 of the run -in period.
6. For the start date of collecting AEs and SAEs see ( Appendix 4)
7. Pregnancy test: for females for child bearing potential only.
8. Pharmacogenetic sample may be drawn at visit [ADDRESS_865111] provide informed 
consent to thestudy  participant.  Subjects can perform the Pre -screening Visit (Visit 0) 
up to 2 weeks prior t o or on the same day  as the Screening Visit (Visit 1) if subject does 
not take or has not taken any  protocol excluded medications.
Modification of the subject’s medications prior to study  participation is based on the 
physician’s judgment according to sound medical practice, principles, and each subject’s 
needs.  A subject’s treatment must not be changed merel y for the purpose of enabling the 
subject’s participation in the study .  A subject number will be assigned at the time the 
informed consent form (ICF ) is signed. No study related procedures may be 
performed until the informed consent form document has been signed by [CONTACT_1560].  
Once the informed consent is signed and if required , changes can be made to the subject’s 
current medication regimen. The i nvestigator should exercise clinical judgment, and is 
discouraged from changing m edications only  for the purpose of the clinical study . 
During the pre -screening Visit 0, t he following information is collected:
Demographic parameters: y ear of birth, gende r, race and ethnicity
Concomitant medications review
COPD exacerbation assessment
From the pre -screening visit onwards concomitant medications, exacerbations and SAEs 
(considered as related to study  participation) must be reported
7.2.2. Critical procedures perfo rmed at Screening (Visit 1)
The following critical assessments will be conducted at Visit 1:
Cardiovascular medical history /risk factors ( as detailed in the eCRF) will be 
assessed at screening
Medical history  including COPD (including date of diagnosis and COPD ty pe 
(emphy sema and/or chronic bronchitis), smoking history , COPD exacerbation 
history , smoking status and previous and/or current medical conditions) 
Concomitant medication review (COPD and non COPD medications in the 3
months prior to Screening ).
12-Lead ECG. (Note: ECG is performed at screening Visit [ADDRESS_865112] for eligibility  
only. See Section 7.4.4 ).
Urine pregnancy  test if applicable 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
47Train subject on the use of eDiary
COPD assessment test ( CAT )and pa tient global rating of COPD severit y in 
eDiary
Pre-and post -albuterol/salbutamol spi[INVESTIGATOR_038]  (reversibility , see Section [IP_ADDRESS] )
Inclusion/Exclusion criteria assessment
Review exacerbations, AEs, (SAEs if relat ed to study  participation)
Train subject on the proper use of their COPD medication inhalation devices
Instruct subject to take their COPD medications as instructed and to enter the time 
they take their medication in the eDiary
Dispense rescue medication
Medical history  will be assessed as related to the inclusion/exclusion criteria listed in 
Section 5.1and Section 5.2.
Assessment of subject’s health status will be ma de at screening using CAT. PRO
questionnaires should be completed by  [CONTACT_646036] y other assessments at a clinic 
visit, in the order specif ied in Section 7.3.1
[IP_ADDRESS]. Albuterol/Salbutamol Reversibility  Assessment
At Visit 1, both pre -and post -albuterol/salbutamol spi[INVESTIGATOR_645991] .  Reversibility  assessment should be performed as follows:
Perform pre -bronchodilator spi[INVESTIGATOR_645936] 1and FVC
Subject to self -admi nister 4 Inhalations (4X100 g) of albuterol/salbutamol MDI
Perform post -bronchodilator spi[INVESTIGATOR_645936] 1and FVC approximately  
10 to 30 minutes after albuterol/salbutamol administration
The results of the spi[INVESTIGATOR_645937]/ERS criteria [Miller , 2005] for 
the subject to continue in the study .
7.2.3. Critical procedures performed at first treatment Visit (Baseline 
V2)
Review and a ssess  compliance with subject’s COPD medications during the run -
inperiod
Review and assess compliance with completing the eDiary during the run -in 
period
Review AEs, SAEs and exacerbations
Urine pregnancy  test, if applicable 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
48Baseline d yspnea Index, BDI , patient global rating of COPD severit y, patient 
global rating of change in COPD , SGRQ -C and CAT questionnaires in eDiary
Review randomization criteria (Section 5.3)
Register and randomize subject in RAMOS NG
Pre-dose spi[INVESTIGATOR_038] ; IC and FEV 1
Train subject on the proper use of ELLIPTA and D ISKUS inhalers
Dispense study  medication
Dispense rescue medication
Optional pharmacogentic sample can be collected at V2 or an y visit after.
7.3. Efficacy Assessments
7.3.1. HRQoL assessments : Completion of PRO questionnaires in the 
Electronic Diary
All subjects will be completing PRO questionnaires in the eDiary . 
It is requested that questionnaires are completed before an y procedures are performed on 
the subject. 
All questionnaires will be completed using the eDiary at clinic and at home. Adequate 
time should be a llowed to complete all items of the questionnaires and the questionnaires 
must be reviewed b y the investigator or designated study  staff for completeness and, if 
necessary , the subject must be encouraged to complete any  missing items. Where more 
than one questionnaire is to be completed at a visit the order should be as follows:
1.Baseline d yspnea index ( Visit 2 ) then Transient dyspnea index at subsequent 
visits
2.Patient global rating of COPD severit y and global rating of change in COPD
3.St George’s respi[INVESTIGATOR_47170]
4.COPD Assessment Test
Instructions for completing the questionnaires can be found in the SRM.
[IP_ADDRESS]. Self A dministered Computerised Baseline Dy spnea Index/Transitional 
Dyspnea Index (SA C BDI/TDI)
The BD I is used to measure the severity of d yspnea i n patients at baseline. The TDI 
measures changes in the patient’s dyspnea from baseline.  The self -administered 
computerized version of the BDI/TDI (SAC BDI /TDI)[ Mahler , 2004 ] is used to measure 
severit y of d yspnea in patients at baseline ( SAC BDI) on Day  1 (Visit 2) of treatment and 
change from the baseline (SAC TDI) at Week 4, 12 and 24 (Visits 3, 4 and 5).  The 
scores in both indexes depend on ratings for three different categories: functional  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
49impairment; magnitude of task, and magnitude of effort. SAC BDI/TDI should be 
completed before performing spi[INVESTIGATOR_038] . 
The SAC BDI/TDI was developed to address issues of potential bias in the interviewer 
administered (original) BDI /TDI [Mahler , 1984 ].  The SAC BDI/TDI provides a 
standardized approach to the measurement of d yspnea, equivalent to the original 
BDI/TDI with advantages over the interviewer method for grading d yspnea in patients 
with COPD by  [CONTACT_646037] b y the interviewers when completing the original BDI/TDI. This also 
removes the need for the same investigator to conduct all interviews with a subject based 
on the patient’s responses. SAC TDI provides a continuous measure of change in d yspnea 
using a visual analogue scale to record responses. 
Details for the completion of the SAC BDI/TDI are provided in the S RM.
[IP_ADDRESS]. SGRQ -C
The St George’s Respi[INVESTIGATOR_6015] -Chronic Obstructive Pulmonary  Disease 
specif ic (SGRQ- C) will be completed by  [CONTACT_646009] ( V2, Day 1), at Week 
4, 12 and 24 or at the Early  Withdrawal Visit (where applicable).
The SGRQ- C [Meguro , 2007] is a well established, disease -specific questionn aire.  It was
designed to measure the impact of respi[INVESTIGATOR_496926] a COPD 
patient’s HRQoL.  As well as producing an overall summary score, scores for the 
individual domains of symptoms, activity  and impacts are also produced.  It has been 
used in studies of COPD subjects and has been translated and validated for use in most 
major languages.  The SGRQ-C is derived from the original SGRQ, and produces scores 
equivalent to the SGRQ instrument [ Meguro , 2007].  
[IP_ADDRESS]. COPD A ssessment Test (CA T)
The COPD Assessment Test [Jones, 2009, Jones, 2012 ]is a validated, short and simple 
patient completed questionnaire which has been developed for use in routine clinical 
practice to measure the health status of patients with COPD. The CAT is an 8 -item 
questionnaire suitable for completion by  [CONTACT_453569].  When 
completing the questionnaire, subjects rate their experience on a 6 -point scale, ranging 
from 0 (no impairment) to 5 (maximum impairment) with a scoring range of [ADDRESS_865113].
The CAT will be completed in the eDiary by [CONTACT_646026] 1 and 
Randomisation Visit 2 to assess their eligibility  to enter the stud y.CAT is also 
completed at Weeks 4, 12 and 24. Additional instructions for completion of the CAT are 
provided in the SRM.
[IP_ADDRESS]. EXACT and the Evaluating Respi[INVESTIGATOR_244774] -COPD (E -RS:
COPD)
EXACT -PRO is a 14 item patient reported outcome instrument designed to capture 
information on the occurrence, frequency , severity , and duration of exacerbations of  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
50disease in patients with COPD [ Leidy, 2011]. EXACT captures information on the 
sever ity of the respi[INVESTIGATOR_645992] a COPD exacerbation as 
reported b y the patient. The instrument is to be completed daily  (typi[INVESTIGATOR_897] 2 hrs before 
bedtime) using the electronic diary .The daily  recording of information allows an 
assess ment of the underly ing day to day  variability  of a patient's s ymptoms and facilitates 
the detection of s ymptom worsening indicative of a COPD exacerbation. The total score 
for EXACT ranges from 0 -100. The entire instrument is intended to be completed in 
about 3 minutes or less (typi[INVESTIGATOR_645940] ).
The E- RS: COPD consists of [ADDRESS_865114] instrument [ Leidy, 
2014].  E-RS: COPD is intended to capture information related to the respi[INVESTIGATOR_244853], i.e. breathlessness, cough, sputum production, chest congestion and 
chest tightness. The E -RS: COPD has a scoring range of 0 -40 higher score s indicate 
more severe s ymptoms.
Three subscales of the E -RS are used to describe different s ymptoms; dy spnea, cough and 
sputum and chest sy mptoms.
The EXACT questionnaire will be completed b y subjects in the eDiary , at home every  
night throughout the enti re study , starting from Screening V1 
[IP_ADDRESS]. Subject Global Rating of COPD Severity  and Global Rating of Change 
in COPD
Subjects will complete the Global Rating of COPD Severit y at Randomization Visit 2
and visits 3, 4 and 5 or Early Withdrawal Visit . This singl e global question will ask 
subjects to rate their severity  of COPD on a four point scale (mild, moderate, severe, and 
very severe).
This question should be used immediately  before the patient completes other visit 
specific questionnaires but after complet ion of SAC TDI  questionnaire . 
Subjects will also complete a Global Rating of Change in COPD (overall disease) 
question at Visits 3, 4 and 5or Earl y Withdrawal Visit.  Response options will be on a 7 
point L ikert scale ranging from much better to much wor se. Completing the question at 
each Visit allows for early detection of response as well as continued response.
7.3.2. Spi[INVESTIGATOR_645964] [ Miller , 2005]. All sites 
will use standardized spi[INVESTIGATOR_645942].
All subjects will have spi[INVESTIGATOR_645943]  (see Section 
[IP_ADDRESS] ) and at Visits 2, 3, [ADDRESS_865115] 3 acceptable spi[INVESTIGATOR_496921] (with no 
more than 8) should be obtained. Acceptable spi[INVESTIGATOR_496922] a satisfactory   2018N377698_00
2016N277425_00 CONFIDENTIA L
[ADDRESS_865116] (i.e. a plateau in the volume time curve) and be free from 
artifacts due to cough, early  termination, poor effort, obstructed mouthpi[INVESTIGATOR_13959], equipment 
malfunction, or other reasons [ Miller , 2005].
The largest FEV1and FVC from the 3 acceptable efforts should be recorded, even if they  
do not come from the same effort.
Spi[INVESTIGATOR_645944] 1and FVC assessments that is not obtained as follows will be 
considered a protocol deviation:
Started between 6:00AM and 11:00AM.
After withholding albuterol/salbutamol (all visits) for ≥4 hours
At Screening Visit 1, after w ash out of medications as specified in the exclusion 
criteria in Section 5.2(Conc omitant Medications).
At Visit [ADDRESS_865117] dose 
of study  treatment
At Visit 3, 4 and 5 after withholding the morning dose of study treatment .
Pre dose assessment performed prior dosing.
Subjects shoul d refrain from smoking for [ADDRESS_865118].
Trough FEV 1measurements for UMC/VI  or UMEC on Weeks 4, 12 and 24 (Visits 3, 4 
and 5) should be performed 23 hours and 24 hours after the previous day ’s dose of study  
medication recor ded in the eDiary . This will also provide trough FEV 1measur ements for 
the evening dose of salmeterol. 
7.3.3. Inspi[INVESTIGATOR_359371] (IC)
Inspi[INVESTIGATOR_645920] y (IC)is the volume of gas that can be taken into the lungs in a normal 
and full inhalation. Starting from the resting inspi[INVESTIGATOR_645945]. IC has been widel y used to assess static and 
dynamic h yperinflation in patients with COPD.
IC will be measured b y spi[INVESTIGATOR_645946]-dose at Visits 2 (30 
and 5 min prior to dosing) and at trough at Visits 3, 4, and 5 ([ADDRESS_865119] dosing 
on the previous day ). For I C determination the average of at least three acceptable 
manoeuvres should be recorded. Subjects should be tested while sitting, relaxed and 
wearing a nose clip. They  should be asked to breathe regularl y for several breaths until 
the end- expi[INVESTIGATOR_645947] (this usually  requires at least three tidal 
manoeuvres) then urged to take a deep breath to Total Lung Capacit y(TLC) with no 
hesitation.
Spi[INVESTIGATOR_645948] 1and FVC assessments 
that is not obtained as follows will be considered a protocol deviation:
Started between 6:00AM and 11:00AM.
After withholding albute rol/salbutamol (all visits) ≥4 hours  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
52At Visit 2 after discontinuation of run -in medication
At Visit 3, 4 and 5 after withholding the morning dose of study drug 
7.3.4. COPD Exacerbation
A mild exacerbation is defined as worsening of s ymptoms that require no treatme nt with 
antibiotics or steroids, andis self managed by [CONTACT_646038]. A moderate COPD exacerbation is defined as worsening s ymptoms of 
COPD that require treatment with oral/sy stemic corticosteroids and/or antibio tics. A 
severe exacerbation is defined as worsening s ymptoms of COPD that require in- patient 
hospi[INVESTIGATOR_645949] [ADDRESS_865120] for the patient to withdraw from the study .
Signs and s ymptoms of COPD included on the electronic diary  cards will not be 
considered AEs and will not be recorded in the eCRF.
The time period for collection of COPD exacerbations will be from the Pre -Screening 
(Visit 0) until completi on of the follow -up contact.  If a subject experiences a COPD 
exacerbation from the time the I CF is signed until randomization, summary  information 
(yes/no status question) will be collected in the eCRF . COPD exacerbations after 
randomization through follo w-up will be recorded on the COPD exacerbation page of the 
eCRF.
7.3.5. Clinically  important deterioration (CID)
Clinically  important deterioration ( CID)is a composite endpoint defined as:
A decrease of  100 mL  from baseline in trough FEV 1
A deterioration in HRQoL defined as 4 units increase from baseline in 
SGRQ
The occurrence of an on -treatment moderate/severe COPD exacerbation
In addition, this study  will explore CAT and TDI  PROs as part of the composite 
endpoint. 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
537.3.6. Rescue albuterl/salbutamol use
Subjects wi ll record the number of dail y albuterol/salbutemol puffs they usein the 
eDiary . In addition, in some countries and selected sites the number of puffs will be 
collected through the e MDI device (Section 6.2) 
7.3.7. Physical activity monitor (study subset)
Physical activity  limitation is a common feature of COPD and its measures are highl y 
related to the degree of disease severity  [Watz , 2009]. 
Reduced ph ysical activity  levels in C OPD is associated with increased morbidity  and 
mortality , sustained disability , depression, and social and phy sical isolation [ Shu-Yi,
2014; Gimeno, 2014] 
Improved activity  has been identified as an important factor that may  modify  morbidity  
and mortality  in COPD [ Moy , 2012 ].
The Actigraph GT9X phy sical activity  monitor will be used to measure levels of activity . 
The activity  monitor will be wor n by [CONTACT_422906]  150 subjects for 7 day s from 
Screening (Visit 1), for 7 day s from Randomisation (Visit 2) ,7 day s from Visit 3 ( Week 
4)and for 7 day s prior to Week 24 (Visit 5).
There will be [ADDRESS_865121] will be given an activity  
monitor and instruction leaflet at the start of each assessment period. Further details of 
distribution, operation and retrieval of the monitors will be provided in the SRM .
7.4. Safet y
Planned time points for all safety assessments are listed in the Time and Events Table 
(Section 7.1)
Safety  endpoint include s:
Incidence of adverse events
7.4.1. Adverse Events (A E)and Serious A dverse Events (S AEs)
The definitions of an AE or SAE can be found in Appendix 4.
The investigator and their designees are responsible for detecting, documenting and 
reporting events that meet the definiti on of an AE or SAE. 
[IP_ADDRESS]. Time period and Frequency for collecting A E and SA E information
Any SAEs assessed as related to study  participation (e.g., protocol- mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004]  2018N377698_00
2016N277425_00 CONFIDENTIA L
[ADDRESS_865122]. 
AEs will be collected from the start of Study  Treatment until the follow -up 
contact (see Section [IP_ADDRESS] ),at the timepoints specified in the Time and Events 
Table (Section 7.1).
Medical occurrences that begin prior to the start of study treatment but after 
obtaining informed consent may  be recorded on the Medical History /Current 
Medical Conditions section of the CRF.
All SAEs will be recorded and reported to [COMPANY_004] within 24 hours, as indicated in 
(Appendix 4, Section 12.4.6 )
Investigators are not obligated to activel y seek AEs or SAEs in former study 
subjects . However, if the investigator learns of an y SAE, including a death, at an y 
time after a subject has been discharged from the study , and he/she considers the 
event reasonab ly related to the study  treatment or study  participation, the 
investigator must promptly  notify  [COMPANY_004].
NOTE: The method of recording ,evaluating and assessing causality  of AEs and SAEs 
plus procedures for completing and transmitting SAE reports to [COMPANY_004] are provided in 
(Appendix 4, Section 12.4.4 to Section 12.4.6 )
[IP_ADDRESS]. Method of Detecting AEs and SA Es
Care will be taken not to introduce bi as when detecting AEs and/or SAEs. Open -ended 
and non-leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrence.  Appropriate questions include:
“How are you feeling?”
“Have you had an y (other) medical problems since your last visit/contact
 “Have you taken an y new medicines, other than those provided in this study , 
since y our last visit/contact ?
[IP_ADDRESS]. Follo w-up of A Es and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
subject a t subsequent visits/contacts.  All SAEs ,and non- serious AEs of special interest 
(as defined in Section 4.6.1 )will be followed until resolution, until the condition 
stabilizes, until the event is otherwise expl ained, or until the subject is lost to follow -up 
(as defined in Section 5.5).
[IP_ADDRESS]. Pneumonia Events
Investigators will be required to fill out a pneumonia event specific eCRF within one 
week of when the pneumonia AE /SAE(s) is first reported.  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
[IP_ADDRESS]. Cardiovascular and Death Events
For an y cardiovascular events detailed in (Section 12.4.3 )and all deaths, whether or not 
they are considered SAEs, specific Cardiovascular (CV) and De ath sections of the CRF 
will be required to be completed. These sections include questions regarding 
cardiovascular (including sudden cardiac death) and non- cardiovascular death. 
The CV CRFs are presented as queries in response to reporting of certain CV MedDRA 
terms. The CV information should be recorded in the specific cardiovascular section of 
the CRF within one week of receipt of a CV Event data query  prompting its completion. 
The Death CRF is provided immediately  after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed within one 
week of when the death is reported.
[IP_ADDRESS]. Disease- Related Events and/or Disease -Related Outcomes Not 
Qualify ing as SA Es
The following disease related events (DREs) are common in subjects with COPD and can 
be serious/life threatening:
COPD exacerbation
COPD exacerbations are associated with the disease to be studied and will not be 
recorded as AEs unless the exacerbation meets the definition of a ‘serious’ AE. 
Exacerbati ons that meet the definition of ‘serious’ AEs will be recorded on the 
appropriate eCRF section and should be reported to [COMPANY_004] for all subjects regardless of 
whether or not they  are randomized to study  medication. Signs and s ymptoms of COPD 
included on the e lectronic diary  will not be considered AEs and will not be recorded in 
the eCRF
[IP_ADDRESS]. Regulatory  Reporting Requirements for SA Es
Prompt notification by [CONTACT_427220] (even 
for non -interventional post-marketing studie s)is essential so that legal obligations and 
ethical responsibilities towards the safet y of subjects and the safety of a product under 
clinical investigation are met. 
[COMPANY_004] has a legal responsibility  to notify  both the local regulatory  authorit y and other 
regulatory  agencies about the safet y of a product under clinical investigation.  [COMPANY_004] will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the 
regulatory  authorit y, Institutional Review Board (IRB)/Independent Ethics Com mittee 
(IEC) and investigators.
Investigator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and [COMPANY_004] policy  and are forwarded 
to investigators as necessary . 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
56An investigator who recei ves an investigator safety report describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from [COMPANY_004] will file it with 
the IB and will notify  the I RB/IEC, if appropriate according to local requirements .
7.4.2. Pregnancy
Details of all pregnancies in female subjects will be collected after the start of 
Screening and until the follow -up contact.
If a pregnancy  is reported then the investigator should inform [COMPANY_004] within 2 
weeks of learning of the pregnancy  and should follow the proce dures outlined in 
Appendix 7.
7.4.3. Medical Device Incidents (Including Malfunctions)
Procedures for documenting medical device incidents are provided in Appendix 6.
7.4.4. Electrocardiogram (E CG)
A Single 12- lead ECG will be obtained at Screening using an ECG machine provided b y 
the investigation alsite that automatically  calculates the heart rate and measures PR, QRS , 
QT, and QTc intervals.
The 12- lead ECG measurement and rh ythm strip (10 seconds) will be obtained before 
spi[INVESTIGATOR_496914]. ECG measurement should be obtained after subjects have rested for 
approximately  [ADDRESS_865123] pr ovide his/her dated signature [CONTACT_24003], attesting to the authenticity  of the ECG machine interpretation. 
7.5. Genetics
Information regarding genetic research is included in Appendix 3
8. DATA MANAG EMENT
For this study  subject data will be entered into [COMPANY_004] defined CRFs, transmitted 
electronically  to [COMPANY_004] or designee and combined with data provided from other 
sources in a validated data sy stem.  
Management of clinical data will be performed in accordance wi th applicable 
[COMPANY_004] standards and data cleaning procedures to ensure the integrit y of the data, 
e.g., removing errors and inconsistencies in the data.
Adverse events and concomitant medications terms will be coded using MedDRA 
(Medical Dictionary  for Regulat ory Activities) and an internal validated 
medication dictionary , [COMPANY_004]Drug.   2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
57CRFs (including queries and audit trails) will be retained b y [COMPANY_004], and copi[INVESTIGATOR_131964] y.  Subject initials 
will not be c ollected or transmitted to [COMPANY_004] according to [COMPANY_004] policy .
9. STATISTICA L CONSIDER ATIONS AND DA TA 
ANALYSES
9.1. Hypotheses
The primary  purpose of this study  is to demonstrate improvements in lung function for 
subjects treated with UMEC/VI  compared with UMEC for 24 we eks. 
The primary  endpoint is change from baseline in trough FEV 1at Week 24.
The null hy pothesis is no difference between treatment groups (H0: μT – μS = 0), with 
the alternative h ypothesis that there is a difference between treatment groups (H1: μT –
μS ≠0), where μ T is the mean change from baseline for UMEC/VI and μS is the mean 
change from baseline for UMEC. 
9.2. Sample Size Considerations
The pr imary  endpoint is change from baseline in trough FEV 1at Week 24. As an 
important aim of the study is to compare UMEC/VI, UMEC and salmeterol with respect 
to HRQoL  the sample size has been calculated to provide sufficient power for the 
comparison of the pr imary  and secondary endpoint TDI ,at Week 24.  
The sample size calculations use a two -sided 5% significance level and an estimate of 
between subject standard deviation for TDI of 2.94 units.  The estimate of SD is based on 
DB2113373 [Donohue , 2013] , a study  which consisted of treatment arms of UMEC/VI 
62.5/25, UMEC 62.5 VI (Vilanterol) 25mcg and placebo and is the value at Day  168 in a 
subgroup of subjects who were ICS free at screening.  Based on these data, 727 eva luable 
subjects per treatment arm will be required to provide 90% power to detect a statistically  
significant difference if the true difference is 0.5 units, ½ the MCI D, between UMEC/VI 
and UMEC. The smallest observed effect predicted to result in a statis tically  significant 
difference between treatment groups is 0.[ADDRESS_865124] >99% power 
assuming a true treatment difference of 80mL between UMEC/VI and UMEC for trough 
FEV1 at 24 weeks at the two-sided 5% significance level. This calculation uses a SD for 
trough FEV1 of 240mL, based on prior results for trials comparing dual bronchodilators 
versus single bronchodilators ( Donohue , 2013; Bateman , 2013). The smallest observed 
effect predicted to result in a statistically  significant difference between treatment groups 
is 25mL . 
In order to account a for a 10% withdrawal rate , approximately  [ADDRESS_865125] SDTreatment Difference Power
TDI 2.54 0.5 96%
2.74 0.5 94%
2.94 0.5 90%
3.14 0.5 86%
3.34 0.5 81%
9.2.3. Sample Size Re -estimation or A djustment
No sample size re -estimation is planned for this study . 
9.3. Data Analysis Considerations
9.3.1. Analysis Populations
Population Definition / Criteria Analyses Evaluated
All 
Subjects 
Enrolled 
(ASE)All subjects for whom a record exists in the 
study  database, including screen failures and 
any subject who was not screened but 
experienced an SAE between the date of 
informed consent and the planned date of the 
Screening visit. Subject 
Disposition
Reasons for 
withdrawal prior 
to randomisation
Inclusion, 
exclusion and 
randomisation 
criteria deviations
SAEs for non-
randomised 
subjects 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
59Population Definition / Criteria Analyses Evaluated
Intent -to-
treat (ITT)All randomized subjects, excluding those who 
were randomized in error and received at least 
one dose of stud y medication. A subject who 
is recorded as a screen or run- in failure and 
also randomized will be considered to be 
randomized in error.  Any other subject who 
receives a randomization number will be 
considered to have been randomized.
Display s will be based on the treatment to 
which the subject was randomized.Study  Population
Efficacy
Safety
Intent -to-
treat ICS 
free (ITT 
ICS free)All subjects in the I TT Population who have 
not received ICS.Study  Population
Efficacy
Safety
9.3.2. Interim Analy sis
No interim anal ysis is planned for the stud y.
9.4. Key Elements of A nalysis Plan
Treatment Comparisons
The primary  treatment comparison of UMEC/VI with UMEC will be performed on the 
ITT population.
The other treatment comparisons of UMEC/VI and UMEC with Salmeterol will be 
performed on the ITT population and ITT ICS free population.
9.4.1. Primary  Analyses
The treatment comparison of primary  interest will be UMEC/VI versus UMEC for the 
primary  endpoint of change from baseline in trough FEV 1at Week 24. The primary  
analyses will be performed using a mixed model repeated measures (MMRM) anal ysis 
and will be based on a two -sided hy pothesis testing approach on the ITT Population. 
In order to account for multiplicity  across treatment comparisons and endpoints, a step-
down closed testing procedure will be applied whereb y inference for secondary  and other 
endpoints or treatment comparisons are dependent upon statistical significance having 
been achieved for the primary  comparison. If the primary  comparison is signi ficant i.e. 
the associated p-value for UMEC/VI versus UMEC for change from baseline in trough 
FEV1 at Week 24 is below 0.05, this will allow inference of treatment comparisons 
(UMEC/VI versus UMEC on all other endpoints, and UMEC/VI versus Salmeterol and 
UMEC versus Salmeterol on all endpoints including the primary  endpoint), which will be 
declared statistically  significant if the associated p -value is below 0.05.   2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
60There will be 2 anal yses one for one for the German Federal Joint Committee (G-BA) 
andone f or the rest of the world (ROW).
The step-down closed testing procedure onl y applies to the ROW.  For the G -BA 
statistical inference for secondary  and other endpoints or treatment comparisons will not 
be conditional on achieving statistical significance of the primary  comparison.  
The primary  endpoint of mean change from baseline in trough FEV1 at the end of Week 
24 and secondary  endpoint change from baseline in TDI score at Week 24 will both be 
analysed using MMRM analy sis. The MMRM analy sis for change f rom baseline in 
trough FEV1 and TDI will include measurements at Treatment Weeks 4, 12 and 24. 
Treatment group (a categorical variable) will be fitted as the explanatory  variable with 
appropriate pre -defined variables, stratum (number of bronchodilators per day during 
run-in) and baseline values, fitted as covariates. Visit (nominal) will be fitted as a 
categorical variable and visit- by-baseline and visit -by-treatment interaction terms will be 
included to allow treatment effects to be estimated at each visit separatel y. The variance 
covariance matrix will be assumed to be unstructured (based on previous experience no 
issues are expected with fitting models with this matrix structure). 
While missing data are not explicitly  imputed in the primary  MMRM analy ses,there is 
an underl ying assumption that the data are missing at random. 
The estimated treatment differences between UMEC/VI versus UMEC for each endpoint 
will be presented with the 95% confidence intervals for the difference and the p -value. 
Full details of the analy ses to be performed on all primary  endpoints will be given in the 
RAP.
9.4.2. Other A nalyses
The MMRM anal ysis will be repeated for the ITT ICS free population. Estimated 
differences between UMEC/VI  or UMEC and Salmeterol will be presented together w ith 
95% confidence intervals (CI s) for the difference and p- values.
Secondary  and o ther efficacy  endpoints and treatment comparisons will be adjusted for 
multiplicity  as per Section 9.4.1 .
Full details of the an alyses to be performed on the other efficacy  endpoints will be given 
in the RAP.
Safety	Analyses
Adverse events (AEs) will be coded using the standard [COMPANY_004] dictionary , Medical
Dictionary  for Regulatory  Activities (MedDRA), and grouped by  [CONTACT_44749]. The 
number and percentage of subjects experiencing at least one AE of an y type, AEs within 
each bod y system and AEs within each preferred term will be presented for each 
treatment group. Separate summaries will be provided for all AEs, drug related AEs, fatal 
AEs, non -fatal SAEs, AESI s and AEs leading to withdrawal.  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
61Deaths and SAEs will be documented in case narrative format. 
Full details of the analy ses to be performed on all safet y endpoints will be given in the 
RAP.
10. STUDY GOVERNANCE CONSIDERATIONS
10.1. Posting of Information on Publicly  Available Clinical Trial 
Registers
Study  information from this protocol will be posted on publicly  available clinical trial 
registers before enrollment of subjects begins.
10.2. Regulatory  and Ethical Considerations, Including the 
Informed Consent Process
Prior to initiation of a site, [COMPANY_004] will obtain favourable opi[INVESTIGATOR_1649]/approval from the 
appropriate regulatory  agency  to conduct the study in accordance with I CH Good Clinical 
Practice (GCP) and applicable country -specific regulatory requirements.
The study  will be conducted in accordance with all applicable regulatory  requirements, 
and with [COMPANY_004] policy .
The study  will also be conducted in accordance with ICH Good Clinical Practice (GCP), 
all applicable subject privacy  requirements, and the guiding principles of the current 
version of the Declaration of Helsinki.  This includes, but is not limited to, the following:
IRB/IEC review and favorable opi[INVESTIGATOR_1649]/approval of the study  protocol and 
amendments as applicable
Obtaining signed informed conse nt
Investigator reporting requirements (e.g. reporting of AEs/SAEs/protocol 
deviations to I RB/IEC)
[COMPANY_004] will provide full details of the above procedures, either verball y, in writing, 
or both.
Signed informed consent must be obtained for each subject prior to participation 
in the study
The IEC/I RB, and where applicable the regulatory authority, approve the clinical 
protocol and all optional assessments, including genetic research.  
Optional assessments (including those in a separate protocol and/or under se parate 
informed consent) and the clinical protocol should be concurrentl y submitted for 
approval unless regulation requires separate submission.  
Approval of the optional assessments may  occur after approval is granted for the 
clinical protocol where requ ired b y regulatory  authorities.  I n this situation, 
written approval of the clinical protocol should state that approval of optional  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
62assessments is being deferred and the study , with the exception of the optional 
assessments, can be initiated.
10.3. Qualit y Control (Study  Monitoring)
In accorda nce with applicable regulations including GCP, and [COMPANY_004] procedures, 
[COMPANY_004] monitors will contact [CONTACT_288627], study  requirements, and their responsibilitie s to satisfy  
regulatory , ethical, and [COMPANY_004] requirements.  
When reviewing data collection procedures, the discussion will also include 
identification, agreement and documentation of data items for which the eCRF
will serve as the source document.
[COMPANY_004] will m onitor the study  and site activity  to verify  that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accordance with the currently  approved protocol and any  
other study  agreements, GCP, and all applicable regulatory  requirements.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents
10.4. Qualit y Assurance
To ensure compliance with GCP and all applicable regulatory  requirements, [COMPANY_004] 
may conduct a quality  assurance assessment and/or audit of the site records, and 
the regulatory  agencies may  conduct a regulatory inspection at any  time during or 
after completion of the study . 
In the event of an assessment, a udit or inspection, the investigator (and institution) 
must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to all 
relevant documents and to allocate their time and the time of their staff to discuss 
the conduct of the stud y, any f indings/relevant issues and to implement any  
corrective and/or preventative actions to address any  findings/issues identified.
10.5. Stud y and Site Closure
Upon completion or premature discontinuation of the study , the [COMPANY_004] monitor will 
conduct site closure activ ities with the investigator or site staff, as appropriate, in 
accorda nce with applicable regulations including GCP, and [COMPANY_004] Standard 
Operating P rocedures.
[COMPANY_004] reserves the right to temporaril y suspend or prematurel y discontinue this 
study  at an y time for r easons including, but not limited to, safety  or ethical issues 
or severe non -compliance . For multicenter studies, this can occur a t one or more 
or at all sites.  
If [COMPANY_004] determines such action is needed, [COMPANY_004] will discuss the reasons for taking 
such action with the investigator or the head of the medical institution (where  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
63applicable).  When feasible, [COMPANY_004] will provide advance notification to the 
investigator or the head of the medical institution, where applicable, of the 
impending action.
If the stud y is su spended or prematurely  discontinued for safet y reasons, [COMPANY_004] will
promptly  inform all investigators, head sof the medical institution s(where 
applicable) and /or institution(s) conducting the study . [COMPANY_004] will also promptly  
inform the relevant regulatory  autho rities of the suspension or premature 
discontinuation of the study  and the reason(s) for the action.  
If required b y applicable regulations, the investigator or the head of the medical 
institution (whe re applicable) must inform the IRB/IECpromptl y and provide the 
reason for the suspension or premature discontinuation.
10.6. Records Retention
Following closure of the study , the investigator or the head of the medical 
institution (where applicable) must maintain all site study  records (except for 
those required b y local regulations to be maintained elsewhere ), in a safe and 
secure location.  
The records must be maintained to allow eas y and timely  retrieval, when needed 
(e.g., for a [COMPANY_004] audit or regulatory inspection) and must be available for review 
in conjunctio n with assessment of the facilit y, supporting s ystems, and relevant 
site staff.  
Where permitted b y local laws/regulations or institutional policy, some or all of 
these records can be maintained in a format other than hard cop y (e.g., microfiche, 
scanned, electronic); however, caution needs to be exercised before such action is 
taken.  
The investigator must ensure that all reproductions are legible and are a true and 
accurate cop y of the original and meet accessibility and retrieval standards, 
including r e-generating a hard cop y, if required.  Furthermore, the investigator 
must ensure there is an acceptable back -up of these reproductions and that an 
acceptable qualit y control process exists for making these reproductions.
[COMPANY_004] will inform the investigator o f the time period for retaining these records to 
comply  with all applicable regulatory  requirements.  The minimum retention time 
will meet the strictest standard applicable to that site for the study, as dictated by 
[CONTACT_65406], [COMPANY_004] 
standards/procedures, and/or institutional requirements. 
The investigator must notify  [COMPANY_004] of any  changes in the archival arrangements, 
including, but not limited to, archival at an off -site facility  ortransfer of 
ownership of th e records in the event the investigator is no longer associated with
the site. 2018N377698_00
2016N277425_00 CONFIDENTIA L
[PHONE_13419].7. Provision of Study  Results to Investigators, Posting of 
Information on Publically  Available Clinical Trials Registers 
and Publication
Where required b y applicable regulatory  requirements, an investigator signatory  will be 
identified for the approval of the clinical study  report.  The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity  to review the com plete study  results at a [COMPANY_004] site or other mutually -
agreeable location.
[COMPANY_004] will also provide the investigator with the full summary  of the stud y results.  The 
investigator is encouraged to share the summary  results with the study  subjects, as 
appropriate.
[COMPANY_004] will provide the investigator with the randomization codes for their site only  after 
completion of the full statistical analy sis.
The procedures and timing for public disclosure of t he results summary and for 
development of a manuscript for publicatio nwill be in accordance with [COMPANY_004] Policy .
A manuscript will be progressed for publication in the scientific literature if the results 
provide important scientific or medical knowledge. 2018N377698_00
2016N277425_00 CONFIDENTIA L
[PHONE_13440]. REFERENCES
Bateman ED, Ferguson GT, Barnes N et al. Dual bronchodilatio n with QVA149 versus 
single bronchodilation therap y: The SHINE study . Eur Respir J. 2013 Dec; 42:1484 -94
Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: 
a summary  of the ATS/ERS position paper. Eur Respir J. 2004; 23:93 2-946.
Chen H, Yu KD, Xu GZ. Association between Variant Y402H in Age- Related Macular 
Degeneration (AMD) Susceptibility  Gene CFH and Treatment Response of AMD: A 
Meta -Anal ysis. PloS ONE 2012; 7: e42464
Dahl R, Chung KF, Buhl R et al. Efficacy  of a new once -daily  long -acting inhaled β2 -
agonist indacaterol versus twice- daily formoterol in COPD. Thorax 2010, 65:473 -479.
Donohue JF, Maleki -Yazdi MR, Kilbride S, et al.  Efficacy  and safet y of once -daily 
umeclindinium/vilanterol 62.5/25mcg in COPD.  Respir Med 20 13; 107: 1538-1546.
European Medicines Agency  (EMA) . Guidelines on clinical investigation of medicinal 
productsin the treatment of chronic obstructive pulmonary  disease (COPD). 
EMA/CHMP/48353572 , 2012.
Feldman G, Maltais F, Khindri S, et al.  A randomized blinded study  to evaluate the 
efficacy  and safet y of umeclidinium 62.5 g compared with tiotropi[INVESTIGATOR_1890] 18 g in patients 
with COPD.  I nternational Journal of COPD 2016; 11: 719 -730
Feldman G, Siler T, Prasad N et al. Efficacy  and safet y of indacaterol 150 μg once -daily 
in COPD: a double -blind, randomised, 12- week study . BMC Pulm Med 2010, 10:11.
Gimeno- Santos E, Frei A, Steurer -Stey C, et al. Determinants and outcomes of phy sical 
activity  in patients with COPD: a sy stematic review. Thorax 2014; 0:1-9
GlaxoSmithKlineDocument Number [RM2006/[ZIP_CODE]/09, Umeclidinium ([COMPANY_004]573719) 
Investigator’s Brochure. Report Date -Aug-2016.
GlaxoSmithKlineDocument Number RM2009/[ZIP_CODE]/07, Umeclidinium + Vilanterol 
Investigator's Brochure. Re port date AUG -2015
GOLD. Global Initiative for Chronic Obstructive Lung Disease [GOLD]. Global Strategy 
for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary  
Disease. Last Updated 2015. http://www.goldcopd.org.
Gorin MB. Genetic ins ights into age -related macular degeneration: Controversies 
addressing risk, causality, and therapeutics. Mol. Asp. Med. 2012; 33: 467 -486.
Hatcher RA, Trussell J, Nelson AL, Cates W Jr, et al, editors. Contraceptive Technology . 
20th revised edition. New Yo rk: Ardent Media, 2011. 2018N377698_00
2016N277425_00 CONFIDENTIA L
[ADDRESS_865126] in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.
Jones, P., Harding, G., Berry , P., Wiklund, I ., Chen, W -H., L eidy, N. Development and 
first validation of the COPD Assessment Test (CAT) Eur Respir J, 2009; 34: 648–654
Jones, P., Harding, G., Wiklund, I ., Berry , P., Tabberer, M., Yu, R., Leidy , N. Tests of 
the Responsiveness of the Chronic Obstructive Pulmonary  Disease (COPD) Assessment 
Test (CAT) Following Acute Exacerbation and Pulmonary  Rehabilitation Chest, 2012, 
142 134 -140
Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Dény  P, Gault E.  Quantifi cation 
of Hepatitis Delta Virus RNA in Serum by  [CONTACT_31861] -Time PCR I ndicates 
Different Patterns of Virological Response to Interferon Therap y in Chronically  Infected 
Patients.  J Clin Microbiol. 2005;43(5):2363– 2369. 
Leidy NK, Sexton CC, Jones PW, No tte SM. et al. Measuring respi[INVESTIGATOR_645951]: reliability  and validity  of a daily  diary . Thorax 2014; 69:5 424 -
430
Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S. Standardizing 
measurement of chronic obstructive pu lmonary  disease exacerbations. Reliability  and 
validity  of a patient- reported diary . Am J Respir Crit Care Med 2011; 183:323-[ADDRESS_865127] J, Fierro -Carrion G, et al. Development of self -administered versions 
of modified baseline and transition dy spnea indexes in COPD. J COPD 2004; 165 –[ADDRESS_865128] 1984, 85: 751-758.
Maleki -Yazdi MR, Kael in T, Richard N, Zvarich M, Church A. Efficacy  and safet y of 
umeclidinium/vilanterol 62.5/25 mcg and tiotropi[INVESTIGATOR_1890] 18 mcg in chronic obstructive 
pulmonary  disease: results of a 24- week, randomized, controlled trial. Respi[INVESTIGATOR_645952]. 2014;108:1752-60.
Maltais F, Singh S, Donald AC, Crater G, Church A, Goh AH, Riley  JH. Effects of a 
combination of umeclidinium/vilanterol on exercise endurance in patients with chronic 
obstructive pulmonary  disease: two randomized, double -blind clinical trials. Ther Adv 
Respi r Dis. 2014;8:[ADDRESS_865129]. 
2007;132:456-463
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coat es A, Crapo R, Enright 
P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacInt yre N, McKay  R,  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
67Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J.  Standardisation of 
spi[INVESTIGATOR_038] .  Eur Respir J.  2005;26: 319-338.
Moy  ML, Weston NA, Wilson EJ , Hess ML , Richardson CR. A pi[INVESTIGATOR_645953]. Respir Med. 2012;106:1342- 50. 
Quanjer P, Stanojevic S, Cole T, Baur X., Hall G, Enright P, et al. on behalf of the ERS 
Global L ung Function Initiative.  Multi -ethnic reference values for spi[INVESTIGATOR_105221] 3 -
95 year age range: the global lung function 2012 equations. Eur Respir J, 2012; 40: 
1324 –1343.
Schmidt SA, Johansen MB, Olsen M et al. The impact of exacerbation frequency  on 
mortality  following acute exacerba tion of COPD: a registry -based cohort study . B Med J. 
Open. 2014;4: (12): e006720
Serevent product information 2003 . Available from 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20236slr028_serevent_lbl.pdf
Shu-Yi Liao, Roberto Benzo et al. Physical Activity  Monitoring in Patients with Chronic 
Obstructive Pulmonary  Disease. Journal of the COPD Foundation 2014; 1: 155 -165
Siler T, Kerwin E, Sousa A, Donald A, Rehan A, Church A, Efficacy  and safet yof 
umeclidinium added to fluticasone furoate/vilan terol in chronic obstructive pulmonary  
disease: Results of two randomized studies.  Respir Med. 2015; 109:1155 -63
Singh D, Maleki -Yazdi MR, Tombs L , Iqbal A, Fah y WA, Naya I. Prevention of 
clinically  important deteriorations in COPD with umeclidinium/vilan terol. Int’l J of 
COPD, 2016; 11:1413 -1424
Tashkin DP, Fabbri LM. Long acting beta -agonists in the management of chronic 
obstructive pulmonary  disease: Current and future agents.  Respir Research, 2010; 11: 
[ADDRESS_865130] N, Mehta R, and Church, A . Umeclidinium in patients with COPD: a 
randomised, placebo -controlled study .  Eur Respir J. 2014; 43: 72–81.
Watz H, Waschki B, Meyer T, Magnussen H: Physical activity  in patients with COPD. 
Eur Respir J 2009, 33:262–272.
Wedzicha JA, Brill SE, Allinson JP, Donalson GC. Mechanism and impact of the 
frequent exacerbator phenoty pe in chronic obstructive pulmonary  disease. BMC 
Medicine, 2013; 11:181 2018N377698_00
2016N277425_00 CONFIDENTIA L
[PHONE_13441]. APPENDICES
12.1. Appendix 1 :Abbreviations and Trademarks
Abbrev iations
AE Adverse Event
ALT Alanine transaminase
AST Aspartate aminotransferase
ATS American Thoracic Society
CAT COPD Assessment Test
CI Confidence Intervals
CID Clinically  important deterioration 
COPD Chronic Obstructive Pulmonary  Disease
CPK Creatine phosphokinase
CRF Case Report Form
CV Card iovascular
DPI [INVESTIGATOR_645954] I nhaler
E-RS Evaluating Respi[INVESTIGATOR_244774] -COPD  To ol
ERS European Respi[INVESTIGATOR_645955] ₁ Forced Expi[INVESTIGATOR_645956] I nitiative for Chronic Obstructive Lung Disease
[COMPANY_004] GlaxoSmithKline
IB Investigator Brochure
ICF Informed Consent Form
ICS Inhaled Corticosteroid
IEC Independent Ethics Committee
IP Investigational product
INR International normalized ratio
IRT Interactive Response Technology
ITT Intent -to-Treat
IUD Intrauterine Device
IUS Intrauterine S ystem
LABA Long Acting Beta -Agonist
LAMA Long -acting Muscarinic Receptor Antagonists
LDH Lactate deh ydrogenase
LTOT Long Term Ox ygen Therapy 2018N377698_00
2016N277425_00 CONFIDENTIA L
[ADDRESS_865131] Upper Limit of Normal
UMEC Umeclidinium ([COMPANY_004]573719)
UMEC/VI Umeclidinium & Vilanterol as a fixed dose combination
VI Vilanterol Trife nate 
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_646013] E-RS
DISKUS EXCACT
ELLIPTA
INCRUSE
SEREVENT 2018N377698_00
2016N277425_00 CONFIDENTIA L
[PHONE_13442].2. Appendix 2: Liver Safety  Required A ctions an d Follow up 
Assessments
Phase III -IV liver chemistry stoppi[INVESTIGATOR_420682] - Liver Stoppi[INVESTIGATOR_53053]- absolute ALT  8xULN
ALT Increase ALT  5xULN but <8xULN  persists for 2 weeks
ALT  3xULN but <5xULN  persists for 4 weeks
Bilirubin1, 2ALT  3xULN andbilirubin 2xULN (>35% direct bilirubin) 
INR2ALT  3xULN andINR>1.5, if INR measured
Cannot 
MonitorALT  5xULN but <8xULN and cannot be monitored weekly for  2 weeks
ALT  3xULN but <5xULN and cannot be monitored weekly for 4 weeks
Symptomatic3ALT   3xULN associated with symptoms (new or worsening) believed to be 
related to  liver injury or hypersensitivity
Required Actions and Follow up Assessments following ANY Liver Stopp ing Event
Actions Follow Up Assessments
Immediately discontinue  study treatment
Report the event to [COMPANY_004] within 24 hours
Complete the liver event CRF and complete 
an SAE data collection tool if the event also 
meets the criteria for an SAE2
Perform liver event follow up assessments 
Monitor the subject until liver chemistries 
resolve , stabilize, or return to within normal 
ranges. baseline (see MONITORING below)
 Do not restart/rechallenge subject 
with study treatment. Permanently 
discontinue stud y treatmen t and may 
continu e subject in the study for any 
protocol specified follow up assessmentsViral hepatitis serology4
Only in those with underlying chron ic 
hepatitis B at study entry (identified by 
[CONTACT_23977] B surface antigen) 
quantitative hepatitis B DNA and hepatitis 
delta antibody5.
Blood sample for pharmacokinetic (PK) 
analysis, obtained within a week after last 
dose6
Serum creatine phosphokin ase (CPK) and 
lactate dehydrogenase (LDH).
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury, or  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
71Liver Chemistry Stoppi[INVESTIGATOR_2121] - Liver Stoppi[INVESTIGATOR_131970]:
For bilirubin or INR criteria:
Repeat l iver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessment s within  24 
hrs
Monitor subjects twice weekly until liver 
chemistries resolve, stabilize or return to 
within normal ranges.
A specialist or hepatology consultation is 
recommended
For All other criteria:
Repeat liver chemistries (include ALT, AST, 
alkali ne phosphatase, bilirubin) and perform 
liver event follow up assessments within  24-
72 hrs 
Monitor subjects weekly until liver 
chemistries resolve, stabilize or return to 
within normal ranges.hypersensitivity, on the AE report form
Record use of concomitant medications on 
the concomitant medications report form
including acetaminophen, herbal 
remedies, other over the counter 
medications .
Record alcohol use on the liver event 
alcohol intake case report form
For bi lirubin or INR criteria:
Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti- liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG or gamma 
globulins).
Serum acetaminophen adduct HPLC 
assay (quantifies potential aceta minophen 
contribution to liver injury in subjects with 
definite or likely acetaminophen use in the 
preceding week [ James ,2009]). NOTE: 
not required in China
Liver imaging (ultrasound, magnetic 
resonance, or computerised tomography) 
and /or liver biopsy to evaluate liver 
disease; complete Liver Imaging and/or 
Liver Biopsy CRF forms.
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that subject if ALT 3xULN andbilirubin 2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations a nd suggesting liver injury. 
2. All events of ALT 3xULN andbilirubin  2xULN (>35% direct bilirubin) or ALT 3xULN andINR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR measurement is not required and the threshold value stated 
will not apply to subjects receiving anticoagulants
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)   
4. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody;  Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  Hepatitis E IgM antibody 
5. If hepatitis delta antibody assay cannot be performed , it can be replaced with a PCR of hepatitis D RNA virus 
(where needed) [ Le Gal , 2005].
6. PK sample may not be required for subjects known to be receiving placebo or non -[COMPANY_004] comparator treatments.  
Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to 
blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the subject’s best  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
72approximation. If the date/time of the last dose cannot be approximated OR a PK sample can not be collected in 
the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shippi[INVESTIGATOR_131971].   2018N377698_00
2016N277425_00 CONFIDENTIA L
[PHONE_13423].3. Appendix 3:Genetic Research
Genetics –Background
Naturall y occurring genetic variation may  contribute to inter -individual variability in 
response to medicines, as well as an individual's risk of developi[INVESTIGATOR_42259]. 
Genetic factors associated with disease characteristics may  also be associated with 
response to therap y, and could help to explain some clinical study  outcomes. For 
example, genetic variants associated with age- related macular degeneration (AMD) are 
reported to account for much of the risk for the condition [ Gorin , 2012] with certain 
variants reported to in fluence treatment response [ Chen, 2012]. Thus, knowledge of the 
genetic etiology  of disease may  better inform understanding of disease and the 
development of medicines. Additionally , genetic variability  may  impact the 
pharmacokinetics (absorption, distribution, metabolism, and elimination), or 
pharmacod ynamics (relationship between concentration and pharmacologic effects or the 
time course of pharmacologic effects) of a specific medicine and/or clinical outcomes 
(efficac y and/or safet y) observed in a clinical study.
Genetic Research Objectives and A nalyses
The objectives of the genetic research are to investigate the relationship between genetic 
variants and: 
Response to medicine, including an y concomitant medicines;
COP Dsusceptibility , severity , and progression ofrelated conditions
Genetic data may  be generated while the study  is underway  or following completion of 
the study .  Genetic evaluations may  include focused candidate gene approaches and/or 
examination of a la rge number of genetic variants throughout the genome (whole genome 
analyses). Genetic anal yses will utilize data collected in the study  and will be limited to 
understanding the objectives highlighted above.  Analy ses may  be performed using data 
from multip le clinical studies to investigate these research objectives.
Planned anal yses and results of genetic investigations will be reported either as part of the 
clinical RAP and study  report, or in a separate genetics RAP and report, as appropriate.
Study Popul ation
Any subject who is enrolled in the study  can participate in genetic research.  Any  subject 
who has received an allogeneic bone marrow transplant must be excluded from the 
genetic research.
Study Assessments and Procedures
A key  component of successful genetic research is the collection of samples during 
clinical studies. Collection of samples, even when no a priori hypothesis has been 
identified, may  enable future genetic anal yses to be conducted to help understand 
variability  in disease and medicine response.    2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
74A 6 ml blood sample will be taken for Deox yribonucleic acid (DNA) extraction. 
A blood sample is collected at the baseline visit, after the subject has been 
randomized and provided informed consent for genetic research. Instructions for 
collecti on and shippi[INVESTIGATOR_428192]. The DNA from the blood sample may  undergo quality  control analy ses to 
confirm the integrit y of the sample. If there are concerns regarding the quality  of 
the sample, then the sam ple may  be destroy ed. The blood sample is taken on a 
single occasion unless a duplicate sample is required due to an inabilit y to utilize 
the original sample.  
The genetic sample is labelled (or “coded”) with the same stud y specific number used to 
label o ther samples and data in the study .   This number can be traced or linked back to 
the subject by  [CONTACT_132018]. Coded samples do not carry  personal 
identifiers (such as name [CONTACT_42405]). 
Samples will be stored securel y and may be kept for up to [ADDRESS_865132] 
completes the study ,or [COMPANY_004] may  destroy  the samples sooner.  [COMPANY_004] or those working 
with [COMPANY_004] (for example, other researchers) will only use samples collected from the study  
for the purpose stated in this protocol and in the informed consent form.  Samples may  be 
used as part of the development of a companion diagnostic to support the [COMPANY_004] medicinal 
product.
Subjects can request their sample to be destro yed at any  time.
Informed Consent
Subjects who do not w ish to participate in the genetic research may  still participate in the 
study .  Genetic informed consent must be obtained prior to any  blood being taken.
Subject Withdrawal from Study
If a subject who has consented to participate in genetic research withdr aws from the 
clinical study  for any  reason other than being lost to follow -up, the subject will be given a 
choice of one of the following options concerning the genetic sample, if already  
collected:
Continue to participate in the genetic research in which case the genetic DNA 
sample is retained
Discontinue participation in the genetic research and destroy  the genetic DNA 
sample 
If a subject withdraws consent for genetic research or requests sample destruction for an y 
reason, the investigator must complete the appropriate documentation to request sample 
destruction within the timeframe specified b y [COMPANY_004] and maintain the documentation in 
the site study  records . 
Genoty pe data may  be generated during the study  or after completion of the study  and 
may be anal yzed during the study  or stored for future anal ysis.  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
75If a subject withdraws consent for genetic research and genot ype data has not been 
analyzed, it will not be analy zed or used for future research.  
Genetic data that has been anal yzed at the time of withdr awn consent will 
continue to be stored and used, as appropriate. 
Screen and Baseline Failures
If a sample for genetic research has been collected and it is determined that the subject 
does not meet the entry  criteria for participation in the study , then t he investigator should 
instruct the subject that their genetic sample will be destroy ed. No forms are required to 
complete this process as it will be completed as part of the consent and sample 
reconciliation process.  In this instance a sample destruction form will not be available to 
include in the site files.
Provision of Study Results and Confidentiality  of Subject’s Genetic Data
[COMPANY_004] may  summarize the genetic research results in the clinical study  report, or 
separately andmay publish the results in sci entific journals. 
[COMPANY_004] may  share genetic research data with other scientists to further scientific 
understanding in alignment with the informed consent. [COMPANY_004] does not inform the subject, 
family  members, insurers, or employ ers of individual genoty pi[INVESTIGATOR_124619] s that are not 
known to be relevant to the subject’s medical care at the time of the study , unless 
required b y law. This is due to the fact that the information generated from genetic 
studies is generally preliminary in nature, and therefore the significance and scientific 
validity  of the results are undetermined.  Further, data generated in a research laboratory  
may not meet regulatory  requirements for inclusion in clinical care. 2018N377698_00
2016N277425_00 CONFIDENTIA L
[PHONE_13424].4. Appendix 4:Definition of and Procedures for Recording , 
Evaluati ng, Follow -Up and Reporting of A dverse Events
12.4.1. Definition of A dverse Events
Adverse Event Definition:
An AE is an y untoward medical occurrence in a patient or clinical investigation 
subject, temporall y associated with the use of a medicinal product, whether or not 
considered related to the medicinal product.
NOTE: An AE can therefore be an yunfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a medicinal product.
Events meeting AE definition include:
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (e.g., ECGs, radiological scans, vital signs 
measurements), including those that worsen from baseline, and felt to be clinically  
significant in the medical and scientific judgement of the investigator.
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions dete cted or diagnosed after study  treatment administration even 
though it may  have been present prior to the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected over dose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE unless this is an intentional overdose taken with possible suicidal/self -
harming intent.  This should be reported regardless of sequelae).
"Lack o f efficacy " or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE.  However, the signs and sy mptoms and/or clinical 
sequelae resulting from lack of efficacy  will be reported if they  fulfil the definition 
of an AE or SA E.
Events NOT meeting definition of an AE include:
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_646030]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
77condition.
Medical or surgical procedure (e.g., end oscopy , appendectom y): the condition that 
leads to the procedure is an AE.
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
12.4.2. Definition of Serious A dverse Events
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_428193] s/symptoms of the disease under study , 
death due to progression of disease, etc).
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, 
at any dose:
a.Results in death
b.Is life -threatening
NOTE:
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
subject was at risk of death at the time of the event.  I t does not refer to an event, which 
hypothetically  might have caused death, if it were more severe.
c.Requires hospi[INVESTIGATOR_23916]:
In general, hospi[INVESTIGATOR_5184] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appropriate in the phy sician’s 
office or out -patient setting.  Complications that occur during hospi[INVESTIGATOR_23918].  If a complication prolongs hospi[INVESTIGATOR_9236], 
the event is serious.  When in doubt as to whether “hospi[INVESTIGATOR_3094]” occurred or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen 
from baseline is not considered an AE.
d.Results in disability/incapacity
NOTE:
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions. 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
78This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea , influenza, 
andaccidental trauma (e.g. sprained ankle) which may  interfere or prevent every day 
life functions but do not constitute a substantial disruption
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in de ciding whether reporting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_23951].  These should also be considered 
serious.
Examples of such events are invasive or malignant cancers, intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood d yscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse
g. Is associated with liver injury andimpaired liver function defined as:
ALT 3xULN and total bilirubin*2xUL N (>35% direct), or
ALT 3xULN and INR**> 1.5.
* Serum bilirubin fractionation should be performed if testing is available; if unavailable, 
measure urinary  bilirubin via dipstick.  I f fractionation is unavailable and ALT 3xULN 
and total bilirubin  2xULN, then the event is still to be reported as an SAE.
** INR testing not required per protocol and the threshold value does not apply  to 
subjects receiving anticoagulants.  If INR measurement is obtained, the value is to be 
recorded on the SAE form.
12.4.3. Definition of Cardiovascular Events
Cardiovascular Events (CV) Definition:
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
79Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thromboembolism
Deep venous thrombosis/pulmonary  embolism
Revascularization
12.4.4. Recording of A Es and SA Es
AEs and SAE Recording:
When an AE/SAE occurs, it is the respons ibility  of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
relative to the event.
The investigator will then record all relevant information regarding an AE/SAE in 
the CRF
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_9238]’s medical 
records to [COMPANY_004] in lieu of completion of the [COMPANY_004], AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_004].  In this instance, all subj ect identifiers, with the exception of the 
subject number, will be blinded on the copi[INVESTIGATOR_131976].
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinic al information.  I n such cases, the diagnosis will be 
documented as the AE/SAE and not the individual signs/sy mptoms.
Subject -completed Value Evidence and Outcomes questionnaires and the collection 
of AE data are independent components of the study .
Respon ses to each question in the Value Evidence and Outcomes questionnaire will 
be treated in accordance with standard scoring and statistical procedures detailed b y 
the scale’s developer.
The use of a single question from a multidimensional health survey  to de signate a 
cause -effect relationship to an AE is inappropriate.
12.4.5. Evaluating AEs and SA Es
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and will assign it to one of the following categories:
Mild:  An event that is easily  tolerated by  [CONTACT_423], causing minimal discomfort 
and not interfering with every day activities. 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
80Moderate:  An event that is sufficiently  discomforting to interfere with normal 
every day activities
Severe:  An e vent that prevents normal every day activities. -an AE that is assessed 
as severe will not be confused with an SAE. Severity  is a category  utilized for rating 
the intensity  of an event; and both AEs and SAEs can be assessed as severe.
An event is defined a s ‘serious’ when it meets at least one of the pre- defined 
outcomes as described in the definition of an SAE.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y treatment and 
the occurrence of each AE/SAE.
A "reasonable possibility " is meant to convey that there are facts/evidence or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled 
out.
The investigator will use clinical judgment to determine the relationship.
Alternative ca uses, such as natural history  of the underly ing diseases, concomitant 
therap y, other risk factors, and the temporal relationship of the event to the study  
treatment will be considered and investigated.
The investigator will also consult the I nvestigator Br ochure (IB) and/or Product 
Information, for marketed products, in the determination of his/her assessment.
For each AE/SAE the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations when an SAE has occurred and the investigator has minimal 
information to include in the initial report to [COMPANY_004].  However, it is very important 
that the investigator always make an assessment of causality for every event 
prior to the initial transmission of the SAE data to [COMPANY_004].
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information, amending the SAE data collection tool accordingl y.
The causality  assessment is one of the criteria used when determinin g regulatory  
reporting requirements.
Follow -up of A Es and SA Es
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as may  be indicated or as requested by  [CONTACT_646031]/or causality  of the AE or SAE.
The investigator is obligated to assist.  This may  include additional laboratory  tests 
or investigations, histopathological examinations or consultation with other health  2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
81care professionals.
If a subject die s during participation in the study  or during a recognized follow -up 
period, the investigator will provide [COMPANY_004] with a copy  of any  post -mortem find ings, 
including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to [COMPANY_004] within the designated 
reporting time frames.
12.4.6. Reporting of SA Es to [COMPANY_004]
SAE reporting to [COMPANY_004] via electronic data collection tool
Primary  mechanism for reporting SAEs to [COMPANY_004] will be the electronic dat a collection 
tool
If the electronic s ystem is unavailable for greater than 24 hours, the site will use the 
paper SAE data collection tool and fax it to the Medical Monitor
Site will enter the serious adverse event data into the electronic s ystem as soon as it 
becomes available.
The investigator will be required to confirm review of the SAE causality  by [CONTACT_90649] ‘reviewed’ box at the bottom of the eCRF page within 72 hours of submission of 
the SAE.
After the stud y is completed at a given site, the electro nic data collection tool (e.g., 
InForm system) will be taken off- line to prevent the entry  of new data or changes to 
existing data
If a site receives a report of a new SAE from a study  subject or receives updated data 
on a previousl y reported SAE after the electronic data collection tool has been taken 
off-line, the site can report this information on a paper SAE form or to the Medical 
Monitor by  [CONTACT_756].
Contacts for SAE receipt can be found at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774]. 2018N377698_00
2016N277425_00 CONFIDENTIA L
[PHONE_13438].5. Appendix 5: COPD Exacerbation Identification, 
Categorization and Treatment Guidelines
12.5.1. Guidelines for Identifying COPD Exacerbations
The following are s ymptoms used to ascertain an exacerbation of COPD:
Worsening of two or more of the following major sy mptoms for at least two consecutive 
days:
Dyspnea
Sputum volume
Sputum purulence (color)
OR
Worsening of an y one major symptom together with any  one of the following minor 
symptoms for at least two consecutive day s:
Sore throat
Colds (nasal discharge and/or nasal congestion)
Fever (oral temperature > 37.5 °C) without other cause
Increased cough
Increased wheeze
Subjects who experience worsening COPD sy mptoms for greater than 24 hours should: 
Contact [CONTACT_496979]/or research coordinator immediately , and 
report to the study  clinic as required
If the subject is unable to contact [CONTACT_23976] y Investigator and/or research 
coordinator, they  should contact [CONTACT_23975] (or other health care 
practitioner as re quired) and contact [CONTACT_496981]
Continue to record their symptoms and rescue albuterol/salbutamol usage in their 
daily  eDiary  
If the subject seeks emergency /acute care for worsening respi[INVESTIGATOR_23908], 
he/she should request the caring Health Care Provider (HCP) to contact [CONTACT_646014].
Subjects with worsening respi[INVESTIGATOR_496947]:
A mild/moderate/severe exacerbation and/or pneumonia
OR
A Lower Respi[INVESTIGATOR_645959] I nfection (L RTI) 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
83Background variability  of COPD
A non- respi[INVESTIGATOR_23910]
Other respi[INVESTIGATOR_23910]
12.5.2. COPD Exacerbation Severity
Each COPD exacerbation will be categorized based on severit y as follows:
Moderate :  Worsening sy mptoms of COPD that require treat ment with 
oral/sy stemic corticosteroids and/or antibiotics.
Severe : Worsening s ymptoms of COPD that require treatment with in -patient 
hospi[INVESTIGATOR_26109] [ADDRESS_865133] x- ray within 48 hours of 
identification of a moderate or severe exacerbation. Details of an exacerbation should 
be recorded in the exacerbation page of the eCRF. However, exacerbations should not be 
recorded in the AE section of the eCRF unless they meet the definition of an SAE. 
(Pneumonia must be recorded in the AE or SAE section of the eCRF and on the 
Pneumonia page of the eCRF.)
Use of antibiotics for the treatment of upper or lower respi[INVESTIGATOR_496948] a COPD exacerbation unless the subject exper iences worsening s ymptoms 
of COPD which match the definition of an exacerbation as given above.
12.5.3. Treatment of COPD Exacerbations
All medications used for the treatment of exacerbations must be recorded in the source 
documents and the exacerbation page of th e eCRF.  All sites should follow the protocol 
treatment guidelines (as outlined below), but an y medications deemed medically  
necessary  may  be used to treat a COPD exacerbation. However, caution is advised in 
using a LABA or LAMA to treat a subject currentl y taking IP as these additional 
medications may  increase the risk of overdose. If necessary  the PI [INVESTIGATOR_645960]’s IP temporaril y in order to treat the COPD exacerbation.
12.5.4. Guidelines for Treatment with Corticosteroids
If in the opi[INVESTIGATOR_689]/treating ph ysician the exacerbation is severe enough 
to warrant the need for oral or sy stemic corticosteroids (with or without antibiotics) the 
following guidelines should be used.
The duration of treatment with oral/s ystemic corticosteroids should be 14 day s 
(dose and t ype according to local practice) 
The duration of treatment with oral/sy stemic corticosteroids should not exceed 14 
days unless approval is given by  [CONTACT_107634]
Any course of oral/s ystemic corticosteroids started within 7 day s of finishing a 
previous course will be considered as treatment for a single exacerbation 2018N377698_00
2016N277425_00 CONFIDENTIA L
[PHONE_13439].5.5. Guidelines for Treatment with A ntibiotics
If there is evidence of respi[INVESTIGATOR_645982]:
The duration of treatment with antibiotics should not exceed 14 day s (dose and ty pe 
according to local practice). If first line antibiotic treatment f ails and additional 
antibiotics are used, the total duration of antibiotic treatment should not exceed 30 
days unless approval is given by  [CONTACT_107634]
Any course of antibiotics started within [ADDRESS_865134] day  (of at least 2 consecutive day s) of worsening s ymptoms 
of COPD as described in Section 12.5.1 .
The date of resolution should be based on when the Investigator and/or subject 
determines that the COPD sy mptoms have returned to pre -exacerbation levels or to a new
baseline.  In determining this resolution date, consideration should be given to diary  
recorded s ymptoms and/or study  subject evaluation.
12.5.7. Guideline for assessing multiple mild exacerbations
Two mild exacerbations can be combined into one, per the Investig ator’s judgement, if a 
subject’s diary  reveals that the two mild COPD exacerbations are separated by  [CONTACT_646016] s.
12.5.8. Guideline for assessing exacerbations that increase in severity
If an exacerbation starts off as mild, but becom es moderate or severe or starts off as 
moderate and becomes severe, the exacerbation should be captured as one exacerbation 
and classified b y its highest level of severity. 2018N377698_00
2016N277425_00 CONFIDENTIA L
[PHONE_13427].6. Appendix 6: Definition of and Procedures for Documenting 
Medical Device Incident s
12.6.1. Definitions of a Medical Device Incident
The detection and documentation procedures described in this protocol apply  to all [COMPANY_004] 
medical devices provided for use in the stud y (see Section 6.2for the list of [COMPANY_004] m edical 
devices).
Medical Device Incident Definition:
Incident –Any malfunction or deterioration in the characteristics and/or performance 
of a device, as well as any  inadequacy  in the labeling or the instructions for use 
which, directl y or indirectly , mig ht lead to or might have led to the death of a 
patient/user/other persons or to a serious deterioration in their state of health.
Not all incidents lead to death or serious deterioration in health.  The non- occurrence 
of such a result might have been due t o other fortunate circumstances or to the 
intervention of health care personnel.
It is sufficient that:
 an incident associated with a device happened and
 the incident was such that, if it occurred again, might lead to death or a serious 
deterioration in health.
 A serious deterioration in state of health can include:
 life-threatening illness
 permanent impairment of body  function or permanent damage to a bod y structure
 a condition necessitating medical or surgical intervention to prevent one of the 
above 
 fetal distress, fetal death or an y congenital abnormality  or birth defects
Examples of incidents
a patient, user, care giver or professional is injured as a result of a medical device 
failure or its misuse
a patient’s treatment is interrupted or compromised by  a medical device failure
misdiagnosis due to medical device failure leads to inappropriate treatment
a patient’s health deteriorates due to medical device failure 2018N377698_00
2016N277425_00 CONFIDENTIA L
[PHONE_13428].6.2. Documenting Medical Device Incidents
Medical Device Incident Documenting:
Any medical device incident occurring during the study  will be documented in the 
subject’s medical records, in accordance with the investigator’s normal clinical 
practice, and on the appropriate form.
For incidents fulfilling the definition of an AE or an SAE, the appropriate AE/SAE 
CRF page will be completed as described in Appendix 4.
The form will be completed as thoroughl y as possible and signe d by [CONTACT_132016].
It is very  important that the investigator provides his/her assessment of causality  to 
the medical device provided by  [CONTACT_132017], and describes 
any corrective or remedial actions t aken to prevent recurrence of the incident.
A remedial action is an y action other than routine maintenance or servicing of a 
device where such action is necessary to prevent recurrence of an incident. This 
includes an y amendment to the design to prevent re currence. 2018N377698_00
2016N277425_00 CONFIDENTIA L
[PHONE_13429].7. Appendix 7: Modified List of Highly  Effective Methods for 
Avoiding Pregnancy  in FRP and Collection of Pregna ncy 
Information
12.7.1. Modified List of Highly Effective Methods for Avoiding Pregnancy  
in Females of Reproductive Potential (FRP)
The list does not apply  to FRP with same sex partners or for subjects who are and will 
continue to be abstinent from penile-vaginal intercourse on a long term and persistent 
basis, when this is their preferred and usual lifest yle. Periodic abstinence (e.g. calendar, 
ovulation, sy mptothermal, post -ovulation methods) and withdrawal are not acceptable 
methods of contraception.
1.Contraceptive subdermal implant
2.Intrauterine device or intrauterine s ystem
3. Combined estrogen and progestogen oral contraceptive [ Hatcher , 2011]
4.Injectable progestogen [ Hatcher , 2011]
5.Contraceptive vaginal ring [ Hatcher , 2011]
6.Percutaneous contraceptive patches [ Hatcher , 2011]
7.Male partner sterilization with documentation of azoospermia prior to the female 
subject's entry  into the study , and this male is the sole partner for that subject 
[Hatcher , 2011]. The documentation on male sterility  can come from the site 
personnel’s: review of subject’s medica l records, medical examination and/or semen 
analysis, or medical history  interview provided b y her or her partner.
These allowed methods of contraception are only  effective when used consistently , 
correctly  and in accordance with the produ ct label. The investigator is responsible for 
ensuring that subjects understand how to properl y use these methods of contraception.
12.7.2. Collection of Pregnancy  Information
Investigator will collect pregnancy  information on any  female subject, who becomes 
pregnant while participating in this study
Information will be recorded on the appropriate form and submitted to [COMPANY_004] within [ADDRESS_865135]'s pregnancy .
Subject will be followed to determine the outcome of the pregnancy . The 
investigator will collect follow up information on mother and infant, which will be 
forwarded to [COMPANY_004].  Generall y, follow -up will not be required for longer than 6 to 8 
weeks bey ond the estimated delivery  date. 
Any termination of pregnancy  will be reported, regardless of fe tal status (presence or 
absence of anomalies) or indication for procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy will be reported as an AE or 
SAE. 2018N377698_00
2016N277425_00 CONFIDENTIA L
201749
88A spontaneous aborti on is alway s considered to be an SAE and will be reported as 
such.  
Any SAE occurring as a result of a post -study  pregnancy  which is considered 
reasonabl y related to the study  treatment by  [CONTACT_093], will be reported to [COMPANY_004] 
as described in Appendix 4. While the investigator is not obligated to actively  seek 
this information in former study  participants, he or she may  learn of an SAE through 
spontaneous reporting.
Any female subject who becomes pregnant while par ticipating 
will be withdrawn from the study 2018N377698_00
2016N277425_00 CONFIDENTIA L
[PHONE_13443].8. Appendix 8 :Country  Specific Requirements
No country -specific requirements exist. 2018N377698_00